spironolactone has been researched along with Heart Failure in 1122 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " spironolactone on left ventricular systolic function by measuring left ventricle ejection fraction (LVEF) in patients with chronic heart failure, especially their effect on preventing hospitalization, reducing mortality, and improving clinical status among patients with chronic HF." | 9.69 | The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF. ( Durak-Nalbantic, A; Karic, A; Naser, N; Sabanovic-Bajramovic, N, 2023) |
| "Eplerenone reduces the risk of cardiovascular death or first hospitalization for heart failure (HF) in patients with HF and a reduced ejection fraction (HFrEF), but it is still frequently underused in routine practice." | 9.69 | Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trial. ( Duarte, K; Ferreira, JP; Girerd, N; McMurray, JJV; Monzo, L; Pitt, B; Pocock, SJ; Swedberg, K; van Veldhuisen, DJ; Zannad, F, 2023) |
| " We aimed to identify the biomarker profile and biological meaning of biomarkers associated with obesity to assess the effect of spironolactone on the circulating biomarkers and to explore whether obesity might modify the effect of spironolactone." | 9.51 | The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial. ( Brunner La Rocca, HP; Clark, AL; Cleland, JGF; Cosmi, F; Cuthbert, J; Ferreira, JP; Girerd, N; Hazebroek, MR; Henkens, MHTM; Heymans, SRB; Mariottoni, B; Pellicori, P; Petutschnigg, J; Pizard, A; Rossignol, P; Verdonschot, JAJ; Waring, OJ; Zannad, F, 2022) |
| "Left ventricular ejection fraction (LVEF) can provide haemodynamic information and may influence the response to spironolactone and other heart failure (HF) therapies." | 9.51 | Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial. ( Bozec, E; Clark, AL; Cleland, JG; Collier, T; Cosmi, F; Cuthbert, J; Díez, J; Edelman, F; Ferreira, JP; Girerd, N; González, A; Hazebroek, M; Heymans, S; Mariottoni, B; Pellicori, P; Petutschnigg, J; Pieske, B; Rossignol, P; Staessen, JA; Verdonschot, JAJ; Zannad, F, 2022) |
| "The TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) suggested clinical benefits of spironolactone treatment among patients with heart failure with preserved ejection fraction enrolled in the Americas." | 9.51 | Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction. ( Basso, M; Cappola, TP; Chirinos, JA; Cohen, JB; Diab, A; Doughty, RN; Ebert, C; Gogain, J; Gordon, DA; Javaheri, A; Kammerhoff, K; Kumar, A; Kvikstad, E; Mann, DL; Maranville, J; Qian, C; Ramirez-Valle, F; Richards, AM; Rietzschel, E; Schafer, P; Seiffert, DA; van Empel, V; Wang, Z; Zamani, P; Zhao, L, 2022) |
| "While median time to cardiac death in the spironolactone group was not statistically significantly different than that in the placebo group, adding spironolactone to conventional therapy resulted in reduced occurrence of AF." | 9.51 | Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy. ( Chambers, H; Fonfara, S; Laskary, A; O'Sullivan, ML, 2022) |
| "An enriched subset of patients with structural and functional echocardiographic features of cardiac amyloidosis had the worst prognosis in the TOPCAT study, but they benefitted similarly from spironolactone therapy." | 9.41 | Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT. ( Hanna, M; Jaber, WA; Shah, SJ; Sperry, BW; Spertus, JA, 2021) |
| "The mineralocorticoid receptor antagonist spironolactone has been shown to improve cardiac function and reverse left ventricular hypertrophy in heart failure patients, but there are no consistent findings on the efficacy and safety in hemodialysis patients." | 9.41 | Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients. ( Chen, Z; Li, Z; Liu, R; Lu, G; Sun, Y; Sun, Z, 2023) |
| "To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure." | 9.41 | The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. ( Ahmed, FZ; Brunner La Rocca, HP; Clark, AL; Cleland, JGF; Collier, TJ; Cosmi, F; Cuthbert, J; Diez, J; Edelmann, F; Ferreira, JP; Girerd, N; González, A; Grojean, S; Hazebroek, M; Heymans, S; Khan, J; Latini, R; Mamas, MA; Mariottoni, B; McDonald, K; Mujaj, B; Pellicori, P; Petutschnigg, J; Pieske, B; Pizard, A; Rossignol, P; Rouet, P; Staessen, JA; Verdonschot, JAJ; Zannad, F, 2021) |
| "Treatment of heart failure with preserved ejection fraction (HFpEF) with spironolactone is associated with lower risk of heart failure hospitalization (HFH) but increased risk of worsening renal function (WRF)." | 9.41 | Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. ( Beldhuis, IE; Bristow, M; Claggett, B; Damman, K; Desai, AS; Fang, JC; Fleg, JL; Lewis, EF; McKinlay, S; Myhre, PL; O'Meara, E; Pfeffer, MA; Pitt, B; Shah, SJ; Solomon, SD; Vardeny, O; Voors, AA, 2021) |
| " The Heart OMics in AGing (HOMAGE) trial aims to investigate the effects of spironolactone on serum markers of collagen metabolism and on cardiovascular structure and function in people at risk of developing HF and potential interactions with a marker of fibrogenic activity, galectin-3." | 9.34 | Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HO ( Ahmed, FZ; Brunner-La Rocca, HP; Clark, AL; Cleland, JGF; Collier, T; Cosmi, F; Cuthbert, JJ; Ferreira, JP; Girerd, N; González, A; Heymans, S; Latini, R; Mariottoni, B; Mujaj, B; Pellicori, P; Petutschnigg, J; Rossignol, P; Staessen, JA; Verdonschot, J; Zannad, F, 2020) |
| "Spironolactone has been demonstrated to reduce heart failure (HF) hospitalization in patients with HF with preserved ejection fraction in the Americas region of the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial)." | 9.34 | Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study. ( Anand, IS; Claggett, BL; de Denus, S; Desai, AS; Jarolim, P; Myhre, PL; O'Meara, E; Pfeffer, MA; Pitt, B; Rouleau, JL; Solomon, SD; Vaduganathan, M, 2020) |
| "In Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure (ATHENA-HF), high-dose spironolactone (100 mg daily) did not improve efficacy endpoints over usual care [placebo or continued low-dose spironolactone (25 mg daily) in patients already receiving spironolactone] in the treatment of acute heart failure (HF)." | 9.34 | Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial. ( Butler, J; de Denus, S; Dubé, MP; Ferreira, JP; Givertz, MM; Jutras, M; Kalogeropoulos, AP; Leclair, G; Mentz, RJ; Oussaïd, E; Rouleau, J; St-Jean, I; Tang, WHW; Zada, YF, 2020) |
| "The AMBER trial demonstrated that concomitant use of patiromer enabled the more persistent use of spironolactone by reducing the risk of hyperkalaemia in patients with resistant hypertension and advanced chronic kidney disease." | 9.34 | Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. ( Ackourey, G; Agarwal, R; Arthur, S; Mayo, MR; Rossignol, P; Warren, S; White, WB; Williams, B, 2020) |
| " These results should be weighed when considering spironolactone for older heart failure with preserved ejection fraction patients." | 9.30 | Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. ( Anand, IS; Beldhuis, I; Claggett, B; Desai, AS; Fang, JC; Lewis, EF; O'Meara, E; Pfeffer, MA; Pitt, B; Rouleau, J; Shah, SJ; Solomon, SD; Sweitzer, NK; Vaduganathan, M; Vardeny, O, 2019) |
| "This study sought to investigate sex differences in outcomes and responses to spironolactone in patients with heart failure with preserved ejection fraction (HFpEF)." | 9.30 | Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. ( Kao, DP; Lindenfeld, J; Merrill, M; Sweitzer, NK, 2019) |
| "Acute heart failure (HF) patients with renal insufficiency and risk factors for diuretic resistance may be most likely to derive incremental improvement in congestion with the addition of spironolactone." | 9.30 | Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. ( Ambrosy, AP; Butler, J; Chakraborty, H; DeVore, AD; Felker, GM; Fudim, M; Giczewska, A; Greene, SJ; Hernandez, AF; Kalogeropoulos, AP; McNulty, SE; Mentz, RJ; Vaduganathan, M, 2019) |
| "We identified patients with RHTN, defined as baseline systolic blood pressure (SBP) between 140 and 160 mm Hg on 3 or more medications, in the Americas cohort of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial, in which patients with HFpEF were randomized to spironolactone vs." | 9.27 | Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction. ( Claggett, BL; Liu, J; Pitt, B; Rossignol, P; Solomon, S; Vardeny, O; Zannad, F, 2018) |
| "This study suggests that spironolactone is well tolerated, and preliminary results support further investigation to evaluate the efficacy of spironolactone in the treatment of cats with cardiac failure due to cardiomyopathy." | 9.27 | The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy. ( Cobb, M; Garelli-Paar, C; Grassi, V; Guillot, E; Huxley, J; James, R, 2018) |
| " We investigated whether the effect of spironolactone on LVDD in patients with heart failure with preserved ejection fraction (HFpEF) depends on its effects on collagen cross-linking and/or deposition." | 9.27 | Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. ( Bach, D; Bachran, D; Delles, C; Díez, J; Dominiczak, AF; Edelmann, F; González, A; Hasenfuss, G; López, B; Pieske, B; Ravassa, S; Trippel, T; Wachter, R, 2018) |
| "To characterize eplerenone pharmacokinetics (PK) in Japanese chronic heart failure (CHF) patients and to estimate the impact of factors that may affect eplerenone PK, population pharmacokinetic (PPK) analysis was conducted." | 9.24 | Population Pharmacokinetics of Eplerenone in Japanese Patients With Chronic Heart Failure. ( Oishi, M; Sweeney, K; Tomono, Y; Zhao, Q, 2017) |
| "In a sub-study of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS trial), BNP and BigET-1 were measured at baseline and at 1month in 476 patients." | 9.24 | Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Ac ( Bramlage, P; Fay, R; Girerd, N; Ketelslegers, JM; Michel, JB; Olivier, A; Pitt, B; Rossignol, P; Vincent, J; Zannad, F, 2017) |
| "While mineralocorticoid receptor antagonists (MRAs) have been shown to benefit patients with reduced left ventricular ejection fraction (LVEF), spironolactone did not reduce the primary endpoint of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest in patients with heart failure with preserved ejection fraction (HFpEF) in the TOPCAT trial, which enrolled patients with LVEF of 45% or greater." | 9.22 | Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. ( Anand, I; Claggett, B; Desai, A; Fleg, JL; Lewis, EF; McKinlay, S; O'Meara, E; Pfeffer, MA; Pitt, B; Shah, SJ; Solomon, SD; Sopko, G; Sweitzer, NK, 2016) |
| "Patients ≥50 years of age, with symptomatic HF and left ventricular ejection fraction ≥45%, were enrolled in Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) and randomized to spironolactone or placebo." | 9.22 | Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. ( Assmann, SF; Claggett, B; Desai, AS; Fang, JC; Heitner, JF; Kenwood, CT; Kim, HY; Lewis, EF; McKinlay, SA; Pfeffer, MA; Pitt, BA; Solomon, SD; Spertus, J, 2016) |
| "The single-centre IMproved exercise tolerance In heart failure With PReserved Ejection fraction by Spironolactone On myocardial fibrosiS In Atrial Fibrillation (IMPRESS-AF) trial aims to establish whether treatment with spironolactone as compared with placebo improves exercise tolerance (cardiopulmonary exercise testing), quality of life and diastolic function in patients with permanent atrial fibrillation." | 9.22 | IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. ( Calvert, M; Fisher, J; Gill, PS; Haynes, R; Kirchhof, P; Lip, GY; Shantsila, E, 2016) |
| "We examined the relationship between different degrees of QRS prolongation and different QRS morphologies and clinical outcomes in patients with heart failure, reduced ejection fraction (HF-REF), and mild symptoms in the Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure trial (EMPHASIS-HF)." | 9.20 | Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF). ( Cannon, JA; Collier, TJ; Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Shen, L; Swedberg, K; Van Veldhuisen, DJ; Vincent, J; Zannad, F, 2015) |
| "Twelve to 18 months of spironolactone therapy was not associated with alterations in cardiac structure or function in patients with heart failure with preserved ejection fraction." | 9.20 | Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. ( Anand, IS; Claggett, B; Deswal, A; Fleg, JL; Pfeffer, MA; Pitt, B; Shah, AM; Shah, SJ; Solomon, SD; Sweitzer, NK, 2015) |
| " The investigation involved 6632 patients of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study." | 9.19 | Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) s ( Challande, P; Fay, R; Lacolley, P; Lagrange, J; Pitt, B; Pizard, A; Regnault, V; Rossignol, P; Safar, ME; Zannad, F, 2014) |
| "The purpose of this study is to evaluate long-term effects of spironolactone, an affordable and widely used aldosterone receptor blocker, in patients with heart failure (HF) and mild or no symptoms." | 9.19 | Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. ( Caretta, G; D'Aloia, A; Dei Cas, L; Faden, G; Lombardi, C; Metra, M; Nodari, S; Pezzali, N; Raddino, R; Vizzardi, E, 2014) |
| "In patients with heart failure receiving optimal therapy, WRF and HK were more frequent when eplerenone was added, but their occurrence did not eliminate the survival benefit of eplerenone." | 9.19 | Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from ( Bakris, G; Dobre, D; Girerd, N; Krum, H; McMurray, JJ; Messig, M; Pitt, B; Rossignol, P; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2014) |
| "Spironolactone, not furosemide, improved insulin resistance in CHF patients probably by the inhibition of inflammatory cytokines and MMPs." | 9.19 | Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure. ( Anker, SD; Doehner, W; Hisatome, I; Kato, M; Kinugasa, Y; Ogino, K; Yamamoto, K, 2014) |
| "High-dose spironolactone added to standard ADHF therapy is likely to induce a more pronounced albuminuria decrease and a significant reduction in the proportion of micro and macroalbuminuria." | 9.19 | The role of albuminuria as a non-invasive marker for congestive acutely decompensated chronic heart failure and the spironolactone effect in elderly Portuguese: a non-randomized trial. ( Almeida, S; Bettencourt, P; Carvalho, H; Ferreira, JP; Marques, I; Santos, M, 2014) |
| "In this randomized, double-blind trial, we assigned 3445 patients with symptomatic heart failure and a left ventricular ejection fraction of 45% or more to receive either spironolactone (15 to 45 mg daily) or placebo." | 9.19 | Spironolactone for heart failure with preserved ejection fraction. ( Anand, IS; Assmann, SF; Boineau, R; Claggett, B; Clausell, N; Desai, AS; Diaz, R; Fleg, JL; Gordeev, I; Harty, B; Heitner, JF; Kenwood, CT; Lewis, EF; McKinlay, SM; O'Meara, E; Pfeffer, MA; Pitt, B; Probstfield, JL; Shaburishvili, T; Shah, SJ; Solomon, SD; Sweitzer, NK; Yang, S, 2014) |
| "We aimed to assess the impact of eplerenone on cardiovascular (CV) outcomes in STEMI without known heart failure, when initiated within 24 h of symptom onset." | 9.19 | Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. ( Flather, M; Hamm, CW; Lopez de Sa, E; Montalescot, G; Orri, M; Pitt, B; Shi, H; Turgonyi, E; Verheugt, F; Vincent, J; Zannad, F, 2014) |
| "Although spironolactone has been shown to decrease morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction, its role in patients with heart failure and preserved left ventricular ejection fraction (HFpEF) is not well defined." | 9.19 | Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. ( Ashton, Y; Deswal, A; Kurrelmeyer, KM; Nagueh, SF; Torre-Amione, G; Xu, J, 2014) |
| "The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients with acute heart failure (AHF) and the association between treatment and outcomes stratified by biomarkers." | 9.19 | Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). ( Butler, J; Clopton, P; de Boer, RA; Jaarsma, T; Maisel, A; Pang, PS; Pitt, B; van Veldhuisen, DJ; Voors, AA; Xue, Y, 2014) |
| "In EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure), eplerenone significantly reduced major cardiovascular events versus placebo in 2737 patients with mild symptoms of heart failure and an ejection fraction of <35%, in addition to recommended therapy." | 9.17 | Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. ( Krum, H; McMurray, J; Pitt, B; Pocock, S; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2013) |
| "The study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerular filtration rate (eGFR) >30 ml/min/1." | 9.17 | Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). ( Eschalier, R; Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Rossignol, P; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2013) |
| "AAs with HF exhibited less hyperkalemia and more hypokalemia with spironolactone compared with non-AAs and seemed to derive less clinical benefit." | 9.17 | Race influences the safety and efficacy of spironolactone in severe heart failure. ( Anand, I; Cavallari, LH; Claggett, B; Desai, AS; Pitt, B; Rossignol, P; Solomon, SD; Vardeny, O; Zannad, F, 2013) |
| "We evaluated the effect of the selective mineralocorticoid receptor antagonist eplerenone on renal function and the interaction between changes in renal function and subsequent cardiovascular outcomes in patients with heart failure and left ventricular systolic dysfunction after an acute myocardial infarction in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)." | 9.16 | Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. ( Bhandari, S; Cleland, JG; Dobre, D; Fay, R; Gustafsson, F; Lamiral, Z; Pitt, B; Rossignol, P; Tala, S; Zannad, F, 2012) |
| "In patients with symptomatically mild CHF who participated in the placebo-controlled Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure, we examined the effect of the aldosterone antagonist, eplerenone, on physician-diagnosed diabetes using univariate Cox proportional hazard analysis." | 9.16 | Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). ( Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Preiss, D; Sattar, N; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2012) |
| "This study investigated the influence of baseline and worsening renal function (WRF) on the efficacy of spironolactone in patients with severe heart failure (HF)." | 9.16 | Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). ( Desai, A; Pitt, B; Rossignol, P; Solomon, SD; Vardeny, O; Wu, DH; Zannad, F, 2012) |
| "In this randomized, double-blind trial, we randomly assigned 2737 patients with New York Heart Association class II heart failure and an ejection fraction of no more than 35% to receive eplerenone (up to 50 mg daily) or placebo, in addition to recommended therapy." | 9.15 | Eplerenone in patients with systolic heart failure and mild symptoms. ( Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2011) |
| "Spironolactone was shown to reduce mortality in patients with heart failure (HF)." | 9.15 | Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure. ( Hadano, Y; Hiratsuka, A; Iwami, T; Kimura, M; Matsuzaki, M; Mochizuki, M; Ogawa, H; Shimizu, A; Takaki, A; Wakeyama, T, 2011) |
| "We evaluated 12-month cost utilization data from 1516 heart failure outpatients enrolled in the Quality-of-Life Substudy of the Eplerenone Post-Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)." | 9.14 | Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). ( Chan, PS; Jones, PG; Nallamothu, BK; Soto, G; Spertus, JA; Weintraub, WS; Zhang, Z, 2009) |
| "In a substudy of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), which evaluated the effects of the selective aldosterone receptor antagonist eplerenone versus placebo, serum levels of collagen biomarkers were measured in 476 patients with congestive heart failure after acute myocardial infarction complicated with left ventricular systolic dysfunction." | 9.14 | Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EP ( Angioi, M; Fay, R; Iraqi, W; Ketelslegers, JM; Nuée, J; Pitt, B; Rossignol, P; Vincent, J; Zannad, F, 2009) |
| "To test the hypothesis that an earlier post-acute myocardial infarction (AMI) eplerenone initiation in patients with left ventricular systolic dysfunction (LVSD) and heart failure (HF) is associated with better long-term outcomes." | 9.14 | Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. ( Adamopoulos, C; Ahmed, A; Angioi, M; Fay, R; Filippatos, G; Pitt, B; Vincent, J; Zannad, F, 2009) |
| "The beneficial effects of spironolactone in chronic heart failure (HF) have been demonstrated in patients with New York Heart Association (NYHA) class III to IV HF." | 9.14 | Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. ( Bordonali, T; Bugatti, S; D'Aloia, A; Dei Cas, A; Dei Cas, L; Giubbini, R; Metra, M; Pezzali, N; Romeo, A; Vizzardi, E, 2010) |
| "In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (n=6632), eplerenone-associated reduction in all-cause mortality was significantly greater in those with a history of hypertension (Hx-HTN)." | 9.13 | History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. ( Ahmed, A; Aschermann, M; Cardoso, JS; Corbalán, R; Krum, H; Love, TE; Nicolau, J; Parkhomenko, A; Pitt, B; Shi, H; Solomon, H; Zannad, F, 2008) |
| "Hospitalized patients with congestive heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction (left ventricular ejection fraction < or =40%) treated with standard therapy were randomized 3 to 14 days after the acute myocardial infarction to additional treatment with eplerenone (25 to 50 mg/d; n=3319) or placebo (n=3313)." | 9.13 | Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). ( Bakris, G; DiCarlo, L; Mukherjee, R; Pitt, B; Ruilope, LM, 2008) |
| "The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) randomized clinical trial demonstrated the efficacy of eplerenone, a new aldosterone antagonist diuretic, with standard treatment versus standard treatment alone in the reduction of cardiovascular mortality and cardiovascular-related hospital readmissions for patients with heart failure after an acute myocardial infarction." | 9.13 | Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study. ( Beillat, M; de Pouvourville, G; Solesse, A, 2008) |
| "Aim of the investigation was the study of influence of spironolactone (25-75 mg/day) on clinico-functional and neurohormonal, 24-hour variability of cardiac rhythm, and ventricular disturbances of heart rhythm in patients with chronic heart failure (CHF) receiving optimal therapy." | 9.13 | [Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy]. ( Baklanova, NA; Belenkov, IuN; Chelmakina, SM; Mareev, VIu; Orlova, IaA; Skvortsov, AA, 2008) |
| "The Randomized Aldactone Evaluation Study (RALES) established the safety and benefit of spironolactone for heart failure (HF) patients with systolic dysfunction." | 9.12 | Appropriateness of spironolactone prescribing in heart failure patients: a population-based study. ( Donovan, LR; Juurlink, DN; Ko, DT; Mamdani, MM; Tu, JV; Wang, JT; You, JJ, 2006) |
| "Our results suggest that reducing cellular magnesium efflux and loss may contribute to the spironolactone-reduced arrhythmias in patients with CHF." | 9.12 | Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. ( Adhikari, CM; Gao, X; Lin, J; Peng, L; Zuo, Z, 2007) |
| "To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure." | 9.12 | Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. ( Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA, 2007) |
| "Aim of the investigation was the study of influence of spironolactone (25 - 75 mg/day) on clinico-functional status, parameters of left ventricular (LV) remodeling, as well as safety of its long term application in patients with chronic heart failure (CHF) receiving optimal therapy." | 9.12 | [Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy]. ( Baklanova, NA; Belenkov, IuN; Chelmakina, SM; Mareev, VY; Skvortsov, AA, 2007) |
| "We randomly assigned 93 chronic heart failure patients to treatment with spironolactone (n = 47) or to a control group (n = 46) and followed them for 12 months." | 9.11 | Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure. ( Bonapace, S; Cicoira, M; Franceschini, L; Francis, DP; Golia, G; Osterziel, KJ; Perrot, A; Rossi, A; Zanolla, L; Zardini, P, 2004) |
| "We prospectively studied the effect of spironolactone, an aldosterone antagonist, on endothelial function in patients with advanced congestive heart failure (CHF) using the brachial artery reactivity method." | 9.11 | Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy. ( Abiose, AK; Barry, M; Hager, D; Mansoor, GA; Nair, CK; Soucier, R, 2004) |
| "To examine whether the favourable effects on endothelial function, vascular angiotensin converting enzyme (ACE) activity, cardiac remodelling, autonomic function, and QT intervals of spironolactone in combination with ACE inhibitor also occur in patients with New York Heart Association class I-II congestive heart failure (CHF) taking optimal treatment (including beta blockers)." | 9.11 | Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. ( Kennedy, N; Macdonald, JE; Struthers, AD, 2004) |
| "In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), aldosterone blockade with eplerenone decreased mortality in patients with left ventricular systolic dysfunction and heart failure after acute myocardial infarction." | 9.11 | Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. ( Caro, J; Goldberg, R; Ishak, J; Kolm, P; Mahoney, EM; Pitt, B; Spertus, JA; Tooley, J; Weintraub, WS; Willke, R; Zhang, Z, 2005) |
| "This study sought to assess the impact of the selective aldosterone blocker eplerenone on mortality 30 days after randomization in patients after acute myocardial infarction (AMI) with a left ventricular ejection fraction (LVEF) < or =40% and clinical signs of heart failure." | 9.11 | Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. ( Aschermann, M; Gheorghiade, M; Krum, H; Martinez, F; Mukherjee, R; Nicolau, J; Pitt, B; van Veldhuisen, DJ; Vincent, J; White, H; Zannad, F, 2005) |
| "To retrospectively investigate elevation of serum potassium when spironolactone (25 or 50 mg/day) and furosemide were administered concomitantly with an angiotensin II converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) to patients with chronic heart failure for 12 months and occurrence of hyperkalemia and hypokalemia because of concomitant administration of spironolactone plus an ACE-I or ARB and furosemide." | 9.11 | Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. ( Hirooka, K; Isobe, F; Saito, M; Takada, M; Yasumura, Y, 2005) |
| "We evaluated whether spironolactone would improve cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure (CHF)." | 9.10 | Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. ( Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Suzuki, T; Takayama, Y; Toyama, T, 2002) |
| "We sought to evaluate the effects of spironolactone on neurohormonal factors in patients with severe congestive heart failure (CHF)." | 9.10 | Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. ( Ahn, S; Duprez, D; Galanti, L; Gurné, O; Ketelslegers, JM; Robert, A; Rousseau, MF; Van Mieghem, W, 2002) |
| "This study was designed to investigate the appropriateness and complications of the use of spironolactone for heart failure (HF) in clinical practice." | 9.10 | Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. ( Agoston, I; Bozkurt, B; Knowlton, AA, 2003) |
| " We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure." | 9.10 | Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. ( Bittman, R; Gatlin, M; Hurley, S; Kleiman, J; Martinez, F; Neaton, J; Pitt, B; Remme, W; Roniker, B; Zannad, F, 2003) |
| "The purpose of our study was to assess the effects of a low dose of spironolactone in patients with moderate congestive heart failure (CHF) on the plasma level of brain natriuretic peptide (BNP), echocardiographic left ventricular ejection fraction (LVEF), and cardiopulmonary function assessed by cardiopulmonary (CP) test." | 9.10 | Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure. ( Deorsola, A; Feola, M; Ferrero, V; Menardi, E; Milanese, U; Ribichini, F; Uslenghi, E; Vado, A; Visconti, G, 2003) |
| "The effects of spironolactone or metoprolol added to a conventional treatment protocol on QT dispersion, which is accepted as a sudden cardiac death predictor, were evaluated in heart failure patients." | 9.10 | Effects of spironolactone and metoprolol on QT dispersion in heart failure. ( Akbulut, M; Arslan, N; Ilkay, E; Karaca, I; Ozbay, Y, 2003) |
| " This manuscript provides an overview of the considerations made regarding quantification of a range of clinical and economic outcomes in the EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study) study, a 6200-patient, randomized, controlled trial of aldosterone blockade in patients with heart failure as a complication of acute myocardial infarction." | 9.10 | Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). ( Deedwania, P; Hurley, S; Jones, P; Mahoney, E; Pitt, B; Poston, C; Spertus, JA; Tooley, J; Weintraub, WS, 2002) |
| "This study was designed to assess the effects of spironolactone (SP) on left ventricular (LV) function and exercise tolerance in patients with chronic heart failure (CHF)." | 9.10 | Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. ( Brighetti, G; Cicoira, M; Franceschini, L; Golia, G; Marino, P; Rossi, A; Zanolla, L; Zardini, P, 2002) |
| "Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure." | 9.09 | The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. ( Castaigne, A; Cody, R; Palensky, J; Perez, A; Pitt, B; Remme, WJ; Wittes, J; Zannad, F, 1999) |
| "The RALES study showed that spironolactone, added to conventional therapy for chronic heart failure, dramatically reduced mortality." | 9.09 | Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. ( Farquharson, CA; Struthers, AD, 2000) |
| "A marked reduction of overall mortality in patients with severe congestive heart failure (CHF) has been demonstrated by addition of the mineralocorticoid receptor antagonist spironolactone to ACE inhibition." | 9.09 | Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES. ( Bauersachs, J; Christ, M; Ertl, G; Fraccarollo, D; Gretz, N; Wehling, M, 2000) |
| "We sought to evaluate the effects of spironolactone on neurohumoral factors and left ventricular remodeling in patients with congestive heart failure (CHF)." | 9.09 | Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Kinoshita, M; Mabuchi, N; Maeda, K; Matsui, T; Matsumoto, T; Ohnishi, M; Sawaki, M; Tsutamoto, T; Tsutsui, T; Wada, A, 2001) |
| " Treatment with spironolactone is reported to be useful when combined with loop diuretics and an angiotensin-converting enzyme (ACE) inhibitor in severe congestive heart failure (CHF)." | 9.08 | Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor. ( Endo, A; Furuse, Y; Hisatome, I; Kato, M; Kato, T; Kinugawa, T; Miyakoda, H; Mori, M; Ogino, K; Omodani, H; Osaki, S; Shigemasa, C; Shimoyama, M, 1998) |
| "Right heart catheterization was performed before and during long-term therapy with prazosin in 27 patients with severe chronic heart failure who underwent serial hemodynamic studies during 3 to 12 weeks of treatment with the drug." | 9.06 | Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. ( Medina, N; Packer, M; Yushak, M, 1986) |
| "The effect of adding spironolactone (Aldactone) on muscle electrolytes was studied in 48 patients with arterial hypertension and/or congestive heart failure who had received conventional diuretic treatment, including a potassium supplement, for more than 1 year." | 9.06 | Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial hypertension. ( Dyckner, T; Wester, PO; Widman, L, 1986) |
| "The efficacy of treatment with spironolactone for congestive heart failure secondary to congenital heart disease was studied in 21 infants under 1 year of age." | 9.05 | Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease. ( Fowler, RS; Hobbins, SM; Korey, AG; Rowe, RD, 1981) |
| "Extra potassium supplements, spironolactone or amiloride were given for 5 months to forty-nine patients with heart failure who were taking furosemide and were in a steady state." | 9.04 | The effects of potassium supplements, spironolactone of amiloride on the potassium status of patients with heart failure. ( Burkinshaw, L; Davidson, C; Morgan, DB, 1978) |
| "Recent studies have shown the efficacy for using spironolactone to treat heart failure with reduced ejection fraction (HFrEF), but the efficacy of spironolactone for heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) is unclear." | 9.01 | Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials. ( Feng, P; Huang, W; Li, Z; Shi, W; Wang, SY; Wen, L; Xiang, R; Xiang, Y; Yang, Y, 2019) |
| " A randomized controlled trial of patients with heart failure and an ejection fraction > 45% showed that spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure." | 8.93 | Clinical Question: In congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes? ( Onarecker, C, 2016) |
| "Eplerenone is a selective mineralocorticoid receptor antagonist that has been recently included in the treatment of patients with chronic heart failure (CHF) and reduced systolic function." | 8.91 | Eplerenone in chronic heart failure with depressed systolic function. ( Iellamo, F; Volterrani, M, 2015) |
| "The TOPCAT study followed the effect of spironolactone on a chronic heart failure with a preserved left ventricular ejection fraction." | 8.91 | [Effect of spironolactone in patients with heart failure and preserved left ventricular function - TOPCAT study]. ( Widimský, J, 2015) |
| "Aldosterone antagonists represented by nonselective spironolactone and mineralocorticoid-selective eplerenone are approved for treatment of symptomatic heart failure with reduced systolic function." | 8.87 | Aldosterone antagonists in heart failure. ( Guglin, M; Kristof-Kuteyeva, O; Novotorova, I; Pratap, P, 2011) |
| "(2) In RALES, low-dose spironolactone in addition to standard of care, produced a 30% improvement in survival in progressive heart failure, commonly assumed to reflect deleterious effects of aldosterone, with spironolactone competing with aldosterone for cardiac mineralocorticoid receptors." | 8.86 | Aldosterone, hypertension and heart failure: insights from clinical trials. ( Funder, JW, 2010) |
| " A newer agent, eplerenone, has been recently licensed for the treatment of heart failure and in the US also for hypertension." | 8.84 | Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. ( George, J; Struthers, AD, 2007) |
| "In patients with NYHA stage III or IV heart failure, addition of spironolactone to the treatment with conversion enzyme inhibitor, diuretic and/or digitalis leads to a reduction in morbidity and mortality, as demonstrated in the RALES study." | 8.82 | [Aldosterone and its antagonists in heart failure]. ( Badoual, T; Cachin, JC; Castaigne, A; Hittinger, L; Le Corvoisier, P; Lopes, ME; Merlet, P; Su, JB; Tabet, JY, 2003) |
| "In the Eplerenone Postacute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) the effects of selective aldosterone blockade with eplerenone on cardiovascular mortality and morbidity were studied in patients with reduced left ventricular function postacute myocardial infarction." | 8.82 | Selective aldosterone blockade with eplerenone in patients with congestive heart failure. ( Salam, AM, 2003) |
| " More recently, the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study has provided firm support for the use of eplerenone (Inspra, Pfizer) in heart failure following acute myocardial infarction in addition to neurohormonal blockade with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta-blockers." | 8.82 | Eplerenone in the treatment of chronic heart failure. ( Krum, H; Liew, D, 2004) |
| "To evaluate the pharmacology, pharmacokinetics, safety, and clinical use of eplerenone in heart failure (HF)." | 8.82 | Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. ( Barnes, BJ; Howard, PA, 2005) |
| "The familiar diuretic spironolactone has taken on new life as a treatment for left-sided congestive heart failure." | 8.81 | Spironolactone in left-sided heart failure: how does it fit in? ( Luttermoser, G; Margo, KL; Shaughnessy, AF, 2001) |
| " In contrast, when the Randomized Aldactone Evaluation Study (RALES) mortality trial was discontinued 18 months early, it was because of the prominent salutary effect of spironolactone, added to standard multidrug therapy consisting of an angiotensin converting enzyme (ACE) inhibitor and loop diuretic (with or without digoxin), in reducing the incidence of death and hospitalization in patients with severe congestive heart failure (CHF)." | 8.80 | Spironolactone in congestive heart failure. ( Soberman, JE; Weber, KT, 2000) |
| "To evaluate evidence supporting the use of spironolactone in managing congestive heart failure." | 8.80 | Spironolactone in the treatment of congestive heart failure. ( Lloyd, SJ; Mauro, VF, 2000) |
| "The mineralocorticoid receptor antagonists (MRAs) eplerenone and spironolactone are beneficial in heart failure with reduced ejection fraction (HFrEF), but have not been prospectively compared." | 8.31 | Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study. ( Denholt, CS; Fosbøl, E; Gustafsson, F; Kristensen, SL; Køber, L; Larsson, JE; Nielsen, OW; Raja, AA; Schou, M; Thune, JJ, 2023) |
| "Sacubitril/valsartan was approved by the Food and Drug Administration in 2015 to reduce the risk of cardiovascular death and hospitalization for heart failure (HHF) in patients with chronic heart failure with reduced ejection fraction defined as left ventricular ejection fraction (LVEF) ≤ 40%." | 8.12 | Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective. ( Clark, J; Gandotra, C; Liu, Q; Rose, M; Senatore, FF; Stockbridge, NL; Zhang, J, 2022) |
| "In the absence of previous direct comparative studies, we aimed to evaluate the effectiveness of spironolactone and eplerenone in patients with heart failure and reduced ejection fraction (HFrEF) in a real-world clinical setting." | 8.12 | Real world comparison of spironolactone and eplerenone in patients with heart failure. ( Almenar-Bonet, L; Barge-Caballero, E; Barge-Caballero, G; Bouzas-Mosquera, A; Couto-Mallón, D; Crespo-Leiro, MG; Muñiz, J; Paniagua-Martín, MJ; Pardo-Martínez, P; Prada-Delgado, Ó; Sagastagoitia-Fornie, M; Vázquez-Rodríguez, JM, 2022) |
| "The impact of the TOPCAT trial publication on spironolactone initiation and subsequent hospitalizations for hyperkalemia among patients with heart failure with preserved ejection fraction (HFpEF) has not been evaluated empirically." | 8.12 | Rates of Spironolactone Initiation and Subsequent Hyperkalemia Hospitalizations in Patients with Heart Failure with Preserved Ejection Fraction Following the TOPCAT trial: A Cohort Study of Medicare Beneficiaries. ( Desai, RJ; Solomon, SD; Vaduganathan, M, 2022) |
| "The aims of this study were to explore phenotypes of heart failure with preserved ejection fraction (HFpEF) and evaluate differential effects of spironolactone treatment." | 8.12 | Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment. ( Choy, M; Dong, Y; Fu, M; He, J; He, X; Liang, W; Liu, C, 2022) |
| "The HOMAGE (Heart 'OMics' in AGEing) trial showed that spironolactone decreased serum PICP concentrations and improved cardiac remodelling over 9 months in a population at risk of developing heart failure (HF)." | 8.12 | The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial. ( Bozec, E; Clark, AL; Cleland, JGF; Cosmi, F; Cuthbert, J; Diez, J; Edelmann, F; Ferreira, JP; Girerd, N; González, A; Hazebroek, M; Heymans, S; Huttin, O; Kevin, D; Kobayashi, M; Mariottoni, B; Pellicori, P; Petutschnigg, J; Pieske, B; Rossignol, P; Staessen, JA; Verdonschot, JAJ; Zannad, F, 2022) |
| "The treatment of heart failure with reduced ejection fraction HFrEF (< 40%) uses hygienic-dietary rules combined with beta-blockers, renin-angiotensin system blockers RASB (alone or in combination with Sacubitril) and spironolactone." | 8.12 | [Impact of Dapagliflozin on echocardiographic parameters in patients with heart failure and reduced ejection fraction: "About a monocentric series of 43 cases"]. ( Bachir, N; Boukabous, A; Terki, A; Zaoui, N, 2022) |
| "This study aimed to investigate the possible use of Procyanidin extracted from Crataegus azarolus in the treatment of induced heart failure in rats." | 8.12 | The Impact of Procyanidin Extracted from Crataegus azarolus on Rats with Induced Heart Failure. ( Dizaye, KF; Z Rashid, B, 2022) |
| "The aim: To evaluate the effect of single daily 25 mg of spironolactone on serum electrolytes and kidney function tests in patients with severe chronic left sided heart failure." | 8.02 | THE EFFECT OF SPIRONOLACTONE ON SERUM ELECTROLYTES AND RENAL FUNCTION TESTS IN PATIENTS WITH SEVERE CHRONIC HEART FAILURE. ( Abdulzahra, MS; Abdurasool Almedeny, S; Hadi, NR; Yasir Al-Mayah, J, 2021) |
| " Spironolactone is an aldosterone antagonist used for managing chronic heart failure (HF) with known antiandrogenic effects." | 8.02 | Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure: A Pharmacoepidemiological study. ( Feldman, RD; Hiebert, BM; Janzen, BW; Kim, JO; Ong, AD; Sanjanwala, RM, 2021) |
| "To explore the short-term effect of high-dose spironolactone (80 mg/d) on chronic congestive heart failure (CHF)." | 8.02 | A retrospective study on the short-term effect of high-dose spironolactone (80 mg/d) on chronic congestive heart failure. ( Jiming, L; Tao, P; Zhitao, T, 2021) |
| "The TOPCAT trial showed no benefit for spironolactone in heart failure patients with preserved ejection fraction (HFpEF)." | 8.02 | A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction. ( Alenghat, FJ; Belkin, MN; Blair, JE; Shah, SJ, 2021) |
| "Spironolactone has been shown to improve outcomes in patients with heart failure (HF) with reduced ejection fraction (EF)." | 7.96 | Spironolactone use is associated with improved outcomes in heart failure with mid-range ejection fraction. ( Enzan, N; Higo, T; Ide, T; Kaku, H; Matsushima, S; Tsuchihashi-Makaya, M; Tsutsui, H, 2020) |
| "The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats." | 7.96 | Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. ( Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020) |
| "It is unclear whether spironolactone reduced heart failure (HF) hospitalizations in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial through potential diuretic or other effects." | 7.96 | Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis. ( Butler, J; Fang, JC; Kalogeropoulos, AP; Thankachen, J, 2020) |
| " We investigated the association of clinical variables and cardiovascular drugs, including furosemide, hydrochlorothiazide, spironolactone, and their doses, with the presence of hyponatremia at admission." | 7.96 | Furosemide and spironolactone doses and hyponatremia in patients with heart failure. ( Bušić, Ž; Čulić, V; Jurić Paić, M; Velat, I, 2020) |
| "This study will investigate the efficacy and safety of spironolactone for the treatment of acute heart failure (AHF)." | 7.96 | Efficacy and safety of spironolactone for the treatment of patients with acute heart failure: A protocol for systematic review. ( Feng, YL; Lu, M, 2020) |
| "To quantify the risk of hyperkalemia and acute kidney injury (AKI) when spironolactone use is added on to loop diuretic use among patients with heart failure, and to evaluate whether the risk is modified by level of kidney function." | 7.96 | Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure. ( Alexander, GC; Chang, AR; Coresh, J; Grams, ME; Inker, LA; Qiao, Y; Secora, AM; Shin, JI, 2020) |
| "The treatment effects of spironolactone on heart failure with reduced (HFrEF LVEF <40%) and preserved (HFpEF LVEF ≥50%) ejection fraction are well characterized." | 7.91 | Outcomes of spironolactone treatment in patients in Northeast China suffering from heart failure with mid-range ejection fraction. ( Chen, X; Hu, J; Hu, WY; Sun, Y; Xin, YG; Zhao, YN, 2019) |
| "Differences in the clinical impacts of the aldosterone receptor antagonists spironolactone and eplerenone in patients with heart failure (HF) are unclear." | 7.91 | Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure. ( Aonuma, K; Baba, M; Hamada-Harimura, Y; Higuchi, H; Ishizu, T; Machino-Ohtsuka, T; Nakatsukasa, T; Nishi, I; Obara, K; Sai, S; Seo, Y; Sugano, A; Yamamoto, M, 2019) |
| "Of the 8206 patients with heart failure and ejection fraction ≤35% without prior spironolactone use in the Medicare-linked OPTIMIZE-HF registry, 6986 were eligible for spironolactone therapy based on serum creatinine criteria (men ≤2." | 7.91 | Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction. ( Ahmed, A; Bayoumi, E; Dooley, DJ; Faselis, C; Fonarow, GC; Lam, PH; Mohammed, SF; Morgan, CJ; Palant, CE; Patel, S; Pitt, B; Sheriff, HM; Singh, S, 2019) |
| "BACKGROUND In the setting of acute decompensated heart failure (ADHF), tolvaptan, a selective V₂ receptor antagonist, did not alter plasma renin activity or angiotensin II level, but significantly increased plasma aldosterone by the activation of V₁ₐ receptor, suggesting that a high-dose mineralocorticoid receptor antagonist (MRA) combined with a V₂ receptor antagonist might be of interest, especially in ADHF patients." | 7.91 | Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report. ( Kajimoto, K; Otsubo, S, 2019) |
| "Certain patients with heart failure (HF) are unable to tolerate spironolactone therapy due to hyperkalemia." | 7.88 | Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. ( Bounthavong, M; Butler, J; Dolan, CM; Dunn, JD; Fisher, KA; Hauptman, PJ; Oestreicher, N; Pitt, B; Veenstra, DL, 2018) |
| " We evaluated whether spironolactone reduced albuminuria at the 1-year visit in a subpopulation (N=744)." | 7.88 | Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. ( Anand, I; Claggett, B; Desai, AS; Fang, JC; Lewis, EF; O'Meara, E; Pfeffer, MA; Pitt, B; Rouleau, JL; Selvaraj, S; Shah, SJ; Solomon, SD; Sweitzer, NK, 2018) |
| "The TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) trial randomized patients with HFpEF and either prior hospitalization for HF or elevated natriuretic peptide levels (B-type NP [BNP] ≥100 pg/ml or N-terminal proBNP ≥360 pg/ml) to spironolactone or placebo." | 7.85 | Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. ( Anand, IS; Claggett, B; Desai, AS; Fleg, JL; Liu, J; O'Meara, E; Pfeffer, MA; Pitt, B; Rector, TS; Shah, AM; Shah, SJ; Solomon, SD, 2017) |
| "The objective of this study was to determine the cost-effectiveness of eplerenone compared with usual care in patients with chronic heart failure and New York Heart Association (NYHA) Class II symptoms." | 7.83 | Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective. ( Ademi, Z; Liew, D; Pasupathi, K, 2016) |
| "Risk of hyperkalemia in heart failure patients was significantly associated with spironolactone use (odds ratio (OR) (95% confidence interval (CI)) = 13." | 7.81 | Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort. ( Abbas, S; Harder, S; Ihle, P; Schubert, I, 2015) |
| "We investigated the relationship between spironolactone use and all-cause mortality in acute decompensated heart failure (ADHF) patients with severe renal dysfunction." | 7.81 | Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: Data from the Korean Heart Failure Registry. ( Chae, SC; Cho, MC; Choi, DJ; Han, S; Hong, N; Jeon, ES; Kang, SM; Kim, JJ; Lee, MM; Oh, BH; Oh, J; Ryu, KH; Song, MK; Yoo, BS; Youn, JC, 2015) |
| "Early spironolactone treatment decreases heart failure development frequency by improving myocardial systolic and diastolic function and attenuating hypertrophy and fibrosis in spontaneously hypertensive rats." | 7.81 | Early Spironolactone Treatment Attenuates Heart Failure Development by Improving Myocardial Function and Reducing Fibrosis in Spontaneously Hypertensive Rats. ( Blotta, DA; Bonomo, C; Campos, DH; Cezar, MD; Cicogna, AC; Damatto, RL; Gomes, MJ; Lima, AR; Martinez, PF; Okoshi, K; Okoshi, MP; Oliveira, SA; Pagan, LU; Rosa, CM, 2015) |
| "Dogs subjected to RVP for 8 weeks in the absence or presence of eplerenone treatment during the final 4 weeks of pacing were assessed by echocardiography, electrophysiology study,ventricular fibrosis measurements, and inflammatory cytokine mRNA expression analysis." | 7.80 | Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure. ( , 2014) |
| " This study's aim was to determine whether chronic spironolactone treatment prevents formation of local electrical activation delays in the cardiomyopathic ventricle by attenuating inflammatory pathways and myocardial fibrosis." | 7.79 | Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation. ( Esposito, CT; Jeyaraj, D; Lu, Y; Stambler, BS; Varahan, S, 2013) |
| "It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors." | 7.79 | [Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors]. ( Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA, 2013) |
| "Two-month-old SHHF rats were randomized to receive no treatment (SHHF group), a standard heart failure therapy (quinapril-torasemide-carvedilol; ST-SHHF group), or the combination of eplerenone and standard heart failure therapy (Eple+ST-SHHF group) for 20 months." | 7.79 | Eplerenone enhances cardioprotective effects of standard heart failure therapy through matricellular proteins in hypertensive heart failure. ( Aragoncillo, P; Caro-Vadillo, A; Casanueva-Eliceiry, S; Egido, J; Fernández-Cruz, A; Gómez-Garre, D; Muñoz-Pacheco, P; Ortega-Hernández, A, 2013) |
| " Spironolactone is well known to have an anti-aldosteronergic effect, and this agent could improve cardiac sympathetic nerve activity (CSNA) in patients with chronic heart failure (CHF)." | 7.79 | Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure. ( Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Matsumoto, N; Minami, K; Sato, Y; Sumino, H; Takayama, Y; Toyama, T, 2013) |
| "We prospectively studied 18 852 patients (age 71±12 years; 28% women) with NYHA I-IV and ejection fraction <40% who were registered in the Swedish Heart Failure Registry between 2000 and 2012 and who were (n=6551) or were not (n=12 301) treated with spironolactone." | 7.79 | Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study. ( Dahlström, U; Edner, M; Hallberg, P; Lund, LH; Melhus, H; Svennblad, B, 2013) |
| " The study aimed to evaluate a potential influence of eplerenone treatment on the total number of EPCs in patients with chronic heart failure." | 7.78 | Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure. ( Barz, D; Betge, S; Ferrari, M; Figulla, HR; Florvaag, A; Franz, M; Fritzenwanger, M; Goebel, B; Jung, C; Kretschmar, D; Kuethe, F; Oberle, V, 2012) |
| "To investigate whether exposure to spironolactone treatment affects the risk of incident breast cancer in women over 55 years of age." | 7.78 | Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. ( Macdonald, TM; Mackenzie, IS; Morant, S; Thompson, A; Wei, L, 2012) |
| "Risk of morbidity and mortality in patients with severe heart failure (HF) is reduced by blockade of aldosterone receptors with spironolactone." | 7.77 | Use, tolerability and compliance of spironolactone in the treatment of heart failure. ( Beauchemin, C; Lachaine, J; Ramos, E, 2011) |
| "The widespread use of spironolactone in patients with congestive heart failure (CHF) has resulted in side effects and complications." | 7.77 | Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic. ( Caspi, A; Goland, S; Korbut, Z; Malnick, S; Naugolny, V; Rozen, I, 2011) |
| "The purpose of this study was to determine whether a diuretic effect may be detectable in patients treated with eplerenone, a mineralocorticoid receptor antagonist, as compared with placebo during the first month of EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival study) (n = 6,080) and whether this was associated with eplerenone's beneficial effects on cardiovascular outcomes." | 7.77 | Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival St ( Fay, R; Gustafsson, F; Ménard, J; Pitt, B; Rossignol, P; Zannad, F, 2011) |
| "To identify patient-specific factors associated with spironolactone-induced potassium level elevation in patients with heart failure." | 7.76 | Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure. ( Cavallari, LH; Dai, Y; Groo, VL; Patel, SR; Stamos, TD; Viana, MA, 2010) |
| "The EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure and Survival Study) showed that the use of aldosterone blockade with eplerenone decreased mortality in patients with heart failure after acute myocardial infarction, and a subsequent analysis showed eplerenone to be highly cost effective in this population." | 7.76 | Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS. ( Caro, J; Kolm, P; Mahoney, EM; Spertus, J; Weintraub, WS; Willke, R; Zhang, Z, 2010) |
| "The purpose of this study was to determine whether spironolactone use is associated with fractures in men with congestive heart failure (CHF)." | 7.74 | Fracture risk in men with congestive heart failure risk reduction with spironolactone. ( Ahmad, K; Bush, AJ; Carbone, LD; Chishti, WA; Cho, T; Cross, JD; Dhawan, S; Dishmon, DA; Gupta, M; Hajjar, MA; Haskin, AR; Khan, BQ; Khan, M; Khouzam, RN; Nasser, W; Nesheiwat, JP; Raza, SH; Sepanski, RJ; Weber, KT; Womack, CR, 2008) |
| "The incidence of hyperkalemia related to spironolactone use is low in stable heart failure; however, it has not been studied during decompensation." | 7.74 | Hyperkalemia during spironolactone use in patients with decompensated heart failure. ( Barretto, AC; Cardoso, JN; Lima, MV; Morgado, PC; Munhoz, RT; Ochiai, ME, 2008) |
| "To investigate if treatment with an aldosterone antagonist affects the outcomes of treatment by fixed dose combination of isosorbide dinitrate/hydralazine (FDC I/H) or placebo in black heart failure (HF) patients treated with contemporary HF medications." | 7.74 | Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial. ( Cohn, JN; Ghali, JK; Lindenfeld, J; Sabolinski, ML; Tam, SW; Taylor, AL; Worcel, M, 2008) |
| "Since the Randomized Aldactone Evaluation Study (RALES), the use of spironolactone is recommended in systolic heart failure (HF) patients that have been in New York Heart Association (NYHA) class III or IV." | 7.74 | Safety of spironolactone use in ambulatory heart failure patients. ( Azevedo, A; Bettencourt, P; Lopes, RJ; Lourenço, AP; Mascarenhas, J, 2008) |
| "Spironolactone use for heart failure (HF) has increased dramatically after the publication of the Randomized Aldactone Evaluation Study trial; yet, few studies have examined its real-world impact." | 7.74 | The effect of spironolactone use on heart failure mortality: a population-based study. ( Cox, JL; Hassan, A; Howlett, J; Johnstone, DE; Ouzounian, M, 2007) |
| "The Epleronone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial demonstrated that selective aldosterone blockade with eplerenone significantly reduced total mortality by 15%, combined cardiovascular (CV) mortality/CV hospitalization by 13%, CV mortality by 17% and sudden cardiac death by 21%, vs." | 7.74 | Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. ( Abuissa, H; O'Keefe, JH; Pitt, B, 2008) |
| "Spironolactone contributes to AF prevention in congestive heart failure dogs induced by chronic rapid ventricular pacing, which is related to atrial fibrosis reduction and independent of hemadynamics." | 7.74 | Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. ( Cao, Y; Dong, G; Han, W; Huo, H; Li, WM; Wang, BC; Wei, N; Xiu, CH; Yang, SS; Zhou, G; Zhou, HY, 2008) |
| "Concerns have been raised about the appropriateness of spironolactone use in some patients with heart failure." | 7.73 | Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. ( Foody, JM; Gross, CP; Havranek, EP; Krumholz, HM; Masoudi, FA; Rathore, SS; Wang, Y, 2005) |
| "After the Randomized Aldactone Evaluation Study (RALES) demonstrated a 30% mortality benefit for treating severe heart failure patients with spironolactone, acceptance of this drug was overwhelming." | 7.73 | The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. ( Gottlieb, SS; Rao, K; Sawyer, R; Shah, KB, 2005) |
| "Atrial fibrosis caused by chronic CHF is reduced by spironolactone." | 7.73 | Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. ( Beaufils, P; Deangelis, N; Delcayre, C; Hatem, SN; Leenhardt, A; Milliez, P; Robidel, E; Rucker-Martin, C; Vicaut, E, 2005) |
| " However, especially in chronic heart failure (CHF) patients plasma angiotensin II and aldosterone levels can be elevated despite ACE inhibition, the so-called ACE escape." | 7.73 | Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. ( Boomsma, F; Lok, DJ; Plokker, HW; van de Wal, RM; van der Horst, FA; van Gilst, WH; van Veldhuisen, DJ; Voors, AA, 2006) |
| "The effect of spironolactone on clinical outcomes in patients with mild heart failure is unclear." | 7.73 | Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis. ( Baliga, RR; Koelling, TM; Pitt, B; Ranganna, P, 2006) |
| " Since chronic inhibition of nitric oxide (NO) synthase with N(omega)-nitro-L-arginine methyl ester (L-NAME) induces systemic hypertension associated with cardiovascular inflammation and remodeling, we examined the potential role of aldosterone in this process using eplerenone, a selective aldosterone receptor antagonist." | 7.73 | The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats. ( Asano, Y; Fujita, M; Hirata, A; Hori, M; Kitakaze, M; Minamino, T; Okada, K; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H; Tsukamoto, O; Yamasaki, S; Yulin, L, 2006) |
| "To retrospectively investigate the effect of carvedilol and spironolactone plus furosemide, administered concomitantly with an angiotensin II converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB) to patients with chronic heart failure (CHF)." | 7.73 | Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil. ( Hirooka, K; Nakayama, D; Saito, M; Takada, M; Yasumura, Y, 2006) |
| "In patients with severe left ventricular dysfunction (EF < 30%) after acute myocardial infarction long-term treatment with spironolactone at daily dose 25-50 mg does not reduce mortality rate in long-term follow-up." | 7.73 | [Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial infarction]. ( Chizyński, K; Goch, JH; Maciejewski, M; Ptaszyński, P; Ruta, J, 2006) |
| "To evaluate the transcardiac extraction of aldosterone before and after spironolactone administration to patients with congestive heart failure, we measured the plasma aldosterone in the aortic root and the coronary sinus in eight congestive heart failure patients with dilated cardiomyopathy." | 7.72 | Transcardiac gradient of aldosterone before and after spironolactone in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Ishii, C; Maeda, K; Matsumoto, T; Ohnishi, M; Takayama, T; Tsutamoto, T; Tsutsui, T; Wada, A; Yamamoto, T, 2003) |
| "The effects of low-dose oral spironolactone (SPIRO) in a rat model of hypertensive heart failure (spontaneously hypertensive heart failure rat) were compared with its effects when combined with captopril (CAP)." | 7.72 | Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. ( Bauer, JA; Ghosh, S; Holycross, BJ; Kambara, A; Kwiatkowski, P; McCune, SA; Schanbacher, B; Wung, P, 2003) |
| "To investigate the effects of adding the selective aldosterone receptor antagonist eplerenone to ACE inhibition on endothelium-dependent vasodilation in rats with chronic heart failure (CHF)." | 7.72 | Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. ( Bauersachs, J; Ertl, G; Fraccarollo, D; Hildemann, SK; Schäfer, A; Tas, P, 2003) |
| "Spironolactone is increasingly being used in the treatment of heart failure." | 7.72 | The safety of spironolactone treatment in patients with heart failure. ( Anton, C; Cox, AR; Ferner, RE; Watson, RD, 2003) |
| "Recent studies have shown a fall in global mortality with minimal side effects in severe congestive heart failure (CHF) patients receiving angiotensin-converting enzyme inhibitors (ACEI) plus spironolactone (SLN)." | 7.72 | Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. ( Cruz, AA; Cruz, CS; Marcílio de Souza, CA, 2003) |
| " In patients with severe left ventricular dysfunction spironolactone could reduce death and hospitalisation." | 7.72 | [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement]. ( Kolloch, R; Offers, E, 2003) |
| "The addition of spironolactone, an aldosterone antagonist, to standard therapy can reduce the risk of both morbidity and mortality in patients with severe heart failure." | 7.72 | Spironolactone use in patients with heart failure. ( Alexander, SL; DiVall, MV; Gonyeau, MJ; Trujillo, JM, 2004) |
| "To determine whether the effects of spironolactone on potassium homeostasis vary by race by comparing serum potassium concentrations and potassium supplement use in African-American and Caucasian patients receiving spironolactone for heart failure." | 7.72 | Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure. ( Beitelshees, AL; Cavallari, LH; Dunlap, SH; Fashingbauer, LA; Groo, VL; Southworth, MR; Viana, MA; Williams, RE, 2004) |
| "Treatment with spironolactone (SPL) is beneficial in patients with severe congestive heart failure (CHF)." | 7.72 | How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? ( Atar, D; Galatius, S; Gustafsson, F; Hildebrandt, PR; Svensson, M, 2004) |
| "To assess how well heart failure patients tolerate spironolactone in routine clinical practice." | 7.72 | Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message. ( Gillespie, ND; Struthers, AD; Witham, MD, 2004) |
| "A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%)." | 7.72 | Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. ( Aaronson, KD; Koelling, TM; Tamirisa, KP, 2004) |
| "This analysis was carried out by assessing all the direct benefits and costs, derived from the association of either spironolactone or placebo with the standard therapy for heart failure in patients with functional degree III and IV." | 7.71 | [Cost-benefit analysis of spironolactone use in the treatment of chronic heart failure]. ( Alvarez, JS; Vílchez, FG, 2001) |
| "In patients with chronic heart failure, spironolactone added to conventional treatment may lead to serious and, occasionally, fatal hyperkalaemia." | 7.71 | Serious adverse events experienced by patients with chronic heart failure taking spironolactone. ( Berry, C; McMurray, JJ, 2001) |
| "We sought to investigate the effects of adding spironolactone (SP) to angiotensin-converting enzyme (ACE) inhibition on endothelium-dependent vasodilation in rats with chronic heart failure (CHF)." | 7.71 | Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. ( Bauersachs, J; Christ, M; Ertl, G; Fraccarollo, D; Heck, M; Hildemann, SK; Wehling, M, 2002) |
| "We compared the rate of prescription of low-dose spironolactone among patients with heart failure in a general medical inpatient setting and in a specialist left ventricular (LV) dysfunction clinic." | 7.71 | Spironolactone prescribing in heart failure: comparison between general medical patients and those attending a specialist left ventricular dysfunction clinic. ( McMullan, R; Silke, B, 2001) |
| "Current guidelines recommend drugs which reduce neurohormonal activation as standard therapy for heart failure: angiotensin converting-enzyme (ACE) inhibitors, beta-blockers and spironolactone." | 7.71 | [Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study]. ( Piérard, L, 2002) |
| "Serum potassium concentration should be measured immediately before operation to detect hyperkalemia in heart failure patients treated with spironolactone." | 7.71 | Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency. ( Carpenter, JP; Cheung, AT; Hu, Y, 2002) |
| "Short- and long-term clinical effects of the angiotensin-converting enzyme (ACE) inhibitor captopril in severe congestive heart failure (CHF) were evaluated during a 3-year open study of 124 inpatients with New York Heart Association (NYHA) functional class III or IV CHF refractory to treatment with cardiac glycosides and high doses of loop diuretics." | 7.68 | Captopril and spironolactone therapy for refractory congestive heart failure. ( Dahlström, U; Karlsson, E, 1993) |
| "In patients with congestive heart failure (CHF), the role of aldosterone in the abnormal sodium (Na+) retention and the determinants of plasma aldosterone (PA) including plasma atrial natriuretic factor (hANF), plasma renin activity (PRA), and plasma potassium (K+) have not been fully elucidated." | 7.68 | Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. ( Abraham, WT; Dürr, JA; Hensen, J; Schrier, RW, 1991) |
| "Although many new drugs useful in the treatment of congestive heart failure have been introduced during the past 25 years, spironolactone continues to have an important role in the management of this condition." | 7.68 | Spironolactone in the management of congestive heart failure. ( Muller, JE, 1990) |
| "Twenty-three optimally digitalized patients with congestive heart failure completed a 4-week treatment period with a fixed-drug association of 20 mg furosemide plus 50 mg spironolactone." | 7.67 | A fixed-dose combination of furosemide and spironolactone in digitalized congestive heart failure patients. ( Collia, LF; Ledesma, GA; Tutera, A; Yasky, J, 1986) |
| "Seventeen non-digitalized congestive heart failure patients were treated with only the fixed-dose combinations of 20 mg furosemide and 50 mg spironolactone or 20 mg furosemide and 100 mg spironolactone, in a daily dose of 1 or 2 capsules, over a 4-week period." | 7.67 | The treatment of non-digitalized congestive heart failure patients with a fixed-dose combination of furosemide and spironolactone. ( Collia, LF; Ledesma, GA; Tutera, A; Yasky, J, 1986) |
| " This report describes 74 patients who had severe congestive heart failure treated with a combination of furosemide and spironolactone in whom this complication developed." | 7.66 | Treatment of refractory congestive heart failure and normokalemic hypochloremic alkalosis with acetazolamide and spironolactone. ( Khan, MI, 1980) |
| "The therapeutic efficacy of 100 mg spironolactone once daily in patients with congestive heart failure was evaluated in a multi-centre study in general practice." | 7.66 | Spironolactone in the long-term management of patients with congestive heart failure. ( Smith, AG, 1980) |
| "The elimination half-life (T1/2) of canrenone, the principal unconjugated metabolite of spironolactone, was 59 h (range 32-105 h) in 5 patients with chronic liver disease and 37 h (range 19-48 h ) in 7 patients withcongestive heart failure." | 7.65 | Elimination of canrenone in congestive heart failure and chronic liver disease. ( Branch, R; Jackson, L; Levine, D; Ramsay, L, 1977) |
| "The renin-angiotensin-aldosterone system and electrolyte levels in 11 patients with heart failure controlled on digoxin and frusemide were investigated after separate periods of Slow K, spironolactone, and amiloride therapy." | 7.65 | Effect of potassium-sparing diuretics on the renin-angiotensin-aldosterone system and potassium retention in heart failure. ( Espiner, EA; Hughes, H; Nicholls, MG; Rogers, T, 1976) |
| "Metabolic balance studies were carried out on five patients with resistant heart failure treated with spironolactone and other diuretics." | 7.64 | Metabolic studies on patients with resistant heart failure treated by spironolactone. ( BAYLEY, TA; FORBATH, PG; HIGGINS, HP; WILSON, JK, 1962) |
| "Spironolactone was evaluated as a diuretic in the therapy of six patients with chronic severe congestive heart failure, during which metabolic balance studies were performed." | 7.64 | EFFECT OF AN ALDOSTERONE ANTAGONIST (SPIRONOLACTONE) ON PATIENTS WITH SEVERE CONGESTIVE HEART FAILURE. ( CARRUTHERS, BM; LEDRAY, RD; MCINTOSH, HW; SERAGLIA, M; WALSH, GC, 1963) |
| "Triamterene therapy was evaluated in 35 patients with congestive heart failure over a period of two and one-half years." | 7.64 | CLINICAL EXPERIENCE WITH A NEW DIURETIC, TRIAMTERENE, IN CONJESTIVE HEART FAILURE. ( LAUFER, ST; MAHABIR, RN, 1964) |
| "Spironolactone therapy was triggered by the detection of subclinical LVD (global longitudinal strain [GLS] ≤16%) or diastolic abnormalities (at least one of E/e' >15, E/e' >10 with left atrial enlargement [LAE] or impaired relaxation [E/A < 0." | 7.11 | Screening-guided spironolactone treatment of subclinical left ventricular dysfunction for heart failure prevention in at-risk patients. ( Harris, J; Marwick, TH; Potter, E; Stephenson, G; Wright, L, 2022) |
| "Obesity is common in heart failure with preserved ejection fraction (HFpEF)." | 7.01 | Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction. ( Butler, J; Elkholey, K; Papadimitriou, L; Stavrakis, S; Thadani, U, 2021) |
| " Cardiac endpoint was defined as cardiac death or euthanasia, recurrence of pulmonary edema, necessity for nonauthorized cardiac drug(s) or a furosemide dosage >8 mg/kg/d." | 7.01 | Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST). ( Atkins, CE; Blondel, T; Coffman, M; Feng, S; Garelli-Paar, C; Guillot, E; Heartsill, S, 2021) |
| " Mineralocorticoid receptor antagonists administered at high doses may relieve congestion, overcome diuretic resistance, and mitigate the effects of adverse neurohormonal activation in AHF." | 6.84 | Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. ( Anstrom, KJ; Braunwald, E; Butler, J; Desvigne-Nickens, P; Felker, GM; Givertz, MM; Hernandez, AF; Kalogeropoulos, AP; Konstam, MA; Mann, DL; Margulies, KB; McNulty, SE; Mentz, RJ; Redfield, MM; Shah, M; Tang, WHW; Whellan, DJ, 2017) |
| "Spironolactone was well tolerated when combined with conventional heart failure treatment." | 6.76 | Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs. ( Clercx, C; McEntee, K; Schuller, S; Van Israël, N; Vanbelle, S, 2011) |
| "Eplerenone was associated with a 1." | 6.74 | The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. ( Blair, JE; Gheorghiade, M; Harinstein, ME; Khan, S; Krum, H; Mukherjee, R; Pitt, B, 2009) |
| "Thiamine levels were determined using the erythrocyte transketolase activity." | 6.73 | Influence of spironolactone therapy on thiamine blood levels in patients with heart failure. ( Albanesi Filho, FM; de Albuquerque, DC; Rocha, RM; Silva, GV; Tura, BR, 2008) |
| "Ventricular arrhythmia was recognized as the most common cause of death in this population." | 6.69 | Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. ( Coelho, O; Gruppi, CJ; Mady, C; Mansur, A; Maranhão, M; Ramires, FJ; Ramires, JA, 2000) |
| "Ventricular arrhythmias detected on 24 hour Holter monitoring didn't differ between the study groups." | 6.69 | [Comparison of the therapeutic efficacy of spironolactone and furosemide in patients with severe congestive heart failure]. ( Bednarz, B; Chamiec, T; Cybulski, J, 2000) |
| " The dosage of both drugs was individually adjusted in time according to the results of serum potassium and renal function." | 6.67 | Combined therapy of captopril and spironolactone for refractory congestive heart failure. ( Han, YL; Hu, XL; Jing, QM; Liu, JQ; Tong, M, 1994) |
| " Studies investigating the optimal spironolactone dosage in such a setting recommend starting with a low dose and careful uptitration." | 6.52 | Heart failure and chronic kidney disease: should we use spironolactone? ( Agrawal, N; Agrawal, S; Garg, J; Gupta, T; Mohandas, R; Segal, M, 2015) |
| "Six prospective trials demonstrated that spironolactone use was safe in ESRD patients on hemodialysis." | 6.46 | Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe? ( Chua, D; Lo, A; Lo, C, 2010) |
| "Aldosterone is an important mediator in the pathogenesis of heart failure, and increased plasma aldosterone levels are associated with a poor prognosis." | 6.44 | Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues. ( Francis, GS; Kalidindi, SR; Tang, WH, 2007) |
| "Eplerenone (Inspra) is a selective aldosterone blocker." | 6.43 | Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure. ( Croom, KF; Plosker, GL, 2005) |
| "Two large trials in heart failure have clearly demonstrated that blocking aldosterone improves mortality and that this benefit occurs over and above standard therapy with angiotensin-converting enzyme (ACE) inhibitors." | 6.43 | Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure. ( Pringle, S; Shah, NC; Struthers, A, 2006) |
| "Aldosterone is an important and independent target for therapeutic intervention in hypertension and hypertension-related diseases." | 6.42 | Aldosterone receptor antagonists for hypertension: what do they offer? ( Krum, H; Liew, D, 2003) |
| "Aldosterone has a variety of detrimental effects on the heart and vasculature and is increasingly recognized as an important target in chronic heart failure, as illustrated by the Randomized Aldactone Evaluation Study." | 6.42 | The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. ( Davies, JI; Dawson, A; Struthers, AD, 2004) |
| "Aldosterone also promotes myocardial fibrosis and cardiac remodelling by enhancing collagen synthesis, resulting in increased myocardial stiffness and increased left ventricular mass." | 6.42 | The clinical implications of aldosterone escape in congestive heart failure. ( Struthers, AD, 2004) |
| "Eplerenone (Inspra) is a selective aldosterone blocker." | 6.42 | Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction. ( Keating, GM; Plosker, GL, 2004) |
| "The renal sodium retention in congestive heart failure is a consequence of the activation of the sympathetic nervous system and of the renin-angiotensin-aldosterone system." | 6.41 | [Diuretic therapy in congestive heart failure--new views on spironolactone therapy]. ( Haller, C, 2000) |
| "This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure." | 6.41 | Aldosterone and myocardial fibrosis in heart failure. ( Brilla, CG, 2000) |
| " New interest in therapy with aldosterone antagonists was stimulated by results of a 2-year study of 1663 patients with heart failure that showed a 30% relative risk reduction of death among patients given a subhemodynamic dosage of spironolactone, a nonselective aldosterone antagonist, compared with placebo, in addition to standard therapy of diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, and digitalis." | 6.41 | Aldosterone, a new appreciation of its role in heart failure. ( Cha, AJ; Judge, KW; Malecha, SE, 2000) |
| "Aldosterone has been identified as a critically important neurohormone with direct detrimental effects on the myocardium." | 6.41 | Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure. ( Miller, AB; Srivastava, P, 2001) |
| "Aldosterone was shown to promote cardiac fibrosis in various experimental models." | 6.41 | Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. ( Alla, F; Dousset, B; Zannad, F, 2001) |
| "Mortality of patients with severe congestive heart failure (CHF) is still high despite combined treatment with angiotensin-converting enzyme (ACE) inhibitors, diuretics, and digitalis." | 6.40 | [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?]. ( Brilla, CG; Rupp, H; Scheer, C; Schencking, M, 1997) |
| "Aldosterone has been shown to have an acute arrhythmogenic effect as well as a potential detrimental effect on baroreflex function, a marker of prognosis in CHF." | 6.39 | Aldosterone escape during ACE inhibitor therapy in chronic heart failure. ( Struthers, AD, 1995) |
| "Eplerenone is a selective mineralocorticoid receptor antagonist." | 5.91 | Role of eplerenone in the threatment of cardiovascular diseases. ( Málek, F, 2023) |
| " spironolactone on left ventricular systolic function by measuring left ventricle ejection fraction (LVEF) in patients with chronic heart failure, especially their effect on preventing hospitalization, reducing mortality, and improving clinical status among patients with chronic HF." | 5.69 | The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF. ( Durak-Nalbantic, A; Karic, A; Naser, N; Sabanovic-Bajramovic, N, 2023) |
| "Eplerenone reduces the risk of cardiovascular death or first hospitalization for heart failure (HF) in patients with HF and a reduced ejection fraction (HFrEF), but it is still frequently underused in routine practice." | 5.69 | Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trial. ( Duarte, K; Ferreira, JP; Girerd, N; McMurray, JJV; Monzo, L; Pitt, B; Pocock, SJ; Swedberg, K; van Veldhuisen, DJ; Zannad, F, 2023) |
| "Spironolactone was initiated prior to admission (PTA) for 54." | 5.62 | Evaluation of the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease. ( Armbruster, AL; Buckallew, AR; Mbachu, G; Miller, W; Seltzer, JR; Tellor, KB; Watson, R; Whitlock, C, 2021) |
| " We aimed to identify the biomarker profile and biological meaning of biomarkers associated with obesity to assess the effect of spironolactone on the circulating biomarkers and to explore whether obesity might modify the effect of spironolactone." | 5.51 | The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial. ( Brunner La Rocca, HP; Clark, AL; Cleland, JGF; Cosmi, F; Cuthbert, J; Ferreira, JP; Girerd, N; Hazebroek, MR; Henkens, MHTM; Heymans, SRB; Mariottoni, B; Pellicori, P; Petutschnigg, J; Pizard, A; Rossignol, P; Verdonschot, JAJ; Waring, OJ; Zannad, F, 2022) |
| "Left ventricular ejection fraction (LVEF) can provide haemodynamic information and may influence the response to spironolactone and other heart failure (HF) therapies." | 5.51 | Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial. ( Bozec, E; Clark, AL; Cleland, JG; Collier, T; Cosmi, F; Cuthbert, J; Díez, J; Edelman, F; Ferreira, JP; Girerd, N; González, A; Hazebroek, M; Heymans, S; Mariottoni, B; Pellicori, P; Petutschnigg, J; Pieske, B; Rossignol, P; Staessen, JA; Verdonschot, JAJ; Zannad, F, 2022) |
| "The Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial (TOPCAT) randomized 3445 stable outpatients with chronic HF with a left ventricular ejection fraction of 45% or greater and either prior hospitalization for HF or elevated natriuretic peptides to treatment with spironolactone or placebo." | 5.51 | Prognostic Impact of Cardiovascular Versus Noncardiovascular Hospitalizations in Heart Failure With Preserved Ejection Fraction: Insights From TOPCAT. ( Barkoudah, E; Claggett, BL; Clausell, N; Desai, AS; Diaz, R; Fleg, JL; Lewis, EF; O'Meara, E; Pfeffer, MA; Pitt, B; Rouleau, JL; Solomon, SD, 2022) |
| "The TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) suggested clinical benefits of spironolactone treatment among patients with heart failure with preserved ejection fraction enrolled in the Americas." | 5.51 | Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction. ( Basso, M; Cappola, TP; Chirinos, JA; Cohen, JB; Diab, A; Doughty, RN; Ebert, C; Gogain, J; Gordon, DA; Javaheri, A; Kammerhoff, K; Kumar, A; Kvikstad, E; Mann, DL; Maranville, J; Qian, C; Ramirez-Valle, F; Richards, AM; Rietzschel, E; Schafer, P; Seiffert, DA; van Empel, V; Wang, Z; Zamani, P; Zhao, L, 2022) |
| "While median time to cardiac death in the spironolactone group was not statistically significantly different than that in the placebo group, adding spironolactone to conventional therapy resulted in reduced occurrence of AF." | 5.51 | Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy. ( Chambers, H; Fonfara, S; Laskary, A; O'Sullivan, ML, 2022) |
| "Acute congestive heart failure (ACHF) is a state of severe, secondary hyperaldosteronism." | 5.48 | Association Between High-Dose Spironolactone and Decongestion in Patients with Acute Heart Failure: An Observational Retrospective Study. ( Barbetseas, J; Bonou, M; Kapelios, CJ; Lund, LH; Mantzouratou, P; Tzanis, G; Vogiatzi, P, 2018) |
| "Spironolactone has been shown to reduce cardiovascular death in patients with mild-to-moderate chronic kidney disease (CKD), but its risks and benefits in advanced CKD remain unsettled." | 5.46 | Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study. ( Chen, YH; Hsu, CC; Hung, SC; Kuo, KL; Liu, JS; Tarng, DC; Tseng, WC, 2017) |
| "An enriched subset of patients with structural and functional echocardiographic features of cardiac amyloidosis had the worst prognosis in the TOPCAT study, but they benefitted similarly from spironolactone therapy." | 5.41 | Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT. ( Hanna, M; Jaber, WA; Shah, SJ; Sperry, BW; Spertus, JA, 2021) |
| "The mineralocorticoid receptor antagonist spironolactone has been shown to improve cardiac function and reverse left ventricular hypertrophy in heart failure patients, but there are no consistent findings on the efficacy and safety in hemodialysis patients." | 5.41 | Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients. ( Chen, Z; Li, Z; Liu, R; Lu, G; Sun, Y; Sun, Z, 2023) |
| "To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure." | 5.41 | The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. ( Ahmed, FZ; Brunner La Rocca, HP; Clark, AL; Cleland, JGF; Collier, TJ; Cosmi, F; Cuthbert, J; Diez, J; Edelmann, F; Ferreira, JP; Girerd, N; González, A; Grojean, S; Hazebroek, M; Heymans, S; Khan, J; Latini, R; Mamas, MA; Mariottoni, B; McDonald, K; Mujaj, B; Pellicori, P; Petutschnigg, J; Pieske, B; Pizard, A; Rossignol, P; Rouet, P; Staessen, JA; Verdonschot, JAJ; Zannad, F, 2021) |
| "Proteomic analyses suggest that spironolactone exerts pleiotropic effects including reduction in fibrosis, inflammation, thrombosis, congestion, and vascular function improvement, all of which may mediate cardiovascular protective effects, potentially slowing progression toward heart failure." | 5.41 | Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. ( Ahmed, FZ; Brunner-La-Rocca, HP; Clark, AL; Cleland, JGF; Collier, T; Cosmi, F; Cuthbert, J; Díez, J; Edelmann, F; Ferreira, JP; Girerd, N; González, A; Grojean, S; Hazebroek, M; Heymans, S; Khan, J; Latini, R; Mamas, MA; Mariottoni, B; Mujaj, B; Pellicori, P; Petutschnigg, J; Pieske, B; Pizard, A; Rossignol, P; Rouet, P; Staessen, JA; Verdonschot, J; Wang, P; Zannad, F, 2021) |
| "Treatment of heart failure with preserved ejection fraction (HFpEF) with spironolactone is associated with lower risk of heart failure hospitalization (HFH) but increased risk of worsening renal function (WRF)." | 5.41 | Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. ( Beldhuis, IE; Bristow, M; Claggett, B; Damman, K; Desai, AS; Fang, JC; Fleg, JL; Lewis, EF; McKinlay, S; Myhre, PL; O'Meara, E; Pfeffer, MA; Pitt, B; Shah, SJ; Solomon, SD; Vardeny, O; Voors, AA, 2021) |
| "Spironolactone was not associated with improved survival, neither in the complete sample (HR 0." | 5.39 | Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study. ( Agewall, S; Atar, D; de Blois, J; Frankenstein, L; Grundtvig, M; Hole, T; Katus, HA; Schellberg, D; Zugck, C, 2013) |
| " A maximal possible effect (E(max)) model was employed to determine the basic pharmacodynamic parameters of spironolactone, measured by high-performance liquid chromatography, in antagonizing the renal effects of aldosterone." | 5.36 | A preclinical pharmacokinetic and pharmacodynamic approach to determine a dose of spironolactone for treatment of congestive heart failure in dog. ( Elliott, J; Guyonnet, J; Kaltsatos, V, 2010) |
| " The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor." | 5.36 | Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone. ( Erden, I; Ozhan, H; Yalcin, S, 2010) |
| " The Heart OMics in AGing (HOMAGE) trial aims to investigate the effects of spironolactone on serum markers of collagen metabolism and on cardiovascular structure and function in people at risk of developing HF and potential interactions with a marker of fibrogenic activity, galectin-3." | 5.34 | Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HO ( Ahmed, FZ; Brunner-La Rocca, HP; Clark, AL; Cleland, JGF; Collier, T; Cosmi, F; Cuthbert, JJ; Ferreira, JP; Girerd, N; González, A; Heymans, S; Latini, R; Mariottoni, B; Mujaj, B; Pellicori, P; Petutschnigg, J; Rossignol, P; Staessen, JA; Verdonschot, J; Zannad, F, 2020) |
| "Spironolactone has been demonstrated to reduce heart failure (HF) hospitalization in patients with HF with preserved ejection fraction in the Americas region of the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial)." | 5.34 | Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study. ( Anand, IS; Claggett, BL; de Denus, S; Desai, AS; Jarolim, P; Myhre, PL; O'Meara, E; Pfeffer, MA; Pitt, B; Rouleau, JL; Solomon, SD; Vaduganathan, M, 2020) |
| "In Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure (ATHENA-HF), high-dose spironolactone (100 mg daily) did not improve efficacy endpoints over usual care [placebo or continued low-dose spironolactone (25 mg daily) in patients already receiving spironolactone] in the treatment of acute heart failure (HF)." | 5.34 | Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial. ( Butler, J; de Denus, S; Dubé, MP; Ferreira, JP; Givertz, MM; Jutras, M; Kalogeropoulos, AP; Leclair, G; Mentz, RJ; Oussaïd, E; Rouleau, J; St-Jean, I; Tang, WHW; Zada, YF, 2020) |
| "The authors pooled data from 3 trials-CHARM Preserved (Candesartan Cilexietil in Heart Failure Assessment of Reduction in Mortality and Morbidity), I-Preserve (Irbesartan in Heart Failure With Preserved Systolic Function), and the Americas region of TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) (N = 8,916)-and examined whether MI before or following enrollment independently predicted CV death and heart failure (HF) hospitalization." | 5.34 | Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. ( Anand, IS; Carson, P; Claggett, BL; Cunningham, JW; Desai, AS; Jhund, PS; John, JE; Kober, L; Lewis, EF; McMurray, JJV; Pfeffer, MA; Pitt, B; Shah, SJ; Solomon, SD; Swedberg, K; Vaduganathan, M; Yusuf, S; Zile, MR, 2020) |
| "The AMBER trial demonstrated that concomitant use of patiromer enabled the more persistent use of spironolactone by reducing the risk of hyperkalaemia in patients with resistant hypertension and advanced chronic kidney disease." | 5.34 | Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. ( Ackourey, G; Agarwal, R; Arthur, S; Mayo, MR; Rossignol, P; Warren, S; White, WB; Williams, B, 2020) |
| "Refractory congestive heart failure (CHF) with diuretic resistance is life-threatening and predicts a short life expectancy." | 5.34 | Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance. ( Ji, Z; Liu, C; Liu, G; Liu, K; Zhen, Y; Zhou, C, 2007) |
| "(8) Spironolactone remains the treatment of choice for patients with heart failure and incapacitating dyspnea despite ACE inhibitor and diuretic therapy." | 5.33 | Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too. ( , 2006) |
| "Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure." | 5.32 | Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003) |
| "Eplerenone is a novel selective aldosterone blocker." | 5.31 | Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. ( Goldstein, S; McMahon, EG; Mishima, T; Morita, H; Rudolph, AE; Sabbah, HN; Sharov, VG; Suzuki, G; Tanhehco, EJ; Todor, A, 2002) |
| "If spironolactone has beneficial effects on HRV, this would contribute to favorable results." | 5.31 | Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. ( Korkmaz, ME; Müderrisoğlu, H; Ozin, B; Uluçam, M, 2000) |
| "Aldosterone promotes collagen synthesis and structural remodeling of target organs such as the heart." | 5.31 | Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Horie, H; Kinoshita, M; Mabuchi, N; Maeda, K; Matsumoto, T; Ohnishi, M; Sawaki, M; Sugimoto, Y; Tsutamoto, T; Tsutsui, T; Wada, A, 2000) |
| "Spironolactone is an aldosterone antagonist which has been used as a mild potassium-sparing diuretic and in treatment of ascites in liver failure." | 5.31 | Spironolactone in heart failure--a revived role for an old drug. ( Bradley, C, 2000) |
| " These results should be weighed when considering spironolactone for older heart failure with preserved ejection fraction patients." | 5.30 | Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. ( Anand, IS; Beldhuis, I; Claggett, B; Desai, AS; Fang, JC; Lewis, EF; O'Meara, E; Pfeffer, MA; Pitt, B; Rouleau, J; Shah, SJ; Solomon, SD; Sweitzer, NK; Vaduganathan, M; Vardeny, O, 2019) |
| "For 1761 participants from North and South America enrolled in the multicenter, double-blinded Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist randomized clinical trial of spironolactone for patients with HFpEF between August 10, 2006, and January 31, 2012, the association of baseline β-blocker use with HF hospitalization and CVD mortality was analyzed using unadjusted and adjusted Cox proportional hazards regression models, overall and in strata of patients with an EF of 50% or greater or less than 50%." | 5.30 | Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial. ( Callas, PW; Dougherty, GB; Infeld, M; Juraschek, SP; Meyer, M; Plante, TB; Silverman, DN, 2019) |
| " We investigated changes in serum concentrations of the collagen synthesis biomarkers N-terminal propeptide of procollagen type III (PIIINP) (primary outcome) and C-terminal propeptide of procollagen type I (PICP) (secondary outcome) after non-randomised initiation of spironolactone as add-on therapy among patients with resistant hypertension enrolled in the 'Anglo-Scandinavian Cardiac Outcomes' trial (ASCOT)." | 5.30 | Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. ( Cleland, JG; Collier, T; Diez, J; Ferreira, JP; Girerd, N; Gonzalez, A; Huby, AC; López, B; Machu, JL; Pizard, A; Rossignol, P; Sattar, N; Sever, PS; Zannad, F, 2019) |
| "This study sought to investigate sex differences in outcomes and responses to spironolactone in patients with heart failure with preserved ejection fraction (HFpEF)." | 5.30 | Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. ( Kao, DP; Lindenfeld, J; Merrill, M; Sweitzer, NK, 2019) |
| "Acute heart failure (HF) patients with renal insufficiency and risk factors for diuretic resistance may be most likely to derive incremental improvement in congestion with the addition of spironolactone." | 5.30 | Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. ( Ambrosy, AP; Butler, J; Chakraborty, H; DeVore, AD; Felker, GM; Fudim, M; Giczewska, A; Greene, SJ; Hernandez, AF; Kalogeropoulos, AP; McNulty, SE; Mentz, RJ; Vaduganathan, M, 2019) |
| "Patients with severe congestive heart failure (New York Heart Association [NYHA] functional classes III-IV) often can tolerate only low doses of angiotensin-converting enzyme (ACE) inhibitors because pronounced hypotension caused by additional ACE inhibitor increments may decrease renal perfusion." | 5.29 | Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. ( Donker, AJ; Nauta, JJ; van Vliet, AA; Verheugt, FW, 1993) |
| "We identified patients with RHTN, defined as baseline systolic blood pressure (SBP) between 140 and 160 mm Hg on 3 or more medications, in the Americas cohort of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial, in which patients with HFpEF were randomized to spironolactone vs." | 5.27 | Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction. ( Claggett, BL; Liu, J; Pitt, B; Rossignol, P; Solomon, S; Vardeny, O; Zannad, F, 2018) |
| "This study suggests that spironolactone is well tolerated, and preliminary results support further investigation to evaluate the efficacy of spironolactone in the treatment of cats with cardiac failure due to cardiomyopathy." | 5.27 | The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy. ( Cobb, M; Garelli-Paar, C; Grassi, V; Guillot, E; Huxley, J; James, R, 2018) |
| " We investigated whether the effect of spironolactone on LVDD in patients with heart failure with preserved ejection fraction (HFpEF) depends on its effects on collagen cross-linking and/or deposition." | 5.27 | Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. ( Bach, D; Bachran, D; Delles, C; Díez, J; Dominiczak, AF; Edelmann, F; González, A; Hasenfuss, G; López, B; Pieske, B; Ravassa, S; Trippel, T; Wachter, R, 2018) |
| "This study assessed the relationship between atrial fibrillation (AF) and outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial, to evaluate whether AF modified the treatment response to spironolactone and whether spironolactone influenced post-randomization AF." | 5.27 | Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial. ( Anand, IS; Cikes, M; Claggett, B; Desai, AS; Fang, JC; Lewis, EF; O'Meara, E; Pfeffer, MA; Pitt, B; Rouleau, JL; Saksena, S; Shah, AM; Shah, SJ; Solomon, SD; Sweitzer, NK, 2018) |
| " The objective of this multicenter, randomized, controlled, double-blind trial was to compare the effects of spironolactone to those of the selective MRA eplerenone on glucose homeostasis among 62 HF patients with glucose intolerance or type II diabetes." | 5.27 | A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial. ( Bernier, M; Chaar, D; de Denus, S; Ducharme, A; Guertin, MC; Jutras, M; Korol, S; Lavoie, J; Leclair, G; Liszkowski, M; Mansour, A; Neagoe, PE; O'Meara, E; Racine, N; Rouleau, JL; Sirois, MG; Tournoux, F; White, M, 2018) |
| "Prudence is indicated in patients with congestive heart failure due to coronary artery disease." | 5.27 | A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure. ( Rutishauser, W, 1983) |
| "Three cases are described of severe congestive heart failure which failed to respond to digitalis, high doses of loop diuretics, and converting-enzyme inhibitors." | 5.27 | Combined spironolactone and converting-enzyme inhibitor therapy for refractory heart failure. ( Crozier, IG; Ikram, H; Lewis, GR; Nicholls, MG; Richards, AM; Webster, MW, 1986) |
| "To characterize eplerenone pharmacokinetics (PK) in Japanese chronic heart failure (CHF) patients and to estimate the impact of factors that may affect eplerenone PK, population pharmacokinetic (PPK) analysis was conducted." | 5.24 | Population Pharmacokinetics of Eplerenone in Japanese Patients With Chronic Heart Failure. ( Oishi, M; Sweeney, K; Tomono, Y; Zhao, Q, 2017) |
| "In a sub-study of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS trial), BNP and BigET-1 were measured at baseline and at 1month in 476 patients." | 5.24 | Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Ac ( Bramlage, P; Fay, R; Girerd, N; Ketelslegers, JM; Michel, JB; Olivier, A; Pitt, B; Rossignol, P; Vincent, J; Zannad, F, 2017) |
| " Steroidal mineralocorticoid receptor antagonists (MRAs - eplerenone and spironolactone) reduce mortality in patients with heart failure with reduced ejection fraction (HFrEF)." | 5.22 | Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective. ( Armani, A; Caprio, M; Infante, M; Marzolla, V; Rizzo, M, 2022) |
| "In short-term studies in patients with CKD and reduced ejection heart failure, with or without T2D, finerenone 20 mg appears to have a better renal outcome compared with spironolactone and a better mortality outcome compared with eplerenone, with significantly lesser hyperkalemia compared to both spironolactone and finerenone." | 5.22 | Finerenone in diabetic kidney disease: A systematic review and critical appraisal. ( Misra, A; Singh, A; Singh, AK; Singh, R, 2022) |
| "While mineralocorticoid receptor antagonists (MRAs) have been shown to benefit patients with reduced left ventricular ejection fraction (LVEF), spironolactone did not reduce the primary endpoint of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest in patients with heart failure with preserved ejection fraction (HFpEF) in the TOPCAT trial, which enrolled patients with LVEF of 45% or greater." | 5.22 | Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. ( Anand, I; Claggett, B; Desai, A; Fleg, JL; Lewis, EF; McKinlay, S; O'Meara, E; Pfeffer, MA; Pitt, B; Shah, SJ; Solomon, SD; Sopko, G; Sweitzer, NK, 2016) |
| "Patients ≥50 years of age, with symptomatic HF and left ventricular ejection fraction ≥45%, were enrolled in Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) and randomized to spironolactone or placebo." | 5.22 | Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. ( Assmann, SF; Claggett, B; Desai, AS; Fang, JC; Heitner, JF; Kenwood, CT; Kim, HY; Lewis, EF; McKinlay, SA; Pfeffer, MA; Pitt, BA; Solomon, SD; Spertus, J, 2016) |
| "The single-centre IMproved exercise tolerance In heart failure With PReserved Ejection fraction by Spironolactone On myocardial fibrosiS In Atrial Fibrillation (IMPRESS-AF) trial aims to establish whether treatment with spironolactone as compared with placebo improves exercise tolerance (cardiopulmonary exercise testing), quality of life and diastolic function in patients with permanent atrial fibrillation." | 5.22 | IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. ( Calvert, M; Fisher, J; Gill, PS; Haynes, R; Kirchhof, P; Lip, GY; Shantsila, E, 2016) |
| "Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) patients with heart failure and preserved left ventricular ejection fraction assigned to spironolactone did not achieve a significant reduction in the primary composite outcome (time to cardiovascular death, aborted cardiac arrest, or hospitalization for management of heart failure) compared with patients receiving placebo." | 5.20 | Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. ( Anand, IS; Assmann, SF; Boineau, R; Claggett, B; Clausell, N; Desai, AS; Diaz, R; Fleg, JL; Gordeev, I; Heitner, JF; Lewis, EF; McKinlay, SM; O'Meara, E; Pfeffer, MA; Pitt, B; Probstfield, JL; Rouleau, JL; Shaburishvili, T; Shah, SJ; Solomon, SD; Sweitzer, NK, 2015) |
| " Characteristics of galectin-3 and its response to spironolactone have not been evaluated in heart failure with preserved ejection fraction (HFpEF)." | 5.20 | Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. ( Düngen, HD; Duvinage, A; Edelmann, F; Gelbrich, G; Halle, M; Hasenfuss, G; Herrmann-Lingen, C; Holzendorf, V; Kraigher-Krainer, E; Nolte, K; Pieske, BM; Schmidt, AG; Stough, WG; Tschöpe, C; Unkelbach, I; Wachter, R, 2015) |
| "We examined the relationship between different degrees of QRS prolongation and different QRS morphologies and clinical outcomes in patients with heart failure, reduced ejection fraction (HF-REF), and mild symptoms in the Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure trial (EMPHASIS-HF)." | 5.20 | Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF). ( Cannon, JA; Collier, TJ; Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Shen, L; Swedberg, K; Van Veldhuisen, DJ; Vincent, J; Zannad, F, 2015) |
| "Twelve to 18 months of spironolactone therapy was not associated with alterations in cardiac structure or function in patients with heart failure with preserved ejection fraction." | 5.20 | Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. ( Anand, IS; Claggett, B; Deswal, A; Fleg, JL; Pfeffer, MA; Pitt, B; Shah, AM; Shah, SJ; Solomon, SD; Sweitzer, NK, 2015) |
| " The investigation involved 6632 patients of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study." | 5.19 | Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) s ( Challande, P; Fay, R; Lacolley, P; Lagrange, J; Pitt, B; Pizard, A; Regnault, V; Rossignol, P; Safar, ME; Zannad, F, 2014) |
| "The purpose of this study is to evaluate long-term effects of spironolactone, an affordable and widely used aldosterone receptor blocker, in patients with heart failure (HF) and mild or no symptoms." | 5.19 | Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. ( Caretta, G; D'Aloia, A; Dei Cas, L; Faden, G; Lombardi, C; Metra, M; Nodari, S; Pezzali, N; Raddino, R; Vizzardi, E, 2014) |
| "In patients with heart failure receiving optimal therapy, WRF and HK were more frequent when eplerenone was added, but their occurrence did not eliminate the survival benefit of eplerenone." | 5.19 | Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from ( Bakris, G; Dobre, D; Girerd, N; Krum, H; McMurray, JJ; Messig, M; Pitt, B; Rossignol, P; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2014) |
| "Spironolactone, not furosemide, improved insulin resistance in CHF patients probably by the inhibition of inflammatory cytokines and MMPs." | 5.19 | Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure. ( Anker, SD; Doehner, W; Hisatome, I; Kato, M; Kinugasa, Y; Ogino, K; Yamamoto, K, 2014) |
| "High-dose spironolactone added to standard ADHF therapy is likely to induce a more pronounced albuminuria decrease and a significant reduction in the proportion of micro and macroalbuminuria." | 5.19 | The role of albuminuria as a non-invasive marker for congestive acutely decompensated chronic heart failure and the spironolactone effect in elderly Portuguese: a non-randomized trial. ( Almeida, S; Bettencourt, P; Carvalho, H; Ferreira, JP; Marques, I; Santos, M, 2014) |
| "In this randomized, double-blind trial, we assigned 3445 patients with symptomatic heart failure and a left ventricular ejection fraction of 45% or more to receive either spironolactone (15 to 45 mg daily) or placebo." | 5.19 | Spironolactone for heart failure with preserved ejection fraction. ( Anand, IS; Assmann, SF; Boineau, R; Claggett, B; Clausell, N; Desai, AS; Diaz, R; Fleg, JL; Gordeev, I; Harty, B; Heitner, JF; Kenwood, CT; Lewis, EF; McKinlay, SM; O'Meara, E; Pfeffer, MA; Pitt, B; Probstfield, JL; Shaburishvili, T; Shah, SJ; Solomon, SD; Sweitzer, NK; Yang, S, 2014) |
| "We aimed to assess the impact of eplerenone on cardiovascular (CV) outcomes in STEMI without known heart failure, when initiated within 24 h of symptom onset." | 5.19 | Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. ( Flather, M; Hamm, CW; Lopez de Sa, E; Montalescot, G; Orri, M; Pitt, B; Shi, H; Turgonyi, E; Verheugt, F; Vincent, J; Zannad, F, 2014) |
| "With appropriate surveillance of potassium and creatinine, the use of spironolactone was associated with less hypokalemia and improved survival in patients with severe heart failure even in the setting of moderate hyperkalemia." | 5.19 | Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. ( Anand, I; Claggett, B; Desai, AS; Pitt, B; Rossignol, P; Solomon, SD; Vardeny, O; Zannad, F, 2014) |
| "Although spironolactone has been shown to decrease morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction, its role in patients with heart failure and preserved left ventricular ejection fraction (HFpEF) is not well defined." | 5.19 | Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. ( Ashton, Y; Deswal, A; Kurrelmeyer, KM; Nagueh, SF; Torre-Amione, G; Xu, J, 2014) |
| "The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients with acute heart failure (AHF) and the association between treatment and outcomes stratified by biomarkers." | 5.19 | Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). ( Butler, J; Clopton, P; de Boer, RA; Jaarsma, T; Maisel, A; Pang, PS; Pitt, B; van Veldhuisen, DJ; Voors, AA; Xue, Y, 2014) |
| "In EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure), eplerenone significantly reduced major cardiovascular events versus placebo in 2737 patients with mild symptoms of heart failure and an ejection fraction of <35%, in addition to recommended therapy." | 5.17 | Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. ( Krum, H; McMurray, J; Pitt, B; Pocock, S; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2013) |
| "The study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerular filtration rate (eGFR) >30 ml/min/1." | 5.17 | Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). ( Eschalier, R; Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Rossignol, P; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2013) |
| "AAs with HF exhibited less hyperkalemia and more hypokalemia with spironolactone compared with non-AAs and seemed to derive less clinical benefit." | 5.17 | Race influences the safety and efficacy of spironolactone in severe heart failure. ( Anand, I; Cavallari, LH; Claggett, B; Desai, AS; Pitt, B; Rossignol, P; Solomon, SD; Vardeny, O; Zannad, F, 2013) |
| "Patients with SRV treated with eplerenone showed an improvement of an altered baseline CTB profile suggesting that reduction of myocardial fibrosis might be a therapeutic target in these patients." | 5.17 | Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study. ( Casaldàliga, J; Dos, L; Estruch, M; Ferreira-González, I; García-Dorado, D; Marsal, JR; Mas, A; Ordóñez-Llanos, J; Pijuan, A; Pons-Lladó, G; Pujadas, S; Serra, R; Subirana, M, 2013) |
| "Treatment of Preserved Cardiac Function with an Aldosterone Antagonist (TOPCAT) is an ongoing randomized controlled trial of spironolactone versus placebo for heart failure with preserved ejection fraction (HFpEF)." | 5.17 | Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. ( Anand, IS; Boineau, R; Clausell, N; Desai, AS; Diaz, R; Fleg, JL; Gordeev, I; Harty, B; Heitner, JF; Kim, HY; Kobulia, B; Lewis, EF; Li, R; Markov, V; O'Meara, E; Pfeffer, MA; Pitt, B; Shaburishvili, T; Shah, SJ; Solomon, SD; Sweitzer, NK, 2013) |
| "We evaluated the effect of the selective mineralocorticoid receptor antagonist eplerenone on renal function and the interaction between changes in renal function and subsequent cardiovascular outcomes in patients with heart failure and left ventricular systolic dysfunction after an acute myocardial infarction in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)." | 5.16 | Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. ( Bhandari, S; Cleland, JG; Dobre, D; Fay, R; Gustafsson, F; Lamiral, Z; Pitt, B; Rossignol, P; Tala, S; Zannad, F, 2012) |
| "In patients with symptomatically mild CHF who participated in the placebo-controlled Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure, we examined the effect of the aldosterone antagonist, eplerenone, on physician-diagnosed diabetes using univariate Cox proportional hazard analysis." | 5.16 | Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). ( Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Preiss, D; Sattar, N; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2012) |
| "This study investigated the influence of baseline and worsening renal function (WRF) on the efficacy of spironolactone in patients with severe heart failure (HF)." | 5.16 | Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). ( Desai, A; Pitt, B; Rossignol, P; Solomon, SD; Vardeny, O; Wu, DH; Zannad, F, 2012) |
| "In this randomized, double-blind trial, we randomly assigned 2737 patients with New York Heart Association class II heart failure and an ejection fraction of no more than 35% to receive eplerenone (up to 50 mg daily) or placebo, in addition to recommended therapy." | 5.15 | Eplerenone in patients with systolic heart failure and mild symptoms. ( Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2011) |
| "Spironolactone was shown to reduce mortality in patients with heart failure (HF)." | 5.15 | Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure. ( Hadano, Y; Hiratsuka, A; Iwami, T; Kimura, M; Matsuzaki, M; Mochizuki, M; Ogawa, H; Shimizu, A; Takaki, A; Wakeyama, T, 2011) |
| "To evaluate efficacy and safety of RLY5016 (a non-absorbed, orally administered, potassium [K+]-binding polymer) on serum K+ levels in patients with chronic heart failure (HF) receiving standard therapy and spironolactone." | 5.15 | Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. ( Anker, SD; Bushinsky, DA; Huang, IZ; Kitzman, DW; Pitt, B; Zannad, F, 2011) |
| "We evaluated 12-month cost utilization data from 1516 heart failure outpatients enrolled in the Quality-of-Life Substudy of the Eplerenone Post-Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)." | 5.14 | Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). ( Chan, PS; Jones, PG; Nallamothu, BK; Soto, G; Spertus, JA; Weintraub, WS; Zhang, Z, 2009) |
| "In a substudy of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), which evaluated the effects of the selective aldosterone receptor antagonist eplerenone versus placebo, serum levels of collagen biomarkers were measured in 476 patients with congestive heart failure after acute myocardial infarction complicated with left ventricular systolic dysfunction." | 5.14 | Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EP ( Angioi, M; Fay, R; Iraqi, W; Ketelslegers, JM; Nuée, J; Pitt, B; Rossignol, P; Vincent, J; Zannad, F, 2009) |
| "We performed this study to assess whether low dose spironolactone could be administered in hemodialysis (HD) patients with moderate to severe heart failure to improve cardiovascular function and reduce hospitalization without inducing hyperkalemia." | 5.14 | Spironolactone in chronic hemodialysis patients improves cardiac function. ( Eshaghian, A; Garakyaraghi, M; Ghassami, M; Mortazavi, M; Pourmoghadas, A; Seirafian, S; Shahidi, S; Taheri, S, 2009) |
| " Of the 6,632 patients with acute myocardial infarctions and left ventricular systolic dysfunction in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), 4,407 had histories of hypertension." | 5.14 | A history of systemic hypertension and incident heart failure hospitalization in patients with acute myocardial infarction and left ventricular systolic dysfunction. ( Ahmed, A; Pitt, B, 2009) |
| " HRT from 24-hour Holter monitoring in 481 hospitalized patients after AMI with heart failure and/or diabetes with left ventricular dysfunction before randomization in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)." | 5.14 | Usefulness of abnormal heart rate turbulence to predict cardiovascular mortality in high-risk patients with acute myocardial infarction and left ventricular dysfunction (from the EPHESUS study). ( Deedwania, P; Stein, PK, 2009) |
| "To test the hypothesis that an earlier post-acute myocardial infarction (AMI) eplerenone initiation in patients with left ventricular systolic dysfunction (LVSD) and heart failure (HF) is associated with better long-term outcomes." | 5.14 | Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. ( Adamopoulos, C; Ahmed, A; Angioi, M; Fay, R; Filippatos, G; Pitt, B; Vincent, J; Zannad, F, 2009) |
| "The beneficial effects of spironolactone in chronic heart failure (HF) have been demonstrated in patients with New York Heart Association (NYHA) class III to IV HF." | 5.14 | Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. ( Bordonali, T; Bugatti, S; D'Aloia, A; Dei Cas, A; Dei Cas, L; Giubbini, R; Metra, M; Pezzali, N; Romeo, A; Vizzardi, E, 2010) |
| "In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (n=6632), eplerenone-associated reduction in all-cause mortality was significantly greater in those with a history of hypertension (Hx-HTN)." | 5.13 | History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. ( Ahmed, A; Aschermann, M; Cardoso, JS; Corbalán, R; Krum, H; Love, TE; Nicolau, J; Parkhomenko, A; Pitt, B; Shi, H; Solomon, H; Zannad, F, 2008) |
| "Hospitalized patients with congestive heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction (left ventricular ejection fraction < or =40%) treated with standard therapy were randomized 3 to 14 days after the acute myocardial infarction to additional treatment with eplerenone (25 to 50 mg/d; n=3319) or placebo (n=3313)." | 5.13 | Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). ( Bakris, G; DiCarlo, L; Mukherjee, R; Pitt, B; Ruilope, LM, 2008) |
| "The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) randomized clinical trial demonstrated the efficacy of eplerenone, a new aldosterone antagonist diuretic, with standard treatment versus standard treatment alone in the reduction of cardiovascular mortality and cardiovascular-related hospital readmissions for patients with heart failure after an acute myocardial infarction." | 5.13 | Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study. ( Beillat, M; de Pouvourville, G; Solesse, A, 2008) |
| "Aim of the investigation was the study of influence of spironolactone (25-75 mg/day) on clinico-functional and neurohormonal, 24-hour variability of cardiac rhythm, and ventricular disturbances of heart rhythm in patients with chronic heart failure (CHF) receiving optimal therapy." | 5.13 | [Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy]. ( Baklanova, NA; Belenkov, IuN; Chelmakina, SM; Mareev, VIu; Orlova, IaA; Skvortsov, AA, 2008) |
| "In EPHESUS, 6,632 patients with LVEF | 5.12 | Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction |
| "The Randomized Aldactone Evaluation Study (RALES) established the safety and benefit of spironolactone for heart failure (HF) patients with systolic dysfunction." | 5.12 | Appropriateness of spironolactone prescribing in heart failure patients: a population-based study. ( Donovan, LR; Juurlink, DN; Ko, DT; Mamdani, MM; Tu, JV; Wang, JT; You, JJ, 2006) |
| "Spironolactone improves prognosis in severe heart failure (HF)." | 5.12 | Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. ( Berry, C; De Vito, G; Fisher, C; Galloway, S; Hillis, WS; McMurray, J; Murphy, N; Murphy, NF; Sattar, N; Seed, A; Vallance, P, 2007) |
| "Our results suggest that reducing cellular magnesium efflux and loss may contribute to the spironolactone-reduced arrhythmias in patients with CHF." | 5.12 | Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. ( Adhikari, CM; Gao, X; Lin, J; Peng, L; Zuo, Z, 2007) |
| "To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure." | 5.12 | Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. ( Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA, 2007) |
| "The objective of this study was to determine if adding spironolactone to an angiotensin II receptor blocker improves left ventricular (LV) function, mass, and volumes in chronic heart failure." | 5.12 | Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. ( Chan, AK; Chan, WW; Lam, W; Lam, YY; Sanderson, JE; So, N; Wang, M; Wang, T; Wong, JT; Wu, EB; Yeung, L; Yip, G; Yu, CM; Zhang, Y, 2007) |
| "Aim of the investigation was the study of influence of spironolactone (25 - 75 mg/day) on clinico-functional status, parameters of left ventricular (LV) remodeling, as well as safety of its long term application in patients with chronic heart failure (CHF) receiving optimal therapy." | 5.12 | [Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy]. ( Baklanova, NA; Belenkov, IuN; Chelmakina, SM; Mareev, VY; Skvortsov, AA, 2007) |
| "We randomly assigned 93 chronic heart failure patients to treatment with spironolactone (n = 47) or to a control group (n = 46) and followed them for 12 months." | 5.11 | Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure. ( Bonapace, S; Cicoira, M; Franceschini, L; Francis, DP; Golia, G; Osterziel, KJ; Perrot, A; Rossi, A; Zanolla, L; Zardini, P, 2004) |
| "A total of 1520 patients who had advanced heart failure (New York Heart Association class III or IV) due to ischemic or nonischemic cardiomyopathies and a QRS interval of at least 120 msec were randomly assigned in a 1:2:2 ratio to receive optimal pharmacologic therapy (diuretics, angiotensin-converting-enzyme inhibitors, beta-blockers, and spironolactone) alone or in combination with cardiac-resynchronization therapy with either a pacemaker or a pacemaker-defibrillator." | 5.11 | Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. ( Boehmer, J; Bristow, MR; Carson, P; De Marco, T; DeMets, D; DeVries, DW; DiCarlo, L; Feldman, AM; Kass, DA; Krueger, S; Saxon, LA; White, BG, 2004) |
| "We prospectively studied the effect of spironolactone, an aldosterone antagonist, on endothelial function in patients with advanced congestive heart failure (CHF) using the brachial artery reactivity method." | 5.11 | Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy. ( Abiose, AK; Barry, M; Hager, D; Mansoor, GA; Nair, CK; Soucier, R, 2004) |
| "To examine whether the favourable effects on endothelial function, vascular angiotensin converting enzyme (ACE) activity, cardiac remodelling, autonomic function, and QT intervals of spironolactone in combination with ACE inhibitor also occur in patients with New York Heart Association class I-II congestive heart failure (CHF) taking optimal treatment (including beta blockers)." | 5.11 | Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. ( Kennedy, N; Macdonald, JE; Struthers, AD, 2004) |
| "Thirty medically treated ambulatory hypertensive patients (19 women, age 62+/-6 years) with exertional dyspnea, ejection fraction >50%, and diastolic dysfunction (E/A <1, E deceleration time >250 m/sec) and without ischemia were randomized to spironolactone 25 mg/d or placebo for 6 months." | 5.11 | Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. ( Cowley, D; Haluska, B; Leano, R; Marwick, TH; Mottram, PM; Stowasser, M, 2004) |
| "In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), aldosterone blockade with eplerenone decreased mortality in patients with left ventricular systolic dysfunction and heart failure after acute myocardial infarction." | 5.11 | Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. ( Caro, J; Goldberg, R; Ishak, J; Kolm, P; Mahoney, EM; Pitt, B; Spertus, JA; Tooley, J; Weintraub, WS; Willke, R; Zhang, Z, 2005) |
| "In RALES, low doses of the mineralocorticoid receptor (MR) antagonist spironolactone, added to standard of care for severe heart failure, improved survival by 30% and lowered hospitalization by 35%." | 5.11 | RALES, EPHESUS and redox. ( Funder, JW, 2005) |
| "This study sought to assess the impact of the selective aldosterone blocker eplerenone on mortality 30 days after randomization in patients after acute myocardial infarction (AMI) with a left ventricular ejection fraction (LVEF) < or =40% and clinical signs of heart failure." | 5.11 | Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. ( Aschermann, M; Gheorghiade, M; Krum, H; Martinez, F; Mukherjee, R; Nicolau, J; Pitt, B; van Veldhuisen, DJ; Vincent, J; White, H; Zannad, F, 2005) |
| " The effects of the mineralocorticoid receptor antagonist spironolactone on left ventricular (LV) function and chamber stiffness associated with myocardial fibrosis were investigated in mildly symptomatic patients with idiopathic dilated cardiomyopathy (DCM)." | 5.11 | Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. ( Amano, T; Asano, H; Ichihara, S; Iino, S; Isobe, S; Izawa, H; Kato, T; Murase, Y; Murohara, T; Nagata, K; Noda, A; Obata, K; Ohshima, S; Okumura, K; Yokota, M, 2005) |
| "To retrospectively investigate elevation of serum potassium when spironolactone (25 or 50 mg/day) and furosemide were administered concomitantly with an angiotensin II converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) to patients with chronic heart failure for 12 months and occurrence of hyperkalemia and hypokalemia because of concomitant administration of spironolactone plus an ACE-I or ARB and furosemide." | 5.11 | Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. ( Hirooka, K; Isobe, F; Saito, M; Takada, M; Yasumura, Y, 2005) |
| "We evaluated whether spironolactone would improve cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure (CHF)." | 5.10 | Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. ( Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Suzuki, T; Takayama, Y; Toyama, T, 2002) |
| "We sought to evaluate the effects of spironolactone on neurohormonal factors in patients with severe congestive heart failure (CHF)." | 5.10 | Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. ( Ahn, S; Duprez, D; Galanti, L; Gurné, O; Ketelslegers, JM; Robert, A; Rousseau, MF; Van Mieghem, W, 2002) |
| "This study was designed to investigate the appropriateness and complications of the use of spironolactone for heart failure (HF) in clinical practice." | 5.10 | Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. ( Agoston, I; Bozkurt, B; Knowlton, AA, 2003) |
| " We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure." | 5.10 | Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. ( Bittman, R; Gatlin, M; Hurley, S; Kleiman, J; Martinez, F; Neaton, J; Pitt, B; Remme, W; Roniker, B; Zannad, F, 2003) |
| "The purpose of our study was to assess the effects of a low dose of spironolactone in patients with moderate congestive heart failure (CHF) on the plasma level of brain natriuretic peptide (BNP), echocardiographic left ventricular ejection fraction (LVEF), and cardiopulmonary function assessed by cardiopulmonary (CP) test." | 5.10 | Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure. ( Deorsola, A; Feola, M; Ferrero, V; Menardi, E; Milanese, U; Ribichini, F; Uslenghi, E; Vado, A; Visconti, G, 2003) |
| "The effects of spironolactone or metoprolol added to a conventional treatment protocol on QT dispersion, which is accepted as a sudden cardiac death predictor, were evaluated in heart failure patients." | 5.10 | Effects of spironolactone and metoprolol on QT dispersion in heart failure. ( Akbulut, M; Arslan, N; Ilkay, E; Karaca, I; Ozbay, Y, 2003) |
| " This manuscript provides an overview of the considerations made regarding quantification of a range of clinical and economic outcomes in the EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study) study, a 6200-patient, randomized, controlled trial of aldosterone blockade in patients with heart failure as a complication of acute myocardial infarction." | 5.10 | Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). ( Deedwania, P; Hurley, S; Jones, P; Mahoney, E; Pitt, B; Poston, C; Spertus, JA; Tooley, J; Weintraub, WS, 2002) |
| "To use data from the Randomized Aldactone Evaluation Study (RALES) to compare clinical outcomes and costs as part of the assessment of the economic implications of spironolactone treatment of advanced heart failure." | 5.10 | Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure. ( Glick, HA; Orzol, SM; Pitt, B; Remme, WJ; Sasayama, S; Tooley, JF, 2002) |
| "This study was designed to assess the effects of spironolactone (SP) on left ventricular (LV) function and exercise tolerance in patients with chronic heart failure (CHF)." | 5.10 | Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. ( Brighetti, G; Cicoira, M; Franceschini, L; Golia, G; Marino, P; Rossi, A; Zanolla, L; Zardini, P, 2002) |
| "Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure." | 5.09 | The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. ( Castaigne, A; Cody, R; Palensky, J; Perez, A; Pitt, B; Remme, WJ; Wittes, J; Zannad, F, 1999) |
| "The RALES study showed that spironolactone, added to conventional therapy for chronic heart failure, dramatically reduced mortality." | 5.09 | Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. ( Farquharson, CA; Struthers, AD, 2000) |
| "A marked reduction of overall mortality in patients with severe congestive heart failure (CHF) has been demonstrated by addition of the mineralocorticoid receptor antagonist spironolactone to ACE inhibition." | 5.09 | Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES. ( Bauersachs, J; Christ, M; Ertl, G; Fraccarollo, D; Gretz, N; Wehling, M, 2000) |
| "We sought to evaluate the effects of spironolactone on neurohumoral factors and left ventricular remodeling in patients with congestive heart failure (CHF)." | 5.09 | Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Kinoshita, M; Mabuchi, N; Maeda, K; Matsui, T; Matsumoto, T; Ohnishi, M; Sawaki, M; Tsutamoto, T; Tsutsui, T; Wada, A, 2001) |
| "We report the findings in 31 patients with stable chronic heart failure (CHF) who were treated with spironolactone (50-100 mg/day) or placebo in addition to diuretics and angiotensin converting enzyme (ACE) inhibition." | 5.08 | Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. ( Barr, CS; MacFadyen, RJ; Struthers, AD, 1997) |
| " Treatment with spironolactone is reported to be useful when combined with loop diuretics and an angiotensin-converting enzyme (ACE) inhibitor in severe congestive heart failure (CHF)." | 5.08 | Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor. ( Endo, A; Furuse, Y; Hisatome, I; Kato, M; Kato, T; Kinugawa, T; Miyakoda, H; Mori, M; Ogino, K; Omodani, H; Osaki, S; Shigemasa, C; Shimoyama, M, 1998) |
| "Right heart catheterization was performed before and during long-term therapy with prazosin in 27 patients with severe chronic heart failure who underwent serial hemodynamic studies during 3 to 12 weeks of treatment with the drug." | 5.06 | Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. ( Medina, N; Packer, M; Yushak, M, 1986) |
| "The effect of adding spironolactone (Aldactone) on muscle electrolytes was studied in 48 patients with arterial hypertension and/or congestive heart failure who had received conventional diuretic treatment, including a potassium supplement, for more than 1 year." | 5.06 | Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial hypertension. ( Dyckner, T; Wester, PO; Widman, L, 1986) |
| "4% were women) recruited in three placebo-controlled RCTs: Randomized Aldactone Evaluation Study (RALES), Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) and Spironolactone for Heart Failure with Preserved Ejection Fraction (TOPCAT)-Americas." | 5.05 | Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. ( Ferreira, JP; Girerd, N; Lam, CSP; McMurray, JJV; Pitt, B; Pocock, SJ; Rossello, X; Rossignol, P; Solomon, SD; Zannad, F, 2020) |
| " Age was an important predictor of clearance in studies involving neonates or infants, other predictors of clearance were weight, height, serum creatinine, coadministration of spironolactone and presence of congestive heart failure." | 5.05 | A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population. ( Abdel Jalil, MH; Abdullah, N; Abu-Hammour, K; Alsous, MM; Saleh, M, 2020) |
| "The efficacy of treatment with spironolactone for congestive heart failure secondary to congenital heart disease was studied in 21 infants under 1 year of age." | 5.05 | Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease. ( Fowler, RS; Hobbins, SM; Korey, AG; Rowe, RD, 1981) |
| "The efficacy and tolerability of two combinations, namely 50 mg spironolactone + 20 mg furosemide (SF) or 50 mg spironolactone + 5 mg butizide (SB), were compared in a randomised intraindividual trial in 22 patients with congestive heart failure." | 5.05 | [Comparative study of 2 diuretic-containing combination preparations in patients with edematous heart failure]. ( Ehrlich, E; Mauersberger, H; Rangoonwala, B, 1985) |
| "Extra potassium supplements, spironolactone or amiloride were given for 5 months to forty-nine patients with heart failure who were taking furosemide and were in a steady state." | 5.04 | The effects of potassium supplements, spironolactone of amiloride on the potassium status of patients with heart failure. ( Burkinshaw, L; Davidson, C; Morgan, DB, 1978) |
| "Recent studies have shown the efficacy for using spironolactone to treat heart failure with reduced ejection fraction (HFrEF), but the efficacy of spironolactone for heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) is unclear." | 5.01 | Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials. ( Feng, P; Huang, W; Li, Z; Shi, W; Wang, SY; Wen, L; Xiang, R; Xiang, Y; Yang, Y, 2019) |
| " Spironolactone and canrenone have a higher risk of hyperkalemia and renal deterioration." | 5.01 | Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials. ( Chen, X; Shen, W; Wu, Q; Wu, T; Xu, G; Xu, X; Yang, P; Zhu, D, 2019) |
| "Spironolactone did not demonstrate benefit with respect to the primary composite endpoint in the global TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) trial in patients with chronic heart failure with preserved ejection fraction (HFpEF)." | 4.95 | Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. ( Butler, J; Fonarow, GC; Patel, RB; Shah, SJ; Vaduganathan, M, 2017) |
| " A randomized controlled trial of patients with heart failure and an ejection fraction > 45% showed that spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure." | 4.93 | Clinical Question: In congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes? ( Onarecker, C, 2016) |
| "Eplerenone is a selective mineralocorticoid receptor antagonist that has been recently included in the treatment of patients with chronic heart failure (CHF) and reduced systolic function." | 4.91 | Eplerenone in chronic heart failure with depressed systolic function. ( Iellamo, F; Volterrani, M, 2015) |
| "The TOPCAT study followed the effect of spironolactone on a chronic heart failure with a preserved left ventricular ejection fraction." | 4.91 | [Effect of spironolactone in patients with heart failure and preserved left ventricular function - TOPCAT study]. ( Widimský, J, 2015) |
| "The role of spironolactone and eplerenone in patients with Heart Failure with preserved Ejection Fraction (HFpEF) is not well defined." | 4.91 | Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). ( Capuano, A; Coats, AJ; Rosano, GM; Rossi, F; Scavone, C; Sportiello, L; Vitale, C, 2015) |
| "Randomized controlled trials demonstrate the efficacy of aldosterone receptor antagonists (spironolactone and eplerenone) as a useful pharmacologic intervention specifically in patients with New York Heart Association (NYHA) class III and IV heart failure, in patients with an ejection fraction <40% after myocardial infarction, and most recently in patients with mildly symptomatic heart failure." | 4.88 | Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications. ( Coplan, NL; Markowitz, M; Messineo, F, 2012) |
| " Interventions included aldosterone antagonists (Aldactone [Pfizer, NY, NY], canrenone, eplerenone) in systolic heart failure." | 4.88 | Eplerenone is not superior to older and less expensive aldosterone antagonists. ( Bolorunduro, O; Chatterjee, S; Lichstein, E; Moeller, C; Moskovits, N; Mukherjee, D; Shah, N, 2012) |
| "The aldosterone receptor antagonists (ARAs) spironolactone (Aldactone) and eplerenone (Inspra) have become part of standard medical therapy for heart failure, having shown clinical efficacy in randomized trials in patients with advanced symptomatic systolic heart failure, postinfarction heart failure with cardiac dysfunction, and systolic heart failure with mild symptoms." | 4.88 | The role of aldosterone receptor antagonists in the management of heart failure: an update. ( Chamsi-Pasha, M; Nagarajan, V; Tang, WH, 2012) |
| "Aldosterone antagonists represented by nonselective spironolactone and mineralocorticoid-selective eplerenone are approved for treatment of symptomatic heart failure with reduced systolic function." | 4.87 | Aldosterone antagonists in heart failure. ( Guglin, M; Kristof-Kuteyeva, O; Novotorova, I; Pratap, P, 2011) |
| "Two aldosterone inhibitors are currently licensed for heart failure (HF) in the UK: spironolactone and eplerenone." | 4.86 | A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure. ( Bakhai, A; Burch, J; Fenwick, L; Harden, M; Lorgelly, P; McKenna, C; Palmer, S; Suekarran, S; Walker, S; Witte, K; Woolacott, N; Wright, K, 2010) |
| "(2) In RALES, low-dose spironolactone in addition to standard of care, produced a 30% improvement in survival in progressive heart failure, commonly assumed to reflect deleterious effects of aldosterone, with spironolactone competing with aldosterone for cardiac mineralocorticoid receptors." | 4.86 | Aldosterone, hypertension and heart failure: insights from clinical trials. ( Funder, JW, 2010) |
| "The aim of this study is to summarize the evidence on the efficacy of spironolactone (SP), eplerenone (EP), or canrenoate (CAN) in patients with left ventricular dysfunction." | 4.85 | Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. ( Ezekowitz, JA; McAlister, FA, 2009) |
| "Eplerenone is an aldosterone receptor antagonist indicated for the treatment of hypertension and congestive heart failure." | 4.85 | The clinical pharmacology of eplerenone. ( Benge, CD; Muldowney, JA; Schoenhard, JA, 2009) |
| " A newer agent, eplerenone, has been recently licensed for the treatment of heart failure and in the US also for hypertension." | 4.84 | Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. ( George, J; Struthers, AD, 2007) |
| " Eplerenone, a mineralocorticoid-receptor antagonist with minimal binding to the progesterone and androgen receptors, is now licensed for treatment of heart failure in Europe and heart failure and hypertension in the US; it has also been proposed as a treatment for a variety of cardiovascular conditions." | 4.84 | Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. ( Connell, JM; McInnes, GT; McManus, F, 2008) |
| "Many patients with heart failure should receive an aldosterone receptor antagonist, ie, either spironolactone (Aldactone) or the newer agent eplerenone (Inspra)--in addition to an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) or both, and a beta-blocker." | 4.83 | Aldosterone receptor antagonists for heart failure: current status, future indications. ( Pitt, B; Rajagopalan, S, 2006) |
| "Based on the RALES study, in patients with moderate to severe chronic heart failure and reduced left ventricular function, the nonselective aldosterone antagonist spironolactone has a well-established role in combination with ACE inhibition, beta-blockade and diuretics." | 4.83 | [Aldosterone receptor blockade after acute myocardial infarction with heart failure]. ( Bauersachs, J; Ertl, G, 2006) |
| "In patients with NYHA stage III or IV heart failure, addition of spironolactone to the treatment with conversion enzyme inhibitor, diuretic and/or digitalis leads to a reduction in morbidity and mortality, as demonstrated in the RALES study." | 4.82 | [Aldosterone and its antagonists in heart failure]. ( Badoual, T; Cachin, JC; Castaigne, A; Hittinger, L; Le Corvoisier, P; Lopes, ME; Merlet, P; Su, JB; Tabet, JY, 2003) |
| "In the Eplerenone Postacute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) the effects of selective aldosterone blockade with eplerenone on cardiovascular mortality and morbidity were studied in patients with reduced left ventricular function postacute myocardial infarction." | 4.82 | Selective aldosterone blockade with eplerenone in patients with congestive heart failure. ( Salam, AM, 2003) |
| " The selective aldosterone blocker, eplerenone (Inspra), is under development for human therapeutic use for treatment of hypertension and heart failure post-myocardial infarction (MI)." | 4.82 | Aldosterone target organ protection by eplerenone. ( McMahon, EG; Rocha, R; Rudolph, AE, 2004) |
| " More recently, the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study has provided firm support for the use of eplerenone (Inspra, Pfizer) in heart failure following acute myocardial infarction in addition to neurohormonal blockade with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta-blockers." | 4.82 | Eplerenone in the treatment of chronic heart failure. ( Krum, H; Liew, D, 2004) |
| "To evaluate the pharmacology, pharmacokinetics, safety, and clinical use of eplerenone in heart failure (HF)." | 4.82 | Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. ( Barnes, BJ; Howard, PA, 2005) |
| "Since the publication of The Randomized Aldactone Study (RALES) in 1999, the association of angiotensin-converting enzyme (ACE) inhibitors and spironolactone has been largely used for the treatment of congestive heart failure (CHF)." | 4.82 | New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia. ( Cruz, CS; Cruz, LS; Domingues, GS; Souza, CA, 2005) |
| "In 1999 a great multi-site clinical trial known as the randomised Aldactone evaluation study (RALES) showed that the use of spironolactone importantly reduced complications attributable to chronic heart failure without major negative side effects." | 4.82 | A landmark for popperian epidemiology: refutation of the randomised Aldactone evaluation study. ( Kirschbaum, A; Koch, E; Otarola, A, 2005) |
| " The 30% improvement in mortality (and 35% in morbidity) seen in the RALES trial with the addition of low-dose spironolactone to best practice therapy in moderate to severe heart failure, similarly points to an unrecognized role for aldosterone in the pathophysiology of heart failure." | 4.81 | Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. ( Funder, JW; Young, MJ, 2002) |
| " The therapeutic efficacy of spironolactone (Pharmacia Corp) in severe chronic heart failure is established." | 4.81 | The role of aldosterone receptor blockade in the management of cardiovascular disease. ( Krum, H; Liew, D, 2002) |
| "Until recently, spironolactone was considered only as an antagonist at the aldosterone receptors of the epithelial cells of the kidney and was used clinically in the treatment of hyperaldosteronism and, occasionally, as a K(+)-sparing diuretic." | 4.81 | The spironolactone renaissance. ( Brown, L; Doggrell, SA, 2001) |
| "Eplerenone, an aldosterone receptor antagonist from Searle is being developed as a potential treatment for renal disease, congestive heart failure and hypertension." | 4.81 | Eplerenone (GD Searle & Co). ( Krum, H; Martin, J, 2001) |
| "The familiar diuretic spironolactone has taken on new life as a treatment for left-sided congestive heart failure." | 4.81 | Spironolactone in left-sided heart failure: how does it fit in? ( Luttermoser, G; Margo, KL; Shaughnessy, AF, 2001) |
| "Author investigated the safety of combined ACE inhibitor (captopril) and spironolacton therapy on 237 pts with severe heart failure (NYHA III-IV." | 4.80 | [Effect of combined captopril-spironolactone therapy of cardiac insufficiency on kidney function and serum electrolyte values]. ( Cserhalmi, L, 1998) |
| " In contrast, when the Randomized Aldactone Evaluation Study (RALES) mortality trial was discontinued 18 months early, it was because of the prominent salutary effect of spironolactone, added to standard multidrug therapy consisting of an angiotensin converting enzyme (ACE) inhibitor and loop diuretic (with or without digoxin), in reducing the incidence of death and hospitalization in patients with severe congestive heart failure (CHF)." | 4.80 | Spironolactone in congestive heart failure. ( Soberman, JE; Weber, KT, 2000) |
| "To evaluate evidence supporting the use of spironolactone in managing congestive heart failure." | 4.80 | Spironolactone in the treatment of congestive heart failure. ( Lloyd, SJ; Mauro, VF, 2000) |
| " Due to the potential importance of these mechanisms, the finding that there is a significant correlation between aldosterone production and mortality in patients with heart failure, as well as evidence that an aldosterone antagonist, spironolactone, when administered to patients with heart failure treated with conventional therapy including an ACE inhibitor results in increased diuresis and symptomatic improvement, an international prospective multicenter study has been organized, the Randomized Aldactone Evaluation Study (RALES Pilot Study), to evaluate the safety of blocking the effects of aldosterone in patients with heart failure treated with an ACE inhibitor." | 4.79 | "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. ( Pitt, B, 1995) |
| "The mineralocorticoid receptor antagonists (MRAs) eplerenone and spironolactone are beneficial in heart failure with reduced ejection fraction (HFrEF), but have not been prospectively compared." | 4.31 | Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study. ( Denholt, CS; Fosbøl, E; Gustafsson, F; Kristensen, SL; Køber, L; Larsson, JE; Nielsen, OW; Raja, AA; Schou, M; Thune, JJ, 2023) |
| " Sacubitril/valsartan has been shown to decrease readmissions for patients with heart failure (HF) and decrease health care costs." | 4.31 | Using Sacubitril/Valsartan to Decrease Health care Costs in Population Health Patients. ( Bernhardt, R; Chapa, J; Damera, N; George, B; Lee, E; Rao, RA; Reese, L; Shah, C, 2023) |
| "Sacubitril/valsartan was approved by the Food and Drug Administration in 2015 to reduce the risk of cardiovascular death and hospitalization for heart failure (HHF) in patients with chronic heart failure with reduced ejection fraction defined as left ventricular ejection fraction (LVEF) ≤ 40%." | 4.12 | Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective. ( Clark, J; Gandotra, C; Liu, Q; Rose, M; Senatore, FF; Stockbridge, NL; Zhang, J, 2022) |
| " The new procedures are illustrated in the clinical trial Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function, which evaluated the effects of spironolactone in patients with heart failure and a preserved left ventricular ejection fraction." | 4.12 | Event-specific win ratios for inference with terminal and non-terminal events. ( Leifer, E; Pak, D; Troendle, J; Yang, S, 2022) |
| "In the absence of previous direct comparative studies, we aimed to evaluate the effectiveness of spironolactone and eplerenone in patients with heart failure and reduced ejection fraction (HFrEF) in a real-world clinical setting." | 4.12 | Real world comparison of spironolactone and eplerenone in patients with heart failure. ( Almenar-Bonet, L; Barge-Caballero, E; Barge-Caballero, G; Bouzas-Mosquera, A; Couto-Mallón, D; Crespo-Leiro, MG; Muñiz, J; Paniagua-Martín, MJ; Pardo-Martínez, P; Prada-Delgado, Ó; Sagastagoitia-Fornie, M; Vázquez-Rodríguez, JM, 2022) |
| "The impact of the TOPCAT trial publication on spironolactone initiation and subsequent hospitalizations for hyperkalemia among patients with heart failure with preserved ejection fraction (HFpEF) has not been evaluated empirically." | 4.12 | Rates of Spironolactone Initiation and Subsequent Hyperkalemia Hospitalizations in Patients with Heart Failure with Preserved Ejection Fraction Following the TOPCAT trial: A Cohort Study of Medicare Beneficiaries. ( Desai, RJ; Solomon, SD; Vaduganathan, M, 2022) |
| " Spironolactone may work through osteoblast MR/OCN axis to exert its therapeutic effects on pathological ventricular remodeling and heart failure in mice and human patients." | 4.12 | Osteoblast MR deficiency protects against adverse ventricular remodeling after myocardial infarction. ( Bai, L; Chen, BY; Du, LJ; Duan, SZ; Guo, XG; Li, RG; Li, YL; Lin, WZ; Liu, T; Liu, Y; Ma, XX; Meng, XQ; Shao, S; Shi, XR; Sun, JY; Wang, YL; Zhou, LJ; Zhu, H, 2022) |
| "The aims of this study were to explore phenotypes of heart failure with preserved ejection fraction (HFpEF) and evaluate differential effects of spironolactone treatment." | 4.12 | Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment. ( Choy, M; Dong, Y; Fu, M; He, J; He, X; Liang, W; Liu, C, 2022) |
| "The HOMAGE (Heart 'OMics' in AGEing) trial showed that spironolactone decreased serum PICP concentrations and improved cardiac remodelling over 9 months in a population at risk of developing heart failure (HF)." | 4.12 | The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial. ( Bozec, E; Clark, AL; Cleland, JGF; Cosmi, F; Cuthbert, J; Diez, J; Edelmann, F; Ferreira, JP; Girerd, N; González, A; Hazebroek, M; Heymans, S; Huttin, O; Kevin, D; Kobayashi, M; Mariottoni, B; Pellicori, P; Petutschnigg, J; Pieske, B; Rossignol, P; Staessen, JA; Verdonschot, JAJ; Zannad, F, 2022) |
| "The treatment of heart failure with reduced ejection fraction HFrEF (< 40%) uses hygienic-dietary rules combined with beta-blockers, renin-angiotensin system blockers RASB (alone or in combination with Sacubitril) and spironolactone." | 4.12 | [Impact of Dapagliflozin on echocardiographic parameters in patients with heart failure and reduced ejection fraction: "About a monocentric series of 43 cases"]. ( Bachir, N; Boukabous, A; Terki, A; Zaoui, N, 2022) |
| "This study aimed to investigate the possible use of Procyanidin extracted from Crataegus azarolus in the treatment of induced heart failure in rats." | 4.12 | The Impact of Procyanidin Extracted from Crataegus azarolus on Rats with Induced Heart Failure. ( Dizaye, KF; Z Rashid, B, 2022) |
| "The aim: To evaluate the effect of single daily 25 mg of spironolactone on serum electrolytes and kidney function tests in patients with severe chronic left sided heart failure." | 4.02 | THE EFFECT OF SPIRONOLACTONE ON SERUM ELECTROLYTES AND RENAL FUNCTION TESTS IN PATIENTS WITH SEVERE CHRONIC HEART FAILURE. ( Abdulzahra, MS; Abdurasool Almedeny, S; Hadi, NR; Yasir Al-Mayah, J, 2021) |
| " Spironolactone is an aldosterone antagonist used for managing chronic heart failure (HF) with known antiandrogenic effects." | 4.02 | Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure: A Pharmacoepidemiological study. ( Feldman, RD; Hiebert, BM; Janzen, BW; Kim, JO; Ong, AD; Sanjanwala, RM, 2021) |
| "To explore the short-term effect of high-dose spironolactone (80 mg/d) on chronic congestive heart failure (CHF)." | 4.02 | A retrospective study on the short-term effect of high-dose spironolactone (80 mg/d) on chronic congestive heart failure. ( Jiming, L; Tao, P; Zhitao, T, 2021) |
| " We aim to explore the effect of eplerenone on cardiovascular outcomes and all-cause mortality in HFrEF patients with diabetes, including those treated with insulin in the EMPHASIS-HF trial (Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms)." | 4.02 | Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. ( Ferreira, JP; Lamiral, Z; McMurray, JJV; Pitt, B; Pocock, SJ; Rossignol, P; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2021) |
| "The TOPCAT trial showed no benefit for spironolactone in heart failure patients with preserved ejection fraction (HFpEF)." | 4.02 | A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction. ( Alenghat, FJ; Belkin, MN; Blair, JE; Shah, SJ, 2021) |
| "This prospective cohort study evaluated the association between the renin angiotensin aldosterone system genotypes and response to spironolactone in 155 Egyptian patients with heart failure with reduced ejection fraction (HFrEF)." | 3.96 | Effect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure. ( Cavallari, LH; El Rouby, NM; El-Wakeel, LM; Khorshid, H; Langaee, T; Sabri, NA; Sarhan, NM; Schaalan, MF; Shahin, MH; Solayman, MH, 2020) |
| "Spironolactone has been shown to improve outcomes in patients with heart failure (HF) with reduced ejection fraction (EF)." | 3.96 | Spironolactone use is associated with improved outcomes in heart failure with mid-range ejection fraction. ( Enzan, N; Higo, T; Ide, T; Kaku, H; Matsushima, S; Tsuchihashi-Makaya, M; Tsutsui, H, 2020) |
| "Potassium-wasting (loop diuretics [LD]) and potassium-sparing (spironolactone) medications used for heart failure (HF) may alter renal potassium handling and confound the use of twenty-four-hour (24-h) urine collections as a surrogate marker for potassium intake, an effect that has been observed with dietary sodium assessment." | 3.96 | Evaluating the confounding effects of medical therapies on potassium intake assessment in patients with heart failure. ( Arcand, J; Dash, S; Mak, S; Malta, D; Newton, GE; Sivakumar, B, 2020) |
| "The TOPCAT trial investigated spironolactone vs placebo in patients with heart failure with preserved ejection fraction (HFpEF)." | 3.96 | Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). ( Brophy, TJ; DeVore, AD; Fonarow, GC; Fudim, M; Hammill, BG; Hernandez, AF; Kelly, JP; Peterson, ED; Pitt, B; Yancy, C, 2020) |
| "The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats." | 3.96 | Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. ( Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020) |
| "It is unclear whether spironolactone reduced heart failure (HF) hospitalizations in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial through potential diuretic or other effects." | 3.96 | Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis. ( Butler, J; Fang, JC; Kalogeropoulos, AP; Thankachen, J, 2020) |
| " We investigated the association of clinical variables and cardiovascular drugs, including furosemide, hydrochlorothiazide, spironolactone, and their doses, with the presence of hyponatremia at admission." | 3.96 | Furosemide and spironolactone doses and hyponatremia in patients with heart failure. ( Bušić, Ž; Čulić, V; Jurić Paić, M; Velat, I, 2020) |
| "As examples, in the RALES trial (more severe HFrEF), the treatment effect metrics for spironolactone versus placebo on heart failure hospitalization and/or cardiovascular death were a hazard ratio (HR) of 0." | 3.96 | Estimating the Lifetime Benefits of Treatments for Heart Failure. ( Claggett, BL; Docherty, KF; Ferreira, JP; Gregson, J; Jhund, PS; McMurray, JJV; Petrie, MC; Pocock, SJ; Solomon, SD; Stienen, S; Zannad, F, 2020) |
| "This study will investigate the efficacy and safety of spironolactone for the treatment of acute heart failure (AHF)." | 3.96 | Efficacy and safety of spironolactone for the treatment of patients with acute heart failure: A protocol for systematic review. ( Feng, YL; Lu, M, 2020) |
| "To quantify the risk of hyperkalemia and acute kidney injury (AKI) when spironolactone use is added on to loop diuretic use among patients with heart failure, and to evaluate whether the risk is modified by level of kidney function." | 3.96 | Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure. ( Alexander, GC; Chang, AR; Coresh, J; Grams, ME; Inker, LA; Qiao, Y; Secora, AM; Shin, JI, 2020) |
| "The treatment effects of spironolactone on heart failure with reduced (HFrEF LVEF <40%) and preserved (HFpEF LVEF ≥50%) ejection fraction are well characterized." | 3.91 | Outcomes of spironolactone treatment in patients in Northeast China suffering from heart failure with mid-range ejection fraction. ( Chen, X; Hu, J; Hu, WY; Sun, Y; Xin, YG; Zhao, YN, 2019) |
| "Differences in the clinical impacts of the aldosterone receptor antagonists spironolactone and eplerenone in patients with heart failure (HF) are unclear." | 3.91 | Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure. ( Aonuma, K; Baba, M; Hamada-Harimura, Y; Higuchi, H; Ishizu, T; Machino-Ohtsuka, T; Nakatsukasa, T; Nishi, I; Obara, K; Sai, S; Seo, Y; Sugano, A; Yamamoto, M, 2019) |
| "Of the 8206 patients with heart failure and ejection fraction ≤35% without prior spironolactone use in the Medicare-linked OPTIMIZE-HF registry, 6986 were eligible for spironolactone therapy based on serum creatinine criteria (men ≤2." | 3.91 | Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction. ( Ahmed, A; Bayoumi, E; Dooley, DJ; Faselis, C; Fonarow, GC; Lam, PH; Mohammed, SF; Morgan, CJ; Palant, CE; Patel, S; Pitt, B; Sheriff, HM; Singh, S, 2019) |
| " Compared with placebo, across all eGFR categories, spironolactone was associated with lower relative risk for the primary efficacy outcome and for hypokalemia, but higher relative risk for hyperkalemia, worsening renal function, and drug discontinuation." | 3.91 | Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. ( Beldhuis, IE; Claggett, B; Damman, K; Desai, AS; Fang, JC; Lewis, EF; Myhre, PL; O'Meara, E; Pfeffer, MA; Pitt, B; Shah, SJ; Solomon, SD; Voors, AA, 2019) |
| "We applied transportability methods to 2 large, multicenter cardiovascular disease treatment trials: the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist; n=3445) comparing spironolactone to placebo for heart failure (for which site anomalies were suspected) and the ACCORD BP trial (Action to Control Cardiovascular Risk in Diabetes-Blood Pressure; n=4733) comparing intensive-to-standard blood pressure treatment (for which site anomalies were not suspected)." | 3.91 | Detecting Anomalies Among Practice Sites Within Multicenter Trials. ( Basu, S; Berkowitz, SA; Rudolph, KE, 2019) |
| "Patient data were pooled from the CHARM-Preserved (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity), I-PRESERVE (Irbesartan in Heart Failure with Preserved Ejection Fraction), and TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial) studies and were examined for the association between having a pacemaker and the risk of the primary composite of cardiovascular death or HF hospitalization, the individual components of the composite, the 2 main modes of cardiovascular death (i." | 3.91 | Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. ( Anand, IS; Carson, PE; Desai, AS; Docherty, KF; Granger, CB; Jhund, PS; Komajda, M; McKelvie, RS; McMurray, JJV; Petrie, MC; Pfeffer, MA; Shen, L; Solomon, SD; Swedberg, K; Zile, MR, 2019) |
| "BACKGROUND In the setting of acute decompensated heart failure (ADHF), tolvaptan, a selective V₂ receptor antagonist, did not alter plasma renin activity or angiotensin II level, but significantly increased plasma aldosterone by the activation of V₁ₐ receptor, suggesting that a high-dose mineralocorticoid receptor antagonist (MRA) combined with a V₂ receptor antagonist might be of interest, especially in ADHF patients." | 3.91 | Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report. ( Kajimoto, K; Otsubo, S, 2019) |
| "For study purposes, advanced heart failure was defined as recurrence of congestive heart failure signs despite receiving the initially prescribed dose of pimobendan, angiotensin-converting-enzyme inhibitor (ACEI), and furosemide >4 mg/kg/day." | 3.88 | Clinical findings and survival time in dogs with advanced heart failure. ( Beaumier, A; Freeman, LM; Rush, JE; Yang, VK, 2018) |
| "Patients with HFpEF, randomized to spironolactone versus placebo in the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) in North and South America, were grouped according to self-described black and nonblack race." | 3.88 | Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. ( Anand, I; Boineau, R; Claggett, B; Desai, AS; Fang, JC; Heitner, JF; Lewis, EF; Liu, J; O'Meara, E; Pfeffer, MA; Pitt, B; Retta, TM; Rouleau, JL; Shah, AM; Shah, SJ; Solomon, SD; Stamos, TD; Sweitzer, NK, 2018) |
| "Certain patients with heart failure (HF) are unable to tolerate spironolactone therapy due to hyperkalemia." | 3.88 | Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. ( Bounthavong, M; Butler, J; Dolan, CM; Dunn, JD; Fisher, KA; Hauptman, PJ; Oestreicher, N; Pitt, B; Veenstra, DL, 2018) |
| " We evaluated whether spironolactone reduced albuminuria at the 1-year visit in a subpopulation (N=744)." | 3.88 | Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. ( Anand, I; Claggett, B; Desai, AS; Fang, JC; Lewis, EF; O'Meara, E; Pfeffer, MA; Pitt, B; Rouleau, JL; Selvaraj, S; Shah, SJ; Solomon, SD; Sweitzer, NK, 2018) |
| "The TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) trial randomized patients with HFpEF and either prior hospitalization for HF or elevated natriuretic peptide levels (B-type NP [BNP] ≥100 pg/ml or N-terminal proBNP ≥360 pg/ml) to spironolactone or placebo." | 3.85 | Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. ( Anand, IS; Claggett, B; Desai, AS; Fleg, JL; Liu, J; O'Meara, E; Pfeffer, MA; Pitt, B; Rector, TS; Shah, AM; Shah, SJ; Solomon, SD, 2017) |
| "The objective of this study was to determine the cost-effectiveness of eplerenone compared with usual care in patients with chronic heart failure and New York Heart Association (NYHA) Class II symptoms." | 3.83 | Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective. ( Ademi, Z; Liew, D; Pasupathi, K, 2016) |
| " We investigated whether spironolactone, an aldosterone receptor blocker, attenuated isoprenaline (Iso)-induced heart failure in rats and also studied the mechanism for the same." | 3.83 | Spirolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats. ( Chen, S; Guo, Z; Liu, J; Xi, D; Zhao, J; Zhou, H, 2016) |
| "Using a propensity score matching of 1:2 ratio, this retrospective claims database study compared spironolactone prescription (n=65) and non-spironolactone therapy (n=130) in hypertensive patients with LVH [left ventricular mass index (LVMI)>125g/m(2) for men and >110g/m(2) for women] and suspected diastolic dysfunction (E/E' ratio between 8 and 15) and without clinical signs or symptoms of heart failure." | 3.83 | Association between long-term prescription of aldosterone antagonist and the progression of heart failure with preserved ejection fraction in hypertensive patients. ( Bian, L; Fan, L; Fan, YQ; Gu, J; Han, ZH; Wang, CQ; Xie, YS; Xu, ZJ; Yin, ZF; Zhang, HL; Zhang, JF, 2016) |
| "Risk of hyperkalemia in heart failure patients was significantly associated with spironolactone use (odds ratio (OR) (95% confidence interval (CI)) = 13." | 3.81 | Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort. ( Abbas, S; Harder, S; Ihle, P; Schubert, I, 2015) |
| "We investigated the relationship between spironolactone use and all-cause mortality in acute decompensated heart failure (ADHF) patients with severe renal dysfunction." | 3.81 | Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: Data from the Korean Heart Failure Registry. ( Chae, SC; Cho, MC; Choi, DJ; Han, S; Hong, N; Jeon, ES; Kang, SM; Kim, JJ; Lee, MM; Oh, BH; Oh, J; Ryu, KH; Song, MK; Yoo, BS; Youn, JC, 2015) |
| "Early spironolactone treatment decreases heart failure development frequency by improving myocardial systolic and diastolic function and attenuating hypertrophy and fibrosis in spontaneously hypertensive rats." | 3.81 | Early Spironolactone Treatment Attenuates Heart Failure Development by Improving Myocardial Function and Reducing Fibrosis in Spontaneously Hypertensive Rats. ( Blotta, DA; Bonomo, C; Campos, DH; Cezar, MD; Cicogna, AC; Damatto, RL; Gomes, MJ; Lima, AR; Martinez, PF; Okoshi, K; Okoshi, MP; Oliveira, SA; Pagan, LU; Rosa, CM, 2015) |
| "Dogs subjected to RVP for 8 weeks in the absence or presence of eplerenone treatment during the final 4 weeks of pacing were assessed by echocardiography, electrophysiology study,ventricular fibrosis measurements, and inflammatory cytokine mRNA expression analysis." | 3.80 | Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure. ( , 2014) |
| " This study's aim was to determine whether chronic spironolactone treatment prevents formation of local electrical activation delays in the cardiomyopathic ventricle by attenuating inflammatory pathways and myocardial fibrosis." | 3.79 | Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation. ( Esposito, CT; Jeyaraj, D; Lu, Y; Stambler, BS; Varahan, S, 2013) |
| "It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors." | 3.79 | [Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors]. ( Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA, 2013) |
| "Two-month-old SHHF rats were randomized to receive no treatment (SHHF group), a standard heart failure therapy (quinapril-torasemide-carvedilol; ST-SHHF group), or the combination of eplerenone and standard heart failure therapy (Eple+ST-SHHF group) for 20 months." | 3.79 | Eplerenone enhances cardioprotective effects of standard heart failure therapy through matricellular proteins in hypertensive heart failure. ( Aragoncillo, P; Caro-Vadillo, A; Casanueva-Eliceiry, S; Egido, J; Fernández-Cruz, A; Gómez-Garre, D; Muñoz-Pacheco, P; Ortega-Hernández, A, 2013) |
| " Spironolactone is well known to have an anti-aldosteronergic effect, and this agent could improve cardiac sympathetic nerve activity (CSNA) in patients with chronic heart failure (CHF)." | 3.79 | Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure. ( Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Matsumoto, N; Minami, K; Sato, Y; Sumino, H; Takayama, Y; Toyama, T, 2013) |
| " For example, studies of the expensive drug eplerenone for congestive heart failure have not included a spironolactone arm, although there is reasonable evidence that spironolactone would be safe and effective, and spironolactone is inexpensive." | 3.79 | Ethics and eplerenone. ( Fugh-Berman, AJ; Gupta, S; Scialli, A, 2013) |
| "We prospectively studied 18 852 patients (age 71±12 years; 28% women) with NYHA I-IV and ejection fraction <40% who were registered in the Swedish Heart Failure Registry between 2000 and 2012 and who were (n=6551) or were not (n=12 301) treated with spironolactone." | 3.79 | Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study. ( Dahlström, U; Edner, M; Hallberg, P; Lund, LH; Melhus, H; Svennblad, B, 2013) |
| " The study aimed to evaluate a potential influence of eplerenone treatment on the total number of EPCs in patients with chronic heart failure." | 3.78 | Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure. ( Barz, D; Betge, S; Ferrari, M; Figulla, HR; Florvaag, A; Franz, M; Fritzenwanger, M; Goebel, B; Jung, C; Kretschmar, D; Kuethe, F; Oberle, V, 2012) |
| " Fifty-five rats with heart failure were then randomized in 5 groups: sham, MI, and MI treated for 4 weeks with spironolactone (10 mg·kg·d), atenolol (1 mg·kg·d), or both." | 3.78 | Effects of spironolactone alone and in addition to a β-blocker on myocardial histological and electrical remodeling in chronic severe failing rat hearts. ( Callebert, J; Champ-Rigot, L; Delcayre, C; Gomes, S; Milliez, P; Samuel, JL, 2012) |
| "0 mEq/l of potassium) ranges from 6 to 12% in patients on spironolactone with congestive cardiac failure (CCF)." | 3.78 | Hyperkalaemia in the age of aldosterone antagonism. ( Ashman, N; Chapagain, A, 2012) |
| "To investigate whether exposure to spironolactone treatment affects the risk of incident breast cancer in women over 55 years of age." | 3.78 | Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. ( Macdonald, TM; Mackenzie, IS; Morant, S; Thompson, A; Wei, L, 2012) |
| "In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial, hospitalized AMI patients complicated by left ventricular ejection fraction ≤40% and symptoms of HF receiving standard therapy were randomized 3-14 days post-AMI to receive eplerenone 25-50 mg/day (n = 3319) or placebo (n = 3313)." | 3.77 | Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. ( Aban, IB; Ahmed, A; Ahmed, MI; Deedwania, PC; Feller, MA; Love, TE; Pitt, B, 2011) |
| "Risk of morbidity and mortality in patients with severe heart failure (HF) is reduced by blockade of aldosterone receptors with spironolactone." | 3.77 | Use, tolerability and compliance of spironolactone in the treatment of heart failure. ( Beauchemin, C; Lachaine, J; Ramos, E, 2011) |
| "The widespread use of spironolactone in patients with congestive heart failure (CHF) has resulted in side effects and complications." | 3.77 | Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic. ( Caspi, A; Goland, S; Korbut, Z; Malnick, S; Naugolny, V; Rozen, I, 2011) |
| "The purpose of this study was to determine whether a diuretic effect may be detectable in patients treated with eplerenone, a mineralocorticoid receptor antagonist, as compared with placebo during the first month of EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival study) (n = 6,080) and whether this was associated with eplerenone's beneficial effects on cardiovascular outcomes." | 3.77 | Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival St ( Fay, R; Gustafsson, F; Ménard, J; Pitt, B; Rossignol, P; Zannad, F, 2011) |
| "To identify patient-specific factors associated with spironolactone-induced potassium level elevation in patients with heart failure." | 3.76 | Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure. ( Cavallari, LH; Dai, Y; Groo, VL; Patel, SR; Stamos, TD; Viana, MA, 2010) |
| "The EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure and Survival Study) showed that the use of aldosterone blockade with eplerenone decreased mortality in patients with heart failure after acute myocardial infarction, and a subsequent analysis showed eplerenone to be highly cost effective in this population." | 3.76 | Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS. ( Caro, J; Kolm, P; Mahoney, EM; Spertus, J; Weintraub, WS; Willke, R; Zhang, Z, 2010) |
| "Despite a marked increased in the use of spironolactone in patients with and without heart failure, no increase was seen in hospital admissions for hyperkalaemia and outpatient hyperkalaemia actually fell." | 3.76 | Spironolactone use and renal toxicity: population based longitudinal analysis. ( Fahey, T; Macdonald, TM; Struthers, AD; Watson, AD; Wei, L, 2010) |
| "A 75-year-old man with post-MI heart failure and an ejection fraction of 15 % was treated with an ACE-inhibitor, spironolactone and a beta-blocker." | 3.76 | [An elderly man with known heart failure admitted with cardiogenic shock]. ( Fagerheim, AK; Hardersen, R; Hovland, A; Nielsen, EW, 2010) |
| "This study's aim was to determine whether chronic eplerenone treatment protects against detrimental ventricular electrical remodeling and development of an arrhythmogenic substrate in a rapid ventricular pacing (RVP)-induced heart failure model." | 3.75 | Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure. ( Hoeker, G; Laurita, KR; Martovitz, NL; Shroff, SC; Stambler, BS, 2009) |
| "The purpose of this study was to determine whether spironolactone use is associated with fractures in men with congestive heart failure (CHF)." | 3.74 | Fracture risk in men with congestive heart failure risk reduction with spironolactone. ( Ahmad, K; Bush, AJ; Carbone, LD; Chishti, WA; Cho, T; Cross, JD; Dhawan, S; Dishmon, DA; Gupta, M; Hajjar, MA; Haskin, AR; Khan, BQ; Khan, M; Khouzam, RN; Nasser, W; Nesheiwat, JP; Raza, SH; Sepanski, RJ; Weber, KT; Womack, CR, 2008) |
| "The incidence of hyperkalemia related to spironolactone use is low in stable heart failure; however, it has not been studied during decompensation." | 3.74 | Hyperkalemia during spironolactone use in patients with decompensated heart failure. ( Barretto, AC; Cardoso, JN; Lima, MV; Morgado, PC; Munhoz, RT; Ochiai, ME, 2008) |
| "To investigate if treatment with an aldosterone antagonist affects the outcomes of treatment by fixed dose combination of isosorbide dinitrate/hydralazine (FDC I/H) or placebo in black heart failure (HF) patients treated with contemporary HF medications." | 3.74 | Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial. ( Cohn, JN; Ghali, JK; Lindenfeld, J; Sabolinski, ML; Tam, SW; Taylor, AL; Worcel, M, 2008) |
| "Since the Randomized Aldactone Evaluation Study (RALES), the use of spironolactone is recommended in systolic heart failure (HF) patients that have been in New York Heart Association (NYHA) class III or IV." | 3.74 | Safety of spironolactone use in ambulatory heart failure patients. ( Azevedo, A; Bettencourt, P; Lopes, RJ; Lourenço, AP; Mascarenhas, J, 2008) |
| " We performed 4 separate studies to investigate whether spironolactone treatment would reduce levels of C-reactive protein (CRP), a marker of inflammation, in serum samples taken from patients suffering from different degrees of heart failure." | 3.74 | Effect of spironolactone on C-reactive protein levels in patients with heart disease. ( Farquharson, CA; Godfrey, V; Macdonald, JE; Struthers, AD; Yee, KM, 2007) |
| "Spironolactone use for heart failure (HF) has increased dramatically after the publication of the Randomized Aldactone Evaluation Study trial; yet, few studies have examined its real-world impact." | 3.74 | The effect of spironolactone use on heart failure mortality: a population-based study. ( Cox, JL; Hassan, A; Howlett, J; Johnstone, DE; Ouzounian, M, 2007) |
| "The Epleronone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial demonstrated that selective aldosterone blockade with eplerenone significantly reduced total mortality by 15%, combined cardiovascular (CV) mortality/CV hospitalization by 13%, CV mortality by 17% and sudden cardiac death by 21%, vs." | 3.74 | Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. ( Abuissa, H; O'Keefe, JH; Pitt, B, 2008) |
| "Fifteen patients with severe OSA, hypertension, and diastolic heart failure were hospitalized to receive IV furosemide, 20 mg, and spironolactone, 100 mg, bid for 3 days." | 3.74 | Diuretics in obstructive sleep apnea with diastolic heart failure. ( Battisti, A; Brussino, L; Bucca, CB; Cicolin, A; Mangiardi, L; Mutani, R; Rolla, G, 2007) |
| "A population-based analysis has suggested that the publication of the RALES (Randomized Aldactone Evaluation Study) in late 1999 was associated with both the wider use of spironolactone to treat heart failure and a corresponding increase in hyperkalaemia-associated morbidity and mortality in patients also being treated with ACE inhibitors." | 3.74 | Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES). ( Gerrits, CM; Hauben, M; Madigan, D; Reich, L, 2007) |
| "Spironolactone contributes to AF prevention in congestive heart failure dogs induced by chronic rapid ventricular pacing, which is related to atrial fibrosis reduction and independent of hemadynamics." | 3.74 | Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. ( Cao, Y; Dong, G; Han, W; Huo, H; Li, WM; Wang, BC; Wei, N; Xiu, CH; Yang, SS; Zhou, G; Zhou, HY, 2008) |
| "Concerns have been raised about the appropriateness of spironolactone use in some patients with heart failure." | 3.73 | Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. ( Foody, JM; Gross, CP; Havranek, EP; Krumholz, HM; Masoudi, FA; Rathore, SS; Wang, Y, 2005) |
| "After the Randomized Aldactone Evaluation Study (RALES) demonstrated a 30% mortality benefit for treating severe heart failure patients with spironolactone, acceptance of this drug was overwhelming." | 3.73 | The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. ( Gottlieb, SS; Rao, K; Sawyer, R; Shah, KB, 2005) |
| "Atrial fibrosis caused by chronic CHF is reduced by spironolactone." | 3.73 | Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. ( Beaufils, P; Deangelis, N; Delcayre, C; Hatem, SN; Leenhardt, A; Milliez, P; Robidel, E; Rucker-Martin, C; Vicaut, E, 2005) |
| "Aldosterone plays an important role in the pathophysiology of congestive heart failure (CHF), and spironolactone improves cardiovascular function and survival rates in patients with CHF." | 3.73 | Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. ( Abassi, Z; Gamliel-Lazarovich, A; Hamoud, S; Hayek, T; Kaplan, M; Karry, R; Keidar, S; Pavlotzky, E, 2005) |
| "We selected three large placebo-controlled trials of patients with chronic heart failure, in which ACE-inhibitors (ACE-Is), beta-blockers, and spironolactone proved to be safe and effective." | 3.73 | Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. ( Balk, AH; Boersma, E; Cleland, JG; Follath, F; Jimenez-Navarro, M; Komajda, M; Lenzen, MJ; Reimer, WJ; Simoons, ML; Swedberg, K, 2005) |
| "The paper contains presentation of basics of clinical pharmacology of aldosterone receptor blockers specifically that of spironolactone and eplerenone, and discussion of results of 2 large randomized placebo controlled trials which showed that long term use of aldosterone receptor blockers allowed to improve prognosis of patients with severe chronic heart failure and postinfarction systolic left ventricular dysfunction, and to reduce requirements in repetitive hospitalizations." | 3.73 | [The place of aldosterone receptor blockers in the treatment of chronic heart failure]. ( , 2005) |
| " However, especially in chronic heart failure (CHF) patients plasma angiotensin II and aldosterone levels can be elevated despite ACE inhibition, the so-called ACE escape." | 3.73 | Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. ( Boomsma, F; Lok, DJ; Plokker, HW; van de Wal, RM; van der Horst, FA; van Gilst, WH; van Veldhuisen, DJ; Voors, AA, 2006) |
| "Patients with congestive heart failure are at risk for hiperkaliemia because of coexisting comorbidities and use of multiple medications that impair potassium excretion--such as angiotensin-converting enzyme inhibitors or spironolactone." | 3.73 | [Late drug-induced hyperkalemia in a patient with congestive heart failure]. ( Bułło, B; Konopa, J; Rutkowski, B, 2005) |
| "The effect of spironolactone on clinical outcomes in patients with mild heart failure is unclear." | 3.73 | Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis. ( Baliga, RR; Koelling, TM; Pitt, B; Ranganna, P, 2006) |
| "Eplerenone suppresses inducibility of sustained atrial tachyarrhythmias, selectively prolongs atrial ERPs, and attenuates LV diastolic remodeling in RVP-induced CHF." | 3.73 | Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. ( Hoit, BD; Martovitz, NL; Ryu, K; Shroff, SC; Stambler, BS, 2006) |
| " Since chronic inhibition of nitric oxide (NO) synthase with N(omega)-nitro-L-arginine methyl ester (L-NAME) induces systemic hypertension associated with cardiovascular inflammation and remodeling, we examined the potential role of aldosterone in this process using eplerenone, a selective aldosterone receptor antagonist." | 3.73 | The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats. ( Asano, Y; Fujita, M; Hirata, A; Hori, M; Kitakaze, M; Minamino, T; Okada, K; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H; Tsukamoto, O; Yamasaki, S; Yulin, L, 2006) |
| "A population-based study and anecdotal reports have indicated that the publication of the Randomized Aldactone Evaluation Study (RALES) was associated with not merely a broader use of spironolactone in the treatment of heart failure, but also with a coinciding sharp increase in hyperkalemia-associated morbidity/mortality in patients also being treated with ACE-inhibitors." | 3.73 | Reports of hyperkalemia after publication of RALES--a pharmacovigilance study. ( Gerrits, CM; Hauben, M; Reich, L, 2006) |
| "To retrospectively investigate the effect of carvedilol and spironolactone plus furosemide, administered concomitantly with an angiotensin II converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB) to patients with chronic heart failure (CHF)." | 3.73 | Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil. ( Hirooka, K; Nakayama, D; Saito, M; Takada, M; Yasumura, Y, 2006) |
| "In patients with severe left ventricular dysfunction (EF < 30%) after acute myocardial infarction long-term treatment with spironolactone at daily dose 25-50 mg does not reduce mortality rate in long-term follow-up." | 3.73 | [Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial infarction]. ( Chizyński, K; Goch, JH; Maciejewski, M; Ptaszyński, P; Ruta, J, 2006) |
| "To evaluate the transcardiac extraction of aldosterone before and after spironolactone administration to patients with congestive heart failure, we measured the plasma aldosterone in the aortic root and the coronary sinus in eight congestive heart failure patients with dilated cardiomyopathy." | 3.72 | Transcardiac gradient of aldosterone before and after spironolactone in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Ishii, C; Maeda, K; Matsumoto, T; Ohnishi, M; Takayama, T; Tsutamoto, T; Tsutsui, T; Wada, A; Yamamoto, T, 2003) |
| "The effects of low-dose oral spironolactone (SPIRO) in a rat model of hypertensive heart failure (spontaneously hypertensive heart failure rat) were compared with its effects when combined with captopril (CAP)." | 3.72 | Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. ( Bauer, JA; Ghosh, S; Holycross, BJ; Kambara, A; Kwiatkowski, P; McCune, SA; Schanbacher, B; Wung, P, 2003) |
| "To investigate the effects of adding the selective aldosterone receptor antagonist eplerenone to ACE inhibition on endothelium-dependent vasodilation in rats with chronic heart failure (CHF)." | 3.72 | Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. ( Bauersachs, J; Ertl, G; Fraccarollo, D; Hildemann, SK; Schäfer, A; Tas, P, 2003) |
| "Spironolactone is increasingly being used in the treatment of heart failure." | 3.72 | The safety of spironolactone treatment in patients with heart failure. ( Anton, C; Cox, AR; Ferner, RE; Watson, RD, 2003) |
| "Recent studies have shown a fall in global mortality with minimal side effects in severe congestive heart failure (CHF) patients receiving angiotensin-converting enzyme inhibitors (ACEI) plus spironolactone (SLN)." | 3.72 | Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. ( Cruz, AA; Cruz, CS; Marcílio de Souza, CA, 2003) |
| " In patients with severe left ventricular dysfunction spironolactone could reduce death and hospitalisation." | 3.72 | [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement]. ( Kolloch, R; Offers, E, 2003) |
| "In mice with MI, eplerenone attenuates progression of heart failure comparably to ACEi, and its effect is independent of BP lowering." | 3.72 | Role of a selective aldosterone blocker in mice with chronic heart failure. ( Carretero, OA; Liu, YH; Peterson, E; Rhaleb, NE; Rudolph, AE; Wang, D; Xu, J; Yang, XP, 2004) |
| "The addition of spironolactone, an aldosterone antagonist, to standard therapy can reduce the risk of both morbidity and mortality in patients with severe heart failure." | 3.72 | Spironolactone use in patients with heart failure. ( Alexander, SL; DiVall, MV; Gonyeau, MJ; Trujillo, JM, 2004) |
| "In a population of previously hospitalised patients with low previous uptake of b-blockers and no uptake of N-LEI, optimal combined uptake of interventions through specialist heart failure services can potentially help prevent or postpone approximately four times as many readmissions and a minimum of twice as many deaths compared with simply optimising uptake of spironolactone (not necessarily requiring specialist services)." | 3.72 | Assessing the impact of heart failure specialist services on patient populations. ( Cook, GA; Edwards, R; Havely, D; Heller, RF; Lyratzopoulos, G; McElduff, P, 2004) |
| "To determine whether the effects of spironolactone on potassium homeostasis vary by race by comparing serum potassium concentrations and potassium supplement use in African-American and Caucasian patients receiving spironolactone for heart failure." | 3.72 | Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure. ( Beitelshees, AL; Cavallari, LH; Dunlap, SH; Fashingbauer, LA; Groo, VL; Southworth, MR; Viana, MA; Williams, RE, 2004) |
| "The Randomized Aldactone Evaluation Study (RALES) demonstrated that spironolactone significantly improves outcomes in patients with severe heart failure." | 3.72 | Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. ( Austin, PC; Juurlink, DN; Kopp, A; Laupacis, A; Lee, DS; Mamdani, MM; Redelmeier, DA, 2004) |
| "Treatment with spironolactone (SPL) is beneficial in patients with severe congestive heart failure (CHF)." | 3.72 | How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? ( Atar, D; Galatius, S; Gustafsson, F; Hildebrandt, PR; Svensson, M, 2004) |
| "To assess how well heart failure patients tolerate spironolactone in routine clinical practice." | 3.72 | Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message. ( Gillespie, ND; Struthers, AD; Witham, MD, 2004) |
| "A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%)." | 3.72 | Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. ( Aaronson, KD; Koelling, TM; Tamirisa, KP, 2004) |
| "854(DFAC), where C(cr) is the estimated creatinine clearance (ml/min); CCB=1 for concomitant administration of calcium channel blockers and CCB=zero otherwise; CHF=1 for the patients with congestive heart failure and CHF=zero otherwise; SPI=1 for concomitant administration of spironolactone and SPI=zero otherwise; DFAC=1 for administration of a half-tablet of digoxin and DFAC=zero otherwise." | 3.71 | Pharmacoepidemiologic detection of calcium channel blocker-induced change on digoxin clearance using multiple trough screen analysis. ( Goto, Y; Higuchi, S; Minemoto, M; Ohdo, S; Suematsu, F; Yukawa, E; Yukawa, M, 2002) |
| "This analysis was carried out by assessing all the direct benefits and costs, derived from the association of either spironolactone or placebo with the standard therapy for heart failure in patients with functional degree III and IV." | 3.71 | [Cost-benefit analysis of spironolactone use in the treatment of chronic heart failure]. ( Alvarez, JS; Vílchez, FG, 2001) |
| "In patients with chronic heart failure, spironolactone added to conventional treatment may lead to serious and, occasionally, fatal hyperkalaemia." | 3.71 | Serious adverse events experienced by patients with chronic heart failure taking spironolactone. ( Berry, C; McMurray, JJ, 2001) |
| " To these we now add anti-aldosterone strategies with the phenomenal success of spironolactone in reducing mortality in severe heart failure." | 3.71 | Exciting new drugs on the horizon - eplerenone, a selective aldosterone receptor antagonist (SARA). ( Coats, AJ, 2001) |
| "The mineralocorticoid (MC) receptor antagonist spironolactone (SL) improves morbidity and mortality in patients with congestive heart failure (CHF)." | 3.71 | Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. ( Beltz, TG; Felder, RB; Francis, J; Johnson, AK; Wei, SG; Weiss, RM; Zimmerman, K, 2001) |
| "We sought to investigate the effects of adding spironolactone (SP) to angiotensin-converting enzyme (ACE) inhibition on endothelium-dependent vasodilation in rats with chronic heart failure (CHF)." | 3.71 | Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. ( Bauersachs, J; Christ, M; Ertl, G; Fraccarollo, D; Heck, M; Hildemann, SK; Wehling, M, 2002) |
| "We compared the rate of prescription of low-dose spironolactone among patients with heart failure in a general medical inpatient setting and in a specialist left ventricular (LV) dysfunction clinic." | 3.71 | Spironolactone prescribing in heart failure: comparison between general medical patients and those attending a specialist left ventricular dysfunction clinic. ( McMullan, R; Silke, B, 2001) |
| "Current guidelines recommend drugs which reduce neurohormonal activation as standard therapy for heart failure: angiotensin converting-enzyme (ACE) inhibitors, beta-blockers and spironolactone." | 3.71 | [Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study]. ( Piérard, L, 2002) |
| "Serum potassium concentration should be measured immediately before operation to detect hyperkalemia in heart failure patients treated with spironolactone." | 3.71 | Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency. ( Carpenter, JP; Cheung, AT; Hu, Y, 2002) |
| "Of those physiological factors which have been examined in this study, age and total body weight were most closely correlated with digoxin clearance." | 3.70 | Population analysis for the optimization of digoxin treatment in Japanese paediatric patients. ( Higuchi, S; Minemoto, M; Suematsu, F; Yukawa, E, 1999) |
| "We report four cases of hyperkalemia induced by the association of spironolactone with ACE inhibitor in geriatric patients." | 3.70 | Elderly heart failure patients with drug-induced serious hyperkalemia. ( Swine, CH; Vanpee, D, 2000) |
| "This case report presents a patient who developed severe life-threatening hyperkalemia following combined treatment with an ACE-inhibitor and the aldosterone-antagonist spironolactone for his congestive heart failure and who also suffered from pre-existing moderate renal failure." | 3.70 | [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure]. ( Ferrari, P; Frey, FJ; Fuster, D, 2000) |
| "Short- and long-term clinical effects of the angiotensin-converting enzyme (ACE) inhibitor captopril in severe congestive heart failure (CHF) were evaluated during a 3-year open study of 124 inpatients with New York Heart Association (NYHA) functional class III or IV CHF refractory to treatment with cardiac glycosides and high doses of loop diuretics." | 3.68 | Captopril and spironolactone therapy for refractory congestive heart failure. ( Dahlström, U; Karlsson, E, 1993) |
| "We have previously demonstrated that baroreceptor discharge sensitivity is depressed in dogs with experimental heart failure and that this depressed sensitivity can be reversed by the Na+,K(+)-ATPase inhibitor ouabain." | 3.68 | Aldosterone reduces baroreceptor discharge in the dog. ( McClain, JM; Wang, W; Zucker, IH, 1992) |
| "In patients with congestive heart failure (CHF), the role of aldosterone in the abnormal sodium (Na+) retention and the determinants of plasma aldosterone (PA) including plasma atrial natriuretic factor (hANF), plasma renin activity (PRA), and plasma potassium (K+) have not been fully elucidated." | 3.68 | Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. ( Abraham, WT; Dürr, JA; Hensen, J; Schrier, RW, 1991) |
| "Although many new drugs useful in the treatment of congestive heart failure have been introduced during the past 25 years, spironolactone continues to have an important role in the management of this condition." | 3.68 | Spironolactone in the management of congestive heart failure. ( Muller, JE, 1990) |
| "In 3 patients with severe cardiac failure high dose therapy with the ACE inhibitor enalapril was instituted during a state of extracellular volume depletion." | 3.67 | [Severe complications during enalapril therapy for heart insufficiency]. ( Stäubli, M; Wieland, T, 1988) |
| "Acute reversible renal failure with hyperkalemia developed in a 42-year-old woman during treatment of heart failure and hypertension with high doses of enalapril and diuretics." | 3.67 | [Acute reversible kidney insufficiency due to enalapril during diuretic-treated heart insufficiency]. ( Degenhardt, S, 1987) |
| "Twenty-three optimally digitalized patients with congestive heart failure completed a 4-week treatment period with a fixed-drug association of 20 mg furosemide plus 50 mg spironolactone." | 3.67 | A fixed-dose combination of furosemide and spironolactone in digitalized congestive heart failure patients. ( Collia, LF; Ledesma, GA; Tutera, A; Yasky, J, 1986) |
| "Seventeen non-digitalized congestive heart failure patients were treated with only the fixed-dose combinations of 20 mg furosemide and 50 mg spironolactone or 20 mg furosemide and 100 mg spironolactone, in a daily dose of 1 or 2 capsules, over a 4-week period." | 3.67 | The treatment of non-digitalized congestive heart failure patients with a fixed-dose combination of furosemide and spironolactone. ( Collia, LF; Ledesma, GA; Tutera, A; Yasky, J, 1986) |
| "In a retrospective study conducted in 213 patients with cardiac pacemakers having severe bradycardiac heart failure with oedema, the addition of the aldosterone-antagonist spironolactone to a diuretic therapy was shown to have a favourable influence on the degree of compensation." | 3.66 | [Spironolactone in digitalis-requiring cardiac insufficiency following pacemaker implantation]. ( Klüsener, W; Sabin, G, 1981) |
| " This report describes 74 patients who had severe congestive heart failure treated with a combination of furosemide and spironolactone in whom this complication developed." | 3.66 | Treatment of refractory congestive heart failure and normokalemic hypochloremic alkalosis with acetazolamide and spironolactone. ( Khan, MI, 1980) |
| "The therapeutic efficacy of 100 mg spironolactone once daily in patients with congestive heart failure was evaluated in a multi-centre study in general practice." | 3.66 | Spironolactone in the long-term management of patients with congestive heart failure. ( Smith, AG, 1980) |
| "The elimination half-life (T1/2) of canrenone, the principal unconjugated metabolite of spironolactone, was 59 h (range 32-105 h) in 5 patients with chronic liver disease and 37 h (range 19-48 h ) in 7 patients withcongestive heart failure." | 3.65 | Elimination of canrenone in congestive heart failure and chronic liver disease. ( Branch, R; Jackson, L; Levine, D; Ramsay, L, 1977) |
| "Dark red nodules that drained an opaque amber liquid developed on the extensor surfaces of both legs in a 69-year-old woman receiving furosemide and spironolactone for congestive heart failure." | 3.65 | Panniculitis of the legs with urate crystal deposition. ( Niemi, KM, 1977) |
| "The renin-angiotensin-aldosterone system and electrolyte levels in 11 patients with heart failure controlled on digoxin and frusemide were investigated after separate periods of Slow K, spironolactone, and amiloride therapy." | 3.65 | Effect of potassium-sparing diuretics on the renin-angiotensin-aldosterone system and potassium retention in heart failure. ( Espiner, EA; Hughes, H; Nicholls, MG; Rogers, T, 1976) |
| "Metabolic balance studies were carried out on five patients with resistant heart failure treated with spironolactone and other diuretics." | 3.64 | Metabolic studies on patients with resistant heart failure treated by spironolactone. ( BAYLEY, TA; FORBATH, PG; HIGGINS, HP; WILSON, JK, 1962) |
| "Spironolactone was evaluated as a diuretic in the therapy of six patients with chronic severe congestive heart failure, during which metabolic balance studies were performed." | 3.64 | EFFECT OF AN ALDOSTERONE ANTAGONIST (SPIRONOLACTONE) ON PATIENTS WITH SEVERE CONGESTIVE HEART FAILURE. ( CARRUTHERS, BM; LEDRAY, RD; MCINTOSH, HW; SERAGLIA, M; WALSH, GC, 1963) |
| "Triamterene therapy was evaluated in 35 patients with congestive heart failure over a period of two and one-half years." | 3.64 | CLINICAL EXPERIENCE WITH A NEW DIURETIC, TRIAMTERENE, IN CONJESTIVE HEART FAILURE. ( LAUFER, ST; MAHABIR, RN, 1964) |
| "Spironolactone did not increase the odds of weight loss but reduced the odds of weight gain." | 3.11 | Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT. ( Claggett, BL; Ferreira, JP; Pfeffer, M; Pitt, B; Rossignol, P; Solomon, SD; Zannad, F, 2022) |
| "Spironolactone therapy was triggered by the detection of subclinical LVD (global longitudinal strain [GLS] ≤16%) or diastolic abnormalities (at least one of E/e' >15, E/e' >10 with left atrial enlargement [LAE] or impaired relaxation [E/A < 0." | 3.11 | Screening-guided spironolactone treatment of subclinical left ventricular dysfunction for heart failure prevention in at-risk patients. ( Harris, J; Marwick, TH; Potter, E; Stephenson, G; Wright, L, 2022) |
| "Treatment with spironolactone did not affect the association significantly." | 3.11 | Time-averaged cumulative blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: analysis from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. ( Huang, R; Liao, X; Lin, Y; Wu, R; Ye, X; Zhong, X; Zhuang, X, 2022) |
| "Additionally, ischemic heart disease adversely impacts the clinical course of HFrEF patients; however, its role in HFpEF is not fully understood." | 3.01 | Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial). ( Elsaid, O; McCullough, PA; Rahimi, G; Tecson, KM, 2021) |
| "Obesity is common in heart failure with preserved ejection fraction (HFpEF)." | 3.01 | Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction. ( Butler, J; Elkholey, K; Papadimitriou, L; Stavrakis, S; Thadani, U, 2021) |
| " Cardiac endpoint was defined as cardiac death or euthanasia, recurrence of pulmonary edema, necessity for nonauthorized cardiac drug(s) or a furosemide dosage >8 mg/kg/d." | 3.01 | Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST). ( Atkins, CE; Blondel, T; Coffman, M; Feng, S; Garelli-Paar, C; Guillot, E; Heartsill, S, 2021) |
| "Treatment with spironolactone in diabetic patients did not lead to large changes in biomarkers." | 3.01 | Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. ( Brunner-La Rocca, HP; Clark, AL; Cleland, JGF; Cosmi, F; Cuthbert, J; Ferreira, JP; Girerd, N; Heymans, SRB; Mariottoni, B; Pellicori, P; Petutschnigg, J; Rossignol, P; Verdonschot, JAJ; Zannad, F, 2021) |
| "Spironolactone was not (P = 0." | 2.87 | Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT. ( Drazner, MH; Fang, JC; Grodin, JL; Pandey, A; Sambandam, K; Tang, WHW; Testani, JM, 2018) |
| "The impact of frailty on outcomes in randomized heart failure with preserved ejection fraction (HFpEF) trials has not been previously reported." | 2.87 | The frailty syndrome and outcomes in the TOPCAT trial. ( Claggett, B; Desai, AS; Fang, JC; Lewis, EF; Liu, J; Pfeffer, MA; Sanders, NA; Solomon, SD; Supiano, MA; Sweitzer, NK, 2018) |
| " Mineralocorticoid receptor antagonists administered at high doses may relieve congestion, overcome diuretic resistance, and mitigate the effects of adverse neurohormonal activation in AHF." | 2.84 | Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. ( Anstrom, KJ; Braunwald, E; Butler, J; Desvigne-Nickens, P; Felker, GM; Givertz, MM; Hernandez, AF; Kalogeropoulos, AP; Konstam, MA; Mann, DL; Margulies, KB; McNulty, SE; Mentz, RJ; Redfield, MM; Shah, M; Tang, WHW; Whellan, DJ, 2017) |
| "Heart failure is a major cause of morbidity and mortality globally." | 2.82 | Effect of Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction and with Reduced Ejection Fraction - A Narrative Review. ( Deoker, A; Lehker, A; Mares, A; Mukherjee, D; Rodriguez, T, 2022) |
| " The ATHENA-HF (Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure) trial is a randomized, double-blind, placebo-controlled study of the safety and efficacy of 100 mg/day spironolactone versus placebo (or continued low-dose spironolactone use in participants who are already receiving spironolactone at baseline) in 360 patients hospitalized for AHF." | 2.82 | Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. ( Anstrom, KJ; Braunwald, E; Butler, J; Felker, GM; Hernandez, AF; Kalogeropoulos, A; Konstam, MA; Redfield, MM; Shah, MR; Tang, WH, 2016) |
| " However, it is feared that an intensified, NT-proBNP-guided therapy carries a risk of adverse effects." | 2.78 | Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF. ( Brunner-La Rocca, HP; Erne, P; Estlinbaum, W; Kiencke, S; Maeder, M; Mayer, K; Muzzarelli, S; Neuhaus, M; Pfisterer, ME; Sanders-van Wijk, S; Tobler, D, 2013) |
| "08), higher dosage of spironolactone at baseline (OR 1." | 2.77 | Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy. ( Brunner-La Rocca, HP; Burkard, T; Julius, B; Maeder, MT; Muzzarelli, S; Nietlispach, F; Pfisterer, ME; Rickli, H; Toggweiler, S, 2012) |
| "Spironolactone was well tolerated when combined with conventional heart failure treatment." | 2.76 | Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs. ( Clercx, C; McEntee, K; Schuller, S; Van Israël, N; Vanbelle, S, 2011) |
| "Eplerenone was associated with a 1." | 2.74 | The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. ( Blair, JE; Gheorghiade, M; Harinstein, ME; Khan, S; Krum, H; Mukherjee, R; Pitt, B, 2009) |
| "Thiamine levels were determined using the erythrocyte transketolase activity." | 2.73 | Influence of spironolactone therapy on thiamine blood levels in patients with heart failure. ( Albanesi Filho, FM; de Albuquerque, DC; Rocha, RM; Silva, GV; Tura, BR, 2008) |
| "Spironolactone was used less frequently than other drugs." | 2.73 | Aldosterone antagonists: the most underutilized class of heart failure medications. ( Awad, KE; Guglin, M; Polavaram, L; Vankayala, H, 2007) |
| " In all patients, diuretics were administered according to a standardized dosing algorithm." | 2.73 | The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. ( Burnett, JC; Chen, HH; Frantz, RP; Hodge, DO; Karon, BL; Miller, WL; Owan, TE; Redfield, MM; Rodeheffer, RJ, 2008) |
| "Among patients with Type 2 diabetes, several Phase II studies of finerenone show promising results, supporting benefits on the heart and kidneys." | 2.72 | Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. ( Agarwal, R; Bakris, G; Bauersachs, J; Haller, H; Kolkhof, P; Wada, T; Zannad, F, 2021) |
| "Ventricular arrhythmia was recognized as the most common cause of death in this population." | 2.69 | Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. ( Coelho, O; Gruppi, CJ; Mady, C; Mansur, A; Maranhão, M; Ramires, FJ; Ramires, JA, 2000) |
| "Ventricular arrhythmias detected on 24 hour Holter monitoring didn't differ between the study groups." | 2.69 | [Comparison of the therapeutic efficacy of spironolactone and furosemide in patients with severe congestive heart failure]. ( Bednarz, B; Chamiec, T; Cybulski, J, 2000) |
| " On long term evaluation in an open design (Phase II), wherein Phase I participants continued Terminalia Arjuna in fixed dosage (500 mg 8-hourly) in addition to flexible diuretic, vasodilator and digitalis dosage for 20-28 months (mean 24 months) on outpatient basis, patients showed continued improvement in symptoms, signs, effort tolerance and NYHA Class, with improvement in quality of life." | 2.68 | Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. ( Bharani, A; Bhargava, KD; Ganguly, A, 1995) |
| " The dosage of both drugs was individually adjusted in time according to the results of serum potassium and renal function." | 2.67 | Combined therapy of captopril and spironolactone for refractory congestive heart failure. ( Han, YL; Hu, XL; Jing, QM; Liu, JQ; Tong, M, 1994) |
| "Aldosterone has been implicated in atrial remodelling representing a potential target for upstream therapies." | 2.53 | Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis. ( Korantzopoulos, P; Letsas, KP; Li, G; Liu, T; Shao, Q; Zhang, Z, 2016) |
| "19." | 2.53 | Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety. ( Bomback, AS, 2016) |
| "They are also beneficial for the treatment of heart failure, primarily due to effects in non-epithelial tissues." | 2.53 | Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences. ( Yang, J; Young, MJ, 2016) |
| " Studies investigating the optimal spironolactone dosage in such a setting recommend starting with a low dose and careful uptitration." | 2.52 | Heart failure and chronic kidney disease: should we use spironolactone? ( Agrawal, N; Agrawal, S; Garg, J; Gupta, T; Mohandas, R; Segal, M, 2015) |
| "Primary aldosteronism, caused by autonomous secretion of aldosterone by the adrenals, is estimated to account for at least 5% of hypertension cases." | 2.52 | Pharmacological treatment of aldosterone excess. ( Deinum, J; Lenders, JW; Riksen, NP, 2015) |
| " The dose-response relationship for natriuresis with spironolactone has not been explored completely as to its combination therapy responses." | 2.50 | Aldosterone and volume management in hypertensive heart disease. ( Sica, DA, 2014) |
| "Hyperkalemia is the main potential side effect of eplerenone, especially when used in combination with other medications that can cause hyperkalemia." | 2.46 | Review article: eplerenone: an underused medication? ( Abuannadi, M; O'Keefe, JH, 2010) |
| "Six prospective trials demonstrated that spironolactone use was safe in ESRD patients on hemodialysis." | 2.46 | Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe? ( Chua, D; Lo, A; Lo, C, 2010) |
| "Aldosterone is an important mediator in the pathogenesis of heart failure, and increased plasma aldosterone levels are associated with a poor prognosis." | 2.44 | Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues. ( Francis, GS; Kalidindi, SR; Tang, WH, 2007) |
| "Primary aldosteronism is one of the few potentially curable forms of hypertension." | 2.44 | Primary aldosteronism. ( Auchus, RJ; Nwariaku, FE, 2007) |
| "Both agents effectively treat hypertension and heart failure but comparisons are complicated by the deficiency of head-to-head trials and differences between patient populations." | 2.44 | A comparison of the aldosterone-blocking agents eplerenone and spironolactone. ( Krum, H; Struthers, A; Williams, GH, 2008) |
| "Aldosterone plays an important role in the pathophysiology of sodium/potassium and water homeostasis of the body." | 2.43 | Cardiovascular effects of aldosterone. ( Murin, J, 2005) |
| "Despite the advances of the treatment of congestive heart failure, nearly half of the patients diagnosed with this disease five years ago are alive today." | 2.43 | [The role of aldosterone-antagonists in the treatment of congestive heart failure]. ( Fügedi, K, 2005) |
| "Eplerenone (Inspra) is a selective aldosterone blocker." | 2.43 | Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure. ( Croom, KF; Plosker, GL, 2005) |
| "Eplerenone has the advantage, compared with spironolactone, to be better tolerated in terms of "hormonal" adverse effects." | 2.43 | [The revived interest in aldosterone antagonists]. ( Waeber, B, 2006) |
| "Two large trials in heart failure have clearly demonstrated that blocking aldosterone improves mortality and that this benefit occurs over and above standard therapy with angiotensin-converting enzyme (ACE) inhibitors." | 2.43 | Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure. ( Pringle, S; Shah, NC; Struthers, A, 2006) |
| "Ischemic heart failure is induced by myocardial ischemia, which is probably the commonest cause of left ventricular systolic dysfunction." | 2.42 | [Ischemic heart failure]. ( Hori, M; Inoue, K, 2003) |
| "Eplerenone is a selective aldosterone receptor blocker that displays little interaction with androgen and progesterone receptors." | 2.42 | Eplerenone: a selective aldosterone blocker. ( Stier, CT, 2003) |
| "Aldosterone is an important and independent target for therapeutic intervention in hypertension and hypertension-related diseases." | 2.42 | Aldosterone receptor antagonists for hypertension: what do they offer? ( Krum, H; Liew, D, 2003) |
| "Heart failure is increasing in incidence and prevalence and is predominantly a condition of the elderly, which confers significant morbidity and mortality risks and places an enormous economic burden on the health care system and society." | 2.42 | Diagnosis and management of heart failure in the long-term care setting. ( Gaulden, L, 2003) |
| "Heart failure is also a major cause of hospital admissions; its amelioration and, as far as possible, prevention is therefore important in terms not only of morbidity and premature mortality for the individual patient, but also containment of healthcare costs." | 2.42 | The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure. ( Funder, JW, 2003) |
| "Chronic heart failure is widely recognised as a common and escalating problem that causes major disability and often shortens life." | 2.42 | Drug therapy in chronic heart failure. ( Cowley, AJ; McKenzie, DB, 2003) |
| "Aldosterone has a variety of detrimental effects on the heart and vasculature and is increasingly recognized as an important target in chronic heart failure, as illustrated by the Randomized Aldactone Evaluation Study." | 2.42 | The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. ( Davies, JI; Dawson, A; Struthers, AD, 2004) |
| "Aldosterone also promotes myocardial fibrosis and cardiac remodelling by enhancing collagen synthesis, resulting in increased myocardial stiffness and increased left ventricular mass." | 2.42 | The clinical implications of aldosterone escape in congestive heart failure. ( Struthers, AD, 2004) |
| "Eplerenone (Inspra) is a selective aldosterone blocker." | 2.42 | Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction. ( Keating, GM; Plosker, GL, 2004) |
| "Eplerenone is a selective aldosterone blocker." | 2.41 | Eplerenone--a novel selective aldosterone blocker. ( Carter, BL; Zillich, AJ, 2002) |
| "Systolic heart failure is the most common cause of CHF presentations." | 2.41 | Clinical treatment regimens for chronic heart failure: a review. ( Gould, PA; Kaye, DM, 2002) |
| "New developments in the drug treatment of heart failure include the possible addition of beta-blockers or spironolactone to diuretic and ACE inhibitor therapy." | 2.41 | Heart failure drugs: what's new? ( , 2000) |
| "The renal sodium retention in congestive heart failure is a consequence of the activation of the sympathetic nervous system and of the renin-angiotensin-aldosterone system." | 2.41 | [Diuretic therapy in congestive heart failure--new views on spironolactone therapy]. ( Haller, C, 2000) |
| "This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure." | 2.41 | Aldosterone and myocardial fibrosis in heart failure. ( Brilla, CG, 2000) |
| " New interest in therapy with aldosterone antagonists was stimulated by results of a 2-year study of 1663 patients with heart failure that showed a 30% relative risk reduction of death among patients given a subhemodynamic dosage of spironolactone, a nonselective aldosterone antagonist, compared with placebo, in addition to standard therapy of diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, and digitalis." | 2.41 | Aldosterone, a new appreciation of its role in heart failure. ( Cha, AJ; Judge, KW; Malecha, SE, 2000) |
| "Aldosterone has been identified as a critically important neurohormone with direct detrimental effects on the myocardium." | 2.41 | Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure. ( Miller, AB; Srivastava, P, 2001) |
| "Recommendations for the treatment of heart failure were carried out by a systematic review of the available evidence of the different pharmacologic treatments." | 2.41 | [Evidence based medical treatment of heart failure]. ( Agustí Escasany, A; Arnau De Bolós, JM; Casas Rodríguez, J; Diogène Fadini, E; Durán Dalmau, M; Galve Basilio, E; Manito Lorite, N; Rodríguez Cumplido, D, 2001) |
| " Pharmacokinetic studies reveal that eplerenone has good bioavailability with low protein binding, good plasma exposure, and is highly metabolized to inactive metabolites and excreted principally in the bile." | 2.41 | Eplerenone: a selective aldosterone receptor antagonist (SARA). ( Cook, CS; Delyani, JA; Levin, S; Rocha, R; Roniker, B; Sing, YL; Tobert, DS; Whelihan, B; Workman, DL, 2001) |
| "Aldosterone was shown to promote cardiac fibrosis in various experimental models." | 2.41 | Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. ( Alla, F; Dousset, B; Zannad, F, 2001) |
| "Spironolactone has been found to increase life expectancy and to reduce hospitalisation frequency when added to the conventional therapeutic regimen of patients with advanced congestive heart failure and systolic dysfunction." | 2.41 | Diuretics in the treatment of patients who present congestive heart failure and hypertension. ( Reyes, AJ, 2002) |
| "Mortality of patients with severe congestive heart failure (CHF) is still high despite combined treatment with angiotensin-converting enzyme (ACE) inhibitors, diuretics, and digitalis." | 2.40 | [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?]. ( Brilla, CG; Rupp, H; Scheer, C; Schencking, M, 1997) |
| " This therapeutic association is very logical, effective and allows reduction in the dosage of the diuretic." | 2.39 | [Classic treatment of chronic heart insufficiency. What if new?]. ( Agnola, D; Aumont, MC; Juliard, JM; Karrillon, G, 1995) |
| "Heart failure has emerged as a major cardiovascular public health syndrome with increasing incidence, reduced quality life, risk of progression, and high mortality." | 2.39 | [Current management of heart failure]. ( Cserhalmi, L, 1994) |
| "Aldosterone has been shown to have an acute arrhythmogenic effect as well as a potential detrimental effect on baroreflex function, a marker of prognosis in CHF." | 2.39 | Aldosterone escape during ACE inhibitor therapy in chronic heart failure. ( Struthers, AD, 1995) |
| "Eplerenone is a selective mineralocorticoid receptor antagonist." | 1.91 | Role of eplerenone in the threatment of cardiovascular diseases. ( Málek, F, 2023) |
| "Heart failure is the main causes of morbidity and mortality." | 1.91 | Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy. ( Alcalai, R; Arad, M; Guetta, T; Hochhauser, E; Kornowski, R; Ofek, E; Petrover, Z; Seidman, CE; Seidman, J; Yadin, D, 2023) |
| "Spironolactone treatment demonstrated significant attenuation of cardiac fibrosis and apoptosis in left ventricular tissue compared to furosemide." | 1.72 | Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction. ( Chang, WT; Chen, CY; Chen, ZC; Lin, YW; Liu, PY; Luo, CY; Shih, JY; Wu, CC, 2022) |
| "Spironolactone was initiated prior to admission (PTA) for 54." | 1.62 | Evaluation of the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease. ( Armbruster, AL; Buckallew, AR; Mbachu, G; Miller, W; Seltzer, JR; Tellor, KB; Watson, R; Whitlock, C, 2021) |
| "Hyperkalemia is a growing concern in the treatment of patients with heart failure and reduced ejection fraction because it limits the use of effective drugs." | 1.56 | Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry. ( Almenar-Bonet, L; Andrés-Novales, J; Barge-Caballero, E; Bayés-Genís, A; Bierge-Valero, D; Bover-Freire, R; Crespo-Leiro, MG; Dalmau González-Gallarza, R; de Juan-Bagudá, J; de la Fuente-Galán, L; Delgado-Jiménez, J; Epelde-Gonzalo, F; Escudero-González, A; Fernández-Vivancos Marquina, C; Gallego-Page, JC; García-Pinilla, JM; González-Costello, J; Lambert-Rodríguez, JL; Lara-Padrón, A; López-Fernández, S; Lund, LH; Maggioni, AP; Muñiz, J; Pascual-Figal, DA; Pérez-Ruiz, JM; Quiles-Granado, J; Ridocci-Soriano, F; Roig-Minguell, E; Sahuquillo-Martínez, A; Sanz-Julve, M; Segovia-Cubero, J; Torres-Calvo, F; Varela-Román, A, 2020) |
| "In conclusion, hypokalemia is extremely common in patients presenting with VT/VF, much more so than in patients with CHF alone." | 1.56 | Electrolyte Abnormalities in Patients Presenting With Ventricular Arrhythmia (from the LYTE-VT Study). ( Basil, A; Cooper, JM; Gangireddy, C; Greenberg, RM; Laslett, DB; Whitman, IR; Yesenosky, GA, 2020) |
| "This study aimed to utilize a population pharmacokinetic method to obtain information about the influence of covariates on the in vivo behavior of digoxin in patients with cardiac insufficiency." | 1.56 | Impact of SLCO4C1 Genotypes, Creatinine, and Spironolactone on Digoxin Population Pharmacokinetic Variables in Patients With Cardiac Insufficiency. ( Du, P; Jia, A; Li, X; Li, Y; Ma, Y; Wang, A, 2020) |
| "Hypertension was reported in 70-92% of patients, irrespective of disease cohort or population." | 1.51 | Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study. ( Blankenburg, M; Eisenring, S; Fett, AK; Gay, A; Haas, G, 2019) |
| "Hyperkalemia is associated with severe clinical outcomes and death in HF." | 1.48 | Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study. ( Adelborg, K; Egfjord, M; Egstrup, K; Garcia-Sanchez, R; Hasvold, P; Nicolaisen, SK; Pedersen, L; Sørensen, HT; Thomsen, RW, 2018) |
| "Acute congestive heart failure (ACHF) is a state of severe, secondary hyperaldosteronism." | 1.48 | Association Between High-Dose Spironolactone and Decongestion in Patients with Acute Heart Failure: An Observational Retrospective Study. ( Barbetseas, J; Bonou, M; Kapelios, CJ; Lund, LH; Mantzouratou, P; Tzanis, G; Vogiatzi, P, 2018) |
| "Spironolactone has been shown to reduce cardiovascular death in patients with mild-to-moderate chronic kidney disease (CKD), but its risks and benefits in advanced CKD remain unsettled." | 1.46 | Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study. ( Chen, YH; Hsu, CC; Hung, SC; Kuo, KL; Liu, JS; Tarng, DC; Tseng, WC, 2017) |
| "Pharmacological treatment for heart failure involves different drugs as: angiotensin-converting enzyme inhibitors, B-adrenergic blockers, digitalis glycosides and diuretics." | 1.46 | [Analysis of the mitochondrial function and ultrastructure in healthy albino mice treated with heart failure medications] ( Baez, A; Bazán, C; Camino Willhuber, GO; Fretes, R; Guzman Mentesana, G; Lo Presti, S; Paglini-Oliva, PA; Rivarola, HW; Strauss, M, 2017) |
| " We describe how the TOPCAT DSMB detected, investigated, and adjudicated an unexpectedly large renal adverse event signal midway through the trial, and offer general guidelines for dealing with similar unanticipated occurrences in future trials." | 1.46 | Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT. ( Assmann, SF; Boineau, R; Bristow, MR; Gersh, BJ; Grady, C; Greenberg, BH; Linas, S; McKinlay, SM; Rice, MM; Sharma, K; Singh, S, 2017) |
| "Extrinsic tricuspid valve stenosis was detected by transthoracic echocardiography." | 1.46 | [Heart failure provoked by a pacemaker lead-induced tricuspid stenosis]. ( Chaudesaygues, E; Ferrini, M; Ritz, B, 2017) |
| "Spironolactone was the predominantly prescribed aldosterone antagonist." | 1.43 | Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction. ( Das, S; de Lemos, JA; Fonarow, GC; Peng, SA; Peterson, ED; Vora, AN; Wang, TY, 2016) |
| "Echocardiography showed 73% dilated cardiomyopathy; 83% showed moderate to severe LV systolic dysfunction (mean EF 36." | 1.43 | Clinical and echocardiographic characteristics and outcomes in congestive heart failure at the Hospital of The State University of Haiti. ( Malebranche, R; Morisset, PH; Raphael, NA; Tabou Moyo, C; Wilentz, JR, 2016) |
| " The main difficulty in choosing the proper therapeutic regimen consists in the lack of suitable dosing guidelines with adapted therapeutic targets for the older multimorbid population, usually not represented in the large controlled trials forming the basis of general recommendations." | 1.42 | [Cardiovascular drugs in aged and multimorbid patients]. ( Follath, F, 2015) |
| "Finerenone reduced cardiac hypertrophy, plasma prohormone of brain natriuretic peptide, and proteinuria more efficiently than eplerenone when comparing equinatriuretic doses." | 1.40 | Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. ( Albrecht-Küpper, B; Bärfacker, L; Delbeck, M; Eitner, F; Hartmann, E; Kolkhof, P; Kretschmer, A; Schäfer, S; Steinke, W, 2014) |
| "Spironolactone was not associated with improved survival, neither in the complete sample (HR 0." | 1.39 | Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study. ( Agewall, S; Atar, D; de Blois, J; Frankenstein, L; Grundtvig, M; Hole, T; Katus, HA; Schellberg, D; Zugck, C, 2013) |
| "In patients with congestive heart failure (CHF), use of loop diuretic therapy may result in acute kidney insufficiency (AKI)." | 1.39 | Predisposing factors for acute kidney injury in Hispanic patients treated with diuretics for decompensated heart failure. ( Cangiano, JL; López, JE; Marmorato, R; Pagán, P; Ramírez, T; Ricci, F; Soto-Salgado, M; Vega, J, 2013) |
| "furosemide dose or were switched furosemide to oral route (fast diuretic response, FDR)." | 1.39 | Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors. ( Almeida, S; Bettencourt, P; Carvalho, H; Ferreira, JP; Marques, I; Santos, M, 2013) |
| "In addition, induction of cardiac hypertrophy by ISO caused remarkable induction in CT-1 mRNA and protein expression levels by approximately 3." | 1.39 | Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection. ( Al-Mazroua, HA; Al-Rasheed, NM; Korashy, HM, 2013) |
| "The treatment of heart failure has seen considerable advances in the past decades." | 1.38 | PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. ( Buysse, JM; Huang, IZ; Pitt, B, 2012) |
| "Enalapril was continued for 42 days." | 1.38 | Therapeutic challenges and management of heart failure during pregnancy (part I). ( Bilińska, ZT; Czajkowski, K; Dangel, J; Demkow, M; Dzielińska, Z; Konka, M; Kryczka, K; Przybylski, A; Różański, J; Szczudlik, J, 2012) |
| "Spironolactone use was associated with a decreased occurrence of gouty arthritis (OR 0." | 1.38 | A case-control study of determinants for the occurrence of gouty arthritis in heart failure patients. ( Hueskes, BA; Janssen, M; Janssens, HJ; Leen, AC; Mantel-Teeuwisse, AK; Ninaber, PA; Roovers, EA; van de Lisdonk, EH; Westra, R; Willems, FF, 2012) |
| " A maximal possible effect (E(max)) model was employed to determine the basic pharmacodynamic parameters of spironolactone, measured by high-performance liquid chromatography, in antagonizing the renal effects of aldosterone." | 1.36 | A preclinical pharmacokinetic and pharmacodynamic approach to determine a dose of spironolactone for treatment of congestive heart failure in dog. ( Elliott, J; Guyonnet, J; Kaltsatos, V, 2010) |
| " The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor." | 1.36 | Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone. ( Erden, I; Ozhan, H; Yalcin, S, 2010) |
| "The influence of chronic administration of eplerenone on the intracrine as well as on the extracellular action of angiotensin II (Ang II) on L-type inward calcium current was investigated in the failing heart of cardiomyopathic hamsters (TO-2)." | 1.35 | Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system. ( De Mello, WC; Gerena, Y, 2008) |
| "Systolic heart failure was detected in 63% of cases." | 1.35 | Evaluation of heart failure management in a Military Hospital. ( Bonnevie, L; Chanudet, X; Chenilleau, MC; Delarbre, D; Fraboulet, R; Guiraudet, O; Héno, P; Lambert de Crémeur, G; Martin, AC; Pelletier, C; Schiano, P, 2008) |
| "The association between low blood pressure (BP) levels and increased mortality has been established in several studies of heart failure (HF)." | 1.35 | Association of blood pressure and its evolving changes with the survival of patients with heart failure. ( Almendral, J; Bardaji, A; Bayes-Genis, A; Cinca, J; de Luna, AB; Fernandez-Palomeque, C; Gonzalez-JuAnatey, JR; Grigorian-Shamagian, L; Jimenez, RP; Macaya, C; Nieto, V; Pascual, D; Vazquez, R, 2008) |
| "The Impact-Reco programme found an improvement in prescription rates and in the dosage of neurohumoral antagonists in French outpatients with stable CHF." | 1.35 | Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme. ( Assyag, P; Clerson, P; de Groote, P; Demil, N; Ducardonnet, A; Galinier, M; Isnard, R; Jondeau, G; Komajda, M; Thebaut, JF, 2009) |
| "Portopulmonary hypertension is characterized by a chronic liver disease associated with a mean pulmonary artery pressure >25 mmHg at rest, an increased pulmonary vascular resistance and a capillary pulmonary pressure <15 mmHg with portal hypertension." | 1.34 | [Portopulmonary hypertension due to schistosomiasis in two Malagasy patients]. ( Rajaona, HR; Rajaonarivelo, P; Ramanampamonjy, RM; Razafimahefa, SH, 2007) |
| "Refractory congestive heart failure (CHF) with diuretic resistance is life-threatening and predicts a short life expectancy." | 1.34 | Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance. ( Ji, Z; Liu, C; Liu, G; Liu, K; Zhen, Y; Zhou, C, 2007) |
| "(8) Spironolactone remains the treatment of choice for patients with heart failure and incapacitating dyspnea despite ACE inhibitor and diuretic therapy." | 1.33 | Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too. ( , 2006) |
| "Of these, 585 (76." | 1.33 | Use and side-effect profile of spironolactone in a private cardiologist's practice. ( Karambelas, MR; Katholi, RE; Williams, EM, 2006) |
| "Their mitral regurgitation (MR) is a result of left ventricular (LV) geometrical distortion." | 1.33 | Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair. ( Bolling, SF; Geltz, A; Spoor, MT, 2006) |
| "Eplerenone-treated HF rats had lower plasma TNF-alpha, interleukin (IL)-1beta and IL-6, less COX-2 staining of small blood vessels penetrating PVN, fewer PVN neurons expressing Fra-like activity (indicating chronic neuronal activation), and fewer PVN neurons staining for TNF-alpha, IL-1beta, and CRH than vehicle-treated HF rats." | 1.33 | Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure. ( Beltz, T; Felder, RB; Johnson, AK; Johnson, RF; Kang, YM; Weiss, RM; Yu, Y; Zhang, ZH, 2006) |
| "The effect of chronic administration of eplerenone on cardiac remodelling and electrical properties was investigated in the failing heart of cardiomyopathic hamsters (TO-2) at five months of age." | 1.33 | Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart. ( De Mello, WC, 2006) |
| " Increased nitric oxide bioavailability can only partially explain the reduced platelet activation by eplerenone and ACE inhibition." | 1.32 | Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. ( Bauersachs, J; Christ, M; Eigenthaler, M; Fraccarollo, D; Hildemann, S; Kobsar, A; Schäfer, A; Walter, U, 2003) |
| "Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure." | 1.32 | Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003) |
| "Spironolactone has undesirable side effects that have limited its clinical use; the most significant are impotence, gynecomastia, and hirsutism." | 1.32 | The resurrection of spironolactone on its golden anniversary. ( Futterman, LG; Lemberg, L, 2004) |
| "Patients with heart failure have scarce knowledge of their condition and frequently report poor quality of life." | 1.32 | Implementation of guidelines for management of heart failure in heart failure clinic: effects beyond pharmacological treatment. ( Lainscak, M, 2004) |
| "Eplerenone is a novel selective aldosterone blocker." | 1.31 | Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. ( Goldstein, S; McMahon, EG; Mishima, T; Morita, H; Rudolph, AE; Sabbah, HN; Sharov, VG; Suzuki, G; Tanhehco, EJ; Todor, A, 2002) |
| "Chronic heart failure is associated with high mortality and morbidity." | 1.31 | [Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic]. ( Frick, M; Gouya, G; Hügel, H; Pachinger, O; Pölzl, G; Ulmer, H, 2002) |
| "If spironolactone has beneficial effects on HRV, this would contribute to favorable results." | 1.31 | Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. ( Korkmaz, ME; Müderrisoğlu, H; Ozin, B; Uluçam, M, 2000) |
| "Aldosterone promotes collagen synthesis and structural remodeling of target organs such as the heart." | 1.31 | Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Horie, H; Kinoshita, M; Mabuchi, N; Maeda, K; Matsumoto, T; Ohnishi, M; Sawaki, M; Sugimoto, Y; Tsutamoto, T; Tsutsui, T; Wada, A, 2000) |
| "Spironolactone is an aldosterone antagonist which has been used as a mild potassium-sparing diuretic and in treatment of ascites in liver failure." | 1.31 | Spironolactone in heart failure--a revived role for an old drug. ( Bradley, C, 2000) |
| " The average starting dosage of spironolactone was 55 mg." | 1.31 | Long-term therapy with spironolactone. ( Bouvy, ML; Heerdink, ER; Herings, RM, 2001) |
| "Heart failure is unique among the major cardiovascular disorders in that it alone is increasing in prevalence while there has been a striking decrease in other conditions." | 1.31 | Treatment of heart failure: state of the art and prospectives. ( Greenberg, B, 2001) |
| "Among the determinants of cardiac failure, the renin-angiotensin-aldosterone system has a central role, and antagonism of the mineralocorticoid receptor (MR) has been proposed as a therapeutic strategy." | 1.31 | Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. ( Beggah, AT; Bocchi, B; Cailmail, S; Delage, V; Delcayre, C; Escoubet, B; Farman, N; Jaisser, F; Ouvrard-Pascaud, A; Peuchmaur, M; Puttini, S, 2002) |
| "Patients with severe congestive heart failure (New York Heart Association [NYHA] functional classes III-IV) often can tolerate only low doses of angiotensin-converting enzyme (ACE) inhibitors because pronounced hypotension caused by additional ACE inhibitor increments may decrease renal perfusion." | 1.29 | Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. ( Donker, AJ; Nauta, JJ; van Vliet, AA; Verheugt, FW, 1993) |
| "Emphasis is on the arrhythmia component and the complex interrelationships of critical electrolytes and pathophysiologic factors that can lead to sudden cardiac death." | 1.28 | Short- and long-term mechanisms of sudden cardiac death in congestive heart failure. ( Helfant, RH, 1990) |
| "Prudence is indicated in patients with congestive heart failure due to coronary artery disease." | 1.27 | A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure. ( Rutishauser, W, 1983) |
| "Three cases are described of severe congestive heart failure which failed to respond to digitalis, high doses of loop diuretics, and converting-enzyme inhibitors." | 1.27 | Combined spironolactone and converting-enzyme inhibitor therapy for refractory heart failure. ( Crozier, IG; Ikram, H; Lewis, GR; Nicholls, MG; Richards, AM; Webster, MW, 1986) |
| "The magnesium deficiency is especially dangerous since it prevents the cells from keeping their high intracellular potassium concentration unchanged." | 1.27 | Potassium-sparing diuretics. ( Dyckner, T; Wester, PO, 1986) |
| "Hyperaldosteronism is an important factor contributing to fluid and sodium retention in infants with heart failure." | 1.26 | The occurrence of hyperaldosteronism in infants with congestive heart failure. ( Baylen, BG; Johnson, G; Kaplan, S; Srivastava, L; Tsang, R, 1980) |
| " The recommended dosage i." | 1.26 | [Experiences with aldactone in pediatric cardiology (author's transl)]. ( Bachl, G; Schlemmer, M; Stiskal, A; Wimmer, M, 1979) |
| "In 50 patients with congestive heart failure a compound diuretic drug aldactone--saltucine was used." | 1.25 | [Use of aldactone-saltucine for patients with chronic circulatory insufficiency]. ( Evsikov, EM; Kharchenko, VI; Savenkov, PM; Sidorenko, BA, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 208 (18.54) | 18.7374 |
| 1990's | 51 (4.55) | 18.2507 |
| 2000's | 405 (36.10) | 29.6817 |
| 2010's | 322 (28.70) | 24.3611 |
| 2020's | 136 (12.12) | 2.80 |
| Authors | Studies |
|---|---|
| Iijima, T | 1 |
| Katoh, M | 1 |
| Takedomi, K | 1 |
| Yamamoto, Y | 1 |
| Akatsuka, H | 1 |
| Shirata, N | 1 |
| Nishi, A | 1 |
| Takakuwa, M | 1 |
| Watanabe, Y | 1 |
| Munakata, H | 1 |
| Koyama, N | 1 |
| Ikeda, T | 1 |
| Iguchi, T | 1 |
| Kato, H | 1 |
| Kikkawa, K | 1 |
| Kawaguchi, T | 1 |
| Sperry, BW | 2 |
| Hanna, M | 1 |
| Shah, SJ | 25 |
| Jaber, WA | 2 |
| Spertus, JA | 9 |
| Berg, J | 1 |
| Jablonowski, R | 1 |
| Mohammad, M | 1 |
| Solem, K | 1 |
| Borgquist, R | 1 |
| Ostenfeld, E | 1 |
| Arheden, H | 1 |
| Carlsson, M | 1 |
| Minamisawa, M | 1 |
| Claggett, B | 23 |
| Suzuki, K | 1 |
| Hegde, SM | 1 |
| Shah, AM | 9 |
| Desai, AS | 29 |
| Lewis, EF | 24 |
| Sweitzer, NK | 20 |
| Fang, JC | 15 |
| Anand, IS | 19 |
| O'Meara, E | 24 |
| Rouleau, JL | 15 |
| Pitt, B | 103 |
| Pfeffer, MA | 35 |
| Solomon, SD | 41 |
| Vardeny, O | 7 |
| Schnelle, M | 1 |
| Leha, A | 1 |
| Eidizadeh, A | 1 |
| Fuhlrott, K | 1 |
| Trippel, TD | 2 |
| Hashemi, D | 2 |
| Toischer, K | 1 |
| Wachter, R | 5 |
| Herrmann-Lingen, C | 4 |
| Hasenfuß, G | 2 |
| Pieske, B | 9 |
| Binder, L | 1 |
| Edelmann, F | 10 |
| Gandotra, C | 1 |
| Clark, J | 1 |
| Liu, Q | 1 |
| Senatore, FF | 1 |
| Rose, M | 1 |
| Zhang, J | 1 |
| Stockbridge, NL | 1 |
| Vakaliuk, IP | 1 |
| Savchuk, NV | 1 |
| Nesterak, RV | 1 |
| Kulynych, HB | 1 |
| Hryhoryshyn, RS | 1 |
| Ferreira, JP | 36 |
| Rossignol, P | 42 |
| Claggett, BL | 9 |
| Pfeffer, M | 1 |
| Zannad, F | 67 |
| Yang, S | 2 |
| Troendle, J | 1 |
| Pak, D | 1 |
| Leifer, E | 1 |
| Yokota, T | 1 |
| Koiwa, H | 1 |
| Matsushima, S | 2 |
| Tsujinaga, S | 1 |
| Naya, M | 1 |
| Morisaki, H | 1 |
| Morisaki, T | 1 |
| Abdurasool Almedeny, S | 1 |
| Yasir Al-Mayah, J | 1 |
| Abdulzahra, MS | 1 |
| Hadi, NR | 1 |
| Weir, RAP | 1 |
| Clements, S | 1 |
| Steedman, T | 1 |
| Dargie, HJ | 1 |
| McMurray, JJV | 11 |
| Verdonschot, JAJ | 6 |
| Pizard, A | 5 |
| Pellicori, P | 12 |
| Brunner La Rocca, HP | 2 |
| Clark, AL | 12 |
| Cosmi, F | 8 |
| Cuthbert, J | 7 |
| Girerd, N | 24 |
| Waring, OJ | 1 |
| Henkens, MHTM | 1 |
| Mariottoni, B | 8 |
| Petutschnigg, J | 12 |
| Hazebroek, MR | 3 |
| Cleland, JGF | 8 |
| Heymans, SRB | 2 |
| Pardo-Martínez, P | 1 |
| Barge-Caballero, E | 2 |
| Bouzas-Mosquera, A | 1 |
| Barge-Caballero, G | 1 |
| Couto-Mallón, D | 1 |
| Paniagua-Martín, MJ | 1 |
| Sagastagoitia-Fornie, M | 1 |
| Prada-Delgado, Ó | 1 |
| Muñiz, J | 2 |
| Almenar-Bonet, L | 2 |
| Vázquez-Rodríguez, JM | 1 |
| Crespo-Leiro, MG | 2 |
| Potter, E | 1 |
| Stephenson, G | 1 |
| Harris, J | 1 |
| Wright, L | 1 |
| Marwick, TH | 3 |
| Martens, P | 2 |
| Vincent, J | 15 |
| Abreu, P | 1 |
| Busselen, M | 1 |
| Mullens, W | 4 |
| Tang, WHW | 5 |
| Böhm, M | 5 |
| Desai, RJ | 1 |
| Vaduganathan, M | 8 |
| Llàcer, P | 2 |
| Núñez, J | 2 |
| García, M | 2 |
| Ruiz, R | 2 |
| López, G | 2 |
| Fabregate, M | 2 |
| Fernández, C | 2 |
| Croset, F | 2 |
| Del Hoyo, B | 2 |
| Gomis, A | 2 |
| Manzano, L | 2 |
| Bozec, E | 2 |
| Collier, T | 5 |
| Hazebroek, M | 5 |
| Heymans, S | 9 |
| Staessen, JA | 11 |
| Edelman, F | 1 |
| Díez, J | 6 |
| González, A | 9 |
| Cleland, JG | 12 |
| Huang, R | 2 |
| Lin, Y | 3 |
| Liu, M | 2 |
| Xiong, Z | 2 |
| Zhang, S | 2 |
| Zhong, X | 3 |
| Ye, X | 3 |
| Huang, Y | 2 |
| Zhuang, X | 3 |
| Liao, X | 3 |
| Harrington, J | 1 |
| Tseliou, E | 1 |
| Shah, S | 2 |
| Shah, KS | 1 |
| Wang, YL | 1 |
| Bai, L | 1 |
| Shi, XR | 1 |
| Zhu, H | 1 |
| Du, LJ | 1 |
| Liu, Y | 2 |
| Ma, XX | 1 |
| Lin, WZ | 1 |
| Liu, T | 2 |
| Sun, JY | 1 |
| Guo, XG | 1 |
| Zhou, LJ | 1 |
| Chen, BY | 1 |
| Shao, S | 1 |
| Meng, XQ | 1 |
| Li, YL | 1 |
| Li, RG | 1 |
| Duan, SZ | 1 |
| Franchini, A | 1 |
| Borgarelli, M | 1 |
| Abbott, JA | 1 |
| Menciotti, G | 1 |
| Crosara, S | 1 |
| Häggström, J | 1 |
| Lahmers, S | 1 |
| Rosenthal, S | 1 |
| Tyrrell, W | 1 |
| Asleh, R | 1 |
| Briasoulis, A | 2 |
| Borlaug, BA | 1 |
| Choy, M | 2 |
| Liang, W | 4 |
| He, J | 5 |
| Fu, M | 1 |
| Dong, Y | 7 |
| He, X | 2 |
| Liu, C | 8 |
| Barkoudah, E | 1 |
| Clausell, N | 5 |
| Diaz, R | 5 |
| Fleg, JL | 13 |
| Koch, V | 1 |
| Gruenewald, LD | 1 |
| Gruber-Rouh, T | 1 |
| Martin, S | 1 |
| Eichler, K | 1 |
| Booz, C | 1 |
| Yel, I | 1 |
| Vogl, TJ | 1 |
| Buchner, K | 1 |
| Hagenmueller, M | 1 |
| März, W | 2 |
| Frey, N | 1 |
| Hardt, SE | 1 |
| Riffel, JH | 1 |
| Kobayashi, M | 3 |
| Kevin, D | 1 |
| Huttin, O | 2 |
| Reddy, YNV | 1 |
| Sundaram, V | 1 |
| Bedrouni, W | 1 |
| Sharma, A | 1 |
| Lam, CSP | 3 |
| Ni, J | 1 |
| McMurray, J | 7 |
| Giannetti, N | 1 |
| Pocock, S | 3 |
| Huynh, T | 3 |
| Ageev, FT | 2 |
| Ovchinnikov, AG | 1 |
| Wu, R | 1 |
| Chang, WT | 1 |
| Lin, YW | 1 |
| Chen, CY | 1 |
| Chen, ZC | 1 |
| Shih, JY | 1 |
| Wu, CC | 1 |
| Luo, CY | 1 |
| Liu, PY | 1 |
| Zaoui, N | 1 |
| Bachir, N | 1 |
| Terki, A | 1 |
| Boukabous, A | 1 |
| Javaheri, A | 1 |
| Diab, A | 1 |
| Zhao, L | 3 |
| Qian, C | 1 |
| Cohen, JB | 2 |
| Zamani, P | 3 |
| Kumar, A | 2 |
| Wang, Z | 3 |
| Ebert, C | 1 |
| Maranville, J | 1 |
| Kvikstad, E | 1 |
| Basso, M | 2 |
| van Empel, V | 1 |
| Richards, AM | 5 |
| Doughty, RN | 1 |
| Rietzschel, E | 1 |
| Kammerhoff, K | 1 |
| Gogain, J | 1 |
| Schafer, P | 1 |
| Seiffert, DA | 2 |
| Gordon, DA | 3 |
| Ramirez-Valle, F | 1 |
| Mann, DL | 3 |
| Cappola, TP | 1 |
| Chirinos, JA | 3 |
| Yu, Y | 3 |
| Guan, W | 1 |
| Masoudi, FA | 3 |
| Wang, B | 1 |
| He, G | 1 |
| Lu, Y | 2 |
| Krumholz, HM | 4 |
| Li, J | 3 |
| Marzolla, V | 1 |
| Infante, M | 1 |
| Armani, A | 1 |
| Rizzo, M | 1 |
| Caprio, M | 1 |
| Singh, AK | 1 |
| Singh, A | 1 |
| Singh, R | 1 |
| Misra, A | 1 |
| Lorente-Ros, M | 1 |
| Aguilar-Gallardo, JS | 1 |
| Shah, A | 1 |
| Narasimhan, B | 1 |
| Aronow, WS | 4 |
| Verdonschot, J | 5 |
| Collier, TJ | 5 |
| Ortega-Paz, L | 1 |
| Cristóbal, H | 1 |
| Ortiz-Perez, JT | 1 |
| García de Frutos, P | 1 |
| Mendieta, G | 1 |
| Sandoval, E | 1 |
| Rodriguez, JJ | 1 |
| Ortega, E | 1 |
| García-Álvarez, A | 1 |
| Brugaletta, S | 1 |
| Sabaté, M | 1 |
| Dantas, AP | 1 |
| Mercuri, M | 1 |
| Gafni, A | 1 |
| Wei, FF | 3 |
| Zhou, Y | 5 |
| Wu, Y | 5 |
| Chen, X | 5 |
| Kalogeropoulos, AP | 8 |
| Jacobs, M | 2 |
| Zhen, Z | 1 |
| Dong, B | 1 |
| Chen, C | 1 |
| Xue, R | 3 |
| Sun, Z | 1 |
| Chen, Z | 1 |
| Liu, R | 1 |
| Lu, G | 1 |
| Li, Z | 4 |
| Sun, Y | 2 |
| Z Rashid, B | 1 |
| Dizaye, KF | 1 |
| Duarte, K | 3 |
| Brunner-La Rocca, HP | 7 |
| Málek, F | 1 |
| Naser, N | 1 |
| Durak-Nalbantic, A | 1 |
| Sabanovic-Bajramovic, N | 1 |
| Karic, A | 1 |
| Campos, J | 1 |
| Larsson, JE | 1 |
| Denholt, CS | 1 |
| Thune, JJ | 1 |
| Raja, AA | 1 |
| Fosbøl, E | 1 |
| Schou, M | 1 |
| Køber, L | 4 |
| Nielsen, OW | 1 |
| Gustafsson, F | 6 |
| Kristensen, SL | 1 |
| Monzo, L | 1 |
| van Veldhuisen, DJ | 18 |
| Swedberg, K | 18 |
| Pocock, SJ | 10 |
| Damera, N | 1 |
| Shah, C | 1 |
| George, B | 1 |
| Chapa, J | 1 |
| Lee, E | 1 |
| Bernhardt, R | 1 |
| Reese, L | 1 |
| Rao, RA | 1 |
| Kim, MM | 1 |
| Prasad, M | 1 |
| Burton, Y | 1 |
| Kolseth, CM | 1 |
| Zhao, Y | 1 |
| Chandrashekar, P | 1 |
| Nazer, B | 1 |
| Masri, A | 1 |
| Yadin, D | 1 |
| Guetta, T | 1 |
| Petrover, Z | 1 |
| Alcalai, R | 1 |
| Seidman, J | 1 |
| Seidman, CE | 1 |
| Ofek, E | 1 |
| Kornowski, R | 2 |
| Hochhauser, E | 1 |
| Arad, M | 1 |
| Georgianos, PI | 1 |
| Vaios, V | 1 |
| Karligkiotis, A | 1 |
| Georgianou, E | 1 |
| Liakopoulos, V | 1 |
| Clarke, B | 1 |
| Przewlocka-Kosmala, M | 1 |
| Mysiak, A | 2 |
| Kosowski, W | 1 |
| Kosmala, W | 2 |
| Sarhan, NM | 1 |
| Shahin, MH | 1 |
| El Rouby, NM | 1 |
| El-Wakeel, LM | 1 |
| Solayman, MH | 1 |
| Langaee, T | 1 |
| Khorshid, H | 1 |
| Schaalan, MF | 1 |
| Sabri, NA | 1 |
| Cavallari, LH | 5 |
| Ramalho, SHR | 1 |
| Segovia-Cubero, J | 1 |
| González-Costello, J | 1 |
| López-Fernández, S | 1 |
| García-Pinilla, JM | 1 |
| de Juan-Bagudá, J | 1 |
| Roig-Minguell, E | 1 |
| Bayés-Genís, A | 3 |
| Sanz-Julve, M | 1 |
| Lambert-Rodríguez, JL | 1 |
| Lara-Padrón, A | 1 |
| Pérez-Ruiz, JM | 1 |
| Fernández-Vivancos Marquina, C | 1 |
| de la Fuente-Galán, L | 1 |
| Varela-Román, A | 1 |
| Torres-Calvo, F | 1 |
| Andrés-Novales, J | 1 |
| Escudero-González, A | 1 |
| Pascual-Figal, DA | 4 |
| Ridocci-Soriano, F | 1 |
| Sahuquillo-Martínez, A | 1 |
| Bierge-Valero, D | 1 |
| Epelde-Gonzalo, F | 1 |
| Gallego-Page, JC | 1 |
| Dalmau González-Gallarza, R | 1 |
| Bover-Freire, R | 1 |
| Quiles-Granado, J | 1 |
| Maggioni, AP | 6 |
| Lund, LH | 4 |
| Delgado-Jiménez, J | 1 |
| Khan, MS | 1 |
| Butler, J | 14 |
| Rossello, X | 3 |
| Eschalier, R | 3 |
| Beldhuis, I | 1 |
| Rouleau, J | 5 |
| Kitzman, DW | 2 |
| Upadhya, B | 1 |
| Silverman, DN | 1 |
| Plante, TB | 1 |
| Infeld, M | 1 |
| Callas, PW | 1 |
| Juraschek, SP | 1 |
| Dougherty, GB | 1 |
| Meyer, M | 1 |
| Prenner, SB | 1 |
| Cvijic, ME | 2 |
| Spires, T | 1 |
| Yarde, M | 2 |
| Bhattacharya, P | 1 |
| Mazurek, J | 1 |
| Seiffert, D | 1 |
| Holzendorf, V | 2 |
| Manolis, AA | 1 |
| Manolis, TA | 1 |
| Melita, H | 1 |
| Manolis, AS | 1 |
| Serenelli, M | 1 |
| Jackson, A | 1 |
| Dewan, P | 1 |
| Jhund, PS | 6 |
| Petrie, MC | 3 |
| Campo, G | 1 |
| Ahmad, T | 3 |
| Desai, NR | 1 |
| Januzzi, JL | 3 |
| Schrauben, SJ | 1 |
| Basso, MD | 1 |
| Bhattacharya, PT | 1 |
| Chirinos, DA | 1 |
| Prenner, S | 1 |
| Car, BD | 1 |
| Margulies, K | 1 |
| Cappola, T | 1 |
| Ahmed, FZ | 4 |
| Cuthbert, JJ | 1 |
| Mujaj, B | 4 |
| Latini, R | 4 |
| Enzan, N | 1 |
| Ide, T | 1 |
| Kaku, H | 1 |
| Higo, T | 1 |
| Tsuchihashi-Makaya, M | 1 |
| Tsutsui, H | 1 |
| Myhre, PL | 5 |
| de Denus, S | 6 |
| Jarolim, P | 2 |
| Kuno, T | 1 |
| Ueyama, H | 1 |
| Fujisaki, T | 1 |
| Briasouli, A | 1 |
| Takagi, H | 1 |
| Sueta, D | 1 |
| Yamamoto, E | 1 |
| Tsujita, K | 1 |
| Kutsche, HS | 1 |
| Schreckenberg, R | 1 |
| Weber, M | 1 |
| Hirschhäuser, C | 1 |
| Rohrbach, S | 1 |
| Li, L | 1 |
| Niemann, B | 1 |
| Schulz, R | 1 |
| Schlüter, KD | 1 |
| Abdel Jalil, MH | 1 |
| Abdullah, N | 1 |
| Alsous, MM | 1 |
| Saleh, M | 1 |
| Abu-Hammour, K | 1 |
| Leclair, G | 3 |
| Dubé, MP | 1 |
| St-Jean, I | 1 |
| Zada, YF | 1 |
| Oussaïd, E | 1 |
| Jutras, M | 3 |
| Givertz, MM | 4 |
| Mentz, RJ | 3 |
| Stienen, S | 2 |
| Sivakumar, B | 1 |
| Malta, D | 1 |
| Mak, S | 2 |
| Dash, S | 1 |
| Newton, GE | 2 |
| Arcand, J | 1 |
| Fudim, M | 2 |
| Kelly, JP | 1 |
| Brophy, TJ | 1 |
| DeVore, AD | 3 |
| Hammill, BG | 1 |
| Peterson, ED | 2 |
| Yancy, C | 1 |
| Fonarow, GC | 7 |
| Hernandez, AF | 7 |
| Krasnova, M | 1 |
| Kulikov, A | 1 |
| Okovityi, S | 1 |
| Ivkin, D | 1 |
| Karpov, A | 1 |
| Kaschina, E | 2 |
| Smirnov, A | 1 |
| Cunningham, JW | 1 |
| John, JE | 1 |
| Zile, MR | 3 |
| Carson, P | 2 |
| Kober, L | 2 |
| Yusuf, S | 2 |
| Williams, B | 1 |
| Mayo, MR | 2 |
| Warren, S | 1 |
| Arthur, S | 1 |
| Ackourey, G | 1 |
| White, WB | 1 |
| Agarwal, R | 2 |
| Thankachen, J | 1 |
| Kalra, R | 1 |
| Gupta, K | 1 |
| Sheets, R | 1 |
| Aryal, S | 1 |
| Ebrahimi, A | 1 |
| Rajapreyar, I | 1 |
| Cribbs, MG | 1 |
| Booker, OJ | 1 |
| Prabhu, SD | 3 |
| Bajaj, NS | 1 |
| Laslett, DB | 1 |
| Cooper, JM | 1 |
| Greenberg, RM | 1 |
| Yesenosky, GA | 1 |
| Basil, A | 1 |
| Gangireddy, C | 1 |
| Whitman, IR | 1 |
| Zhu, W | 2 |
| Wu, Z | 2 |
| Simitsis, P | 1 |
| Skopicki, HA | 1 |
| Mehmood, M | 1 |
| Velat, I | 2 |
| Bušić, Ž | 1 |
| Jurić Paić, M | 1 |
| Čulić, V | 2 |
| Du, P | 2 |
| Wang, A | 2 |
| Ma, Y | 2 |
| Jia, A | 2 |
| Li, Y | 3 |
| Li, X | 3 |
| Verbrugge, FH | 3 |
| Damman, K | 4 |
| Ho, JE | 1 |
| Rico-Mesa, JS | 1 |
| White, A | 1 |
| Ahmadian-Tehrani, A | 1 |
| Anderson, AS | 1 |
| Hiebert, BM | 1 |
| Janzen, BW | 1 |
| Sanjanwala, RM | 1 |
| Ong, AD | 1 |
| Feldman, RD | 1 |
| Kim, JO | 1 |
| Docherty, KF | 2 |
| Gregson, J | 1 |
| Kolkhof, P | 6 |
| Bakris, G | 3 |
| Bauersachs, J | 11 |
| Haller, H | 1 |
| Wada, T | 1 |
| Tang, Y | 1 |
| Jones, PG | 2 |
| Feng, YL | 1 |
| Lu, M | 1 |
| Secora, AM | 1 |
| Shin, JI | 1 |
| Qiao, Y | 1 |
| Alexander, GC | 1 |
| Chang, AR | 1 |
| Inker, LA | 1 |
| Coresh, J | 1 |
| Grams, ME | 1 |
| Asakura, M | 2 |
| Ito, S | 1 |
| Yamada, T | 4 |
| Saito, Y | 2 |
| Kimura, K | 2 |
| Yamashina, A | 3 |
| Hirayama, A | 1 |
| Kobayashi, Y | 3 |
| Hanatani, A | 2 |
| Tsujimoto, M | 1 |
| Yasuda, S | 2 |
| Abe, Y | 1 |
| Higashino, Y | 1 |
| Tamaki, Y | 1 |
| Sugino, H | 1 |
| Niinuma, H | 1 |
| Okuhara, Y | 1 |
| Koitabashi, T | 1 |
| Momomura, SI | 1 |
| Asai, K | 2 |
| Nomura, A | 1 |
| Kawai, H | 1 |
| Satoh, Y | 2 |
| Yoshikawa, T | 2 |
| Hirata, KI | 1 |
| Yokoi, Y | 1 |
| Tanaka, J | 1 |
| Shibata, Y | 1 |
| Maejima, Y | 1 |
| Tamaki, S | 1 |
| Kawata, H | 1 |
| Iwahashi, N | 1 |
| Higuchi, Y | 1 |
| Kada, A | 2 |
| Yamamoto, H | 2 |
| Kitakaze, M | 3 |
| Paulus, R | 1 |
| Schmidt, B | 1 |
| Tanaka, S | 1 |
| Imamura, T | 1 |
| Ueno, H | 2 |
| Kinugawa, K | 1 |
| Mamas, MA | 3 |
| Khan, J | 2 |
| McDonald, K | 1 |
| Rouet, P | 3 |
| Grojean, S | 2 |
| Tsujimoto, T | 3 |
| Kajio, H | 3 |
| Wei, F | 1 |
| Wu, D | 1 |
| Byrd, JB | 1 |
| Sbolli, M | 1 |
| O'Connor, CM | 2 |
| Rahimi, G | 2 |
| Tecson, KM | 2 |
| Elsaid, O | 1 |
| McCullough, PA | 2 |
| Buckallew, AR | 1 |
| Tellor, KB | 1 |
| Watson, R | 1 |
| Miller, W | 1 |
| Mbachu, G | 1 |
| Whitlock, C | 1 |
| Seltzer, JR | 1 |
| Armbruster, AL | 1 |
| Elkholey, K | 1 |
| Papadimitriou, L | 1 |
| Thadani, U | 1 |
| Stavrakis, S | 1 |
| Murphy, SP | 1 |
| Wang, P | 1 |
| Brunner-La-Rocca, HP | 1 |
| Tao, P | 1 |
| Zhitao, T | 1 |
| Jiming, L | 1 |
| Khan, SS | 1 |
| Huffman, MD | 1 |
| Harrington, K | 1 |
| Baldridge, AS | 1 |
| Yu, J | 2 |
| Neal, B | 1 |
| Arnott, C | 1 |
| Beldhuis, IE | 3 |
| Bristow, M | 1 |
| McKinlay, S | 4 |
| Voors, AA | 9 |
| Nabati, M | 1 |
| Tabiban, S | 1 |
| Khani, A | 1 |
| Yazdani, J | 1 |
| Vafainezhad, H | 1 |
| Fan, Y | 1 |
| Xu, X | 2 |
| Guo, Y | 1 |
| Sun, X | 2 |
| Zhou, H | 2 |
| Yang, D | 1 |
| Rocca, HB | 1 |
| Thijs, L | 1 |
| Jacobs, D | 1 |
| Moreno, V | 1 |
| Rubio, A | 1 |
| Moote, R | 1 |
| Lipscomb, J | 1 |
| Davis, H | 1 |
| Allen, S | 1 |
| Oliver, A | 1 |
| Coffman, M | 1 |
| Guillot, E | 3 |
| Blondel, T | 1 |
| Garelli-Paar, C | 2 |
| Feng, S | 1 |
| Heartsill, S | 1 |
| Atkins, CE | 1 |
| Young, MJ | 3 |
| Kanki, M | 1 |
| Karthigan, N | 1 |
| Konstandopoulos, P | 1 |
| Lamiral, Z | 2 |
| Mares, A | 1 |
| Rodriguez, T | 1 |
| Deoker, A | 1 |
| Lehker, A | 1 |
| Mukherjee, D | 2 |
| Laskary, A | 1 |
| Fonfara, S | 1 |
| Chambers, H | 1 |
| O'Sullivan, ML | 1 |
| Belkin, MN | 1 |
| Blair, JE | 2 |
| Alenghat, FJ | 1 |
| Liu, J | 5 |
| Rector, TS | 1 |
| Tseng, WC | 1 |
| Liu, JS | 1 |
| Hung, SC | 1 |
| Kuo, KL | 1 |
| Chen, YH | 1 |
| Tarng, DC | 1 |
| Hsu, CC | 1 |
| O'Neal, WT | 5 |
| Sandesara, P | 2 |
| Patel, N | 1 |
| Venkatesh, S | 2 |
| Samman-Tahhan, A | 5 |
| Hammadah, M | 4 |
| Kelli, HM | 5 |
| Soliman, EZ | 3 |
| Sandesara, PB | 3 |
| Lavoie, J | 2 |
| Ahmed, A | 12 |
| Blackman, MR | 2 |
| White, M | 4 |
| Anker, SD | 7 |
| Ter Maaten, JM | 1 |
| Masson, S | 1 |
| Tognoni, G | 1 |
| Tavazzi, L | 4 |
| Signorini, S | 1 |
| Holzgreve, H | 2 |
| Patel, RB | 1 |
| Yan, S | 1 |
| Xia, Z | 1 |
| Zhu, B | 1 |
| Hu, J | 2 |
| Anstrom, KJ | 2 |
| Felker, GM | 3 |
| Konstam, MA | 4 |
| Margulies, KB | 1 |
| McNulty, SE | 2 |
| Redfield, MM | 4 |
| Whellan, DJ | 1 |
| Shah, M | 1 |
| Desvigne-Nickens, P | 1 |
| Braunwald, E | 3 |
| Schelbert, EB | 1 |
| Miller, CA | 1 |
| Vazir, A | 1 |
| Anand, I | 7 |
| Sweitzer, N | 1 |
| Fang, J | 2 |
| Fleg, J | 1 |
| Selvaraj, S | 3 |
| Solomon, S | 1 |
| Onarecker, C | 1 |
| James, R | 1 |
| Huxley, J | 1 |
| Grassi, V | 1 |
| Cobb, M | 1 |
| Duprez, D | 2 |
| Toleuova, A | 1 |
| Topel, M | 1 |
| Sperling, LS | 1 |
| Levi, A | 1 |
| Leshem-Lev, D | 1 |
| Weissler-Snir, A | 1 |
| Hasin, T | 1 |
| Mats, I | 1 |
| Murninkas, D | 1 |
| Lev, EI | 1 |
| Ben-Gal, T | 1 |
| Beaumier, A | 1 |
| Rush, JE | 1 |
| Yang, VK | 1 |
| Freeman, LM | 1 |
| Retta, TM | 1 |
| Heitner, JF | 8 |
| Stamos, TD | 3 |
| Boineau, R | 7 |
| Ravassa, S | 1 |
| Trippel, T | 1 |
| Bach, D | 1 |
| Bachran, D | 1 |
| López, B | 2 |
| Hasenfuss, G | 3 |
| Delles, C | 1 |
| Dominiczak, AF | 1 |
| Bakris, GL | 1 |
| Weir, MR | 1 |
| Freeman, MW | 1 |
| Lainscak, M | 4 |
| Garza, D | 1 |
| Zawadzki, R | 1 |
| Berman, L | 1 |
| Bushinsky, DA | 2 |
| Thomsen, RW | 1 |
| Nicolaisen, SK | 1 |
| Hasvold, P | 1 |
| Garcia-Sanchez, R | 1 |
| Pedersen, L | 1 |
| Adelborg, K | 1 |
| Egfjord, M | 1 |
| Egstrup, K | 1 |
| Sørensen, HT | 1 |
| Greenberg, B | 3 |
| Dankowski, R | 1 |
| Kotwica, T | 1 |
| Szyszka, A | 1 |
| Przewłocka-Kosmala, M | 1 |
| Sacharczuk, W | 1 |
| Karolko, B | 1 |
| Kobusiak-Prokopowicz, M | 1 |
| Cooper, LB | 1 |
| Camino Willhuber, GO | 1 |
| Guzman Mentesana, G | 1 |
| Baez, A | 1 |
| Lo Presti, S | 1 |
| Bazán, C | 1 |
| Strauss, M | 1 |
| Fretes, R | 1 |
| Paglini-Oliva, PA | 1 |
| Rivarola, HW | 1 |
| Grodin, JL | 3 |
| Testani, JM | 1 |
| Pandey, A | 3 |
| Sambandam, K | 1 |
| Drazner, MH | 2 |
| Schröder, J | 1 |
| Goltz, L | 1 |
| Knoth, H | 1 |
| Kapelios, CJ | 1 |
| Bonou, M | 1 |
| Vogiatzi, P | 1 |
| Tzanis, G | 1 |
| Mantzouratou, P | 1 |
| Barbetseas, J | 1 |
| Franken, PR | 1 |
| Woltersdorf, R | 1 |
| Löfman, I | 1 |
| Szummer, K | 1 |
| Olsson, H | 1 |
| Carrero, JJ | 1 |
| Jernberg, T | 1 |
| Tromp, J | 1 |
| Cikes, M | 1 |
| Saksena, S | 1 |
| Piccini, JP | 1 |
| Korol, S | 2 |
| Tournoux, F | 1 |
| Racine, N | 1 |
| Ducharme, A | 1 |
| Liszkowski, M | 1 |
| Mansour, A | 1 |
| Guertin, MC | 1 |
| Bernier, M | 1 |
| Neagoe, PE | 1 |
| Chaar, D | 1 |
| Sirois, MG | 1 |
| Machu, JL | 1 |
| Huby, AC | 1 |
| Sattar, N | 3 |
| Sever, PS | 1 |
| Rickenbacher, P | 2 |
| Li, S | 2 |
| Zhang, X | 1 |
| Dong, M | 1 |
| Gong, S | 1 |
| Shang, Z | 1 |
| Jia, X | 1 |
| Chen, W | 1 |
| Yang, J | 2 |
| Xin, YG | 1 |
| Zhao, YN | 1 |
| Hu, WY | 1 |
| Bounthavong, M | 1 |
| Dolan, CM | 1 |
| Dunn, JD | 1 |
| Fisher, KA | 1 |
| Oestreicher, N | 1 |
| Hauptman, PJ | 1 |
| Veenstra, DL | 1 |
| Fernandes, BP | 1 |
| Conceição, LSR | 1 |
| Martins-Filho, PRS | 1 |
| de Santana Motta, DRM | 1 |
| Carvalho, VO | 1 |
| Yamamoto, M | 1 |
| Seo, Y | 1 |
| Ishizu, T | 1 |
| Nishi, I | 1 |
| Hamada-Harimura, Y | 1 |
| Machino-Ohtsuka, T | 1 |
| Higuchi, H | 1 |
| Sai, S | 1 |
| Nakatsukasa, T | 1 |
| Sugano, A | 1 |
| Baba, M | 1 |
| Obara, K | 1 |
| Aonuma, K | 1 |
| Sanders, NA | 1 |
| Supiano, MA | 1 |
| Bayoumi, E | 1 |
| Lam, PH | 2 |
| Dooley, DJ | 2 |
| Singh, S | 2 |
| Faselis, C | 1 |
| Morgan, CJ | 3 |
| Patel, S | 1 |
| Sheriff, HM | 1 |
| Mohammed, SF | 1 |
| Palant, CE | 1 |
| Ariti, C | 1 |
| Drzayich Antol, D | 1 |
| Waldman Casebeer, A | 1 |
| Khoury, R | 1 |
| Michael, T | 1 |
| Renda, A | 1 |
| Hopson, S | 1 |
| Parikh, A | 1 |
| Stein, A | 1 |
| Costantino, M | 1 |
| Stemkowski, S | 1 |
| Bunce, M | 1 |
| Nevo, N | 1 |
| Abu-Abeid, S | 1 |
| Hazzan, D | 1 |
| Lahat, G | 1 |
| Nachmani, I | 1 |
| Eldar, SM | 1 |
| Zhang, L | 1 |
| Xia, X | 1 |
| Zhong, Y | 1 |
| Xie, D | 1 |
| Liu, S | 1 |
| Wang, X | 1 |
| Tu, J | 1 |
| Faconti, L | 1 |
| Mills, CE | 1 |
| Govoni, V | 1 |
| Gu, H | 1 |
| Morant, S | 2 |
| Jiang, B | 1 |
| Cruickshank, JK | 1 |
| Webb, AJ | 1 |
| Lin, J | 2 |
| Wu, YJ | 1 |
| Liang, X | 1 |
| Ji, M | 1 |
| Ying, HM | 1 |
| Wang, XY | 1 |
| Shao, CH | 1 |
| Zhan, LX | 1 |
| Zhang, Y | 3 |
| Czamara, K | 1 |
| Karnas, E | 1 |
| Majka, Z | 1 |
| Wojcik, T | 1 |
| Zuba-Surma, EK | 1 |
| Baranska, M | 1 |
| Kaczor, A | 1 |
| Liu, X | 1 |
| Zhou, F | 1 |
| Yang, Y | 2 |
| Wang, W | 2 |
| Niu, L | 1 |
| Zuo, D | 1 |
| Hua, H | 1 |
| Zhang, B | 1 |
| Kou, Y | 1 |
| Guo, J | 1 |
| Kong, F | 1 |
| Pan, W | 1 |
| Gao, D | 1 |
| Meves, JM | 1 |
| Sun, H | 1 |
| Xue, M | 1 |
| Zhang, Q | 1 |
| Wang, Y | 2 |
| Tang, R | 1 |
| Iso, T | 1 |
| Haruyama, H | 1 |
| Sunaga, H | 1 |
| Matsui, H | 1 |
| Matsui, M | 1 |
| Tanaka, R | 1 |
| Umbarawan, Y | 1 |
| Syamsunarno, MRAA | 1 |
| Putri, M | 1 |
| Yamaguchi, A | 1 |
| Hanaoka, H | 1 |
| Negishi, K | 1 |
| Yokoyama, T | 1 |
| Kurabayashi, M | 4 |
| Palomo-Briones, R | 1 |
| Esquivel-González, S | 1 |
| Aizpuru, A | 1 |
| Gómez-Hernández, N | 1 |
| Casas-Flores, S | 1 |
| Barba de la Rosa, AP | 1 |
| Arriaga, S | 1 |
| Peterson, ME | 1 |
| Carothers, MA | 1 |
| Gamble, DA | 1 |
| Rishniw, M | 1 |
| Wu, WT | 1 |
| Chu, CY | 1 |
| Hsu, PC | 1 |
| Lee, WH | 1 |
| Su, HM | 1 |
| Yen, HW | 1 |
| Voon, WC | 1 |
| Lai, WT | 1 |
| Sheu, SH | 1 |
| Lin, TH | 1 |
| Thomas, JD | 1 |
| Kinno, M | 1 |
| Lewis, E | 1 |
| Linssen, GC | 1 |
| Smeele, FJ | 1 |
| van Drimmelen, AA | 1 |
| Schaafsma, HJ | 1 |
| Westendorp, PH | 1 |
| Rademaker, PC | 1 |
| van de Kamp, HJ | 1 |
| Hoes, AW | 2 |
| Brugts, JJ | 1 |
| Harty, BJ | 1 |
| McKinlay, SM | 7 |
| Joseph, J | 2 |
| Hammer, F | 1 |
| Malzahn, U | 1 |
| Donhauser, J | 1 |
| Betz, C | 1 |
| Schneider, MP | 1 |
| Grupp, C | 1 |
| Pollak, N | 1 |
| Störk, S | 2 |
| Wanner, C | 1 |
| Krane, V | 1 |
| Philips, S | 1 |
| Nijst, P | 2 |
| White-Guay, B | 1 |
| Dorais, M | 1 |
| Perreault, S | 1 |
| Merrill, M | 1 |
| Lindenfeld, J | 3 |
| Kao, DP | 1 |
| Andersson, C | 1 |
| Hansen, PW | 1 |
| Steffensen, IE | 1 |
| Andreasen, C | 1 |
| Weeke, PE | 1 |
| Gislason, GH | 1 |
| Torp-Pedersen, C | 1 |
| Berkowitz, SA | 1 |
| Rudolph, KE | 1 |
| Basu, S | 1 |
| Xiang, Y | 1 |
| Shi, W | 1 |
| Wang, SY | 2 |
| Xiang, R | 1 |
| Feng, P | 1 |
| Wen, L | 1 |
| Huang, W | 1 |
| Segar, MW | 1 |
| Patel, KV | 1 |
| Berry, JD | 1 |
| Shen, L | 2 |
| Carson, PE | 2 |
| Granger, CB | 3 |
| Komajda, M | 4 |
| McKelvie, RS | 2 |
| Yang, P | 1 |
| Shen, W | 1 |
| Zhu, D | 1 |
| Wu, T | 1 |
| Xu, G | 1 |
| Wu, Q | 1 |
| Blankenburg, M | 1 |
| Fett, AK | 1 |
| Eisenring, S | 1 |
| Haas, G | 1 |
| Gay, A | 1 |
| Neefs, J | 1 |
| van den Berg, NWE | 1 |
| Krul, SPJ | 1 |
| Boekholdt, SM | 1 |
| de Groot, JR | 1 |
| Greene, SJ | 1 |
| Giczewska, A | 1 |
| Ambrosy, AP | 1 |
| Chakraborty, H | 1 |
| Kajimoto, K | 1 |
| Otsubo, S | 1 |
| Bansal, S | 3 |
| Munoz, K | 1 |
| Brune, S | 1 |
| Bailey, S | 1 |
| Prasad, A | 1 |
| Velagapudi, C | 1 |
| Frankenstein, L | 2 |
| Seide, S | 1 |
| Täger, T | 1 |
| Jensen, K | 1 |
| Fröhlich, H | 1 |
| Seiz, M | 1 |
| Katus, HA | 3 |
| Nee, P | 1 |
| Uhlmann, L | 1 |
| Naci, H | 1 |
| Atar, D | 5 |
| Raparelli, V | 1 |
| Wali, MA | 1 |
| Pilote, L | 2 |
| Esposito, CT | 1 |
| Varahan, S | 1 |
| Jeyaraj, D | 1 |
| Stambler, BS | 3 |
| Rossi, R | 1 |
| Crupi, N | 1 |
| Coppi, F | 1 |
| Monopoli, D | 1 |
| Sgura, F | 1 |
| Andreev, DA | 1 |
| Gappoeva, ZK | 1 |
| Sychev, DA | 1 |
| Giliarov, MIu | 1 |
| Krum, H | 19 |
| Shi, H | 7 |
| Maeder, MT | 2 |
| Rickli, H | 2 |
| Abbühl, H | 1 |
| Gutmann, M | 1 |
| Erne, P | 2 |
| Vuilliomenet, A | 1 |
| Peter, M | 1 |
| Pfisterer, M | 1 |
| Sanders-van Wijk, S | 1 |
| Muzzarelli, S | 2 |
| Neuhaus, M | 1 |
| Kiencke, S | 1 |
| Maeder, M | 1 |
| Estlinbaum, W | 1 |
| Tobler, D | 1 |
| Mayer, K | 1 |
| Pfisterer, ME | 2 |
| Grundtvig, M | 2 |
| Hole, T | 2 |
| de Blois, J | 1 |
| Schellberg, D | 1 |
| Zugck, C | 1 |
| Agewall, S | 1 |
| Ricci, F | 1 |
| Ramírez, T | 1 |
| Marmorato, R | 1 |
| Vega, J | 1 |
| Pagán, P | 1 |
| López, JE | 1 |
| Soto-Salgado, M | 1 |
| Cangiano, JL | 1 |
| Bart, BA | 1 |
| Nelson, S | 1 |
| McMurray, JJ | 11 |
| Santos, M | 5 |
| Almeida, S | 3 |
| Marques, I | 4 |
| Bettencourt, P | 7 |
| Carvalho, H | 4 |
| Caballero, L | 1 |
| Gonzalez-Juanatey, JR | 3 |
| Vazquez, R | 2 |
| Bayes de Luna, A | 1 |
| Cinca, J | 2 |
| Dos, L | 1 |
| Pujadas, S | 1 |
| Estruch, M | 1 |
| Mas, A | 1 |
| Ferreira-González, I | 1 |
| Pijuan, A | 1 |
| Serra, R | 1 |
| Ordóñez-Llanos, J | 1 |
| Subirana, M | 1 |
| Pons-Lladó, G | 1 |
| Marsal, JR | 1 |
| García-Dorado, D | 1 |
| Casaldàliga, J | 1 |
| Springer, J | 1 |
| Tschirner, A | 1 |
| Haghikia, A | 1 |
| von Haehling, S | 2 |
| Lal, H | 1 |
| Grzesiak, A | 1 |
| Palus, S | 1 |
| Pötsch, M | 1 |
| von Websky, K | 1 |
| Hocher, B | 1 |
| Latouche, C | 1 |
| Jaisser, F | 3 |
| Morawietz, L | 1 |
| Coats, AJ | 4 |
| Beadle, J | 1 |
| Argiles, JM | 1 |
| Thum, T | 1 |
| Földes, G | 1 |
| Doehner, W | 2 |
| Hilfiker-Kleiner, D | 1 |
| Force, T | 1 |
| Borgdorff, MA | 1 |
| Bartelds, B | 1 |
| Dickinson, MG | 1 |
| Steendijk, P | 1 |
| Berger, RM | 1 |
| Muñoz-Pacheco, P | 1 |
| Ortega-Hernández, A | 1 |
| Caro-Vadillo, A | 1 |
| Casanueva-Eliceiry, S | 1 |
| Aragoncillo, P | 1 |
| Egido, J | 1 |
| Fernández-Cruz, A | 1 |
| Gómez-Garre, D | 1 |
| Regnault, V | 1 |
| Lagrange, J | 1 |
| Safar, ME | 2 |
| Fay, R | 7 |
| Challande, P | 2 |
| Lacolley, P | 2 |
| Gelbrich, G | 2 |
| Duvinage, A | 2 |
| Stahrenberg, R | 1 |
| Behrens, A | 1 |
| Prettin, C | 1 |
| Kraigher-Krainer, E | 2 |
| Schmidt, AG | 2 |
| Düngen, HD | 2 |
| Kamke, W | 1 |
| Tschöpe, C | 2 |
| Halle, M | 2 |
| Vizzardi, E | 2 |
| Nodari, S | 1 |
| Caretta, G | 1 |
| D'Aloia, A | 2 |
| Pezzali, N | 2 |
| Faden, G | 1 |
| Lombardi, C | 1 |
| Raddino, R | 1 |
| Metra, M | 2 |
| Dei Cas, L | 2 |
| Sopko, G | 2 |
| Li, G | 3 |
| Assmann, SF | 8 |
| Overbeck, P | 2 |
| Eng, M | 1 |
| Duchenne, J | 1 |
| Bertrand, PB | 1 |
| Dupont, M | 2 |
| Tang, WH | 7 |
| Dobre, D | 3 |
| Messig, M | 1 |
| Ogino, K | 2 |
| Kinugasa, Y | 1 |
| Kato, M | 3 |
| Yamamoto, K | 2 |
| Hisatome, I | 2 |
| Iqbal, J | 1 |
| Parviz, Y | 1 |
| Newell-Price, J | 1 |
| Al-Mohammad, A | 1 |
| Neskovic, AN | 1 |
| Łabuzek, K | 1 |
| Liber, S | 1 |
| Bułdak, Ł | 1 |
| Krupej-Kędzierska, J | 1 |
| Machnik, G | 1 |
| Bobrzyk, M | 1 |
| Okopień, B | 1 |
| Delbeck, M | 1 |
| Kretschmer, A | 1 |
| Steinke, W | 1 |
| Hartmann, E | 1 |
| Bärfacker, L | 1 |
| Eitner, F | 1 |
| Albrecht-Küpper, B | 1 |
| Schäfer, S | 1 |
| Carillo, S | 1 |
| Angioi, M | 3 |
| Sutradhor, SC | 1 |
| O'Connor, C | 1 |
| Gordeev, I | 4 |
| Harty, B | 2 |
| Kenwood, CT | 3 |
| Probstfield, JL | 2 |
| Shaburishvili, T | 4 |
| Montalescot, G | 2 |
| Lopez de Sa, E | 1 |
| Hamm, CW | 1 |
| Flather, M | 1 |
| Verheugt, F | 1 |
| Turgonyi, E | 1 |
| Orri, M | 1 |
| Inampudi, C | 3 |
| Parvataneni, S | 1 |
| Deedwania, P | 5 |
| Sanders, PW | 2 |
| Forman, DE | 1 |
| Allman, RM | 2 |
| Kurrelmeyer, KM | 1 |
| Ashton, Y | 1 |
| Xu, J | 2 |
| Nagueh, SF | 1 |
| Torre-Amione, G | 2 |
| Deswal, A | 3 |
| Hassan, M | 1 |
| Qureshi, W | 1 |
| Sroujieh, LS | 1 |
| Albashaireh, D | 1 |
| BouMalham, S | 1 |
| Liroff, M | 1 |
| Amjad, W | 1 |
| Khalid, F | 1 |
| Hadid, H | 1 |
| Alirhayim, Z | 1 |
| Dalzell, JR | 1 |
| Efthimiadis, GK | 1 |
| Zegkos, T | 1 |
| Karvounis, H | 1 |
| Kumar, N | 1 |
| Garg, N | 1 |
| Morawietz, H | 1 |
| Bornstein, SR | 1 |
| Sica, DA | 2 |
| Penders, J | 1 |
| Lewey, J | 1 |
| Haythe, J | 1 |
| Markov, V | 2 |
| Ryabov, V | 1 |
| Reis, G | 1 |
| Maisel, A | 1 |
| Xue, Y | 1 |
| Jaarsma, T | 2 |
| Pang, PS | 1 |
| Clopton, P | 1 |
| de Boer, RA | 1 |
| Bell, SP | 1 |
| Adkisson, DW | 1 |
| Lawson, MA | 1 |
| Wang, L | 1 |
| Ooi, H | 1 |
| Sawyer, DB | 1 |
| Kronenberg, MW | 1 |
| Kelly, J | 1 |
| Rada, G | 1 |
| Peña, J | 1 |
| Nolte, K | 1 |
| Unkelbach, I | 1 |
| Stough, WG | 2 |
| Pieske, BM | 1 |
| Boccanelli, A | 2 |
| Pulignano, G | 1 |
| Fiuzat, M | 1 |
| Burnett, JC | 2 |
| Calvier, L | 1 |
| Martinez-Martinez, E | 1 |
| Miana, M | 1 |
| Cachofeiro, V | 1 |
| Rousseau, E | 1 |
| Sádaba, JR | 1 |
| López-Andrés, N | 1 |
| Kiehl, EL | 1 |
| Shivapour, DM | 1 |
| Goenka, AH | 1 |
| Hirata, K | 1 |
| Hirayakma, A | 1 |
| Momomura, S | 1 |
| Nakagawa, Y | 1 |
| Nishi, Y | 1 |
| Uesaka, H | 1 |
| Ruschitzka, F | 1 |
| Michel, A | 1 |
| Martín-Pérez, M | 1 |
| Ruigómez, A | 1 |
| García Rodríguez, LA | 1 |
| Murphy, GK | 1 |
| McAlister, FA | 6 |
| Eurich, DT | 1 |
| Hamo, CE | 1 |
| Kim, HY | 3 |
| Gheorghiade, M | 6 |
| Ponikowski, P | 3 |
| Nowack, C | 5 |
| Kim, SY | 5 |
| Pieper, A | 2 |
| Kimmeskamp-Kirschbaum, N | 2 |
| Filippatos, G | 5 |
| Abbas, S | 1 |
| Ihle, P | 1 |
| Harder, S | 1 |
| Schubert, I | 1 |
| Balderia, PG | 1 |
| Wongrakpanich, S | 1 |
| Patel, M | 1 |
| Stanek, M | 1 |
| Shinagawa, K | 1 |
| Tannenbaum, S | 1 |
| Sayer, GT | 1 |
| Moret, M | 1 |
| Darbellay, P | 1 |
| Lebowitz, D | 1 |
| Alves, C | 1 |
| Sabeh, N | 1 |
| Carballo, S | 1 |
| Oh, J | 1 |
| Kang, SM | 1 |
| Song, MK | 1 |
| Hong, N | 1 |
| Youn, JC | 1 |
| Han, S | 1 |
| Jeon, ES | 1 |
| Cho, MC | 1 |
| Kim, JJ | 1 |
| Yoo, BS | 1 |
| Chae, SC | 1 |
| Oh, BH | 1 |
| Choi, DJ | 1 |
| Lee, MM | 1 |
| Ryu, KH | 1 |
| Oliveira, JC | 1 |
| Volterrani, M | 1 |
| Iellamo, F | 1 |
| Weisberg, HI | 1 |
| Pontes, VP | 1 |
| Widimský, J | 1 |
| Ferrari, R | 1 |
| Paulus, WJ | 1 |
| Rapezzi, C | 1 |
| Agrawal, S | 1 |
| Agrawal, N | 1 |
| Garg, J | 1 |
| Mohandas, R | 1 |
| Gupta, T | 1 |
| Segal, M | 1 |
| Cannon, JA | 1 |
| Cezar, MD | 1 |
| Damatto, RL | 1 |
| Pagan, LU | 1 |
| Lima, AR | 1 |
| Martinez, PF | 1 |
| Bonomo, C | 1 |
| Rosa, CM | 1 |
| Campos, DH | 1 |
| Cicogna, AC | 1 |
| Gomes, MJ | 1 |
| Oliveira, SA | 1 |
| Blotta, DA | 1 |
| Okoshi, MP | 1 |
| Okoshi, K | 1 |
| Deinum, J | 1 |
| Riksen, NP | 1 |
| Lenders, JW | 1 |
| Follath, F | 4 |
| Desai, A | 2 |
| Capuano, A | 1 |
| Scavone, C | 1 |
| Vitale, C | 1 |
| Sportiello, L | 1 |
| Rossi, F | 1 |
| Rosano, GM | 1 |
| Mitter, SS | 1 |
| Takahashi, F | 1 |
| Goto, M | 1 |
| Wada, Y | 2 |
| Hasebe, N | 1 |
| Ayuzawa, N | 1 |
| Nagase, M | 1 |
| Ueda, K | 1 |
| Nishimoto, M | 1 |
| Kawarazaki, W | 1 |
| Marumo, T | 1 |
| Aiba, A | 1 |
| Sakurai, T | 1 |
| Shindo, T | 1 |
| Fujita, T | 1 |
| Eyuboglu, M | 1 |
| Medeiros, PB | 1 |
| Carvalho, HC | 1 |
| Kénizou, D | 1 |
| Korantzopoulos, P | 1 |
| Shao, Q | 1 |
| Zhang, Z | 4 |
| Letsas, KP | 1 |
| Bomback, AS | 1 |
| Hsu, WT | 1 |
| Shen, LJ | 1 |
| Lee, CM | 1 |
| Wang, TY | 1 |
| Vora, AN | 1 |
| Peng, SA | 1 |
| Das, S | 1 |
| de Lemos, JA | 1 |
| Wettersten, N | 1 |
| Maisel, AS | 1 |
| Spertus, J | 2 |
| McKinlay, SA | 1 |
| Pitt, BA | 1 |
| Claggett, BC | 1 |
| Sato, N | 1 |
| Ajioka, M | 1 |
| Myoishi, M | 1 |
| Shiga, T | 1 |
| Beygui, F | 1 |
| Cayla, G | 1 |
| Roule, V | 1 |
| Roubille, F | 1 |
| Delarche, N | 1 |
| Silvain, J | 1 |
| Van Belle, E | 1 |
| Belle, L | 1 |
| Galinier, M | 2 |
| Motreff, P | 1 |
| Cornillet, L | 1 |
| Collet, JP | 1 |
| Furber, A | 1 |
| Goldstein, P | 1 |
| Ecollan, P | 1 |
| Legallois, D | 1 |
| Lebon, A | 1 |
| Rousseau, H | 1 |
| Machecourt, J | 1 |
| Vicaut, E | 2 |
| Condorelli, G | 1 |
| Jotti, GS | 1 |
| Pagiatakis, C | 1 |
| Palombo, G | 1 |
| Ademi, Z | 1 |
| Pasupathi, K | 1 |
| Liew, D | 4 |
| Xi, D | 1 |
| Zhao, J | 1 |
| Chen, S | 1 |
| Guo, Z | 1 |
| Bristow, MR | 3 |
| Saxon, LA | 2 |
| Feldman, AM | 3 |
| Mei, C | 1 |
| Anderson, SA | 1 |
| DeMets, DL | 1 |
| Araujo, CM | 1 |
| Hermidorff, MM | 1 |
| Amancio, Gde C | 1 |
| Lemos, Dda S | 1 |
| Silva, ME | 1 |
| de Assis, LV | 1 |
| Isoldi, MC | 1 |
| Gu, J | 1 |
| Fan, YQ | 1 |
| Han, ZH | 1 |
| Fan, L | 1 |
| Bian, L | 1 |
| Zhang, HL | 1 |
| Xu, ZJ | 1 |
| Yin, ZF | 1 |
| Xie, YS | 1 |
| Zhang, JF | 1 |
| Wang, CQ | 1 |
| Flatt, DM | 1 |
| Brown, MC | 1 |
| Mizeracki, AM | 1 |
| King, BJ | 1 |
| Weber, KT | 8 |
| Malebranche, R | 1 |
| Tabou Moyo, C | 1 |
| Morisset, PH | 1 |
| Raphael, NA | 1 |
| Wilentz, JR | 1 |
| Kalogeropoulos, A | 1 |
| Shah, MR | 1 |
| Heggermont, WA | 1 |
| Goethals, M | 1 |
| Dierckx, R | 1 |
| Verstreken, S | 1 |
| Bartunek, J | 1 |
| Vanderheyden, M | 1 |
| Shantsila, E | 1 |
| Haynes, R | 1 |
| Calvert, M | 1 |
| Fisher, J | 1 |
| Kirchhof, P | 1 |
| Gill, PS | 1 |
| Lip, GY | 2 |
| Hoss, S | 1 |
| Elizur, Y | 1 |
| Luria, D | 1 |
| Keren, A | 1 |
| Lotan, C | 1 |
| Gotsman, I | 1 |
| Arundel, C | 1 |
| Wu, WC | 1 |
| Anker, MS | 1 |
| Love, TE | 3 |
| Sharma, K | 1 |
| Linas, S | 1 |
| Gersh, BJ | 1 |
| Grady, C | 1 |
| Rice, MM | 1 |
| Greenberg, BH | 1 |
| Oishi, M | 1 |
| Tomono, Y | 1 |
| Zhao, Q | 1 |
| Sweeney, K | 1 |
| Chaudesaygues, E | 1 |
| Ferrini, M | 1 |
| Ritz, B | 1 |
| Olivier, A | 1 |
| Michel, JB | 1 |
| Ketelslegers, JM | 3 |
| Bramlage, P | 1 |
| Tregubov, VG | 1 |
| Kanorskiy, SG | 1 |
| Pokrovskiy, VM | 1 |
| Rocha, RM | 1 |
| Silva, GV | 1 |
| de Albuquerque, DC | 1 |
| Tura, BR | 1 |
| Albanesi Filho, FM | 1 |
| Nicolau, J | 2 |
| Cardoso, JS | 1 |
| Parkhomenko, A | 2 |
| Aschermann, M | 2 |
| Corbalán, R | 2 |
| Solomon, H | 2 |
| Ezekowitz, JA | 4 |
| Lee, DS | 4 |
| Tu, JV | 4 |
| Newman, AM | 1 |
| De Mello, WC | 2 |
| Gerena, Y | 1 |
| Mulder, P | 1 |
| Mellin, V | 1 |
| Favre, J | 1 |
| Vercauteren, M | 1 |
| Remy-Jouet, I | 1 |
| Monteil, C | 1 |
| Richard, V | 1 |
| Renet, S | 1 |
| Henry, JP | 1 |
| Jeng, AY | 1 |
| Webb, RL | 1 |
| Thuillez, C | 1 |
| Carbone, LD | 2 |
| Cross, JD | 1 |
| Raza, SH | 1 |
| Bush, AJ | 1 |
| Sepanski, RJ | 1 |
| Dhawan, S | 1 |
| Khan, BQ | 1 |
| Gupta, M | 1 |
| Ahmad, K | 1 |
| Khouzam, RN | 2 |
| Dishmon, DA | 2 |
| Nesheiwat, JP | 1 |
| Hajjar, MA | 1 |
| Chishti, WA | 1 |
| Nasser, W | 1 |
| Khan, M | 1 |
| Womack, CR | 1 |
| Cho, T | 1 |
| Haskin, AR | 1 |
| Cohen-Solal, A | 4 |
| Guiraudet, O | 1 |
| Lambert de Crémeur, G | 1 |
| Bonnevie, L | 1 |
| Héno, P | 1 |
| Pelletier, C | 1 |
| Fraboulet, R | 1 |
| Schiano, P | 1 |
| Martin, AC | 1 |
| Chenilleau, MC | 1 |
| Delarbre, D | 1 |
| Chanudet, X | 1 |
| Grigorian-Shamagian, L | 1 |
| Pascual, D | 1 |
| Fernandez-Palomeque, C | 1 |
| Bardaji, A | 1 |
| Almendral, J | 1 |
| Nieto, V | 1 |
| Macaya, C | 1 |
| Jimenez, RP | 1 |
| de Luna, AB | 1 |
| Yoshimura, M | 3 |
| Nakayama, M | 1 |
| Yamamuro, M | 1 |
| Nishijima, T | 1 |
| Kusuhara, K | 1 |
| Nagayoshi, Y | 1 |
| Kojima, S | 1 |
| Kaikita, K | 1 |
| Sumida, H | 1 |
| Sugiyama, S | 1 |
| Ogawa, H | 2 |
| Ruilope, LM | 1 |
| DiCarlo, L | 2 |
| Mukherjee, R | 5 |
| Lima, MV | 1 |
| Ochiai, ME | 1 |
| Cardoso, JN | 1 |
| Morgado, PC | 1 |
| Munhoz, RT | 1 |
| Barretto, AC | 1 |
| Ramaraj, R | 1 |
| Ghali, JK | 1 |
| Tam, SW | 1 |
| Sabolinski, ML | 1 |
| Taylor, AL | 2 |
| Cohn, JN | 2 |
| Worcel, M | 1 |
| Lopes, RJ | 1 |
| Lourenço, AP | 1 |
| Mascarenhas, J | 2 |
| Azevedo, A | 2 |
| de Pouvourville, G | 1 |
| Solesse, A | 1 |
| Beillat, M | 1 |
| Chan, PS | 1 |
| Soto, G | 1 |
| Nallamothu, BK | 1 |
| Weintraub, WS | 5 |
| de Groote, P | 1 |
| Isnard, R | 1 |
| Clerson, P | 1 |
| Jondeau, G | 1 |
| Assyag, P | 1 |
| Demil, N | 1 |
| Ducardonnet, A | 1 |
| Thebaut, JF | 1 |
| Macintyre, K | 1 |
| Simpson, CR | 1 |
| Lewsey, JD | 1 |
| Stewart, S | 2 |
| Redpath, A | 1 |
| Chalmers, JW | 1 |
| Capewell, S | 2 |
| Rasmussen, ZZ | 1 |
| Barfod, T | 1 |
| Klit, J | 1 |
| Saran, R | 1 |
| Karagiannis, A | 1 |
| Athyros, VG | 1 |
| Mikhailidis, DP | 2 |
| Muldowney, JA | 1 |
| Schoenhard, JA | 1 |
| Benge, CD | 1 |
| Yumino, D | 1 |
| Wang, H | 1 |
| Floras, JS | 1 |
| Ruttanaumpawan, P | 1 |
| Parker, JD | 1 |
| Bradley, TD | 1 |
| Iraqi, W | 1 |
| Nuée, J | 1 |
| Taheri, S | 2 |
| Mortazavi, M | 2 |
| Shahidi, S | 1 |
| Pourmoghadas, A | 2 |
| Garakyaraghi, M | 1 |
| Seirafian, S | 1 |
| Eshaghian, A | 1 |
| Ghassami, M | 1 |
| Laurita, KR | 1 |
| Shroff, SC | 2 |
| Hoeker, G | 1 |
| Martovitz, NL | 2 |
| Stein, PK | 1 |
| Berger, R | 2 |
| Shankar, A | 1 |
| Fruhwald, F | 1 |
| Fahrleitner-Pammer, A | 1 |
| Freemantle, N | 1 |
| Pacher, R | 2 |
| Kandula, P | 1 |
| Shah, R | 1 |
| Tanaka, H | 1 |
| Watanabe, K | 1 |
| Harima, M | 1 |
| Thanikachalam, PV | 1 |
| Yamaguchi, K | 1 |
| Tachikawa, H | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Trzaska, E | 1 |
| Gumułka, W | 1 |
| Makulska-Nowak, HE | 1 |
| Haynes, BA | 1 |
| Mookadam, F | 1 |
| Shafiq, MM | 1 |
| Miller, AB | 2 |
| Jolobe, OM | 4 |
| Khan, S | 2 |
| Harinstein, ME | 1 |
| Li, MJ | 1 |
| Huang, CX | 1 |
| Okello, E | 1 |
| Yanhong, T | 1 |
| Mohamed, S | 1 |
| Mori, T | 1 |
| Kurumazuka, D | 1 |
| Matsumoto, C | 1 |
| Shirakawa, H | 1 |
| Kimura, S | 1 |
| Kitada, K | 1 |
| Kobayashi, K | 1 |
| Matsuda, H | 1 |
| Hayashi, T | 2 |
| Kitaura, Y | 1 |
| Matsumura, Y | 1 |
| Schrier, RW | 2 |
| Adamopoulos, C | 1 |
| Mehta, S | 1 |
| Vijayakumar, M | 1 |
| Lopes, R | 1 |
| Lourenco, P | 1 |
| Yamaji, M | 2 |
| Tsutamoto, T | 6 |
| Kawahara, C | 2 |
| Nishiyama, K | 2 |
| Yamamoto, T | 5 |
| Fujii, M | 5 |
| Horie, M | 2 |
| O'Donoghue, M | 1 |
| Groo, VL | 3 |
| Viana, MA | 3 |
| Dai, Y | 1 |
| Patel, SR | 1 |
| Mahoney, EM | 2 |
| Kolm, P | 2 |
| Caro, J | 2 |
| Willke, R | 2 |
| Tsuda, E | 1 |
| Matsuo, M | 1 |
| Sakaguchi, H | 1 |
| Hosoda, K | 1 |
| Miyazaki, A | 1 |
| Moertl, D | 1 |
| Peter, S | 1 |
| Ahmadi, R | 1 |
| Huelsmann, M | 1 |
| Yamuti, S | 1 |
| Wagner, B | 1 |
| Poggio, R | 1 |
| Grancelli, HO | 1 |
| Miriuka, SG | 1 |
| Udelson, JE | 1 |
| Solomon, HA | 1 |
| Derer, W | 1 |
| Dechend, R | 1 |
| Müller, DN | 1 |
| Ovaert, P | 1 |
| Elliott, J | 2 |
| Bernay, F | 1 |
| Bardon, T | 1 |
| Waldum, B | 1 |
| Westheim, AS | 1 |
| Sandvik, L | 1 |
| Flønaes, B | 1 |
| Gullestad, L | 1 |
| Os, I | 1 |
| Ozhan, H | 2 |
| Balaban, Y | 1 |
| Wei, L | 2 |
| Struthers, AD | 15 |
| Fahey, T | 1 |
| Watson, AD | 1 |
| Macdonald, TM | 2 |
| McKenna, C | 1 |
| Burch, J | 1 |
| Suekarran, S | 1 |
| Walker, S | 1 |
| Bakhai, A | 1 |
| Witte, K | 1 |
| Harden, M | 1 |
| Wright, K | 1 |
| Woolacott, N | 1 |
| Lorgelly, P | 1 |
| Fenwick, L | 1 |
| Palmer, S | 1 |
| Guyonnet, J | 1 |
| Kaltsatos, V | 1 |
| Hovland, A | 1 |
| Fagerheim, AK | 1 |
| Hardersen, R | 1 |
| Nielsen, EW | 1 |
| Funder, JW | 9 |
| Lopukhova, VV | 1 |
| Sapel'nikov, OV | 1 |
| Grishin, IR | 1 |
| Erastova, NV | 1 |
| Latypov, RS | 1 |
| Mareev, IuV | 1 |
| Chernova, NA | 1 |
| Saidova, MA | 1 |
| Akchurin, RS | 1 |
| Karpov, IuA | 1 |
| Martinez, FA | 1 |
| Setoguchi, S | 1 |
| Choudhry, NK | 1 |
| Levin, R | 1 |
| Shrank, WH | 1 |
| Winkelmayer, WC | 1 |
| Erden, I | 1 |
| Yalcin, S | 1 |
| Abuannadi, M | 1 |
| O'Keefe, JH | 2 |
| Schuller, S | 1 |
| Van Israël, N | 1 |
| Vanbelle, S | 1 |
| Clercx, C | 1 |
| McEntee, K | 1 |
| Chua, D | 1 |
| Lo, A | 1 |
| Lo, C | 1 |
| Giubbini, R | 1 |
| Bordonali, T | 1 |
| Bugatti, S | 1 |
| Romeo, A | 1 |
| Dei Cas, A | 1 |
| Armstrong, PW | 6 |
| Guglin, M | 2 |
| Kristof-Kuteyeva, O | 1 |
| Novotorova, I | 1 |
| Pratap, P | 1 |
| Kimura, M | 1 |
| Wakeyama, T | 1 |
| Takaki, A | 1 |
| Iwami, T | 1 |
| Hadano, Y | 1 |
| Mochizuki, M | 1 |
| Hiratsuka, A | 1 |
| Shimizu, A | 1 |
| Matsuzaki, M | 1 |
| de Peuter, OR | 1 |
| Souverein, PC | 1 |
| Klungel, OH | 1 |
| de Boer, A | 1 |
| Büller, HR | 1 |
| Kamphuisen, PW | 1 |
| Edfors, K | 1 |
| Andersen, SE | 1 |
| Huang, IZ | 2 |
| Deedwania, PC | 1 |
| Ahmed, MI | 1 |
| Feller, MA | 1 |
| Aban, IB | 1 |
| Merx, MW | 1 |
| Ertl, G | 8 |
| Dastidar, AG | 1 |
| Tomaschitz, A | 1 |
| Pilz, S | 1 |
| Gus, M | 1 |
| Fuchs, FD | 1 |
| Sanchez-Mas, J | 1 |
| Lauten, A | 1 |
| Ferrari, M | 2 |
| Goebel, B | 2 |
| Rademacher, W | 1 |
| Schumm, J | 1 |
| Uth, O | 1 |
| Kiehntopf, M | 1 |
| Figulla, HR | 2 |
| Jung, C | 2 |
| Vergaro, G | 1 |
| Emdin, M | 2 |
| Iervasi, A | 1 |
| Zyw, L | 1 |
| Gabutti, A | 1 |
| Poletti, R | 1 |
| Mammini, C | 1 |
| Giannoni, A | 1 |
| Fontana, M | 1 |
| Passino, C | 2 |
| Agostoni, P | 2 |
| Lachaine, J | 1 |
| Beauchemin, C | 1 |
| Ramos, E | 1 |
| Kobayashi, D | 1 |
| Murakami, S | 1 |
| Oda, M | 1 |
| Hanawa, H | 1 |
| Kuroda, T | 1 |
| Nakano, M | 1 |
| Narita, I | 1 |
| Goland, S | 1 |
| Naugolny, V | 1 |
| Korbut, Z | 1 |
| Rozen, I | 1 |
| Caspi, A | 2 |
| Malnick, S | 1 |
| Birocchi, S | 1 |
| Cernuschi, GC | 1 |
| Bielecka-Dabrowa, A | 1 |
| Rysz, J | 1 |
| Banach, M | 1 |
| Richardson, P | 1 |
| Bozkurt, B | 2 |
| Ariti, CA | 1 |
| Wang, D | 4 |
| Torigoe, K | 2 |
| Tamura, A | 2 |
| Kawano, Y | 2 |
| Shinozaki, K | 2 |
| Kotoku, M | 2 |
| Kadota, J | 2 |
| Ménard, J | 1 |
| Pastormerlo, LE | 1 |
| Leopold, JA | 1 |
| Lee, T | 1 |
| Funder, J | 1 |
| Bhandari, S | 1 |
| Tala, S | 1 |
| Chabot, A | 1 |
| Jiang, BH | 1 |
| Shi, Y | 1 |
| Tardif, JC | 1 |
| Dupuis, J | 1 |
| Li, R | 2 |
| Toggweiler, S | 1 |
| Nietlispach, F | 1 |
| Julius, B | 1 |
| Burkard, T | 1 |
| Buysse, JM | 1 |
| Kasama, S | 3 |
| Toyama, T | 3 |
| Sumino, H | 2 |
| Kumakura, H | 3 |
| Takayama, Y | 3 |
| Minami, K | 1 |
| Ichikawa, S | 3 |
| Matsumoto, N | 2 |
| Sato, Y | 2 |
| Molloy, GJ | 1 |
| O'Carroll, RE | 1 |
| Witham, MD | 4 |
| McMurdo, ME | 1 |
| Collins, SP | 1 |
| Teerlink, JR | 2 |
| Walsh, MN | 1 |
| Albert, NM | 1 |
| Westlake Canary, CA | 1 |
| Colvin-Adams, M | 1 |
| Hershberger, RE | 1 |
| Katz, SD | 1 |
| Rogers, JG | 2 |
| Stevenson, WG | 1 |
| Starling, RC | 1 |
| Kryczka, K | 1 |
| Dzielińska, Z | 1 |
| Przybylski, A | 1 |
| Szczudlik, J | 1 |
| Dangel, J | 1 |
| Konka, M | 1 |
| Czajkowski, K | 1 |
| Różański, J | 1 |
| Bilińska, ZT | 1 |
| Demkow, M | 1 |
| Noda, K | 1 |
| Kobara, M | 1 |
| Hamada, J | 1 |
| Yoshifuji, Y | 1 |
| Shiraishi, T | 1 |
| Tanaka, T | 1 |
| Wang, J | 1 |
| Toba, H | 1 |
| Nakata, T | 1 |
| Seyrafian, S | 1 |
| Alipour, Z | 1 |
| Karimi, S | 1 |
| Preiss, D | 1 |
| Costanzo, MR | 1 |
| Heywood, JT | 2 |
| Massie, BM | 2 |
| Iwashita, J | 1 |
| Henderson, L | 1 |
| Mamatsashvili, M | 1 |
| Sisakian, H | 1 |
| Hayrapetyan, H | 1 |
| Sager, P | 1 |
| Albrecht, D | 1 |
| Florvaag, A | 1 |
| Oberle, V | 1 |
| Fritzenwanger, M | 1 |
| Kretschmar, D | 1 |
| Kuethe, F | 1 |
| Betge, S | 1 |
| Franz, M | 1 |
| Barz, D | 1 |
| Sundar, S | 1 |
| Dickinson, PD | 1 |
| Patel, CB | 1 |
| Milano, CA | 1 |
| Milliez, P | 4 |
| Gomes, S | 1 |
| Champ-Rigot, L | 1 |
| Callebert, J | 1 |
| Samuel, JL | 1 |
| Delcayre, C | 4 |
| Chapagain, A | 1 |
| Ashman, N | 1 |
| Hueskes, BA | 1 |
| Willems, FF | 1 |
| Leen, AC | 1 |
| Ninaber, PA | 1 |
| Westra, R | 1 |
| Mantel-Teeuwisse, AK | 1 |
| Janssens, HJ | 1 |
| van de Lisdonk, EH | 1 |
| Roovers, EA | 1 |
| Janssen, M | 1 |
| Markowitz, M | 1 |
| Messineo, F | 1 |
| Coplan, NL | 1 |
| Taylor, J | 1 |
| Mackenzie, IS | 1 |
| Thompson, A | 1 |
| Hawkins, NM | 1 |
| Scholes, S | 1 |
| Bajekal, M | 1 |
| Love, H | 1 |
| O'Flaherty, M | 1 |
| Raine, R | 1 |
| Chatterjee, S | 1 |
| Moeller, C | 1 |
| Shah, N | 1 |
| Bolorunduro, O | 1 |
| Lichstein, E | 1 |
| Moskovits, N | 1 |
| Cowie, MR | 1 |
| Talatinian, A | 1 |
| Chow, SL | 1 |
| Nagarajan, V | 1 |
| Chamsi-Pasha, M | 1 |
| Kamyshnikova, LA | 1 |
| Efremova, OA | 1 |
| Gupta, S | 1 |
| Fugh-Berman, AJ | 1 |
| Scialli, A | 1 |
| Krämer, B | 1 |
| Kiernan, MS | 1 |
| Wu, DH | 1 |
| Hu, LJ | 1 |
| Chen, YQ | 1 |
| Deng, SB | 1 |
| Du, JL | 1 |
| She, Q | 1 |
| Fanta, S | 1 |
| Kobulia, B | 1 |
| Al-Mazroua, HA | 1 |
| Al-Rasheed, NM | 1 |
| Korashy, HM | 1 |
| Svennblad, B | 1 |
| Melhus, H | 1 |
| Hallberg, P | 1 |
| Dahlström, U | 2 |
| Edner, M | 1 |
| Lakatos, E | 1 |
| Williams, ES | 1 |
| Miller, JM | 1 |
| Suematsu, F | 2 |
| Yukawa, E | 2 |
| Yukawa, M | 1 |
| Minemoto, M | 2 |
| Ohdo, S | 1 |
| Higuchi, S | 2 |
| Goto, Y | 2 |
| Porcu, M | 1 |
| Lindbloom, EJ | 1 |
| Koenig, CJ | 1 |
| McKelvie, R | 4 |
| Blaustein, DA | 1 |
| Babu, K | 1 |
| Reddy, A | 1 |
| Schwenk, MH | 1 |
| Avram, MM | 1 |
| Obialo, CI | 1 |
| Ofili, EO | 1 |
| Mirza, T | 1 |
| Zillich, AJ | 1 |
| Carter, BL | 1 |
| Smith, ES | 1 |
| Trussell, S | 1 |
| Mencer, LJ | 1 |
| Suzuki, T | 2 |
| Sanderson, JE | 2 |
| Rittenhouse, SK | 1 |
| Simko, F | 1 |
| Bada, V | 1 |
| Simková, M | 1 |
| Simko, J | 1 |
| Kovács, L | 1 |
| Hulín, I | 1 |
| Rousseau, MF | 1 |
| Gurné, O | 1 |
| Van Mieghem, W | 1 |
| Robert, A | 1 |
| Ahn, S | 1 |
| Galanti, L | 1 |
| Gould, PA | 1 |
| Kaye, DM | 1 |
| Suzuki, G | 1 |
| Morita, H | 1 |
| Mishima, T | 1 |
| Sharov, VG | 1 |
| Todor, A | 1 |
| Tanhehco, EJ | 1 |
| Rudolph, AE | 5 |
| McMahon, EG | 5 |
| Goldstein, S | 2 |
| Sabbah, HN | 2 |
| Pölzl, G | 1 |
| Gouya, G | 1 |
| Hügel, H | 1 |
| Frick, M | 1 |
| Ulmer, H | 1 |
| Pachinger, O | 1 |
| Francis, J | 3 |
| Weiss, RM | 5 |
| Johnson, AK | 3 |
| Felder, RB | 5 |
| Francis, GS | 2 |
| Agoston, I | 1 |
| Knowlton, AA | 2 |
| Jourdain, P | 1 |
| Funck, F | 1 |
| Bellorini, M | 1 |
| Guillard, N | 1 |
| Loiret, J | 1 |
| Thebault, B | 1 |
| Desnos, M | 1 |
| Duboc, D | 1 |
| Lopes, ME | 1 |
| Le Corvoisier, P | 1 |
| Tabet, JY | 1 |
| Su, JB | 1 |
| Badoual, T | 1 |
| Cachin, JC | 1 |
| Merlet, P | 1 |
| Castaigne, A | 3 |
| Hittinger, L | 2 |
| Jessup, M | 1 |
| Remme, W | 2 |
| Neaton, J | 2 |
| Martinez, F | 3 |
| Roniker, B | 3 |
| Bittman, R | 2 |
| Hurley, S | 3 |
| Kleiman, J | 2 |
| Gatlin, M | 1 |
| Wada, A | 3 |
| Maeda, K | 3 |
| Hayashi, M | 3 |
| Tsutsui, T | 3 |
| Ohnishi, M | 3 |
| Matsumoto, T | 3 |
| Takayama, T | 1 |
| Ishii, C | 1 |
| Rajagopalan, S | 3 |
| Aaronson, K | 1 |
| Azar, R | 1 |
| Hogede, L | 1 |
| Carru, V | 1 |
| Fenwick, S | 1 |
| Bell, GM | 1 |
| Inoue, K | 1 |
| Hori, M | 3 |
| Kambara, A | 1 |
| Holycross, BJ | 1 |
| Wung, P | 1 |
| Schanbacher, B | 1 |
| Ghosh, S | 1 |
| McCune, SA | 1 |
| Bauer, JA | 1 |
| Kwiatkowski, P | 1 |
| Fraccarollo, D | 7 |
| Schäfer, A | 2 |
| Hildemann, S | 1 |
| Christ, M | 4 |
| Eigenthaler, M | 1 |
| Kobsar, A | 1 |
| Walter, U | 1 |
| Qin, W | 1 |
| Bond, BR | 1 |
| Rocha, R | 4 |
| Blomme, EA | 1 |
| Goellner, JJ | 1 |
| Hildemann, SK | 2 |
| Tas, P | 1 |
| Rutten, FH | 1 |
| Grobbee, DE | 1 |
| Coletta, AP | 1 |
| Nikitin, N | 1 |
| Louis, A | 1 |
| Clark, A | 2 |
| Wrenger, E | 1 |
| Müller, R | 1 |
| Moesenthin, M | 1 |
| Welte, T | 1 |
| Frölich, JC | 1 |
| Neumann, KH | 1 |
| Salam, AM | 1 |
| Havranek, EP | 3 |
| Wolfe, P | 1 |
| Gross, CP | 2 |
| Rathore, SS | 2 |
| Steiner, JF | 1 |
| Ordin, DL | 1 |
| Anton, C | 1 |
| Cox, AR | 1 |
| Watson, RD | 1 |
| Ferner, RE | 1 |
| McKee, SP | 1 |
| Leslie, SJ | 1 |
| LeMaitre, JP | 1 |
| Webb, DJ | 1 |
| Denvir, MA | 1 |
| Stier, CT | 2 |
| Cruz, CS | 2 |
| Cruz, AA | 1 |
| Marcílio de Souza, CA | 1 |
| Feola, M | 1 |
| Menardi, E | 1 |
| Ribichini, F | 1 |
| Vado, A | 1 |
| Deorsola, A | 1 |
| Ferrero, V | 1 |
| Visconti, G | 1 |
| Milanese, U | 1 |
| Uslenghi, E | 1 |
| Hackam, DG | 1 |
| Trifonov, IR | 1 |
| NORTH, JD | 1 |
| HOWIE, RN | 1 |
| SIMS, FH | 1 |
| OGDEN, DA | 1 |
| SCHERR, L | 1 |
| SPRITZ, N | 1 |
| RUBIN, AL | 1 |
| PERRIN, A | 1 |
| FROMENT, R | 1 |
| SETTEL, E | 2 |
| MARSICO, F | 1 |
| DE FILIPPIS, V | 1 |
| PEDICINI, S | 1 |
| VIALA, JJ | 1 |
| FATH, A | 1 |
| JUSTIN-BESANCON, L | 2 |
| LAROCHE, C | 2 |
| NENNA, A | 2 |
| ETIENNE, JP | 2 |
| CREMER, G | 2 |
| GHIRINGHELLI, L | 1 |
| COMOLI, G | 1 |
| STRATA, A | 1 |
| PREIS, H | 1 |
| LINTRUP, J | 2 |
| FRIIS, T | 2 |
| NISSEN, NI | 2 |
| MICHAUX, J | 1 |
| NAPIORKOWSKA, W | 1 |
| ZIELINSKI, J | 1 |
| OLESEN, K | 3 |
| SANDOE, E | 3 |
| GRAZIANI, G | 1 |
| MOLE, R | 1 |
| GREENOUGH, WB | 1 |
| SONNENBLICK, EH | 1 |
| JANUSZEWICZ, V | 1 |
| LARAGH, JH | 3 |
| JAKOBSON, T | 1 |
| JENKINSON, VM | 1 |
| BAYLEY, TA | 1 |
| FORBATH, PG | 1 |
| WILSON, JK | 1 |
| HIGGINS, HP | 1 |
| SALA, G | 1 |
| D'AMICO, G | 1 |
| VAN CAUWENBERGE, H | 1 |
| LEFEBVRE, P | 1 |
| WAREMBOURG, H | 1 |
| LEKIEFFRE, J | 1 |
| ANDRIEU, J | 1 |
| PEYRIDIEUX, R | 1 |
| ISORNI, P | 1 |
| BRILLANTE, C | 1 |
| CHIERICI, F | 2 |
| SURIANI, L | 1 |
| MANZINI, E | 1 |
| PINELLI, G | 1 |
| CARIANI, A | 1 |
| AGNOLI, GC | 1 |
| DE MARTINIS, C | 1 |
| PUPITA, F | 1 |
| MENSA, R | 1 |
| FRANCAVIGLIA, A | 1 |
| GAGLIO, M | 1 |
| CONDORELLI, M | 1 |
| MAZZONE, O | 1 |
| MODICA, G | 1 |
| RAGUSA, G | 1 |
| SMILARI, L | 1 |
| TAMBURINO, G | 1 |
| BLASI, A | 1 |
| ZINNARI, A | 1 |
| HORKY, K | 2 |
| KUECHEL, O | 1 |
| BARNETT, AJ | 1 |
| BAUMGARTEN, A | 1 |
| BRANDSTATER, M | 1 |
| KUKES, VG | 1 |
| CARRUTHERS, BM | 1 |
| LEDRAY, RD | 1 |
| SERAGLIA, M | 1 |
| MCINTOSH, HW | 1 |
| WALSH, GC | 1 |
| STEINBECK, AW | 1 |
| THAYER, JM | 1 |
| HEALY, FA | 1 |
| SANDERS, LL | 1 |
| MELBY, JC | 1 |
| SELLER, RH | 2 |
| SWARTZ, CD | 1 |
| RAMIREZ-MUXO, O | 1 |
| BREST, AH | 1 |
| MOYER, JH | 1 |
| DEMARTINIS, C | 1 |
| FONZO, D | 1 |
| CONTE, M | 1 |
| FOUET, P | 1 |
| JACOBS, C | 1 |
| EVANS, DW | 1 |
| FLEAR, CT | 1 |
| DOMENET, JG | 1 |
| KISSEL, P | 1 |
| DUREUX, JB | 1 |
| SCHMITT, J | 1 |
| GILSANZ, V | 1 |
| BARRIO, E | 1 |
| CEBRIAN, L | 1 |
| ESTELLA, J | 1 |
| LOCKWOOD, CH | 1 |
| NICHOLLS, DM | 1 |
| LEWIS, JA | 1 |
| TROOP, VL | 1 |
| BELLISARIO, G | 1 |
| CORDOVA, C | 1 |
| LOCOCO, G | 1 |
| NATOLI, A | 1 |
| SANTUCCI, A | 1 |
| JOHNSTON, LC | 1 |
| GRIEBLE, HG | 1 |
| SCHOENBERGER, JA | 1 |
| FULLER, JB | 1 |
| ARMASCRUZ, R | 1 |
| GOMEZ, R | 1 |
| MARDONES, J | 1 |
| PLAZADELOSREYES, M | 1 |
| DITTRICH, H | 1 |
| SEIFERT, E | 1 |
| BAGROS, P | 1 |
| OLESEN, KH | 4 |
| JOOSSENS, JV | 1 |
| VERWILGEN, R | 1 |
| VERBERCKMOES, R | 1 |
| KATO, E | 1 |
| OSAWA, S | 1 |
| WAKASUGI, A | 1 |
| KIRIU, Y | 1 |
| ATO, T | 1 |
| MITSUNO, K | 1 |
| ITAZU, Y | 1 |
| HIERHOLZER, K | 2 |
| SHETH, UK | 1 |
| VAIDYA, A | 1 |
| KHOKHANI, RC | 1 |
| SHAH, MJ | 1 |
| LAUFER, ST | 1 |
| MAHABIR, RN | 1 |
| STOKES, W | 1 |
| BLAGG, CR | 1 |
| GLANVILLE, JN | 1 |
| GOLINELLI, G | 1 |
| MELLI, A | 1 |
| TOURNIAIRE, A | 3 |
| BLUM, J | 3 |
| GUYOT, R | 3 |
| GOLDBERGER, E | 1 |
| MAHER, JF | 1 |
| SCHREINER, GE | 1 |
| DAVID, P | 1 |
| AERICHIDE, N | 1 |
| BERNSTEIN, A | 1 |
| ODZE, M | 1 |
| CREWS, A | 1 |
| SIMON, F | 1 |
| BERCONSKY, I | 1 |
| NIJENSOHN, CM | 1 |
| BRUNO, PL | 1 |
| KUCHEL, O | 1 |
| DONOCIK, A | 1 |
| LEPPLA, W | 1 |
| TIEFENSEE, H | 1 |
| PAGET, M | 1 |
| LANGERON, L | 1 |
| CROCCEL, L | 1 |
| ROUTIER, G | 1 |
| CROCCEL, E | 1 |
| PROTIN, M | 1 |
| SoRelle, R | 1 |
| DiBianco, R | 1 |
| Lee, TH | 1 |
| Akbulut, M | 1 |
| Ozbay, Y | 1 |
| Ilkay, E | 1 |
| Karaca, I | 1 |
| Arslan, N | 1 |
| Gaulden, L | 1 |
| Svensson, M | 3 |
| Galatius, S | 3 |
| Hildebrandt, PR | 3 |
| Gama, MG | 1 |
| Rocha, G | 1 |
| McKenzie, DB | 1 |
| Cowley, AJ | 1 |
| Kolloch, R | 1 |
| Offers, E | 1 |
| Liu, YH | 1 |
| Yang, XP | 1 |
| Rhaleb, NE | 1 |
| Peterson, E | 1 |
| Carretero, OA | 1 |
| Grimm, W | 1 |
| Maisch, B | 1 |
| Dawson, A | 1 |
| Davies, JI | 2 |
| Futterman, LG | 1 |
| Lemberg, L | 1 |
| Riggs, JM | 1 |
| Trujillo, JM | 1 |
| Gonyeau, MJ | 1 |
| DiVall, MV | 1 |
| Alexander, SL | 1 |
| Jolobe, O | 1 |
| Cicoira, M | 2 |
| Rossi, A | 2 |
| Bonapace, S | 1 |
| Zanolla, L | 2 |
| Perrot, A | 1 |
| Francis, DP | 1 |
| Golia, G | 2 |
| Franceschini, L | 2 |
| Osterziel, KJ | 1 |
| Zardini, P | 2 |
| Boehmer, J | 1 |
| Krueger, S | 1 |
| Kass, DA | 1 |
| De Marco, T | 1 |
| DeMets, D | 1 |
| White, BG | 1 |
| DeVries, DW | 1 |
| Lyratzopoulos, G | 1 |
| Cook, GA | 1 |
| McElduff, P | 1 |
| Havely, D | 1 |
| Edwards, R | 1 |
| Heller, RF | 1 |
| Aforismo, JF | 1 |
| Adams, KF | 1 |
| Khan, NU | 1 |
| Movahed, A | 1 |
| Abiose, AK | 1 |
| Mansoor, GA | 1 |
| Barry, M | 1 |
| Soucier, R | 1 |
| Nair, CK | 1 |
| Hager, D | 1 |
| Macdonald, JE | 2 |
| Kennedy, N | 2 |
| Thohan, V | 1 |
| Koerner, MM | 1 |
| Fashingbauer, LA | 1 |
| Beitelshees, AL | 1 |
| Southworth, MR | 1 |
| Williams, RE | 1 |
| Dunlap, SH | 1 |
| Wimett, L | 1 |
| Laustsen, G | 1 |
| Soto, GE | 1 |
| Jones, P | 2 |
| Mottram, PM | 1 |
| Haluska, B | 1 |
| Leano, R | 1 |
| Cowley, D | 1 |
| Stowasser, M | 1 |
| Juurlink, DN | 3 |
| Mamdani, MM | 2 |
| Kopp, A | 1 |
| Austin, PC | 1 |
| Laupacis, A | 1 |
| Redelmeier, DA | 1 |
| Kochsiek, K | 1 |
| Gottlieb, S | 3 |
| Sligl, W | 1 |
| Ezekowitz, J | 1 |
| Weinberger, MH | 1 |
| Kolyvanos Naumann, U | 1 |
| Käser, L | 1 |
| Vetter, W | 1 |
| Gillespie, ND | 2 |
| Keating, GM | 1 |
| Plosker, GL | 2 |
| Opasich, C | 3 |
| De Feo, S | 2 |
| Ambrosio, GA | 1 |
| Bellis, P | 1 |
| Di Lenarda, A | 1 |
| Di Tano, G | 1 |
| Fico, D | 1 |
| Gonzini, L | 1 |
| Lavecchia, R | 1 |
| Tomasi, C | 1 |
| Dzau, VJ | 1 |
| Goldfarb, DS | 1 |
| Cavallari, L | 1 |
| Vaitkus, P | 1 |
| Groo, V | 1 |
| Newsome, BB | 1 |
| Warnock, DG | 1 |
| Kjeldsen, K | 1 |
| Barnes, BJ | 1 |
| Howard, PA | 1 |
| Magini, A | 1 |
| Andreini, D | 1 |
| Contini, M | 1 |
| Apostolo, A | 1 |
| Bussotti, M | 1 |
| Cattadori, G | 1 |
| Palermo, P | 1 |
| Tamirisa, KP | 1 |
| Aaronson, KD | 1 |
| Koelling, TM | 2 |
| Hansten, PD | 1 |
| Fukuchi, K | 1 |
| Sasaki, H | 1 |
| Yokoya, T | 1 |
| Noguchi, T | 1 |
| Hayashida, K | 1 |
| Ishida, Y | 1 |
| Román-Sánchez, P | 1 |
| Conthe, P | 1 |
| García-Alegría, J | 1 |
| Forteza-Rey, J | 1 |
| Montero, M | 1 |
| Montoto, C | 1 |
| Ostrenga, A | 1 |
| Pitcock, J | 1 |
| Pitcock, M | 1 |
| Kuster, GM | 1 |
| Kotlyar, E | 1 |
| Rude, MK | 1 |
| Siwik, DA | 1 |
| Liao, R | 1 |
| Colucci, WS | 1 |
| Sam, F | 1 |
| Conti, CR | 2 |
| Blue, L | 1 |
| Thompson, DR | 1 |
| Roebuck, A | 1 |
| Haaijer-Ruskamp, FM | 2 |
| Sturm, H | 1 |
| Erdmann, E | 1 |
| Ishak, J | 1 |
| Goldberg, R | 1 |
| Tooley, J | 2 |
| Sueta, CA | 1 |
| Bertoni, AG | 1 |
| Massing, MW | 1 |
| McArdle, J | 1 |
| Duren-Winfield, V | 1 |
| Davis, J | 1 |
| Croft, JB | 1 |
| Goff, DC | 1 |
| Watz, R | 1 |
| Ekstrand, AB | 1 |
| Engelbrektson, V | 1 |
| Beermann, B | 1 |
| Yano, M | 1 |
| Uchida, K | 1 |
| Nakano, S | 1 |
| Kigoshi, T | 1 |
| Takata, Y | 1 |
| Asano, K | 1 |
| Cox, JL | 2 |
| Ramer, SA | 1 |
| Humphries, K | 1 |
| Svenson, L | 1 |
| Murin, J | 1 |
| Fügedi, K | 1 |
| Karram, T | 1 |
| Abbasi, A | 1 |
| Keidar, S | 2 |
| Golomb, E | 1 |
| Hochberg, I | 1 |
| Winaver, J | 1 |
| Hoffman, A | 1 |
| Abassi, Z | 2 |
| Maison, P | 1 |
| Cunin, P | 1 |
| Hemery, F | 1 |
| Fric, F | 1 |
| Elie, N | 1 |
| Del'volgo, A | 1 |
| Dubois-Randé, JL | 1 |
| Macquin-Mavier, I | 1 |
| Galuppo, P | 2 |
| Schmidt, I | 1 |
| Dinsdale, C | 1 |
| Wani, M | 1 |
| Steward, J | 1 |
| O'Mahony, MS | 1 |
| Foody, JM | 1 |
| Nehme, JA | 1 |
| Labat, C | 1 |
| Robidel, E | 2 |
| Perret, C | 1 |
| Leenhardt, A | 2 |
| Cruz, LS | 1 |
| Domingues, GS | 1 |
| Souza, CA | 1 |
| Ojeda, S | 1 |
| Anguita, M | 1 |
| Delgado, M | 1 |
| Atienza, F | 1 |
| Rus, C | 1 |
| Granados, AL | 1 |
| Ridocci, F | 1 |
| Vallés, F | 1 |
| Velasco, JA | 1 |
| White, H | 1 |
| Dietz, R | 2 |
| Eichhorn, E | 2 |
| Erhardt, L | 2 |
| Hobbs, FD | 2 |
| Maggioni, A | 2 |
| Piña, IL | 1 |
| Soler-Soler, J | 2 |
| Houpe, D | 1 |
| Peltier, M | 1 |
| Béguin, M | 1 |
| Lévy, F | 1 |
| Slama, M | 1 |
| Chapelain, K | 1 |
| Tribouilloy, C | 1 |
| Hu, X | 1 |
| Lala, DS | 1 |
| Singer, RB | 1 |
| Newman, A | 1 |
| Kimber, S | 1 |
| Cujec, B | 1 |
| Sturm, HB | 1 |
| van Gilst, WH | 3 |
| Shah, KB | 1 |
| Rao, K | 1 |
| Sawyer, R | 1 |
| Gottlieb, SS | 1 |
| Deangelis, N | 1 |
| Rucker-Martin, C | 1 |
| Beaufils, P | 1 |
| Hatem, SN | 1 |
| Nattel, S | 1 |
| Mandolini, C | 1 |
| Vacca, K | 1 |
| Borgia, MC | 1 |
| Gamliel-Lazarovich, A | 1 |
| Kaplan, M | 1 |
| Pavlotzky, E | 1 |
| Hamoud, S | 1 |
| Hayek, T | 1 |
| Karry, R | 1 |
| Lenzen, MJ | 2 |
| Boersma, E | 1 |
| Reimer, WJ | 1 |
| Balk, AH | 1 |
| Jimenez-Navarro, M | 2 |
| Simoons, ML | 1 |
| Fiscella, K | 1 |
| van de Wal, RM | 2 |
| Asselbergs, FW | 1 |
| Plokker, HW | 2 |
| Smilde, TD | 1 |
| Lok, D | 1 |
| Koch, E | 1 |
| Otarola, A | 1 |
| Kirschbaum, A | 1 |
| Croom, KF | 1 |
| Izawa, H | 1 |
| Murohara, T | 1 |
| Nagata, K | 1 |
| Isobe, S | 1 |
| Asano, H | 1 |
| Amano, T | 1 |
| Ichihara, S | 1 |
| Kato, T | 2 |
| Ohshima, S | 1 |
| Murase, Y | 1 |
| Iino, S | 1 |
| Obata, K | 1 |
| Noda, A | 1 |
| Okumura, K | 1 |
| Yokota, M | 1 |
| Landmesser, U | 1 |
| Drexler, H | 1 |
| Saito, M | 2 |
| Takada, M | 2 |
| Hirooka, K | 2 |
| Isobe, F | 1 |
| Yasumura, Y | 2 |
| Lok, DJ | 1 |
| Boomsma, F | 1 |
| van der Horst, FA | 1 |
| Shibata, MC | 1 |
| Nilsson, C | 1 |
| Hervas-Malo, M | 1 |
| Jacobs, P | 1 |
| Tsuyuki, RT | 1 |
| Mohacsi, P | 1 |
| Tendera, M | 1 |
| Fowler, MB | 1 |
| Roecker, EB | 1 |
| Packer, M | 2 |
| Farah, V | 1 |
| Flax, SD | 1 |
| Konopa, J | 1 |
| Bułło, B | 1 |
| Rutkowski, B | 1 |
| Anderson, JL | 1 |
| Klug, EQ | 1 |
| Ko, DT | 1 |
| You, JJ | 1 |
| Wang, JT | 1 |
| Donovan, LR | 1 |
| Thai, HM | 1 |
| Do, BQ | 1 |
| Tran, TD | 1 |
| Gaballa, MA | 1 |
| Goldman, S | 1 |
| Williams, EM | 1 |
| Katholi, RE | 1 |
| Karambelas, MR | 1 |
| Baliga, RR | 1 |
| Ranganna, P | 1 |
| Ryu, K | 1 |
| Hoit, BD | 1 |
| Ram, R | 1 |
| Van Wagoner, DR | 1 |
| Yamazaki, T | 1 |
| van Jaarsveld, CH | 1 |
| Ranchor, AV | 1 |
| Arnold, R | 1 |
| de Jongste, MJ | 1 |
| Haaijer Ruskamp, FM | 1 |
| Senni, M | 1 |
| Gori, M | 1 |
| Alari, G | 1 |
| Duino, V | 1 |
| Siccardo, R | 1 |
| Grosu, A | 1 |
| Santilli, G | 1 |
| Parrella, P | 1 |
| Saronni, P | 1 |
| Pezzoli, F | 1 |
| Migliori, M | 1 |
| Minetti, B | 1 |
| Suter, F | 1 |
| De Maria, R | 1 |
| Ferrazzi, P | 1 |
| Gavazzi, A | 1 |
| Tsukamoto, O | 1 |
| Minamino, T | 1 |
| Sanada, S | 1 |
| Okada, K | 1 |
| Hirata, A | 1 |
| Fujita, M | 1 |
| Shintani, Y | 1 |
| Yulin, L | 1 |
| Asano, Y | 1 |
| Takashima, S | 1 |
| Yamasaki, S | 1 |
| Tomoike, H | 1 |
| Satoh, M | 2 |
| Ishikawa, Y | 1 |
| Minami, Y | 1 |
| Akatsu, T | 2 |
| Nakamura, M | 2 |
| Hauben, M | 2 |
| Reich, L | 2 |
| Gerrits, CM | 2 |
| Strassburg, S | 1 |
| Spoor, MT | 1 |
| Geltz, A | 1 |
| Bolling, SF | 1 |
| Tatsumi, T | 1 |
| Matsubara, H | 1 |
| Godfrey, V | 1 |
| Farquharson, CA | 2 |
| Yee, KM | 2 |
| Gosse, P | 1 |
| Macfadyen, RJ | 2 |
| Kang, YM | 2 |
| Zhang, ZH | 3 |
| Johnson, RF | 1 |
| Beltz, T | 1 |
| Waeber, B | 1 |
| Ohtani, T | 1 |
| Ohta, M | 1 |
| Mano, T | 1 |
| Sakata, Y | 1 |
| Nishio, M | 1 |
| Takeda, Y | 1 |
| Yoshida, J | 1 |
| Miwa, T | 1 |
| Okamoto, M | 1 |
| Masuyama, T | 1 |
| Nonaka, Y | 1 |
| Mundhenke, M | 1 |
| Epstein, M | 1 |
| Roik, M | 1 |
| Starczewska, MH | 1 |
| Stawicki, S | 1 |
| Huczek, Z | 1 |
| Kochanowski, J | 1 |
| Oreziak, A | 1 |
| Furmańczyk, A | 1 |
| Opolski, G | 1 |
| Shah, NC | 1 |
| Pringle, S | 1 |
| Struthers, A | 2 |
| Berry, C | 3 |
| Murphy, NF | 1 |
| Murphy, N | 1 |
| De Vito, G | 1 |
| Galloway, S | 1 |
| Seed, A | 1 |
| Fisher, C | 1 |
| Vallance, P | 1 |
| Hillis, WS | 1 |
| Nakayama, D | 1 |
| Jotkowitz, AB | 1 |
| Porath, A | 1 |
| Shotan, A | 1 |
| Mittelman, M | 1 |
| Grossman, E | 1 |
| Zimlichman, R | 1 |
| Lewis, BS | 1 |
| Garty, M | 1 |
| Wei, SG | 2 |
| Chu, Y | 1 |
| Alam, S | 1 |
| Palevsky, HI | 1 |
| Awad, KE | 1 |
| Polavaram, L | 1 |
| Vankayala, H | 1 |
| Güder, G | 1 |
| Frantz, S | 1 |
| Weismann, D | 1 |
| Allolio, B | 1 |
| Angermann, CE | 1 |
| Ramanampamonjy, RM | 1 |
| Razafimahefa, SH | 1 |
| Rajaonarivelo, P | 1 |
| Rajaona, HR | 1 |
| Ouzounian, M | 1 |
| Hassan, A | 1 |
| Johnstone, DE | 1 |
| Howlett, J | 1 |
| Gao, X | 1 |
| Peng, L | 1 |
| Adhikari, CM | 1 |
| Zuo, Z | 1 |
| Abuissa, H | 1 |
| Watanabe, J | 1 |
| Tornel, PL | 1 |
| Valdes, M | 1 |
| Teive, HA | 1 |
| Munhoz, RP | 1 |
| Werneck, LC | 1 |
| Momary, KM | 1 |
| Camp, JR | 1 |
| Barbato, JC | 1 |
| Kalidindi, SR | 1 |
| Ruta, J | 1 |
| Ptaszyński, P | 1 |
| Maciejewski, M | 1 |
| Chizyński, K | 1 |
| Goch, JH | 1 |
| Leenen, FH | 1 |
| Carmona-Bayonas, A | 1 |
| Soler, IO | 1 |
| Gómez, FI | 1 |
| Billalabeitia, EG | 1 |
| Saura, HP | 1 |
| Tafalla, MS | 1 |
| Díaz, MP | 1 |
| Chan, AK | 1 |
| Wang, T | 1 |
| Lam, W | 1 |
| Yip, G | 1 |
| Wang, M | 1 |
| Lam, YY | 1 |
| Yeung, L | 1 |
| Wu, EB | 1 |
| Chan, WW | 1 |
| Wong, JT | 1 |
| So, N | 1 |
| Yu, CM | 1 |
| Bucca, CB | 1 |
| Brussino, L | 1 |
| Battisti, A | 1 |
| Mutani, R | 1 |
| Rolla, G | 1 |
| Mangiardi, L | 1 |
| Cicolin, A | 1 |
| Liu, G | 1 |
| Zhou, C | 1 |
| Ji, Z | 1 |
| Zhen, Y | 1 |
| Liu, K | 1 |
| Rastogi, S | 1 |
| Mishra, S | 1 |
| Zacà, V | 1 |
| Alesh, I | 1 |
| Gupta, RC | 1 |
| Auchus, RJ | 1 |
| Nwariaku, FE | 1 |
| George, J | 1 |
| Madigan, D | 1 |
| Macić-Dzanković, A | 1 |
| Dzanković, F | 1 |
| Pojskić, B | 1 |
| Skopljak, A | 1 |
| McManus, F | 1 |
| McInnes, GT | 1 |
| Connell, JM | 1 |
| Yang, SS | 1 |
| Han, W | 1 |
| Zhou, HY | 1 |
| Dong, G | 1 |
| Wang, BC | 1 |
| Huo, H | 1 |
| Wei, N | 1 |
| Cao, Y | 1 |
| Zhou, G | 1 |
| Xiu, CH | 1 |
| Li, WM | 1 |
| Verma, A | 1 |
| Galve, E | 1 |
| Weir, RA | 1 |
| Puu, M | 1 |
| Olofsson, B | 1 |
| Michelson, EL | 1 |
| Skvortsov, AA | 2 |
| Mareev, VY | 1 |
| Chelmakina, SM | 2 |
| Baklanova, NA | 2 |
| Belenkov, IuN | 2 |
| Mareev, VIu | 1 |
| Orlova, IaA | 1 |
| Schraut, S | 1 |
| Kneitz, S | 1 |
| van Rooijen, N | 1 |
| Broadfoot, F | 1 |
| McGuire, P | 1 |
| Williams, GH | 2 |
| Kramer, F | 1 |
| Sandner, P | 1 |
| Klein, M | 1 |
| Krahn, T | 1 |
| Whitehead, M | 1 |
| Watson, P | 1 |
| Owan, TE | 1 |
| Chen, HH | 1 |
| Frantz, RP | 1 |
| Karon, BL | 1 |
| Miller, WL | 1 |
| Rodeheffer, RJ | 1 |
| Hodge, DO | 1 |
| Lasser, RP | 1 |
| Ramirez, O | 1 |
| Brest, AN | 1 |
| Roguski, J | 1 |
| Hasik, J | 1 |
| Hryniewiecki, L | 1 |
| Roguska, J | 1 |
| Grala, T | 1 |
| Makowska, K | 1 |
| Lütz, G | 1 |
| Pape, K | 1 |
| Bock, HA | 1 |
| Thiel, G | 1 |
| Brunner, FP | 1 |
| Howell, DM | 1 |
| Gumbiner, CH | 1 |
| Martin, GE | 1 |
| Daum, S | 2 |
| Goerg, R | 2 |
| Mack, D | 1 |
| Hsieh, YY | 1 |
| Lin, MS | 1 |
| Chen, JH | 1 |
| Hsu, KL | 1 |
| Wu, TL | 1 |
| Su, CT | 1 |
| Shu, MY | 1 |
| Hsu, JC | 1 |
| Hsu, WS | 1 |
| Chen, JS | 1 |
| Bachour, G | 1 |
| Schlehe, H | 1 |
| Rutishauser, W | 1 |
| Waagstein, F | 1 |
| Hjalmarson, A | 1 |
| Swedeberg, K | 1 |
| Wallentin, I | 1 |
| Baylen, BG | 1 |
| Johnson, G | 1 |
| Tsang, R | 1 |
| Srivastava, L | 1 |
| Kaplan, S | 1 |
| Lewy, JE | 1 |
| Hobbins, SM | 1 |
| Fowler, RS | 1 |
| Rowe, RD | 1 |
| Korey, AG | 1 |
| Lawson, DH | 1 |
| O'Connor, PC | 1 |
| Jick, H | 1 |
| Herbinger, W | 1 |
| Koate, P | 2 |
| Diouf, S | 2 |
| Sylla, M | 1 |
| Diop, G | 2 |
| Diop, SN | 1 |
| Sabin, G | 1 |
| Klüsener, W | 1 |
| Khan, MI | 1 |
| Smith, AG | 1 |
| Aumont, MC | 1 |
| Agnola, D | 1 |
| Juliard, JM | 1 |
| Karrillon, G | 1 |
| Barr, CS | 2 |
| Lang, CC | 1 |
| Hanson, J | 1 |
| Arnott, M | 1 |
| Bharani, A | 1 |
| Ganguly, A | 1 |
| Bhargava, KD | 1 |
| Han, YL | 1 |
| Tong, M | 1 |
| Jing, QM | 1 |
| Hu, XL | 1 |
| Liu, JQ | 1 |
| Cserhalmi, L | 2 |
| van Vliet, AA | 1 |
| Donker, AJ | 2 |
| Nauta, JJ | 1 |
| Verheugt, FW | 1 |
| Karlsson, E | 1 |
| Villarreal, D | 2 |
| Pitt, D | 1 |
| Brilla, CG | 2 |
| Schencking, M | 1 |
| Scheer, C | 1 |
| Rupp, H | 1 |
| Kinugawa, T | 1 |
| Furuse, Y | 1 |
| Shimoyama, M | 1 |
| Mori, M | 1 |
| Endo, A | 1 |
| Omodani, H | 1 |
| Osaki, S | 1 |
| Miyakoda, H | 1 |
| Shigemasa, C | 1 |
| Brilla, C | 1 |
| Haller, C | 2 |
| Noerr, B | 1 |
| Remme, WJ | 2 |
| Cody, R | 1 |
| Perez, A | 2 |
| Palensky, J | 1 |
| Wittes, J | 1 |
| Nicholls, MG | 3 |
| Schwinger, RH | 2 |
| van Guldener, C | 1 |
| Kulbertus, H | 2 |
| Miller, JL | 1 |
| DeMaria, A | 1 |
| Kjeldsen, KP | 1 |
| Nørgaard, A | 1 |
| Thygesen, K | 1 |
| Comarow, A | 1 |
| Weinberger, J | 1 |
| Lock, M | 1 |
| Chun, R | 1 |
| Fernandez, HM | 1 |
| Leipzig, RM | 1 |
| Larkin, RJ | 1 |
| Atlas, SA | 1 |
| Donohue, TJ | 1 |
| Glick, G | 1 |
| Vanpee, D | 2 |
| Swine, C | 1 |
| Young, J | 1 |
| Angehrn, W | 1 |
| Ghali, WA | 1 |
| Cornuz, J | 1 |
| Georges, B | 1 |
| Beguin, C | 1 |
| Jadoul, M | 1 |
| Moore, CK | 1 |
| López Herrero, F | 1 |
| Pardo Alvarez, J | 1 |
| Sastre García, F | 1 |
| García Bernabé, C | 1 |
| López Reinoso, C | 1 |
| Arribas Mir, L | 1 |
| Soto Alvarez, J | 2 |
| Ramires, FJ | 1 |
| Mansur, A | 1 |
| Coelho, O | 1 |
| Maranhão, M | 1 |
| Gruppi, CJ | 1 |
| Mady, C | 1 |
| Ramires, JA | 1 |
| Azpitarte Almagro, J | 1 |
| Korkmaz, ME | 1 |
| Müderrisoğlu, H | 1 |
| Uluçam, M | 1 |
| Ozin, B | 1 |
| Kukin, ML | 1 |
| Hameedi, A | 1 |
| Chadow, HL | 1 |
| Mabuchi, N | 2 |
| Sawaki, M | 2 |
| Horie, H | 1 |
| Sugimoto, Y | 1 |
| Kinoshita, M | 2 |
| Soberman, JE | 1 |
| Cha, AJ | 1 |
| Malecha, SE | 1 |
| Judge, KW | 1 |
| Muntwyler, J | 1 |
| Gretz, N | 1 |
| Wehling, M | 2 |
| Swine, CH | 1 |
| Bednarz, B | 1 |
| Cybulski, J | 1 |
| Chamiec, T | 1 |
| Bradley, C | 1 |
| Alla, F | 2 |
| Dousset, B | 2 |
| Lloyd, SJ | 1 |
| Mauro, VF | 1 |
| Kayser, SR | 1 |
| Geraci, JM | 1 |
| Alvarez, JS | 1 |
| Vílchez, FG | 1 |
| Fuster, D | 1 |
| Frey, FJ | 1 |
| Ferrari, P | 1 |
| Mapstone, J | 1 |
| Houston, B | 1 |
| Gogarty, M | 1 |
| Diercks, GF | 1 |
| Overdiek, JW | 1 |
| Sealey, JE | 1 |
| Barbour, MM | 1 |
| Zuwallack, A | 1 |
| Parmley, WW | 1 |
| Matsui, T | 1 |
| Doggrell, SA | 1 |
| Brown, L | 1 |
| Pringle, SD | 1 |
| Srivastava, P | 1 |
| Agustí Escasany, A | 1 |
| Durán Dalmau, M | 1 |
| Arnau De Bolós, JM | 1 |
| Rodríguez Cumplido, D | 1 |
| Diogène Fadini, E | 1 |
| Casas Rodríguez, J | 1 |
| Galve Basilio, E | 1 |
| Manito Lorite, N | 1 |
| Williams, G | 1 |
| Lopez-Sendon, J | 1 |
| Burns, D | 1 |
| Hobbs, R | 1 |
| Pina, I | 1 |
| Martin, J | 1 |
| Negut, C | 1 |
| González Vilchez, F | 1 |
| Bouvy, ML | 1 |
| Heerdink, ER | 1 |
| Herings, RM | 1 |
| Delyani, JA | 1 |
| Cook, CS | 1 |
| Tobert, DS | 1 |
| Levin, S | 1 |
| Workman, DL | 1 |
| Sing, YL | 1 |
| Whelihan, B | 1 |
| Beltz, TG | 1 |
| Zimmerman, K | 1 |
| Margo, KL | 1 |
| Luttermoser, G | 1 |
| Shaughnessy, AF | 1 |
| Fleming, T | 1 |
| Borer, J | 1 |
| Lipicky, R | 1 |
| Kalra, PR | 1 |
| Sharma, R | 1 |
| John, J | 1 |
| Dhawan, J | 1 |
| Heck, M | 1 |
| McMullan, R | 1 |
| Silke, B | 1 |
| Rossi, GP | 1 |
| Cavallin, M | 1 |
| Nussdorfer, GG | 1 |
| Pessina, AC | 1 |
| Gronda, E | 1 |
| Mangiavacchi, M | 1 |
| Andreuzzi, B | 1 |
| Municinò, A | 1 |
| Shetty, K | 1 |
| Elkayam, U | 1 |
| Mehboob, A | 1 |
| Ahsan, N | 1 |
| Sucov, A | 1 |
| Piérard, L | 1 |
| Saitoh, H | 1 |
| Satoh, H | 1 |
| Iwasaka, J | 1 |
| Masuda, T | 1 |
| Hiramori, K | 1 |
| Poston, C | 1 |
| Mahoney, E | 1 |
| Molero, E | 1 |
| de Teresa, E | 1 |
| Volpi, A | 1 |
| Reyes, AJ | 1 |
| Beggah, AT | 1 |
| Escoubet, B | 1 |
| Puttini, S | 1 |
| Cailmail, S | 1 |
| Delage, V | 1 |
| Ouvrard-Pascaud, A | 1 |
| Bocchi, B | 1 |
| Peuchmaur, M | 1 |
| Farman, N | 1 |
| Mazón Ramos, P | 1 |
| Glick, HA | 1 |
| Orzol, SM | 1 |
| Tooley, JF | 1 |
| Sasayama, S | 1 |
| Hu, Y | 1 |
| Carpenter, JP | 1 |
| Cheung, AT | 1 |
| Hayashi, Y | 1 |
| Ohtani, M | 1 |
| Hiraishi, T | 1 |
| Brighetti, G | 1 |
| Marino, P | 1 |
| Freude, J | 1 |
| Ehrlich, U | 1 |
| Klepzig, H | 1 |
| Levy, B | 1 |
| Schröder, R | 4 |
| Wimmer, M | 1 |
| Bachl, G | 1 |
| Schlemmer, M | 1 |
| Stiskal, A | 1 |
| Coulibaly, D | 1 |
| Kébé, MB | 1 |
| Dia, B | 1 |
| Ba, E | 1 |
| Sanogho, S | 1 |
| Seck, G | 1 |
| Wilkinson, PR | 1 |
| Osswald, H | 1 |
| Datey, KK | 1 |
| Bhagat, SJ | 1 |
| Barat, AK | 1 |
| Surana, MC | 1 |
| Davidson, C | 1 |
| Burkinshaw, L | 1 |
| Morgan, DB | 1 |
| Masson, JP | 1 |
| Bass, O | 1 |
| Baur, HR | 1 |
| Ohnhaus, EE | 1 |
| Hall, WD | 1 |
| Gorbach, HC | 1 |
| Bräuninger, HJ | 1 |
| Mahood, JM | 1 |
| Jackson, L | 1 |
| Branch, R | 1 |
| Levine, D | 1 |
| Ramsay, L | 1 |
| Niemi, KM | 1 |
| Savenkov, MP | 1 |
| Florkiewicz, H | 1 |
| Rymar, B | 1 |
| Rumiński, W | 1 |
| Staśkiewicz, J | 1 |
| Espiner, EA | 1 |
| Hughes, H | 1 |
| Rogers, T | 1 |
| Morozov, KA | 1 |
| Goriainova, AN | 1 |
| Korochkin, IM | 2 |
| Matveeva, IV | 2 |
| Sigurd, B | 2 |
| Wennevold, A | 1 |
| Rowe, WS | 1 |
| Sidorenko, BA | 2 |
| Savenkov, PM | 1 |
| Kharchenko, VI | 1 |
| Evsikov, EM | 1 |
| Bobkova, VI | 1 |
| Kartitskií, VS | 1 |
| Lapkes, TG | 1 |
| Mazurova, SV | 1 |
| McClain, JM | 1 |
| Zucker, IH | 1 |
| Hensen, J | 1 |
| Abraham, WT | 1 |
| Dürr, JA | 1 |
| Hue, DP | 1 |
| Culank, LS | 1 |
| Toase, PD | 1 |
| Maguire, GA | 1 |
| Helfant, RH | 1 |
| Muller, JE | 1 |
| Wieland, T | 1 |
| Stäubli, M | 1 |
| Medina, N | 1 |
| Yushak, M | 1 |
| Muller, J | 1 |
| Ikram, H | 1 |
| Webster, MW | 1 |
| Lewis, GR | 1 |
| Crozier, IG | 1 |
| Degenhardt, S | 1 |
| Dyckner, T | 2 |
| Wester, PO | 2 |
| Lucsko, M | 1 |
| Ayad, A | 1 |
| Yasky, J | 2 |
| Ledesma, GA | 2 |
| Tutera, A | 2 |
| Collia, LF | 2 |
| Widman, L | 1 |
| Lant, A | 1 |
| Massie, B | 1 |
| Mauersberger, H | 1 |
| Rangoonwala, B | 1 |
| Ehrlich, E | 1 |
| Valentin, N | 1 |
| Noble, MI | 1 |
| Trenchard, D | 1 |
| Guz, A | 1 |
| Thind, GS | 1 |
| Blakemore, WS | 1 |
| Zinsser, HF | 1 |
| Madignier, M | 2 |
| Lvoff, R | 1 |
| Wilcken, DE | 1 |
| Carey, RM | 1 |
| Wooster, LD | 1 |
| Hook, EW | 1 |
| Mathew, KJ | 1 |
| Franciosa, JA | 1 |
| Snow, JA | 1 |
| Fleming, JS | 1 |
| Ramdohr, B | 2 |
| Hüttemann, U | 2 |
| Schüren, KP | 2 |
| von Leitner, E | 2 |
| Koch-Weser, J | 2 |
| Miraglia, G | 1 |
| Nava, A | 1 |
| Dalla Volta, S | 1 |
| Bernik, V | 1 |
| Sycheva, IM | 6 |
| Vinogradov, AV | 7 |
| Pongpaew, C | 1 |
| Songkhla, RN | 1 |
| Kozam, RL | 1 |
| Speranskaia, NV | 1 |
| Kramer, AA | 2 |
| Ignatova, TA | 1 |
| Schwarzbach, W | 1 |
| Bunzl, W | 1 |
| Krämer, KD | 1 |
| Ghabussi, P | 1 |
| Hochrein, H | 1 |
| Greenblatt, DJ | 1 |
| Nitter-Hauge, S | 1 |
| Brodwall, EK | 1 |
| Rootwelt, K | 1 |
| Krauss, J | 1 |
| von Lilienfeld-Toal, H | 1 |
| Buckesfeld, RP | 1 |
| Bolte, HD | 1 |
| Lankisch, PG | 1 |
| Larbig, D | 1 |
| Szám, I | 1 |
| Vass, A | 1 |
| Hegedüs-Wein, I | 1 |
| Căruntu, M | 1 |
| Mihail, A | 1 |
| Steiness, E | 1 |
| Sadée, W | 1 |
| Dagcioglu, M | 1 |
| Linèt, O | 1 |
| Kuz'mina, AE | 1 |
| Kiseleva, ZM | 1 |
| Sánchez, A | 1 |
| Leiter, L | 1 |
| Radó, JP | 2 |
| Marosi, J | 2 |
| Takó, J | 2 |
| Anderton, JL | 1 |
| Kincaid-Smith, P | 1 |
| Reubi, FC | 1 |
| Dévényi, I | 1 |
| Baglin, A | 1 |
| Safar, M | 1 |
| Gazes, PC | 1 |
| Hilmer, W | 1 |
| Gãbor, G | 1 |
| Bekes, M | 1 |
| Polãk, G | 1 |
| Rausch, J | 1 |
| Gulyãs, A | 1 |
| Mashford, ML | 1 |
| Robertson, MB | 1 |
| Horbach, L | 2 |
| Michaelis, J | 2 |
| Kaufmann, W | 4 |
| Dürr, F | 3 |
| Neuhaus, GA | 2 |
| Praetorius, F | 2 |
| Matveev, LN | 3 |
| Casanova, P | 1 |
| Delboy, C | 1 |
| Shanoff, HM | 1 |
| Eriksson, I | 1 |
| Siegel, C | 1 |
| Bauer, J | 1 |
| Steiner, B | 1 |
| Meurer, KA | 1 |
| Behn, C | 1 |
| Köhler, JA | 1 |
| White, R | 1 |
| McAlister, J | 1 |
| Hamer, J | 1 |
| Davis, DA | 1 |
| Medline, NM | 1 |
| Kühn, P | 1 |
| Probst, P | 1 |
| Gentili, G | 1 |
| Liberti, R | 1 |
| Petitier, H | 1 |
| Hua, G | 1 |
| Weiller, M | 1 |
| Faivre, G | 1 |
| Lenzi, F | 1 |
| Drozdova, ES | 1 |
| Bull, MB | 1 |
| Yasui, H | 1 |
| Helal, SM | 1 |
| Arshakuni, RO | 1 |
| Vancura, P | 1 |
| Smolenskiĭ, VS | 1 |
| Gel'fond, MB | 1 |
| Khodzhamirov, VS | 1 |
| Samosiuk, IM | 1 |
| Awamura, M | 1 |
| Ledingham, JG | 1 |
| Bayliss, RI | 1 |
| Soulié, P | 1 |
| Gaudeau, S | 1 |
| Antalóczy, Z | 1 |
| Ludvigh, G | 1 |
| Herman, E | 1 |
| Rado, J | 1 |
| Botticelli, JT | 1 |
| Schlueter, DP | 1 |
| Lange, RL | 1 |
| Gerasimova, EN | 1 |
| Kononiachenko, VA | 1 |
| Wallnöfer, H | 1 |
| Hanusch, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure. A Proof of Concept Clinical Trial Within the EU FP 7 (European Union FP7) HOMAGE Programme Heart OMics in AGing "[NCT02556450] | Phase 2 | 528 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure[NCT00232180] | Phase 3 | 2,743 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)[NCT00094302] | Phase 3 | 3,445 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| China Patient-centered Evaluative Assessment of Cardiac Events (PEACE): Retrospective Study of Patients With Heart Failure (HF)[NCT02877914] | 10,000 participants (Anticipated) | Observational | 2016-09-30 | Recruiting | |||
| Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337] | Phase 1 | 20 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in Heart Failure With Preserved Ejection Fraction (BLOCK HFpEF) Trial[NCT04434664] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | ||
| Use of Determination of Drug Levels to Optimize Pharmacotherapy of Heart Failure[NCT06035978] | Phase 4 | 100 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure[NCT02627196] | 1,200 participants (Anticipated) | Interventional | 2016-04-19 | Active, not recruiting | |||
| Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)[NCT02235077] | Phase 2 | 360 participants (Actual) | Interventional | 2014-12-30 | Completed | ||
| The Transition From Hypertension to Hypertensive Heart Disease and Heart Failure, the PREFERS Hypertension Study[NCT04190420] | 310 participants (Anticipated) | Observational | 2018-10-01 | Enrolling by invitation | |||
| A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy Receiving Angiotensin-converting Enzyme Inhibitor (ACEI) and[NCT01371747] | Phase 2 | 324 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Diuretic and Natriuretic Effect of High-dose Spironolactone in Patients With Acute Heart Failure[NCT04618601] | Phase 4 | 50 participants (Anticipated) | Interventional | 2020-10-20 | Active, not recruiting | ||
| A Phase 4, Randomized, Open Label, Multicenter Prospective Comparative Study To Evaluate The Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure[NCT04160000] | Phase 4 | 360 participants (Anticipated) | Interventional | 2020-07-26 | Recruiting | ||
| Randomized Clinical Trial of Radiofrequency Ablation for Atrial Fibrillation in Patients With Heart Failure With Preserved Ejection Fraction for Reduced Healthcare Utilization[NCT04327596] | 2 participants (Actual) | Interventional | 2021-01-25 | Terminated (stopped due to lack of enrollment) | |||
| A Comparison of the Effects of Selective and Non Selective Mineralocorticoid Antagonism on Glucose Homeostasis and Lipid Profile of Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes.[NCT01586442] | Phase 3 | 62 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| A Non-interventional, Multicenter, Observational Clinical Trial to Assess Eplerenone Treatment in Patients With Heart Failure.[NCT02344199] | 450 participants (Actual) | Observational | 2015-03-31 | Completed | |||
| Aldosterone Antagonists in Systemic Right Ventricle: a Randomized Clinical Trial.[NCT00703352] | Phase 4 | 26 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function - a Multi-center, Double-blind, Randomized, Placebo-controlled Clinical Trial - SERVE Trial[NCT03049540] | Phase 3 | 100 participants (Actual) | Interventional | 2017-10-25 | Completed | ||
| PRospectIve Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in PatiEnts With Heart Failure and Preserved Ejection Fraction[NCT04128891] | Phase 3 | 0 participants (Actual) | Interventional | 2020-02-01 | Withdrawn (stopped due to Funding not approved) | ||
| High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure[NCT02429388] | Phase 4 | 0 participants (Actual) | Interventional | 2014-05-31 | Withdrawn (stopped due to Principal Investigator left institution prior to subjects being enrolled) | ||
| Characterization of Myocardial Interstitial Fibrosis and Cardiomyocyte Hypertrophy by Cardiac MRI In Heart Failure: Implication on Early Remodeling and on the Transition to Heart Failure[NCT03084679] | 90 participants (Anticipated) | Interventional | 2017-11-01 | Recruiting | |||
| UK Heart Failure With Preserved Ejection Fraction Registry[NCT05441839] | 10,000 participants (Anticipated) | Observational | 2022-10-07 | Recruiting | |||
| Mechanisms and Management of Exercise Intolerance in Older Heart Failure Patients With Preserved Ejection Fraction[NCT03111017] | 12 participants (Actual) | Interventional | 2017-04-17 | Completed | |||
| A Double-blind, Randomized, Placebo-controlled Trial Evaluating The Safety And Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial Infarction[NCT01176968] | Phase 4 | 1,012 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Novel Treatment for Diastolic Heart Failure in Women[NCT00206232] | Phase 4 | 48 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy[NCT00879060] | Phase 4 | 53 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Effect of Aldosterone on Energy Starvation in Heart Failure[NCT00574119] | Phase 4 | 16 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Phase III, Single-Center, Open Label, Trial Evaluating the Safety and Efficacy of PectaSol-C Modified Citrus Pectin on PSA Kinetics in Prostate Cancer in the Setting of Serial Increases in PSA[NCT01681823] | Phase 2 | 60 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systo[NCT01807221] | Phase 2 | 1,066 participants (Actual) | Interventional | 2013-06-17 | Completed | ||
| A Retrospective Observational Analysis of a Cohort With Heart Failure With Preserved Ejection Fraction From a BNP Pathway Clinic[NCT04233086] | 500 participants (Actual) | Observational | 2020-02-03 | Completed | |||
| A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of BAY94-8862 in Japanese Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction[NCT01955694] | Phase 2 | 72 participants (Actual) | Interventional | 2013-11-11 | Completed | ||
| Aldosterone Lethal Effects Blocked in AMI Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-up: THE ALBATROSS TRIAL[NCT01059136] | Phase 3 | 1,603 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Baseline Characteristics, Processes of Care, System-related Factors, and Clinical Outcomes Associated With the Quality and Safety of Initial Management for ST-segment Elevation Myocardial Infarction: A Multicenter Cohort Study[NCT02788344] | 6,920 participants (Actual) | Observational | 2017-05-15 | Completed | |||
| Efficacy and Safety of Finerenone in Patients With Heart Failure With Reduced Ejection Fraction[NCT05974566] | 60 participants (Anticipated) | Observational | 2023-08-01 | Not yet recruiting | |||
| Improved Exercise Tolerance in Participants With PReserved Ejection Fraction by Spironolactone on Myocardial Fibrosis in Atrial Fibrillation[NCT02673463] | Phase 4 | 250 participants (Anticipated) | Interventional | 2015-01-31 | Active, not recruiting | ||
| Bisoprolol Plasma Residual Concentrations for the Optimization of Drug Management in Heart Failure With Mild to Reduced Ejection Fraction[NCT03644446] | 81 participants (Anticipated) | Observational [Patient Registry] | 2017-11-02 | Recruiting | |||
| American Registry of Ambulatory or Acute Decompensated Heart Failure[NCT05295641] | 1,380 participants (Anticipated) | Observational [Patient Registry] | 2022-04-01 | Recruiting | |||
| Impact of 3-week SPA Therapy on Sleep Apnea in Patients With Obstructive Sleep Apnea Syndrome and Chronic Venous Insufficiency: A Randomized, Controlled Study[NCT02559427] | 0 participants (Actual) | Interventional | 2016-10-31 | Withdrawn (stopped due to no patients randomized after more than one year sponsor decided to withdrawn the study.) | |||
| The Effects of Eplerenone on Left Ventricular Remodelling Post-Acute Myocardial Infarction: a Double-Blind Placebo-Controlled Cardiac MR-Based Study[NCT00132093] | Phase 4 | 100 participants | Interventional | 2005-04-30 | Completed | ||
| A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation[NCT01772108] | 42 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to As recruitment rate was lower than anticipated) | |||
| NT-BNP Guided Care in Addition to Multidisciplinary Care in Patients With Chronic Heart Failure A Three-Arm, Prospective, Randomised Study[NCT00355017] | 0 participants | Interventional | 2003-09-30 | Terminated | |||
| A Randomized, Double-Blind, Multi-Center,Study Evaluating the Effects of Eplerenone Versus Placebo on Ventricular Remodeling in Patient's With Left Ventricular Systolic Dysfunction (EF Less Than or Equal to 35%) and Mild to Moderate Heart Failure[NCT00082589] | Phase 4 | 250 participants | Interventional | 2004-04-30 | Completed | ||
| A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer[NCT01708798] | Phase 2/Phase 3 | 44 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to Futility) | ||
| MINeralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST-Elevation Myocardial Infarction (STEMI)[NCT01882179] | Phase 3 | 61 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Efficacy of an m-Health Cardiac Rehabilitation Program in Heart Failure With Preserved Ejection Fraction: A Pilot Randomized Controlled Trial[NCT05002075] | 80 participants (Anticipated) | Interventional | 2021-11-20 | Recruiting | |||
| A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of Patiromer in Heart Failure Patients[NCT00868439] | Phase 2 | 120 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Aldosterone Antagonism in Diastolic Heart Failure[NCT00108251] | Phase 4 | 48 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial[NCT04345289] | Phase 3 | 147 participants (Actual) | Interventional | 2020-05-01 | Terminated (stopped due to DSMB advise due to high probability of futility) | ||
| A Randomized, Double-blind, Multi-center Study to Assess Safety and Tolerability of Different Oral Doses of BAY94-8862 in Subjects With Stable Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Mild (Part A) or Moderate (Part B) Chronic [NCT01345656] | Phase 2 | 457 participants (Actual) | Interventional | 2011-05-09 | Completed | ||
| A Phase 2, Randomized, Double-Blind, Multi-center Study Comparing CLP Versus Placebo in Heart Failure Patients With Chronic Kidney Disease[NCT01265524] | Phase 2 | 113 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Surgical or Medical Treatment of Breast Cancer Metastasis: A Multicentre Observational Study[NCT06093022] | 720 participants (Anticipated) | Observational [Patient Registry] | 2018-04-01 | Recruiting | |||
| Preoperative Imaging Diagnostic Evaluation Model Based on Evidence-based Pathological Diagnose Criteria for Renal Cell Carcinoma Tumor Thrombus With Inferior Vena Cava Wall Invasion[NCT05589207] | 232 participants (Anticipated) | Observational | 2023-01-01 | Recruiting | |||
| Multicenter Study for the Prevention of Post-Operative Cardiac Arrhythmias[NCT04234906] | Phase 4 | 870 participants (Anticipated) | Interventional | 2023-01-31 | Not yet recruiting | ||
| Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer[NCT02766582] | Phase 2 | 29 participants (Actual) | Interventional | 2016-10-31 | Active, not recruiting | ||
| Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720] | Phase 2 | 120 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart[NCT00326690] | 0 participants (Actual) | Interventional | 2005-11-30 | Withdrawn (stopped due to Unable to recruit and enroll patients) | |||
| Intracoronary Autologous Stem Cell Transplantation in ST Elevation Myocardial Infarction: TRACIA Study.[NCT00725738] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2008-05-31 | Recruiting | ||
| Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)[NCT02354170] | Phase 2 | 16 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Eplerenone for Central Serous Chorioretinopathy: A Pilot Study[NCT01822561] | Phase 2 | 17 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| [NCT00000516] | Phase 3 | 0 participants | Interventional | 1985-07-31 | Completed | ||
| Acute Feedback on Left ventrIcular Lead Implantation Location for Cardiac Resynchronization Therapy[NCT01996397] | 34 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)[NCT02026102] | 15 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| A Randomized and Double-blind Study to Evaluate the Benefit of the Treatment With Testosterone in Chronic Heart Failure Testosterone Deficiency Subjects[NCT01813201] | Phase 4 | 14 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure[NCT00180258] | Phase 2/Phase 3 | 2,200 participants | Interventional | 2000-01-31 | Completed | ||
| Beta-blocker Uptitration in Heart Failure Patients Receiving Cardiac Resynchronization Therapy With Optivol Fluid Status Monitoring System[NCT00433043] | Phase 4 | 2 participants (Actual) | Interventional | 2007-01-31 | Terminated (stopped due to Insufficient enrollment) | ||
| CRT-P or CRT-D in Patients With Dilated Cardiomyopathy and Heart Failure Without LGE-CMR High-risk Markers[NCT04139460] | 924 participants (Anticipated) | Interventional | 2020-06-30 | Not yet recruiting | |||
| High Intensity His Bundle Pacing in Heart Failure Patients With Narrow QRS Outcome Study[NCT05491655] | 34 participants (Anticipated) | Interventional | 2023-03-29 | Recruiting | |||
| The Characterisation of Vascular Biomarkers Before and After Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure and Their Role in Predicting Response[NCT02541773] | 58 participants (Anticipated) | Observational | 2013-11-30 | Active, not recruiting | |||
| Pacemaker Induced Transient Dyssynchrony for Treating Heart Failure (PITA-HF): Feasibility, Safety, and Tolerability[NCT04159454] | 8 participants (Actual) | Interventional | 2020-11-20 | Completed | |||
| ElectroCRT - Left Ventricular Lead Implant and Optimization Guided by Electrocardiography in Cardiac Resynchronization Therapy[NCT02346097] | 122 participants (Actual) | Interventional | 2015-02-16 | Completed | |||
| Electrical Activation Mapping Guided Tailor Made Approach for Cardiac Resynchronization Therapy[NCT03356652] | 93 participants (Anticipated) | Interventional | 2018-03-08 | Recruiting | |||
| Usability and Utility Assessment of Passive Remote Monitoring of Multiple Novel Indicators of Heart Failure[NCT04267744] | 165 participants (Anticipated) | Interventional | 2020-02-11 | Active, not recruiting | |||
| Observatory: Search for Prognostic Factors of Pulmonary Hypertension Post-capillary in Heart Failure.[NCT01545180] | 665 participants (Actual) | Observational | 2012-02-29 | Completed | |||
| Hair Cortisol and Testosterone Levels and Their Correlation With Heart Failure Status in Patients With Chronic Congestive Heart Failure[NCT01139697] | 46 participants (Actual) | Observational | 2010-08-31 | Completed | |||
| Long-term Prednisone Use in Patients With Advanced Heart Failure (ACCF/AHA Stage D) and Hyperuricemia[NCT02282683] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2013-12-31 | Recruiting | ||
| Effect of Short-Term Prednisone Therapy on C-reactive Protein Change in Emergency Department Patients With Acute Heart Failure and Elevated Inflammatory Markers[NCT05916586] | 120 participants (Anticipated) | Interventional | 2023-08-11 | Recruiting | |||
| Effects of Eplerenone on Left Ventricular Hypertrophy in Patients With Resistant Hypertension and Obstructive Sleep Apnoea[NCT03186742] | Phase 4 | 125 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial[NCT02948998] | Phase 4 | 260 participants (Anticipated) | Interventional | 2018-05-14 | Not yet recruiting | ||
| Congestive Heart Failure Atrial Arrhythmia Monitoring and Pacing (CHAMP)[NCT00156728] | Phase 4 | 172 participants | Interventional | 2003-10-31 | Completed | ||
| Exercise Intolerance in Elderly Diastolic Heart Failure[NCT00123955] | Phase 3 | 80 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| A Study Of The Usage Of Statins In A Community Heart Failure Population: The Impact of HMG Co-Enzyme A Reductase Inhibitors on Heart Structural Parameters, Brain Naturetic Peptide, Markers of Inflammation and Fibrosis[NCT00795912] | Phase 4 | 56 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension[NCT03835676] | Phase 4 | 30 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | ||
| E_Stethoscope : Portable Digital Auscultation Based on Wireless Sensor Node to Diagnose Diastolic Dysfunction in Hypertensive Heart Disease[NCT02809040] | 60 participants (Anticipated) | Observational | 2015-02-28 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) |
|---|---|
| Eplerenone: Double-blind Phase | 288 |
| Placebo: Double-blind Phase | 392 |
CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010)
| Intervention | participants (Number) |
|---|---|
| Eplerenone: Double-blind Phase | 249 |
| Placebo: Double-blind Phase | 356 |
Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 408 | 463 |
| Placebo: Double-blind Phase | 491 | 552 |
Death due to any cause. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 171 | 205 |
| Placebo: Double-blind Phase | 213 | 253 |
Death due to any cause or hospitalization due to any cause. Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 462 | 530 |
| Placebo: Double-blind Phase | 569 | 636 |
Death due to any cause or first of occurrence HF hospitalization. HF hospitalization is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 270 | 311 |
| Placebo: Double-blind Phase | 376 | 418 |
First occurrence of CV hospitalization. CV hospitalization is defined as hospitalization due to HF (first or subsequent), acute myocardial infarction, angina pectoris (unstable), cardiac arrhythmia (atrial fibrillation [AF], atrial flutter, supraventricular arrhythmias, or ventricular arrhythmias), stroke/CVA, other CV reasons (such as hypotension or peripheral vascular disease), implantation of a cardioverter defibrillator (ICD), or cardiac resynchronization therapy (CRT) with CV event as the primary reason for hospitalization as determined by endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 304 | 346 |
| Placebo: Double-blind Phase | 399 | 439 |
CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 147 | 178 |
| Placebo: Double-blind Phase | 185 | 215 |
(NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 45 | 49 |
| Placebo: Double-blind Phase | 33 | 40 |
(NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 21 | 24 |
| Placebo: Double-blind Phase | 26 | 31 |
First occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 164 | 186 |
| Placebo: Double-blind Phase | 253 | 277 |
Death due to HF or first occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 170 | 194 |
| Placebo: Double-blind Phase | 262 | 287 |
First occurrence of hospitalization due to hyperkalemia. Hospitalization due to hyperkalemia is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to hyperkalemia as the primary reason for hospitalization as determined by endpoint committee adjudicator. Hyperkalemia is defined as serum potassium level greater than (>) 5.5 milliequivalents per liter (mEq/L). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 4 | 4 |
| Placebo: Double-blind Phase | 3 | 3 |
First occurrence of hospitalization due to worsening renal function. Hospitalization due to worsening renal function is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to worsening renal function as the primary reason for hospitalization as determined by endpoint committee adjudicator. Worsening renal function is defined as doubling of serum creatinine level from baseline level. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 9 | 10 |
| Placebo: Double-blind Phase | 8 | 10 |
First occurrence of implantation of cardiac defibrillator (ICD). ICD is an electronic device capable of monitoring the heart rhythm. When the heart is beating normally, the device remains inactive. If the heart develops a life-threatening tachycardia, the ICD delivers electrical shocks to the heart to terminate the abnormal rhythm and return the heart rhythm to normal. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 61 | 76 |
| Placebo: Double-blind Phase | 59 | 78 |
First occurrence of implantation of resynchronization device. CRT is use of a specialized pacemaker to re-coordinate the action of the right and left ventricles in heart failure. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 33 | 45 |
| Placebo: Double-blind Phase | 41 | 53 |
New onset of atrial fibrillation or flutter is defined as the diagnosis of atrial fibrillation or flutter in a participant after randomization, where atrial fibrillation was not present before randomization. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 950, 937) | Up to 59.5 months (complete DB) (n= 956, 940) | |
| Eplerenone: Double-blind Phase | 32 | 41 |
| Placebo: Double-blind Phase | 52 | 59 |
The definition of new onset diabetes mellitus is the diagnosis of diabetes mellitus in a participant after randomization, when DM was not present before randomization. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 904, 973) | Up to 59.5 months (complete DB) (n= 907, 975) | |
| Eplerenone: Double-blind Phase | 34 | 42 |
| Placebo: Double-blind Phase | 40 | 47 |
First incidence of aborted cardiac arrest (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.09 |
| Spironolactone | 0.05 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 4.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 3.1 |
| Spironolactone | 2.8 |
Hospitalization for MI, stroke or the management of heart failure, whichever occurred first (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.2 |
| Spironolactone | 5.5 |
Average post-baseline Chloride, taking into consideration baseline Chloride, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 102.33 |
| Spironolactone | 102.26 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 7.8 |
| Spironolactone | 7.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.6 |
| Spironolactone | 5.9 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
"Average post-baseline depression, taking into consideration baseline depression, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Patient Health Questionnaire (PHQ) is a 10-item, self-administered instrument for screening, diagnosing, monitoring and measuring the severity of depression. Scores can range from 0-27, in which lower scores reflect better mental health status. The PH-Q was administered at the following study visits: baseline, month 12 and annually thereafter. Valid translations of this questionnaire were only available for subjects enrolled in the United States and Canada." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 5.6 |
| Spironolactone | 5.1 |
First incidence of a deterioration of renal function. The TOPCAT protocol defines deterioration of renal function as occurring if a subject has a serum creatinine value which is at least double the baseline value for that subject, and is also above the upper limit of normal (assumed to be 1.0 mg/dL for females and 1.2 mg/dL for males.) (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 2.2 |
| Spironolactone | 3.2 |
First incidence of atrial fibrillation among subjects without a history of atrial fibrillation at baseline (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.4 |
| Spironolactone | 1.4 |
Average post-baseline GFR, taking into consideration baseline GFR, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mL/min/1.73m2 (Least Squares Mean) |
|---|---|
| Placebo | 67.50 |
| Spironolactone | 65.20 |
First incidence of a hospitalization for any reason (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 20.0 |
| Spironolactone | 18.8 |
First incidence of a hospitalization for the management of heart failure (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 3.8 |
First incidence of myocardial infarction (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.2 |
First incidence of new onset diabetes mellitus among subjects without a history of diabetes mellitus at baseline. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.7 |
| Spironolactone | 0.7 |
Average post-baseline Potassium, taking into consideration baseline Potassium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 4.32 |
| Spironolactone | 4.49 |
"Average post-baseline quality of life, taking into consideration baseline quality of life and treatment group.~The McMaster Overall Treatment Evaluation questionnaire is a self-administered 3-item instrument that measures a patient's perception of change in their health-related quality of life since the start of therapy. The questionnaire consists of a single question - Since treatment started, has there been any change in your activity limitation, symptoms and/or feelings related to your heart condition? Scores can range from -7 to +7, and higher scores reflect better health status. The questionnaire was administered at the following study visits: month 4 and month 12. Valid translations of this questionnaire were only available for subjects enrolled in the United States, Canada and Argentina." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.2 |
| Spironolactone | 1.2 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The EuroQOL visual analog scale (EQ5D) is a single-item, self-administered instrument that quantifies current health status. Scores can range from 0-100, in which higher scores reflect better health status. The EQ5D was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 65.9 |
| Spironolactone | 66.4 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The KCCQ was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 63.1 |
| Spironolactone | 64.4 |
Average post-baseline serum creatinine, taking into consideration baseline serum creatinine, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 1.11 |
| Spironolactone | 1.17 |
Average post-baseline Sodium, taking into consideration baseline Sodium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 140.95 |
| Spironolactone | 140.33 |
First incidence of stroke (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 8.3 |
| Spironolactone | 6.8 |
Baseline body weight assessment will be completed, and changes in weight documented daily through 96 hours or earlier discharge (NCT02235077)
Timeframe: Randomization through 96 hours or earlier discharge
| Intervention | pounds (Mean) |
|---|---|
| Spironolactone | -8.1 |
| Placebo | -7.5 |
Clinical congestion score will be assessed at randomization, 96 hours, and at discharge. Scale consisted of sum of six signs and symptoms of congestion, each scored 0-3. Zero indicates no sign/symptom and 3 indicates worst case of sign/symptom. Score range 0-18 with 18 being worst score. (NCT02235077)
Timeframe: Randomization through 96 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Spironolactone | -5.59 |
| Placebo | -5.82 |
Dyspnea visual analog scale change from randomization to 96 hours. Scale range 0-100 with 100 being the best possible score. (NCT02235077)
Timeframe: Randomization to 96 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Spironolactone | 17.2 |
| Placebo | 17.9 |
The Core Laboratory at Vermont will determine NT-proBNP levels for calculation of the endpoint from samples obtained at randomization and 96 hours respectively. NT-proBNP was converted to log scale. (NCT02235077)
Timeframe: Randomization to 96 hours
| Intervention | log pg/ml (Mean) |
|---|---|
| Spironolactone | -0.58 |
| Placebo | -0.61 |
Renal function via serum creatinine, will be assessed at randomization and daily through 96 hours (NCT02235077)
Timeframe: Randomization through 96 hours
| Intervention | mg/dl (Mean) |
|---|---|
| Spironolactone | 0.15 |
| Placebo | 0.16 |
Change in serum potassium levels at 96 hours as compared to baseline. (NCT02235077)
Timeframe: Baseline, 96 hours
| Intervention | mEq/L (Mean) |
|---|---|
| Spironolactone | 0.31 |
| Placebo | 0.15 |
Fluid intake and urine output will be assessed daily while in hospital through 96 hours. Net fluid output (output minus input) through 96 hours is reported. (NCT02235077)
Timeframe: Randomization through 96 hours
| Intervention | ml (Mean) |
|---|---|
| Spironolactone | 5824 |
| Placebo | 5507 |
Medications will be reviewed to assess loop diuretic dose requirements through Day 30 following randomization (NCT02235077)
Timeframe: Randomization through Day 30
| Intervention | mg (Mean) |
|---|---|
| Spironolactone | 19.66 |
| Placebo | 30.70 |
All participants will be contacted by telephone at 60 days, +/- 3 days post randomization to assess vital status (death). (NCT02235077)
Timeframe: 60 days post randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Spironolactone | 8 |
| Placebo | 10 |
Outpatient worsening heart failure symptoms will be assessed from discharge through Day 30 (NCT02235077)
Timeframe: Hospital discharge through Day 30
| Intervention | Participants (Count of Participants) |
|---|---|
| Spironolactone | 19 |
| Placebo | 17 |
Least squares mean changes from Baseline to Day 3 were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates. (NCT01371747)
Timeframe: Baseline to Day 3
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.26 |
| Stratum 1: 16.8 g/d Patiromer | -0.28 |
| Stratum 1: 25.2 g/d Patiromer | -0.31 |
| Stratum 2: 16.8 g/d Patiromer | -0.65 |
| Stratum 2: 25.2 g/d Patiromer | -0.59 |
| Stratum 2: 33.6 g/d Patiromer | -0.53 |
Least square mean changes from Baseline to Week 4/first titration were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates. (NCT01371747)
Timeframe: Baseline to Week 4 or First Titration which could occur at any scheduled study visit after patiromer initiation.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.35 |
| Stratum 1: 16.8 g/d Patiromer | -0.51 |
| Stratum 1: 25.2 g/d Patiromer | -0.55 |
| Stratum 2: 16.8 g/d Patiromer | -0.87 |
| Stratum 2: 25.2 g/d Patiromer | -0.97 |
| Stratum 2: 33.6 g/d Patiromer | -0.92 |
Least squares mean changes from Baseline to Week 8/first titration were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates. (NCT01371747)
Timeframe: Baseline to Week 8 or First Titration which could occur at any scheduled study visit after patiromer initiation.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.35 |
| Stratum 1: 16.8 g/d Patiromer | -0.47 |
| Stratum 1: 25.2 g/d Patiromer | -0.54 |
| Stratum 2: 16.8 g/d Patiromer | -0.88 |
| Stratum 2: 25.2 g/d Patiromer | -0.95 |
| Stratum 2: 33.6 g/d Patiromer | -0.91 |
(NCT01371747)
Timeframe: Baseline to Week 52
| Intervention | mEq/L (Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.54 |
| Stratum 1: 16.8 g/d Patiromer | -0.44 |
| Stratum 1: 25.2 g/d Patiromer | -0.50 |
| Stratum 2: 16.8 g/d Patiromer | -1.00 |
| Stratum 2: 25.2 g/d Patiromer | -0.96 |
| Stratum 2: 33.6 g/d Patiromer | -1.17 |
(NCT01371747)
Timeframe: Week 52 or Last Patiromer Dose (if Occurred before Week 52) to Following up Visit Plus 7 Days
| Intervention | mEq/L (Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 0.36 |
| Stratum 1: 16.8 g/d Patiromer | 0.22 |
| Stratum 1: 25.2 g/d Patiromer | 0.30 |
| Stratum 2: 16.8 g/d Patiromer | 0.41 |
| Stratum 2: 25.2 g/d Patiromer | 0.39 |
| Stratum 2: 33.6 g/d Patiromer | 0.58 |
(NCT01371747)
Timeframe: Baseline to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 100 |
| Stratum 1: 16.8 g/d Patiromer | 100 |
| Stratum 1: 25.2 g/d Patiromer | 98.4 |
| Stratum 2: 16.8 g/d Patiromer | 91.7 |
| Stratum 2: 25.2 g/d Patiromer | 95.8 |
| Stratum 2: 33.6 g/d Patiromer | 95.5 |
(NCT01371747)
Timeframe: Baseline to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 95.2 |
| Stratum 1: 16.8 g/d Patiromer | 90.8 |
| Stratum 1: 25.2 g/d Patiromer | 81.3 |
| Stratum 2: 16.8 g/d Patiromer | 79.2 |
| Stratum 2: 25.2 g/d Patiromer | 91.7 |
| Stratum 2: 33.6 g/d Patiromer | 77.3 |
(NCT01371747)
Timeframe: Baseline to Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 86.3 |
| Stratum 1: 16.8 g/d Patiromer | 81.6 |
| Stratum 1: 25.2 g/d Patiromer | 88.9 |
| Stratum 2: 16.8 g/d Patiromer | 86.7 |
| Stratum 2: 25.2 g/d Patiromer | 89.5 |
| Stratum 2: 33.6 g/d Patiromer | 93.3 |
(NCT01371747)
Timeframe: Baseline to Week 8
| Intervention | Days (Median) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 4 |
| Stratum 1: 16.8 g/d Patiromer | 4 |
| Stratum 1: 25.2 g/d Patiromer | 4 |
| Stratum 2: 16.8 g/d Patiromer | 8 |
| Stratum 2: 25.2 g/d Patiromer | 7.5 |
| Stratum 2: 33.6 g/d Patiromer | 8 |
The occurrence of first occurrence of BNP >200 pg/mL or NT-proBNP >450, >900 or >1800 pg/mL for ages <50 years, 50 to 75 years and >75 years, respectively (recorded 28 days or later post-randomization). Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Events (Number) |
|---|---|
| Eplerenone Plus Standard of Care | 81 |
| Placebo Plus Standard of Care | 131 |
The occurrence of cardiovascular mortality from randomization. Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Events (Number) |
|---|---|
| Eplerenone Plus Standard of Care | 2 |
| Placebo Plus Standard of Care | 2 |
Change in serum level of ICTP at 6 months post-randomization. The continuous endpoint was assessed using ANCOVA model, fitted with corresponding baseline and treatment. It was analyzed at 6 months based on LOCF and also using all available data up to end of study. (NCT01176968)
Timeframe: 6 months
| Intervention | μg/L (Median) |
|---|---|
| Eplerenone Plus Standard of Care | 3.70 |
| Placebo Plus Standard of Care | 3.70 |
Change in serum level of Interleukin-6 at 6 months post-randomization. The continuous endpoint was assessed using ANCOVA model, fitted with corresponding baseline and treatment. It was analyzed at 6 months based on LOCF and also using all available data up to end of study. (NCT01176968)
Timeframe: 6 months
| Intervention | pg/mL (Median) |
|---|---|
| Eplerenone Plus Standard of Care | 1.845 |
| Placebo Plus Standard of Care | 1.755 |
The decision to provide an ICD or CRT. Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Events (Number) |
|---|---|
| Eplerenone Plus Standard of Care | 3 |
| Placebo Plus Standard of Care | 3 |
The occurrence of first diagnosis of heart failure from the date of randomization. Time-to-event analyses were measured from the date of randomization, and a subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Events (Number) |
|---|---|
| Eplerenone Plus Standard of Care | 7 |
| Placebo Plus Standard of Care | 11 |
Electrocardiogram Q wave to the end of the S wave corresponding to ventricle depolarization (QRS) duration at 6 months post-randomization. The continuous endpoints were assessed using analysis of covariance (ANCOVA) model, fitted with corresponding baseline and treatment. These were analyzed at 6 months based on last observation carried forward (LOCF) and also using all available data up to end of study. (NCT01176968)
Timeframe: 6 months
| Intervention | Milliseconds (msec) (Mean) |
|---|---|
| Eplerenone Plus Standard of Care | 93.31 |
| Placebo Plus Standard of Care | 94.62 |
The occurrence of first and each subsequent episode (after an event-free interval of ≥ 48 hours) of sustained ventricular tachycardia or ventricular fibrillation. Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Events (Number) |
|---|---|
| Eplerenone Plus Standard of Care | 0 |
| Placebo Plus Standard of Care | 0 |
Cardiovascular mortality is defined as any mortality adjudicated as death due to sudden cardiac death, myocardial infarction (MI), worsening heart failure, cardiac arrhythmia, other cause (such as pulmonary embolism, peripheral arterial disease [PAD], etc.). Hospitalization due to congestive heart failure (CHF) and requires extended hospital stay or frequent visits to emergency room, observation unit or in-patient care, due to CHF as the primary or secondary diagnosis supported by a discharge report or clinical summary for hospitalization as determined by the endpoint adjudication committee (EAC). A composite of time to first event of cardiovascular mortality (CV), re-hospitalization or extended initial hospital stay due to diagnosis of heart failure, sustained ventricular tachycardia or fibrillation, ejection fraction ≤40% after 1 month or BNP >200 pg/mL or NT-proBNP >450 pg/mL (age <50 years); >900 pg/mL (age 50 to 75 years) or >1800 pg/mL (age >75 years) after 1 month. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Events (Number) |
|---|---|
| Eplerenone Plus Standard of Care | 92 |
| Placebo Plus Standard of Care | 149 |
The occurrence of first recorded EF ≤40% (recorded 28 days or later post-randomization). Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Events (Number) |
|---|---|
| Eplerenone Plus Standard of Care | 20 |
| Placebo Plus Standard of Care | 19 |
The occurrence of second or subsequent nonfatal MI. Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Events (Number) |
|---|---|
| Eplerenone Plus Standard of Care | 10 |
| Placebo Plus Standard of Care | 6 |
Change in serum levels of aldosterone and cortisol at 6 months post-randomization. The continuous endpoints were assessed using ANCOVA model, fitted with corresponding baseline and treatment. These were analyzed at 6 months based on LOCF and also using all available data up to end of study. (NCT01176968)
Timeframe: 6 months
| Intervention | nmol/L (Median) | |
|---|---|---|
| Aldosterone | Serum Cortisol | |
| Eplerenone Plus Standard of Care | 0.355 | 379.0 |
| Placebo Plus Standard of Care | 0.210 | 366.0 |
Change in serum levels of PIIINP, Galectin 3, and PINP at 6 months post-randomization. The continuous endpoints were assessed using ANCOVA model, fitted with corresponding baseline and treatment. These were analyzed at 6 months based on LOCF and also using all available data up to end of study. (NCT01176968)
Timeframe: 6 months
| Intervention | ng/mL (Median) | ||
|---|---|---|---|
| PIIINP | Galectin 3 | PINP | |
| Eplerenone Plus Standard of Care | 4.20 | 11.20 | 30.0 |
| Placebo Plus Standard of Care | 4.30 | 10.60 | 32.0 |
LAD recorded each time an echocardiogram is conducted. The continuous endpoints were assessed using ANCOVA model, fitted with corresponding baseline and treatment. These were analyzed at 6 months based on LOCF and also using all available data up to end of study. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Centimeters (cm) (Mean) | |
|---|---|---|
| Month 6 (N = 268, 243) | Final Visit (N = 393, 378) | |
| Eplerenone Plus Standard of Care | 3.92 | 3.91 |
| Placebo Plus Standard of Care | 3.90 | 3.87 |
Specific variables of collagen turnover markers that will be evaluated include markers of collagen synthesis (PINP, PIIINP), and marker of collagen degradation (ICTP). A two-sample t-test was used to compare the differences between these collagen turnover markers at baseline and the absolute differences in change from baseline to 12 months of follow-up. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | micrograms/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline (PINP) | 12 Months (PINP) | Baseline (PIIINP) | 12 Months (PIIINP) | Baseline (ICTP) | 12 Months (ICTP) | |
| Placebo Control | 2.1 | 0.6 | 4.5 | 1.6 | 2.5 | -2.3 |
| Spironolactone | 2.1 | 0.7 | 4.7 | 2.0 | 2.2 | 2.7 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | millimeters (Mean) | |
|---|---|---|
| Left Atrial Dimension (Baseline) | Left Atrial Dimension (12-Month Follow-Up) | |
| Placebo Control | 41 | 40 |
| Spironolactone | 40 | 40 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic (LVED) cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | mm/m^2 (Mean) | |
|---|---|---|
| LVED Cavity Size (Baseline) | LVED Cavity Size (12-Month Follow-Up) | |
| Placebo Control | 145 | 146 |
| Spironolactone | 133 | 129 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | millimeters (Mean) | |
|---|---|---|
| Maximum Left Ventricular Wall Thickness (Baseline) | Maximum Left Ventricular Wall Thickness (12-Month Follow-Up) | |
| Placebo Control | 21 | 19 |
| Spironolactone | 22 | 22 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Percentage of Total LV Mass (Mean) | |
|---|---|---|
| LGE Assessment of Myocardial Fibrosis (Baseline) | LGE Assessment of Myocardial Fibrosis (12-Month Follow-Up) | |
| Placebo Control | 2.5 | 2.8 |
| Spironolactone | 1.1 | 1.8 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to determine if spironolactone improves a subject's functional capacity during exercise (peak oxygen consumption levels/peak VO2). Peak VO2 levels were measured in ml/kg/min. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | ml/kg/min (Mean) | |
|---|---|---|
| Peak VO2 (Baseline) | Peak VO2 (12-Month Follow-Up) | |
| Placebo Control | 28 | 29 |
| Spironolactone | 30 | 29 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to assess heart failure symptoms according to the New York Heart Association (NYHA) functional class, which is an estimate of a patients functional ability. The NYHA functional classes include: Class I (no limitation of physical activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity), and Class IV (unable to carry out any physical acitivity without discomfort). (NCT00879060)
Timeframe: Time points were measured at Baseline and again at 12 months (follow-up)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| NYHA Class (Baseline) | NYHA Class (12-Month Follow Up) | |
| Placebo Control | 1.5 | 1.6 |
| Spironolactone | 1.6 | 1.7 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to measure indices of diastolic function by Tissue Doppler Echocardiography using the Septal E/e' ratio. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Ratio (Mean) | |
|---|---|---|
| Diastolic Function (Baseline) | Diastolic Function (12-month Follow-Up) | |
| Placebo Control | 15 | 13 |
| Spironolactone | 14 | 13 |
6MWT assesses distance walked over 6 minutes (NCT00574119)
Timeframe: 6 months
| Intervention | meters (Median) |
|---|---|
| Results With Spironolactone | 542 |
6MWT assesses distance walked over 6 minutes (NCT00574119)
Timeframe: baseline
| Intervention | meters (Median) |
|---|---|
| Results With Spironolactone | 521 |
T1=left ventricular relaxation rate on magnetic resonance imaging, which is correlated with interstitial fibrosis. (NCT00574119)
Timeframe: baseline and 6 months
| Intervention | msec (Mean) |
|---|---|
| Results With Spironolactone | 6 |
WMI=[left ventricular stroke work/decay rate of 11C-acetate] (NCT00574119)
Timeframe: 6 months
| Intervention | (x10^6), mL x mm Hg/m^2 (Median) |
|---|---|
| Results With Spironolactone | 5.4 |
WMI=[left ventricular stroke work/decay rate of 11C-acetate] (NCT00574119)
Timeframe: baseline
| Intervention | (x10^6), mL x mm Hg/m^2 (Median) |
|---|---|
| Results With Spironolactone | 7.4 |
The questionnaire is comprised of 21 important physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. Each question is scored from 0 (none or not applicable) to 5 (very much). Total scores range from 0-105. Low scores indicate less adverse impact, while higher scores reflect more adverse impact of heart failure. (NCT00574119)
Timeframe: baseline
| Intervention | score on a scale (Median) |
|---|---|
| Results With Spironolactone | 54 |
The questionnaire is comprised of 21 important physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. Each question is scored from 0 (none or not applicable) to 5 (very much). Total scores range from 0-105. Low scores indicate less adverse impact, while higher scores reflect more adverse impact of heart failure. (NCT00574119)
Timeframe: 6 months
| Intervention | score on a scale (Median) |
|---|---|
| Results With Spironolactone | 22 |
MPRI =calculated myocardial perfusion reserve index based on Gadolinium accretion into myocardium. MPRI was calculated as the ratio of stress/rest relative perfusion upslope, corrected for LV cavity upslope. (NCT00574119)
Timeframe: 6 months
| Intervention | MPRI (Mean) |
|---|---|
| Results With Spironolactone | 1.80 |
MPRI =calculated myocardial perfusion reserve index based on Gadolinium accretion into myocardium. MPRI was calculated as the ratio of stress/rest relative perfusion upslope, corrected for LV cavity upslope. (NCT00574119)
Timeframe: baseline
| Intervention | MPRI (Mean) |
|---|---|
| Results With Spironolactone | 1.72 |
N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute and chronic heart failure (CHF) and may be useful to establish prognosis in heart failure. (NCT01807221)
Timeframe: Baseline and Day 90
| Intervention | Percentage of participants (Number) |
|---|---|
| Eplerenone (INSPRA®) | 37.2 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 30.9 |
| Finerenone (BAY94-8862) 5-10 mg OD | 32.5 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 37.3 |
| Finerenone (BAY94-8862) 10-20 mg OD | 38.8 |
| Finerenone (BAY94-8862) 15-20 mg OD | 34.2 |
(NCT01807221)
Timeframe: Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | millimeter for mercury (mmHg) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Day 7 | Day 14 | Day 30 | Day 60 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 71.633 | -1.351 | -3.442 | -0.503 | -0.613 | -0.716 | -3.185 | -1.218 |
| Finerenone (BAY94-8862) 10-20 mg OD | 70.343 | -0.738 | -2.387 | -0.094 | 0.17 | -0.545 | -2.96 | -0.298 |
| Finerenone (BAY94-8862) 15-20 mg OD | 71.145 | -1.166 | -0.625 | -1.163 | -0.575 | -0.877 | -0.083 | -0.172 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 71.044 | -1.693 | -0.537 | 0.146 | -0.199 | -0.106 | 0.868 | 0.696 |
| Finerenone (BAY94-8862) 5-10 mg OD | 71.442 | -2.143 | 1.608 | -0.845 | -2.144 | -1.738 | -2.194 | -0.444 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 70.61 | 0.013 | -0.083 | -0.068 | -0.85 | -1.121 | 4.101 | -1.16 |
EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L): participant rated questionnaire to assess health-related quality of life. It consists of EQ-5D descriptive system and EQ-5D Visual Analog Scale (VAS). EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1), some problems (2), and extreme problems (3). For this population, the possible EQ-5D-3L index scores ranges from -0.11 (that is, 3 for all 5 dimensions) to 1.0 (that is, 1 for all 5 dimensions), where higher scores indicate a better health state. (NCT01807221)
Timeframe: Baseline, Day 30, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Scores on scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 30 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 0.58 | 0.06 | 0.08 | -0.12 | 0.06 |
| Finerenone (BAY94-8862) 10-20 mg OD | 0.56 | 0.06 | 0.1 | -0.05 | 0.07 |
| Finerenone (BAY94-8862) 15-20 mg OD | 0.59 | 0.02 | 0.06 | 0 | 0.04 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 0.59 | 0.02 | 0.03 | -0.06 | 0.01 |
| Finerenone (BAY94-8862) 5-10 mg OD | 0.62 | 0.02 | 0.04 | -0.09 | 0.01 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 0.58 | 0.07 | 0.08 | -0.1 | 0.08 |
(NCT01807221)
Timeframe: Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Beats per minute (Beats/min) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Day 7 | Day 14 | Day 30 | Day 60 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 74.957 | -0.8 | -3.109 | 0.294 | 0.297 | -0.189 | -2.278 | -1.281 |
| Finerenone (BAY94-8862) 10-20 mg OD | 73.852 | -0.548 | 0.423 | -0.802 | 0.192 | -0.71 | 4.733 | 0.834 |
| Finerenone (BAY94-8862) 15-20 mg OD | 74.329 | -1.176 | -3.969 | -1.633 | -1.608 | -1.145 | -2.072 | -1.317 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 73.369 | 1.073 | 0.599 | 1.064 | -0.975 | -1.647 | -1.424 | -2.057 |
| Finerenone (BAY94-8862) 5-10 mg OD | 72.681 | -0.63 | 1.842 | 0.435 | -1.741 | -2.89 | -0.222 | -0.626 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 74.184 | -0.719 | -1.324 | -0.349 | -2.318 | -2.212 | 1.101 | -1.326 |
The Kansas City Cardiomyopathy Questionnaire (KCCQ) was the leading health related quality of life measure for subjects with CHF. KCCQ was a 23 item questionnaire that independently measures the impact of subjects HF, or its treatment, on 7 distinct domains: self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. KCCQ clinical summary score is a composite assessment of physical limitations and total symptom scores. Results from the total symptom summary score are presented. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. In the below table, categorical data represents change from baseline data at respective time points. (NCT01807221)
Timeframe: Baseline, Day 30 and Day 90
| Intervention | Scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Day 30 | Day 90 | |
| Eplerenone (INSPRA®) | 43.7 | 20.5 | 24.3 |
| Finerenone (BAY94-8862) 10-20 mg OD | 42.3 | 24.9 | 28.3 |
| Finerenone (BAY94-8862) 15-20 mg OD | 43.2 | 20.6 | 22.2 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 42.8 | 18.2 | 21.3 |
| Finerenone (BAY94-8862) 5-10 mg OD | 45.4 | 19.3 | 24.5 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 42.1 | 23 | 29.3 |
(NCT01807221)
Timeframe: Baseline, Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | millimoles per liter (mmol/L) (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 30 | Day 60 | Day 90 | Follow-up | |
| Eplerenone (INSPRA®) | 4.159 | 0.057 | 0.179 | 0.307 | 0.117 |
| Finerenone (BAY94-8862) 10-20 mg OD | 4.131 | 0.21 | 0.274 | 0.275 | 0.175 |
| Finerenone (BAY94-8862) 15-20 mg OD | 4.117 | 0.193 | 0.216 | 0.245 | 0.036 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 4.081 | 0.135 | 0.091 | 0.184 | 0.226 |
| Finerenone (BAY94-8862) 5-10 mg OD | 4.211 | 0.075 | 0.131 | 0.153 | 0.054 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 4.174 | 0.085 | 0.171 | 0.164 | 0.05 |
(NCT01807221)
Timeframe: Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | millimeter of mercury (mmHg) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Day 7 | Day 14 | Day 30 | Day 60 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 120.554 | -0.541 | -3.442 | 0.067 | 0.684 | -0.967 | -2.991 | 0.188 |
| Finerenone (BAY94-8862) 10-20 mg OD | 116.024 | 0.162 | -3.099 | 1.786 | 0.981 | 1.216 | -2.32 | 2.041 |
| Finerenone (BAY94-8862) 15-20 mg OD | 116.941 | -0.546 | -2.906 | 0.899 | 0.667 | 0.956 | -0.028 | 3.037 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 119.492 | -3.178 | -4.488 | -0.824 | 0.337 | 0.922 | -0.41 | 2.869 |
| Finerenone (BAY94-8862) 5-10 mg OD | 118.498 | -2.565 | 4.142 | -0.367 | -1.249 | 0.047 | -2.167 | 1.95 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 119.087 | 0.568 | 1.241 | 0.374 | -1.811 | -0.664 | 9.391 | -0.928 |
Hospitalizations were defined as any unplanned admission to hospital, i.e. completion of hospital admission procedures and one overnight [i.e. date change] stay or until the death of subject occurred. Hospitalizations and deaths were classified by 2 primary categories: CV and non-CV. The pre-specified subcategories for CV hospitalizations were as follows: 1. Worsening heart failure, 2.Acute myocardial infarction, 3. Arrhythmia, 4.Transient ischemic attack and stroke, 5. Other CV hospitalizations. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Day 30 | Day 60 | Day 90 | Follow-up | |
| Eplerenone (INSPRA®) | 28 | 43 | 45 | 56 |
| Finerenone (BAY94-8862) 10-20 mg OD | 7 | 15 | 22 | 27 |
| Finerenone (BAY94-8862) 15-20 mg OD | 15 | 23 | 28 | 34 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 23 | 33 | 35 | 43 |
| Finerenone (BAY94-8862) 5-10 mg OD | 14 | 23 | 26 | 38 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 8 | 21 | 29 | 36 |
Death due to any cause include cardiovascular (CV) death and Non-CV death. Non-CV death was classified by 2 subcategories: non-malignant causes and malignant causes. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Day 30 | Day 60 | Day 90 | Follow-up | |
| Eplerenone (INSPRA®) | 6 | 7 | 9 | 15 |
| Finerenone (BAY94-8862) 10-20 mg OD | 0 | 0 | 1 | 2 |
| Finerenone (BAY94-8862) 15-20 mg OD | 2 | 4 | 5 | 8 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 5 | 7 | 10 | 16 |
| Finerenone (BAY94-8862) 5-10 mg OD | 1 | 3 | 4 | 7 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 1 | 2 | 4 | 11 |
Emergency presentations for WCHF were defined as newly developing signs and symptoms of WCHF after start of treatment with study drug, requiring an additional emergency presentation to hospital and IV treatment with diuretics and/or positive inotropic agents. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Day 30 | Day 60 | Day 90 | Follow-up | |
| Eplerenone (INSPRA®) | 21 | 35 | 37 | 47 |
| Finerenone (BAY94-8862) 10-20 mg OD | 7 | 14 | 18 | 26 |
| Finerenone (BAY94-8862) 15-20 mg OD | 15 | 22 | 28 | 34 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 19 | 30 | 32 | 40 |
| Finerenone (BAY94-8862) 5-10 mg OD | 12 | 20 | 22 | 30 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 9 | 17 | 24 | 30 |
B-type natriuretic peptide (BNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| Day 30 | Day 60 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 0.925 | 0.783 | 0.723 | 0.896 | 0.795 |
| Finerenone (BAY94-8862) 10-20 mg OD | 0.852 | 0.711 | 0.706 | 0.848 | 0.729 |
| Finerenone (BAY94-8862) 15-20 mg OD | 0.879 | 0.824 | 0.771 | 1.044 | 0.852 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 0.944 | 0.864 | 0.813 | 1.104 | 0.815 |
| Finerenone (BAY94-8862) 5-10 mg OD | 0.878 | 0.854 | 0.839 | 1.006 | 0.886 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 0.832 | 0.79 | 0.719 | 0.884 | 0.726 |
N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| Day 30 | Day 60 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 0.883 | 0.749 | 0.688 | 0.948 | 0.747 |
| Finerenone (BAY94-8862) 10-20 mg OD | 0.822 | 0.748 | 0.728 | 1.133 | 0.746 |
| Finerenone (BAY94-8862) 15-20 mg OD | 0.921 | 0.829 | 0.771 | 0.965 | 0.849 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 0.98 | 0.822 | 0.789 | 1.369 | 0.747 |
| Finerenone (BAY94-8862) 5-10 mg OD | 0.874 | 0.814 | 0.765 | 1.267 | 0.887 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 0.888 | 0.81 | 0.783 | 0.927 | 0.809 |
(NCT00868439)
Timeframe: Baseline and Day 28
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Patiromer | -0.21 |
| Placebo | 0.23 |
Analysis based on local laboratory data. (NCT00868439)
Timeframe: 28 Days
| Intervention | percentage of participants (Number) |
|---|---|
| Patiromer | 0 |
| Placebo | 6.1 |
(NCT00868439)
Timeframe: 28 Days
| Intervention | percentage of participants (Number) |
|---|---|
| Patiromer | 90.9 |
| Placebo | 73.5 |
Analysis based on central laboratory data. (NCT00868439)
Timeframe: 28 Days
| Intervention | percentage of participants (Number) |
|---|---|
| Patiromer | 7.3 |
| Placebo | 24.5 |
(NCT00868439)
Timeframe: Baseline and Day 28
| Intervention | percentage of participants (Number) |
|---|---|
| Patiromer | 12.7 |
| Placebo | 24.5 |
(NCT00868439)
Timeframe: 28 Days
| Intervention | days (Median) |
|---|---|
| Patiromer | NA |
| Placebo | NA |
Increase in the 6 minute walk test (6MWT) distance from baseline to Week 8. The test was performed according to the American Thoracic Society (ATS)Guidelines 2002. (NCT01265524)
Timeframe: Baseline and 8 weeks
| Intervention | m (Mean) |
|---|---|
| Investigational Drug: CLP | 39.3 |
| Placebo | 19.7 |
Change in serum potassium from baseline to Week 8. (NCT01265524)
Timeframe: Baseline and 8 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| Investigational Drug: CLP | 0.15 |
| Placebo | 0.05 |
The frequency of marked or disabling exertional dyspnea was physician assessed based on physical exam at week 4. (NCT01265524)
Timeframe: 4 weeks
| Intervention | participants (Number) |
|---|---|
| Investigational Drug: CLP | 10 |
| Placebo | 14 |
The frequency of marked or disabling exertional dyspnea was physician assessed based on physical exam at week 8. (NCT01265524)
Timeframe: 8 weeks
| Intervention | participants (Number) |
|---|---|
| Investigational Drug: CLP | 5 |
| Placebo | 12 |
(NCT01265524)
Timeframe: Baseline and 8 weeks
| Intervention | participants (Number) |
|---|---|
| Investigational Drug: CLP | 20 |
| Placebo | 8 |
(NCT01265524)
Timeframe: Baseline and 1 week
| Intervention | kg (Mean) |
|---|---|
| Investigational Drug: CLP | -0.71 |
| Placebo | 0.11 |
(NCT01265524)
Timeframe: Baseline and 2 weeks
| Intervention | kg (Mean) |
|---|---|
| Investigational Drug: CLP | -0.83 |
| Placebo | 0.29 |
"Time to progression free survival (PFS) is the period from study entry (first dose of therapy) until disease progression, death or date of last contact.~All patients underwent baseline computed tomographic scans prior to initiation of therapy. The residual disease information was collected from surgical operative reports as well as post operative CT scans. Treatment responses were assessed with CA 125 at each cycle of therapy. CT scans were performed post-operatively prior to initiation of systemic therapy, at the completion of combination platinum, taxane, and pembrolizumab therapy, and at the completion of maintenance pembrolizumab therapy. CT scans were also performed with increasing CA 125 or if clinically indicated per treating physician and assessments were made using response evaluation criteria in solid tumor (RECIST) criteria defined as a 20% increase in the sum of the longest diameter of target lesions, or measurable increase in non-target l" (NCT02766582)
Timeframe: measured from date of completion of primary therapy to the date of the first clinical, biochemical or radiologic evidence of disease progression or death due to any cause
| Intervention | months (Median) |
|---|---|
| Chemotherapy Combined With Pembrolizumab | 13.2 |
"Each cycle is 21 days. All participants were asked to complete FACT-O surveys at baseline/ time of enrollment, at 3 months, 6 months and 18 months from initiation of therapy.~FACT-O is a validated 26-item summary score 112 points that captures the FACT-General (FACT-G) QOL dimensions of Physical Well-Being (7 items), Functional Well-Being (7 items), and an Ovarian Cancer Subscale (12 items). FACT-0 is a survey with 39 items self administered survey. Each item is scored on 5 point Likert-type scale. The FACT-0 scoring range is from 0-44. The subscale scoring ranges for FACT-G is 0-108. The higher the total score the better the patient well-being. the outcome measure data represent FACT-G scoring as it is the section that pertains to QOL.~https://www.facit.org/measures/FACT-O" (NCT02766582)
Timeframe: Time of enrollment until 18 months from initiation of therapy
| Intervention | score on a scale (Median) | |||
|---|---|---|---|---|
| screening | 3 months | 6 months | 18 months | |
| Chemotherapy Combined With Pembrolizumab | 85 | 88 | 83.9 | 86 |
Visual acuity will be measured with standard eye charts, with manifest refraction at the initiation and conclusion of treatment. Although an important measure, this was not chosen as the primary outcome measure, as some patients with central serous chorioretinopathy may have a normal visual acuity when properly refracted (refraction can change with elevation of the macula by sub-retinal fluid) (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | logMAR (Mean) |
|---|---|
| Patients That Took Eplerenone | -0.03 |
Automated software to calculate the thickness of the macula is standard on commercial OCT devices. Macular thickness before and after treatment will be assessed and compared. (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | Microns (Mean) |
|---|---|
| Patients That Received Eplerenone | -26 |
Eplerenone can cause elevation of serum potassium. After initial screening, serum potassium was evaluated at 1 and 4 weeks after baseline. (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | mEq/L (Mean) |
|---|---|
| Patients That Received Eplerenone | 0.11 |
Choroidal thickness can be measured using optical coherence tomography, and is known to be affected in patients with central serous chorioretinopathy. Thickness of the choroid under the fovea will be manually calculated in both the study eye. (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | microns (Mean) |
|---|---|
| Patients That Received Eplerenone | 29.8 |
Optical coherence tomography is an imaging technique capable of extremely high resolution (~5-7 microns) imaging of the macula, and is able to detect the presence and amount of subretinal fluid present, the key anatomic abnormality in Central Serous Chorioretinopathy (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | participants (Number) |
|---|---|
| Patients That Took Eplerenone | 0 |
"Left ventricle measurements by MRI:~Mass/end diastolic volume ratio: g/ml" (NCT00123955)
Timeframe: Baseline, 9 month
| Intervention | g/ml (Mean) | |
|---|---|---|
| baseline | 9 month | |
| Placebo | 1.7 | 1.6 |
| Spironolactone | 1.8 | 1.7 |
Peak exercise VO2 (NCT00123955)
Timeframe: Baseline, 4 and 9 months
| Intervention | ml/kg/min (Mean) | ||
|---|---|---|---|
| Baseline | 4 months | 9 months | |
| Placebo | 13.3 | 13.5 | 13.9 |
| Spironolactone | 13.5 | 13.6 | 13.8 |
"Echocardiography Doppler measurement of left ventricular diastolic function:~Early mitral annulus velocity (lateral) (Ea; cm/s)" (NCT00123955)
Timeframe: Baseline, 4 month and 9 month
| Intervention | cm/s (Mean) | ||
|---|---|---|---|
| baseline | 4 month | 9 month | |
| Placebo | 6.8 | 6.8 | 6.6 |
| Spironolactone | 7.0 | 7.0 | 7.4 |
"The Minnesota Living with Heart Failure Questionnaire (MLHF) is a self-administered disease-specific questionnaire for patients with Heart Failure, comprising 21 items rated on six-point Likert scales, representing different degrees of impact of HF on HRQoL, from 0 (none) to 5 (very much). It provides a total score (range 0-105, from best to worst HRQoL), as well as scores for two dimensions, physical (8 items, range 0-40) and emotional (5 items, range 0-25). The other eight items (of the total of 21) are only considered for the calculation of the total score.~Scale of 0-105:The higher the score the worse the heart failure related Quality of Life." (NCT00123955)
Timeframe: Baseline, 4 and 9 months
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 4 months | Final- 9 months | |
| Placebo | 28 | 29 | 25 |
| Spironolactone | 32 | 29 | 29 |
200 reviews available for spironolactone and Heart Failure
| Article | Year |
|---|---|
Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eplerenone; Heart Failure; Humans; Hyperkalemia; | 2022 |
Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eplerenone; Heart Failure; Humans; Hyperkalemia; | 2022 |
Finerenone in diabetic kidney disease: A systematic review and critical appraisal.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eplerenone; Glycated Hemoglobin; Heart Failure; H | 2022 |
Finerenone in diabetic kidney disease: A systematic review and critical appraisal.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eplerenone; Glycated Hemoglobin; Heart Failure; H | 2022 |
Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients.
Topics: Aldosterone; Heart Failure; Humans; Hypertrophy, Left Ventricular; Multicenter Studies as Topic; Pro | 2023 |
Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients.
Topics: Aldosterone; Heart Failure; Humans; Hypertrophy, Left Ventricular; Multicenter Studies as Topic; Pro | 2023 |
Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives.
Topics: Administration, Oral; Clinical Decision-Making; Diuretics; Dosage Forms; Drug Compounding; Flavoring | 2019 |
Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives.
Topics: Administration, Oral; Clinical Decision-Making; Diuretics; Dosage Forms; Drug Compounding; Flavoring | 2019 |
Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials.
Topics: Eplerenone; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Randomized | 2020 |
Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials.
Topics: Eplerenone; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Randomized | 2020 |
Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotens | 2020 |
Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotens | 2020 |
Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists.
Topics: Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Receptors, | 2020 |
Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists.
Topics: Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Receptors, | 2020 |
A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population.
Topics: Child; Digoxin; Heart Failure; Humans; Infant; Infant, Newborn; Models, Biological; Nonlinear Dynami | 2020 |
A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population.
Topics: Child; Digoxin; Heart Failure; Humans; Infant; Infant, Newborn; Models, Biological; Nonlinear Dynami | 2020 |
Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone.
Topics: Diabetic Nephropathies; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridine | 2020 |
Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone.
Topics: Diabetic Nephropathies; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridine | 2020 |
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Mineraloco | 2021 |
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Mineraloco | 2021 |
The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor-Directed Therapies in Heart Failure.
Topics: Animals; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Molecular Targeted Therapy; | 2021 |
The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor-Directed Therapies in Heart Failure.
Topics: Animals; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Molecular Targeted Therapy; | 2021 |
Effect of Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction and with Reduced Ejection Fraction - A Narrative Review.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; Ventri | 2022 |
Effect of Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction and with Reduced Ejection Fraction - A Narrative Review.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; Ventri | 2022 |
Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.
Topics: Diuretics; Heart Failure; Humans; Medication Adherence; Mineralocorticoid Receptor Antagonists; Spir | 2017 |
Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.
Topics: Diuretics; Heart Failure; Humans; Medication Adherence; Mineralocorticoid Receptor Antagonists; Spir | 2017 |
Clinical Question: In congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes?
Topics: Cardiovascular Diseases; Heart Arrest; Heart Failure; Hospitalization; Humans; Mineralocorticoid Rec | 2016 |
Clinical Question: In congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes?
Topics: Cardiovascular Diseases; Heart Arrest; Heart Failure; Hospitalization; Humans; Mineralocorticoid Rec | 2016 |
Combined use of an ACE-inhibitor and spironolactone in patients with heart insufficiency.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diuretics; Drug Therapy, Combination; Heart Failure; Human | 2017 |
Combined use of an ACE-inhibitor and spironolactone in patients with heart insufficiency.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diuretics; Drug Therapy, Combination; Heart Failure; Human | 2017 |
[Heart failure with "mid-range" ejection fraction: a new clinical entity?]
Topics: Aged; Aminobutyrates; Benzimidazoles; Biomarkers; Biphenyl Compounds; Comorbidity; Coronary Disease; | 2018 |
[Heart failure with "mid-range" ejection fraction: a new clinical entity?]
Topics: Aged; Aminobutyrates; Benzimidazoles; Biomarkers; Biphenyl Compounds; Comorbidity; Coronary Disease; | 2018 |
Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.
Topics: Aged; Diuretics; Exercise Tolerance; Female; Heart Failure; Humans; Male; Middle Aged; Randomized Co | 2018 |
Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.
Topics: Aged; Diuretics; Exercise Tolerance; Female; Heart Failure; Humans; Male; Middle Aged; Randomized Co | 2018 |
Effect of Mineralocorticoid Receptor Antagonists in Individuals With Heart Failure With Preserved Ejection Fraction: A Systematic Review.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; Treatm | 2018 |
Effect of Mineralocorticoid Receptor Antagonists in Individuals With Heart Failure With Preserved Ejection Fraction: A Systematic Review.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; Treatm | 2018 |
Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials.
Topics: Death, Sudden, Cardiac; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Co | 2019 |
Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials.
Topics: Death, Sudden, Cardiac; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Co | 2019 |
Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials.
Topics: Heart Failure; Hospitalization; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Procollagen; | 2019 |
Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials.
Topics: Heart Failure; Hospitalization; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Procollagen; | 2019 |
Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
Topics: Eplerenone; Heart Failure; Hospitalization; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagon | 2019 |
Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
Topics: Eplerenone; Heart Failure; Hospitalization; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagon | 2019 |
Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials.
Topics: Canrenone; Diuretics; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Net | 2020 |
Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials.
Topics: Canrenone; Diuretics; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Net | 2020 |
Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.
Topics: Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolact | 2014 |
Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.
Topics: Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolact | 2014 |
Heart failure: the role for mineralocorticoid receptor antagonists.
Topics: Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Spironolact | 2014 |
Heart failure: the role for mineralocorticoid receptor antagonists.
Topics: Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Spironolact | 2014 |
Aldosterone and volume management in hypertensive heart disease.
Topics: Aldosterone; Area Under Curve; Diuretics; Eplerenone; Heart Failure; Humans; Hypertension; Mineraloc | 2014 |
Aldosterone and volume management in hypertensive heart disease.
Topics: Aldosterone; Area Under Curve; Diuretics; Eplerenone; Heart Failure; Humans; Hypertension; Mineraloc | 2014 |
Cardiomyopathy in pregnancy.
Topics: Adrenergic beta-Antagonists; Adult; Anesthesia, Obstetrical; Angiotensin-Converting Enzyme Inhibitor | 2014 |
Cardiomyopathy in pregnancy.
Topics: Adrenergic beta-Antagonists; Adult; Anesthesia, Obstetrical; Angiotensin-Converting Enzyme Inhibitor | 2014 |
Heart failure therapies in 2014: Mixed results for heart failure therapies.
Topics: Aminobutyrates; Anemia, Iron-Deficiency; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardi | 2015 |
Heart failure therapies in 2014: Mixed results for heart failure therapies.
Topics: Aminobutyrates; Anemia, Iron-Deficiency; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardi | 2015 |
Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Car | 2015 |
Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Car | 2015 |
Eplerenone in chronic heart failure with depressed systolic function.
Topics: Chronic Disease; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomiz | 2015 |
Eplerenone in chronic heart failure with depressed systolic function.
Topics: Chronic Disease; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomiz | 2015 |
[Effect of spironolactone in patients with heart failure and preserved left ventricular function - TOPCAT study].
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Ventricular Function, | 2015 |
[Effect of spironolactone in patients with heart failure and preserved left ventricular function - TOPCAT study].
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Ventricular Function, | 2015 |
Heart failure with preserved ejection fraction: uncertainties and dilemmas.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Diuretics; Heart Failure; Humans; Pro | 2015 |
Heart failure with preserved ejection fraction: uncertainties and dilemmas.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Diuretics; Heart Failure; Humans; Pro | 2015 |
Heart failure and chronic kidney disease: should we use spironolactone?
Topics: Diuretics; Heart Failure; Humans; Kidney Failure, Chronic; Potassium; Renin-Angiotensin System; Spir | 2015 |
Heart failure and chronic kidney disease: should we use spironolactone?
Topics: Diuretics; Heart Failure; Humans; Kidney Failure, Chronic; Potassium; Renin-Angiotensin System; Spir | 2015 |
Pharmacological treatment of aldosterone excess.
Topics: Aldosterone; Cytochrome P-450 CYP11B2; Dihydropyridines; Drug Interactions; Epithelial Sodium Channe | 2015 |
Pharmacological treatment of aldosterone excess.
Topics: Aldosterone; Cytochrome P-450 CYP11B2; Dihydropyridines; Drug Interactions; Epithelial Sodium Channe | 2015 |
Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Tri | 2015 |
Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Tri | 2015 |
Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Tr | 2015 |
Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Tr | 2015 |
Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis.
Topics: Aldosterone; Atrial Fibrillation; Cardiac Surgical Procedures; Eplerenone; Heart Failure; Humans; Mi | 2016 |
Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis.
Topics: Aldosterone; Atrial Fibrillation; Cardiac Surgical Procedures; Eplerenone; Heart Failure; Humans; Mi | 2016 |
Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety.
Topics: Aldosterone; Blood Pressure; Disease Progression; Eplerenone; Heart Failure; Humans; Kidney Failure, | 2016 |
Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety.
Topics: Aldosterone; Blood Pressure; Disease Progression; Eplerenone; Heart Failure; Humans; Kidney Failure, | 2016 |
Biomarkers for Heart Failure: An Update for Practitioners of Internal Medicine.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Calcitonin; Comorbidity; Diagnosis, Differential; Diu | 2016 |
Biomarkers for Heart Failure: An Update for Practitioners of Internal Medicine.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Calcitonin; Comorbidity; Diagnosis, Differential; Diu | 2016 |
Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences.
Topics: Aldosterone; Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid | 2016 |
Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences.
Topics: Aldosterone; Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid | 2016 |
After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume | 2016 |
After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume | 2016 |
Lessons Learned and Insights Gained in the Design, Analysis, and Outcomes of the COMPANION Trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2016 |
Lessons Learned and Insights Gained in the Design, Analysis, and Outcomes of the COMPANION Trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2016 |
Mineralocorticoid Receptor Antagonists in the Management of Heart Failure and Resistant Hypertension: A Review.
Topics: Eplerenone; Heart Failure; Humans; Hyperkalemia; Hypertension; Mineralocorticoid Receptor Antagonist | 2016 |
Mineralocorticoid Receptor Antagonists in the Management of Heart Failure and Resistant Hypertension: A Review.
Topics: Eplerenone; Heart Failure; Humans; Hyperkalemia; Hypertension; Mineralocorticoid Receptor Antagonist | 2016 |
Should MRAs be at the front row in heart failure? A plea for the early use of mineralocorticoid receptor antagonists in medical therapy for heart failure based on clinical experience.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Practice Guidelines as To | 2016 |
Should MRAs be at the front row in heart failure? A plea for the early use of mineralocorticoid receptor antagonists in medical therapy for heart failure based on clinical experience.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Practice Guidelines as To | 2016 |
Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
Topics: Animals; Cardio-Renal Syndrome; Diabetic Nephropathies; Endothelial Cells; Eplerenone; Fibroblasts; | 2017 |
Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
Topics: Animals; Cardio-Renal Syndrome; Diabetic Nephropathies; Endothelial Cells; Eplerenone; Fibroblasts; | 2017 |
Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.
Topics: Aged; Cause of Death; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mineralocor | 2009 |
Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.
Topics: Aged; Cause of Death; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mineralocor | 2009 |
The clinical pharmacology of eplerenone.
Topics: Animals; Controlled Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hyperkalemia; Miner | 2009 |
The clinical pharmacology of eplerenone.
Topics: Animals; Controlled Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hyperkalemia; Miner | 2009 |
[The use of aldosterone antagonists in the cardiovascular diseases].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers | 2009 |
[The use of aldosterone antagonists in the cardiovascular diseases].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers | 2009 |
Male gynecomastia.
Topics: Dose-Response Relationship, Drug; Follow-Up Studies; Gynecomastia; Heart Failure; Humans; Male; Midd | 2009 |
Male gynecomastia.
Topics: Dose-Response Relationship, Drug; Follow-Up Studies; Gynecomastia; Heart Failure; Humans; Male; Midd | 2009 |
Blocking aldosterone in heart failure.
Topics: Aldosterone; Cardiovascular Agents; Drug Therapy, Combination; Eplerenone; Fibrosis; Heart Failure; | 2009 |
Blocking aldosterone in heart failure.
Topics: Aldosterone; Cardiovascular Agents; Drug Therapy, Combination; Eplerenone; Fibrosis; Heart Failure; | 2009 |
Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?
Topics: Heart Failure; Humans; Liver Cirrhosis; Mineralocorticoid Receptor Antagonists; Natriuretic Agents; | 2009 |
Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?
Topics: Heart Failure; Humans; Liver Cirrhosis; Mineralocorticoid Receptor Antagonists; Natriuretic Agents; | 2009 |
Natriuretic peptides in heart failure: should therapy be guided by BNP levels?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Age | 2010 |
Natriuretic peptides in heart failure: should therapy be guided by BNP levels?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Age | 2010 |
Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism.
Topics: Aldosterone; Diuretics; Evidence-Based Medicine; Heart Failure; Humans; Hyperkalemia; Mineralocortic | 2010 |
Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism.
Topics: Aldosterone; Diuretics; Evidence-Based Medicine; Heart Failure; Humans; Hyperkalemia; Mineralocortic | 2010 |
[Mineralocorticoid receptor antagonists: inhibition of the renin angiotensin system].
Topics: Albuminuria; Diabetes Mellitus, Type 2; Eplerenone; Female; Heart Failure; Humans; Hyperaldosteronis | 2010 |
[Mineralocorticoid receptor antagonists: inhibition of the renin angiotensin system].
Topics: Albuminuria; Diabetes Mellitus, Type 2; Eplerenone; Female; Heart Failure; Humans; Hyperaldosteronis | 2010 |
Aldosterone receptor antagonists--how cardiovascular actions may explain their beneficial effects in heart failure.
Topics: Animals; Autonomic Nervous System; Cardiovascular System; Dog Diseases; Dogs; Eplerenone; Heart Fail | 2010 |
Aldosterone receptor antagonists--how cardiovascular actions may explain their beneficial effects in heart failure.
Topics: Animals; Autonomic Nervous System; Cardiovascular System; Dog Diseases; Dogs; Eplerenone; Heart Fail | 2010 |
A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
Topics: Bayes Theorem; Clinical Trials as Topic; Cost-Benefit Analysis; Eplerenone; Heart Failure; Humans; M | 2010 |
A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
Topics: Bayes Theorem; Clinical Trials as Topic; Cost-Benefit Analysis; Eplerenone; Heart Failure; Humans; M | 2010 |
Aldosterone, hypertension and heart failure: insights from clinical trials.
Topics: Aldosterone; Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Dihydrotesto | 2010 |
Aldosterone, hypertension and heart failure: insights from clinical trials.
Topics: Aldosterone; Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Dihydrotesto | 2010 |
Review article: eplerenone: an underused medication?
Topics: Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Hyperkalemia; Hypertension; Hypertrophy, | 2010 |
Review article: eplerenone: an underused medication?
Topics: Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Hyperkalemia; Hypertension; Hypertrophy, | 2010 |
Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?
Topics: Diuretics; Heart Failure; Humans; Kidney Failure, Chronic; Renal Dialysis; Spironolactone | 2010 |
Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?
Topics: Diuretics; Heart Failure; Humans; Kidney Failure, Chronic; Renal Dialysis; Spironolactone | 2010 |
Aldosterone antagonists in heart failure.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor An | 2011 |
Aldosterone antagonists in heart failure.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor An | 2011 |
[Heart failure].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Benzazepines; Cardiac Resynchronization Therapy | 2011 |
[Heart failure].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Benzazepines; Cardiac Resynchronization Therapy | 2011 |
What is the risk of hyperkalaemia in heart failure?
Topics: Heart Failure; Homeostasis; Humans; Hyperkalemia; Population Groups; Potassium; Potassium Channels; | 2011 |
What is the risk of hyperkalaemia in heart failure?
Topics: Heart Failure; Homeostasis; Humans; Hyperkalemia; Population Groups; Potassium; Potassium Channels; | 2011 |
Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling.
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorti | 2011 |
Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling.
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorti | 2011 |
Mineralocorticoid receptor antagonists for heart failure.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Ran | 2011 |
Mineralocorticoid receptor antagonists for heart failure.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Ran | 2011 |
Interventions to enhance adherence to medications in patients with heart failure: a systematic review.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Behavior Therapy; Female; Hea | 2012 |
Interventions to enhance adherence to medications in patients with heart failure: a systematic review.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Behavior Therapy; Female; Hea | 2012 |
The role of mineralocorticoid receptor antagonists in patients with American College of Cardiology/American Heart Association stage B heart failure.
Topics: Adrenal Glands; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Enalapril; Endotheli | 2012 |
The role of mineralocorticoid receptor antagonists in patients with American College of Cardiology/American Heart Association stage B heart failure.
Topics: Adrenal Glands; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Enalapril; Endotheli | 2012 |
Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications.
Topics: Arrhythmias, Cardiac; Coronary Artery Disease; Diuretics; Heart Failure; Humans; Mineralocorticoid R | 2012 |
Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications.
Topics: Arrhythmias, Cardiac; Coronary Artery Disease; Diuretics; Heart Failure; Humans; Mineralocorticoid R | 2012 |
Eplerenone is not superior to older and less expensive aldosterone antagonists.
Topics: Canrenone; Cause of Death; Cost-Benefit Analysis; Drug Costs; Eplerenone; Heart Failure; Humans; Min | 2012 |
Eplerenone is not superior to older and less expensive aldosterone antagonists.
Topics: Canrenone; Cause of Death; Cost-Benefit Analysis; Drug Costs; Eplerenone; Heart Failure; Humans; Min | 2012 |
Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure.
Topics: Death, Sudden, Cardiac; Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor | 2012 |
Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure.
Topics: Death, Sudden, Cardiac; Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor | 2012 |
The role of aldosterone receptor antagonists in the management of heart failure: an update.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2012 |
The role of aldosterone receptor antagonists in the management of heart failure: an update.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2012 |
Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis.
Topics: Canrenone; Chronic Disease; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonist | 2013 |
Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis.
Topics: Canrenone; Chronic Disease; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonist | 2013 |
Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system.
Topics: Aldosterone; Animals; Cardiomegaly; Cardiovascular System; Heart Failure; Humans; Hyperaldosteronism | 2002 |
Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system.
Topics: Aldosterone; Animals; Cardiomegaly; Cardiovascular System; Heart Failure; Humans; Hyperaldosteronism | 2002 |
Heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2002 |
Heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2002 |
Eplerenone--a novel selective aldosterone blocker.
Topics: Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoi | 2002 |
Eplerenone--a novel selective aldosterone blocker.
Topics: Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoi | 2002 |
Prevention of heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Complications; Heart Failure; Heart Transplantati | 2002 |
Prevention of heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Complications; Heart Failure; Heart Transplantati | 2002 |
Spironolactone for heart failure: a worthy addition to therapy.
Topics: Cardiovascular Agents; Diuretics; Drug Therapy, Combination; Heart Failure; Humans; Mineralocorticoi | 2001 |
Spironolactone for heart failure: a worthy addition to therapy.
Topics: Cardiovascular Agents; Diuretics; Drug Therapy, Combination; Heart Failure; Humans; Mineralocorticoi | 2001 |
New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone.
Topics: Aldosterone; Animals; Cardiomegaly; Clinical Trials as Topic; Desoxycorticosterone; Eplerenone; Fibr | 2002 |
New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone.
Topics: Aldosterone; Animals; Cardiomegaly; Clinical Trials as Topic; Desoxycorticosterone; Eplerenone; Fibr | 2002 |
[The significance of aldosterone in chronic heart failure: the RALES study].
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2002 |
[The significance of aldosterone in chronic heart failure: the RALES study].
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2002 |
The role of aldosterone receptor blockade in the management of cardiovascular disease.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Hypertension; Mine | 2002 |
The role of aldosterone receptor blockade in the management of cardiovascular disease.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Hypertension; Mine | 2002 |
Clinical treatment regimens for chronic heart failure: a review.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Convertin | 2002 |
Clinical treatment regimens for chronic heart failure: a review.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Convertin | 2002 |
Heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2002 |
Heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2002 |
[Aldosterone and its antagonists in heart failure].
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; | 2003 |
[Aldosterone and its antagonists in heart failure].
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; | 2003 |
Aldosterone as a target in congestive heart failure.
Topics: Aldosterone; Cardiovascular Agents; Endothelium, Vascular; Eplerenone; Heart Failure; Humans; Minera | 2003 |
Aldosterone as a target in congestive heart failure.
Topics: Aldosterone; Cardiovascular Agents; Endothelium, Vascular; Eplerenone; Heart Failure; Humans; Minera | 2003 |
[Ischemic heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Fib | 2003 |
[Ischemic heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Fib | 2003 |
Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Mineralo | 2003 |
Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Mineralo | 2003 |
Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans.
Topics: Anticoagulants; Cardiac Pacing, Artificial; Defibrillators, Implantable; Electrocardiography; Eplere | 2003 |
Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans.
Topics: Anticoagulants; Cardiac Pacing, Artificial; Defibrillators, Implantable; Electrocardiography; Eplere | 2003 |
Selective aldosterone blockade with eplerenone in patients with congestive heart failure.
Topics: Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; | 2003 |
Selective aldosterone blockade with eplerenone in patients with congestive heart failure.
Topics: Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; | 2003 |
Eplerenone: a selective aldosterone blocker.
Topics: Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hypertension; Hypertrophy, Lef | 2003 |
Eplerenone: a selective aldosterone blocker.
Topics: Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hypertension; Hypertrophy, Lef | 2003 |
Aldosterone receptor antagonists for hypertension: what do they offer?
Topics: Aldosterone; Clinical Trials as Topic; Diuretics; Eplerenone; Heart Failure; Humans; Hypertension; M | 2003 |
Aldosterone receptor antagonists for hypertension: what do they offer?
Topics: Aldosterone; Clinical Trials as Topic; Diuretics; Eplerenone; Heart Failure; Humans; Hypertension; M | 2003 |
MANAGEMENT OF RENAL DYSFUNCTION IN CONGESTIVE HEART FAILURE.
Topics: Acetazolamide; Benzothiadiazines; Chlorthalidone; Diuretics; Heart Failure; Humans; Kidney Diseases; | 1963 |
MANAGEMENT OF RENAL DYSFUNCTION IN CONGESTIVE HEART FAILURE.
Topics: Acetazolamide; Benzothiadiazines; Chlorthalidone; Diuretics; Heart Failure; Humans; Kidney Diseases; | 1963 |
[SECONDARY HYPERALDOSTERONISM. PHYSIOPATHOLOGIC, CLINICAL AND THERAPEUTIC CONSIDERATIONS].
Topics: Adrenal Cortex Hormones; Angiotensins; Blood Transfusion; Capillary Permeability; Diet; Diet Therapy | 1963 |
[SECONDARY HYPERALDOSTERONISM. PHYSIOPATHOLOGIC, CLINICAL AND THERAPEUTIC CONSIDERATIONS].
Topics: Adrenal Cortex Hormones; Angiotensins; Blood Transfusion; Capillary Permeability; Diet; Diet Therapy | 1963 |
Aldosterone blockade in patients with systolic left ventricular dysfunction.
Topics: Aldosterone; Eplerenone; Forecasting; Heart Failure; Humans; Hypercholesterolemia; Hypertension; Mal | 2003 |
Aldosterone blockade in patients with systolic left ventricular dysfunction.
Topics: Aldosterone; Eplerenone; Forecasting; Heart Failure; Humans; Hypercholesterolemia; Hypertension; Mal | 2003 |
Update on therapy for heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Convertin | 2003 |
Update on therapy for heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Convertin | 2003 |
Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease.
Topics: Animals; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Miner | 2003 |
Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease.
Topics: Animals; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Miner | 2003 |
Diagnosis and management of heart failure in the long-term care setting.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; | 2003 |
Diagnosis and management of heart failure in the long-term care setting.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; | 2003 |
The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; | 2003 |
The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; | 2003 |
Drug therapy in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Car | 2003 |
Drug therapy in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Car | 2003 |
[Significance of aldosterone antagonist therapy].
Topics: Aldosterone; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Dr | 2004 |
[Significance of aldosterone antagonist therapy].
Topics: Aldosterone; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Dr | 2004 |
The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade.
Topics: Aldosterone; Autonomic Nervous System Diseases; Endomyocardial Fibrosis; Eplerenone; Heart Failure; | 2004 |
The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade.
Topics: Aldosterone; Autonomic Nervous System Diseases; Endomyocardial Fibrosis; Eplerenone; Heart Failure; | 2004 |
New therapies for heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Diuret | 2004 |
New therapies for heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Diuret | 2004 |
Aldosterone target organ protection by eplerenone.
Topics: Aldosterone; Blood Vessels; Brain; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hype | 2004 |
Aldosterone target organ protection by eplerenone.
Topics: Aldosterone; Blood Vessels; Brain; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hype | 2004 |
Eplerenone in the treatment of chronic heart failure.
Topics: Aldosterone; Chronic Disease; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineraloc | 2004 |
Eplerenone in the treatment of chronic heart failure.
Topics: Aldosterone; Chronic Disease; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineraloc | 2004 |
Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Humans; Mineralocorticoid Recep | 2004 |
Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Humans; Mineralocorticoid Recep | 2004 |
The role of aldosterone and aldosterone-receptor antagonists in heart failure.
Topics: Aldosterone; Eplerenone; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; My | 2004 |
The role of aldosterone and aldosterone-receptor antagonists in heart failure.
Topics: Aldosterone; Eplerenone; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; My | 2004 |
Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Enalapril; Eplerenone; Heart Fa | 2004 |
Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Enalapril; Eplerenone; Heart Fa | 2004 |
Inspra improves survival for CHF patients.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Eplerenone; Heart F | 2004 |
Inspra improves survival for CHF patients.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Eplerenone; Heart F | 2004 |
Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction.
Topics: Adolescent; Adult; Aged; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Recepto | 2004 |
Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction.
Topics: Adolescent; Adult; Aged; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Recepto | 2004 |
The clinical implications of aldosterone escape in congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Death, Sudden, Cardiac; Endothelium, Vascular | 2004 |
The clinical implications of aldosterone escape in congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Death, Sudden, Cardiac; Endothelium, Vascular | 2004 |
The use of selective aldosterone antagonists.
Topics: Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Eplerenone; Female; Heart Fail | 2004 |
The use of selective aldosterone antagonists.
Topics: Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Eplerenone; Female; Heart Fail | 2004 |
Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.
Topics: Animals; Area Under Curve; Economics, Pharmaceutical; Eplerenone; Half-Life; Heart Failure; Humans; | 2004 |
Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.
Topics: Animals; Area Under Curve; Economics, Pharmaceutical; Eplerenone; Half-Life; Heart Failure; Humans; | 2004 |
Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Co | 2004 |
Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Co | 2004 |
Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
Topics: Animals; Cardiovascular Agents; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antago | 2005 |
Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
Topics: Animals; Cardiovascular Agents; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antago | 2005 |
Heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspir | 2004 |
Heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspir | 2004 |
A new selective aldosterone antagonist. Inspra's role in hypertension and post-MI heart failure.
Topics: Arrhythmias, Cardiac; Drug Interactions; Eplerenone; Evidence-Based Medicine; Heart Failure; Humans; | 2005 |
A new selective aldosterone antagonist. Inspra's role in hypertension and post-MI heart failure.
Topics: Arrhythmias, Cardiac; Drug Interactions; Eplerenone; Evidence-Based Medicine; Heart Failure; Humans; | 2005 |
How much responsibility should heart failure nurses take?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzothiadiazines; Comorbidit | 2005 |
How much responsibility should heart failure nurses take?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzothiadiazines; Comorbidit | 2005 |
Management of heart failure in The Netherlands.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiology; Digoxin; Diuretic | 2005 |
Management of heart failure in The Netherlands.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiology; Digoxin; Diuretic | 2005 |
[Aldosterone antagonist therapy for chronic heart failure].
Topics: Aldosterone; Chronic Disease; Death, Sudden, Cardiac; Diuretics; Eplerenone; Fibrosis; Heart Failure | 2005 |
[Aldosterone antagonist therapy for chronic heart failure].
Topics: Aldosterone; Chronic Disease; Death, Sudden, Cardiac; Diuretics; Eplerenone; Fibrosis; Heart Failure | 2005 |
Heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspir | 2004 |
Heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspir | 2004 |
Cardiovascular effects of aldosterone.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Heart Failure; Humans; Hypertension; Mineralocorticoi | 2005 |
Cardiovascular effects of aldosterone.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Heart Failure; Humans; Hypertension; Mineralocorticoi | 2005 |
[The role of aldosterone-antagonists in the treatment of congestive heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Hu | 2005 |
[The role of aldosterone-antagonists in the treatment of congestive heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Hu | 2005 |
Autonomic effects of spironolactone and MR blockers in heart failure.
Topics: Aldosterone; Autonomic Nervous System; Diuretics; Heart Failure; Heart Rate; Humans; Mineralocortico | 2005 |
Autonomic effects of spironolactone and MR blockers in heart failure.
Topics: Aldosterone; Autonomic Nervous System; Diuretics; Heart Failure; Heart Rate; Humans; Mineralocortico | 2005 |
The role of aldosterone blockade in patients with heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diuretics; Eplerenone; Heart Failure; Humans; Mineralocort | 2005 |
The role of aldosterone blockade in patients with heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diuretics; Eplerenone; Heart Failure; Humans; Mineralocort | 2005 |
New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
Topics: Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Heart Failure; Humans; H | 2005 |
New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
Topics: Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Heart Failure; Humans; H | 2005 |
The risks and benefits of aldosterone antagonists.
Topics: Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Spironolact | 2005 |
The risks and benefits of aldosterone antagonists.
Topics: Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Spironolact | 2005 |
Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Hypertension; Ligands; Mineralocorticoid Receptor A | 2005 |
Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Hypertension; Ligands; Mineralocorticoid Receptor A | 2005 |
New aldosteron receptor inhibitors in heart failure.
Topics: Decision Trees; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironola | 2005 |
New aldosteron receptor inhibitors in heart failure.
Topics: Decision Trees; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironola | 2005 |
A landmark for popperian epidemiology: refutation of the randomised Aldactone evaluation study.
Topics: Epidemiologic Methods; Heart Failure; Logic; Mineralocorticoid Receptor Antagonists; Philosophy, Med | 2005 |
A landmark for popperian epidemiology: refutation of the randomised Aldactone evaluation study.
Topics: Epidemiologic Methods; Heart Failure; Logic; Mineralocorticoid Receptor Antagonists; Philosophy, Med | 2005 |
Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
Topics: Aged; Cost-Benefit Analysis; Economics, Pharmaceutical; Eplerenone; Female; Heart Failure; Heart Rup | 2005 |
Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
Topics: Aged; Cost-Benefit Analysis; Economics, Pharmaceutical; Eplerenone; Female; Heart Failure; Heart Rup | 2005 |
Chronic heart failure: an overview of conventional treatment versus novel approaches.
Topics: Angiotensin II Type 1 Receptor Blockers; Apoptosis; Cardiac Glycosides; Erythropoietin; Heart Failur | 2005 |
Chronic heart failure: an overview of conventional treatment versus novel approaches.
Topics: Angiotensin II Type 1 Receptor Blockers; Apoptosis; Cardiac Glycosides; Erythropoietin; Heart Failur | 2005 |
Aldosterone receptor antagonists for heart failure: current status, future indications.
Topics: Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Forecasting; Heart Failure; Humans; Mineraloco | 2006 |
Aldosterone receptor antagonists for heart failure: current status, future indications.
Topics: Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Forecasting; Heart Failure; Humans; Mineraloco | 2006 |
[Aldosterone antagonist].
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2006 |
[Aldosterone antagonist].
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2006 |
[Aldosterone receptor blockade after acute myocardial infarction with heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Diu | 2006 |
[Aldosterone receptor blockade after acute myocardial infarction with heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Diu | 2006 |
Metabolic and immunologic derangements in cardiac cachexia: where to from here?
Topics: Angiotensin-Converting Enzyme Inhibitors; Cachexia; Dietary Supplements; Disease Progression; Exerci | 2006 |
Metabolic and immunologic derangements in cardiac cachexia: where to from here?
Topics: Angiotensin-Converting Enzyme Inhibitors; Cachexia; Dietary Supplements; Disease Progression; Exerci | 2006 |
[Cardioprotective effect of aldosterone antagonists for ventricular remodeling].
Topics: Aldosterone; Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid | 2006 |
[Cardioprotective effect of aldosterone antagonists for ventricular remodeling].
Topics: Aldosterone; Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid | 2006 |
Does eplerenone have a future in the management of hypertension in Europe?
Topics: Clinical Trials as Topic; Drug Costs; Eplerenone; Europe; Heart Failure; Humans; Hypertension; Miner | 2006 |
Does eplerenone have a future in the management of hypertension in Europe?
Topics: Clinical Trials as Topic; Drug Costs; Eplerenone; Europe; Heart Failure; Humans; Hypertension; Miner | 2006 |
[The revived interest in aldosterone antagonists].
Topics: Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Eplerenone; Heart Failure; Human | 2006 |
[The revived interest in aldosterone antagonists].
Topics: Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Eplerenone; Heart Failure; Human | 2006 |
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
Topics: Aldosterone; Algorithms; Disease Progression; Disease Susceptibility; Drug Labeling; Eplerenone; Fib | 2006 |
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
Topics: Aldosterone; Algorithms; Disease Progression; Disease Susceptibility; Drug Labeling; Eplerenone; Fib | 2006 |
Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2006 |
Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2006 |
Standard therapies for pulmonary arterial hypertension.
Topics: Anticoagulants; Calcium Channel Blockers; Comorbidity; Diuretics; Heart Failure; Humans; Hypertensio | 2007 |
Standard therapies for pulmonary arterial hypertension.
Topics: Anticoagulants; Calcium Channel Blockers; Comorbidity; Diuretics; Heart Failure; Humans; Hypertensio | 2007 |
[Spironolactone as a cardio-protective drug].
Topics: Diuresis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trial | 2007 |
[Spironolactone as a cardio-protective drug].
Topics: Diuresis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trial | 2007 |
[Eplerenone for treatment of heart failure].
Topics: Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hydrocortisone; Hypertension; Mineraloc | 2007 |
[Eplerenone for treatment of heart failure].
Topics: Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hydrocortisone; Hypertension; Mineraloc | 2007 |
[Aldosterone antagonists: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Aldosterone; Chronic Disease; Contraindications; Eplerenone; Heart Failure; Humans; Mineralocorticoi | 2007 |
[Aldosterone antagonists: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Aldosterone; Chronic Disease; Contraindications; Eplerenone; Heart Failure; Humans; Mineralocorticoi | 2007 |
Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
Topics: Aldosterone; Contraindications; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hypert | 2007 |
Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
Topics: Aldosterone; Contraindications; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hypert | 2007 |
Primary aldosteronism.
Topics: Adenoma; Heart Failure; Humans; Hyperaldosteronism; Mass Screening; Mineralocorticoid Receptor Antag | 2007 |
Primary aldosteronism.
Topics: Adenoma; Heart Failure; Humans; Hyperaldosteronism; Mass Screening; Mineralocorticoid Receptor Antag | 2007 |
Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
Topics: Animals; Antihypertensive Agents; Cardiovascular Agents; Drug and Narcotic Control; Eplerenone; Hear | 2007 |
Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
Topics: Animals; Antihypertensive Agents; Cardiovascular Agents; Drug and Narcotic Control; Eplerenone; Hear | 2007 |
Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist.
Topics: Animals; Cardiovascular Diseases; Disease Models, Animal; Eplerenone; Heart Failure; Humans; Hyperte | 2008 |
Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist.
Topics: Animals; Cardiovascular Diseases; Disease Models, Animal; Eplerenone; Heart Failure; Humans; Hyperte | 2008 |
Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist.
Topics: Eplerenone; Evidence-Based Medicine; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor | 2007 |
Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist.
Topics: Eplerenone; Evidence-Based Medicine; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor | 2007 |
[Antialdosteronic agents: their role in heart failure].
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2008 |
[Antialdosteronic agents: their role in heart failure].
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2008 |
A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
Topics: Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolact | 2008 |
A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
Topics: Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolact | 2008 |
[Diuretic therapy in cardiac insufficiency].
Topics: Benzothiadiazines; Diuretics; Drug Interactions; Heart Failure; Hemodynamics; Humans; Kidney; Sodium | 1984 |
[Diuretic therapy in cardiac insufficiency].
Topics: Benzothiadiazines; Diuretics; Drug Interactions; Heart Failure; Hemodynamics; Humans; Kidney; Sodium | 1984 |
Diuretics in infancy.
Topics: Acute Disease; Benzothiadiazines; Diet, Sodium-Restricted; Diuretics; Diuretics, Osmotic; Edema; Eth | 1981 |
Diuretics in infancy.
Topics: Acute Disease; Benzothiadiazines; Diet, Sodium-Restricted; Diuretics; Diuretics, Osmotic; Edema; Eth | 1981 |
[Classic treatment of chronic heart insufficiency. What if new?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Digitalis Glycosides; Diuretics; Drug The | 1995 |
[Classic treatment of chronic heart insufficiency. What if new?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Digitalis Glycosides; Diuretics; Drug The | 1995 |
"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Drug Evaluation; Heart Failure; Humans; Hyper | 1995 |
"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Drug Evaluation; Heart Failure; Humans; Hyper | 1995 |
[Current management of heart failure].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Digitalis Glycosides; Female; Heart Failure; Humans | 1994 |
[Current management of heart failure].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Digitalis Glycosides; Female; Heart Failure; Humans | 1994 |
Aldosterone and antialdosterone therapy in congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Diuretics; Heart Failure; Humans; Mi | 1993 |
Aldosterone and antialdosterone therapy in congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Diuretics; Heart Failure; Humans; Mi | 1993 |
Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Heart; | 1993 |
Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Heart; | 1993 |
Role of aldosterone in congestive heart failure.
Topics: Aldosterone; Atrial Natriuretic Factor; Heart Failure; Humans; Renin-Angiotensin System; Spironolact | 1993 |
Role of aldosterone in congestive heart failure.
Topics: Aldosterone; Atrial Natriuretic Factor; Heart Failure; Humans; Renin-Angiotensin System; Spironolact | 1993 |
Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Chronic Disease; Drug T | 1995 |
Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Chronic Disease; Drug T | 1995 |
[Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Topics: Animals; Diuretics; Endomyocardial Fibrosis; Heart Failure; Humans; Microcirculation; Mineralocortic | 1997 |
[Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Topics: Animals; Diuretics; Endomyocardial Fibrosis; Heart Failure; Humans; Microcirculation; Mineralocortic | 1997 |
[Effect of combined captopril-spironolactone therapy of cardiac insufficiency on kidney function and serum electrolyte values].
Topics: Captopril; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heart Failure; Humans; Kidne | 1998 |
[Effect of combined captopril-spironolactone therapy of cardiac insufficiency on kidney function and serum electrolyte values].
Topics: Captopril; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heart Failure; Humans; Kidne | 1998 |
Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Heart Failure; Humans; Miner | 1999 |
Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Heart Failure; Humans; Miner | 1999 |
Spironolactone.
Topics: Diuretics; Heart Failure; Humans; Infant, Newborn; Infant, Premature; Intensive Care, Neonatal; Kidn | 1999 |
Spironolactone.
Topics: Diuretics; Heart Failure; Humans; Infant, Newborn; Infant, Premature; Intensive Care, Neonatal; Kidn | 1999 |
[Anti-aldosterone therapy in severe heart failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Diuretics | 1999 |
[Anti-aldosterone therapy in severe heart failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Diuretics | 1999 |
[Value of diuretics and aldosterone antagonists in the treatment of heart failure].
Topics: Benzothiadiazines; Diuretics; Drug Interactions; Drug Resistance; Heart Failure; Humans; Hyponatremi | 1999 |
[Value of diuretics and aldosterone antagonists in the treatment of heart failure].
Topics: Benzothiadiazines; Diuretics; Drug Interactions; Drug Resistance; Heart Failure; Humans; Hyponatremi | 1999 |
Update on the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Exercise; Heart Failure; Humans; Mine | 1999 |
Update on the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Exercise; Heart Failure; Humans; Mine | 1999 |
[Medical treatment of heart failure: old facts in new lights].
Topics: Adrenergic beta-Antagonists; Diuretics; Heart Failure; Humans; Spironolactone | 2000 |
[Medical treatment of heart failure: old facts in new lights].
Topics: Adrenergic beta-Antagonists; Diuretics; Heart Failure; Humans; Spironolactone | 2000 |
Heart failure drugs: what's new?
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Convertin | 2000 |
Heart failure drugs: what's new?
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Convertin | 2000 |
[Diuretic therapy in congestive heart failure--new views on spironolactone therapy].
Topics: Antidiuretic Hormone Receptor Antagonists; Diuretics; Drug Therapy, Combination; Heart Failure; Huma | 2000 |
[Diuretic therapy in congestive heart failure--new views on spironolactone therapy].
Topics: Antidiuretic Hormone Receptor Antagonists; Diuretics; Drug Therapy, Combination; Heart Failure; Huma | 2000 |
Aldosterone and myocardial fibrosis in heart failure.
Topics: Adult; Aldosterone; Animals; Cardiomyopathies; Dose-Response Relationship, Drug; Fibrosis; Heart Fai | 2000 |
Aldosterone and myocardial fibrosis in heart failure.
Topics: Adult; Aldosterone; Animals; Cardiomyopathies; Dose-Response Relationship, Drug; Fibrosis; Heart Fai | 2000 |
Beta-blockers and spironolactone in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Mineralocort | 2000 |
Beta-blockers and spironolactone in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Mineralocort | 2000 |
The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
Topics: Aldosterone; Animals; Antihypertensive Agents; Eplerenone; Heart Failure; Humans; Hypertension; Mine | 2000 |
The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
Topics: Aldosterone; Animals; Antihypertensive Agents; Eplerenone; Heart Failure; Humans; Hypertension; Mine | 2000 |
Spironolactone in congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Heart Failure; Humans; Mineralocorti | 2000 |
Spironolactone in congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Heart Failure; Humans; Mineralocorti | 2000 |
Aldosterone, a new appreciation of its role in heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Mineralocorticoid Rece | 2000 |
Aldosterone, a new appreciation of its role in heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Mineralocorticoid Rece | 2000 |
Spironolactone in the treatment of congestive heart failure.
Topics: Clinical Trials as Topic; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonist | 2000 |
Spironolactone in the treatment of congestive heart failure.
Topics: Clinical Trials as Topic; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonist | 2000 |
[Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Therapy, Combi | 2001 |
[Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Therapy, Combi | 2001 |
K(+) depletion and the progression of hypertensive disease or heart failure. The pathogenic role of diuretic-induced aldosterone secretion.
Topics: Aldosterone; Animals; Antihypertensive Agents; Benzothiadiazines; Clinical Trials as Topic; Disease | 2001 |
K(+) depletion and the progression of hypertensive disease or heart failure. The pathogenic role of diuretic-induced aldosterone secretion.
Topics: Aldosterone; Animals; Antihypertensive Agents; Benzothiadiazines; Clinical Trials as Topic; Disease | 2001 |
Pharmacotherapy of systolic heart failure: emphasis on mortality outcomes.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2001 |
Pharmacotherapy of systolic heart failure: emphasis on mortality outcomes.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2001 |
The spironolactone renaissance.
Topics: Aldosterone; Androgen Antagonists; Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Colla | 2001 |
The spironolactone renaissance.
Topics: Aldosterone; Androgen Antagonists; Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Colla | 2001 |
Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2001 |
Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2001 |
[Evidence based medical treatment of heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 2001 |
[Evidence based medical treatment of heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 2001 |
Manipulation of the renin-angiotensin system.
Topics: Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Hypertension; Mineralocorticoid Rec | 2001 |
Manipulation of the renin-angiotensin system.
Topics: Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Hypertension; Mineralocorticoid Rec | 2001 |
Eplerenone (GD Searle & Co).
Topics: Animals; Antihypertensive Agents; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hyper | 2001 |
Eplerenone (GD Searle & Co).
Topics: Animals; Antihypertensive Agents; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hyper | 2001 |
Eplerenone: a selective aldosterone receptor antagonist (SARA).
Topics: Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoi | 2001 |
Eplerenone: a selective aldosterone receptor antagonist (SARA).
Topics: Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoi | 2001 |
Spironolactone in left-sided heart failure: how does it fit in?
Topics: Contraindications; Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spirono | 2001 |
Spironolactone in left-sided heart failure: how does it fit in?
Topics: Contraindications; Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spirono | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
Topics: Aldosterone; Animals; Cardiovascular System; Clinical Trials as Topic; Endothelium, Vascular; Eplere | 2001 |
Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
Topics: Aldosterone; Animals; Cardiovascular System; Clinical Trials as Topic; Endothelium, Vascular; Eplere | 2001 |
What is the optimal medical management of ischaemic heart failure?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Car | 2001 |
What is the optimal medical management of ischaemic heart failure?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Car | 2001 |
[Arrhythmia risk stratification in patients with heart failure according to drug treatment and its effects].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; A | 2001 |
[Arrhythmia risk stratification in patients with heart failure according to drug treatment and its effects].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; A | 2001 |
Impaired endothelium-mediated vasodilation in heart failure: clinical evidence and the potential for therapy.
Topics: Endothelium, Vascular; Heart Failure; Humans; Nitric Oxide; Spironolactone; Vasodilation | 2002 |
Impaired endothelium-mediated vasodilation in heart failure: clinical evidence and the potential for therapy.
Topics: Endothelium, Vascular; Heart Failure; Humans; Nitric Oxide; Spironolactone; Vasodilation | 2002 |
[The process of drug development. The "case" of spironolactone].
Topics: Animals; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin | 2002 |
[The process of drug development. The "case" of spironolactone].
Topics: Animals; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin | 2002 |
Rationale for the use of aldosterone antagonists in congestive heart failure.
Topics: Aldosterone; Animals; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Cont | 2002 |
Rationale for the use of aldosterone antagonists in congestive heart failure.
Topics: Aldosterone; Animals; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Cont | 2002 |
Diuretics in the treatment of patients who present congestive heart failure and hypertension.
Topics: Diuretics; Heart Failure; Humans; Hypertension; Spironolactone | 2002 |
Diuretics in the treatment of patients who present congestive heart failure and hypertension.
Topics: Diuretics; Heart Failure; Humans; Hypertension; Spironolactone | 2002 |
Diuretics. Clinical pharmacology and therapeutic use (Part II).
Topics: Amiloride; Canrenoic Acid; Diuretics; Diuretics, Osmotic; Drug Interactions; Hearing Disorders; Hear | 1985 |
Diuretics. Clinical pharmacology and therapeutic use (Part II).
Topics: Amiloride; Canrenoic Acid; Diuretics; Diuretics, Osmotic; Drug Interactions; Hearing Disorders; Hear | 1985 |
Correlation of pathophysiology and pharmacotherapy in primary hypertension.
Topics: Blood Pressure; Cardiac Output; Cardiac Volume; Diuretics; Furosemide; Guanethidine; Heart Failure; | 1973 |
Correlation of pathophysiology and pharmacotherapy in primary hypertension.
Topics: Blood Pressure; Cardiac Output; Cardiac Volume; Diuretics; Furosemide; Guanethidine; Heart Failure; | 1973 |
[The problem of potassium and diuretics].
Topics: Administration, Oral; Amiloride; Benzothiadiazines; Clopamide; Digitalis Glycosides; Diuretics; Drug | 1972 |
[The problem of potassium and diuretics].
Topics: Administration, Oral; Amiloride; Benzothiadiazines; Clopamide; Digitalis Glycosides; Diuretics; Drug | 1972 |
[Role of aldosterone in the pathogenesis of cardiac insufficiency (review of the literature)].
Topics: Aldosterone; Animals; Cats; Chlorine; Depression, Chemical; Dogs; Edema; Heart Failure; Humans; Hype | 1967 |
[Role of aldosterone in the pathogenesis of cardiac insufficiency (review of the literature)].
Topics: Aldosterone; Animals; Cats; Chlorine; Depression, Chemical; Dogs; Edema; Heart Failure; Humans; Hype | 1967 |
[Steroid spirolactones--antagonists of mineralocorticoids].
Topics: Adrenalectomy; Animals; Ascites; Chemistry Techniques, Analytical; Desoxycorticosterone; Dogs; Feces | 1969 |
[Steroid spirolactones--antagonists of mineralocorticoids].
Topics: Adrenalectomy; Animals; Ascites; Chemistry Techniques, Analytical; Desoxycorticosterone; Dogs; Feces | 1969 |
[Depletion therapy of chronic congestive heart failure].
Topics: Bloodletting; Carbonic Anhydrase Inhibitors; Chlorides; Diet, Sodium-Restricted; Digitalis Glycoside | 1968 |
[Depletion therapy of chronic congestive heart failure].
Topics: Bloodletting; Carbonic Anhydrase Inhibitors; Chlorides; Diet, Sodium-Restricted; Digitalis Glycoside | 1968 |
Combinations of diuretics in the treatment of edema.
Topics: Acetazolamide; Benzothiadiazines; Chlorthalidone; Diuretics; Edema; Ethacrynic Acid; Furosemide; Glu | 1970 |
Combinations of diuretics in the treatment of edema.
Topics: Acetazolamide; Benzothiadiazines; Chlorthalidone; Diuretics; Edema; Ethacrynic Acid; Furosemide; Glu | 1970 |
Diuretics. II. Clinical considerations.
Topics: Administration, Oral; Aminophylline; Ascites; Calcium; Carbohydrate Metabolism; Carbonic Anhydrase I | 1971 |
Diuretics. II. Clinical considerations.
Topics: Administration, Oral; Aminophylline; Ascites; Calcium; Carbohydrate Metabolism; Carbonic Anhydrase I | 1971 |
Combination diuretic drug therapy.
Topics: Amiloride; Benzothiadiazines; Diet; Diuretics; Drug Therapy, Combination; Ethacrynic Acid; Furosemid | 1971 |
Combination diuretic drug therapy.
Topics: Amiloride; Benzothiadiazines; Diet; Diuretics; Drug Therapy, Combination; Ethacrynic Acid; Furosemid | 1971 |
219 trials available for spironolactone and Heart Failure
| Article | Year |
|---|---|
Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT.
Topics: Amyloidosis; Echocardiography; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Phenot | 2021 |
Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT.
Topics: Amyloidosis; Echocardiography; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Phenot | 2021 |
Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial.
Topics: Biomarkers; Heart Failure; Hospitalization; Humans; Placebos; Spironolactone; Stroke Volume | 2021 |
Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial.
Topics: Biomarkers; Heart Failure; Hospitalization; Humans; Placebos; Spironolactone; Stroke Volume | 2021 |
Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT.
Topics: Female; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Spironolacto | 2022 |
Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT.
Topics: Female; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Spironolacto | 2022 |
The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial.
Topics: Biomarkers; Female; Glucose Intolerance; Heart Failure; Humans; Male; Mineralocorticoid Receptor Ant | 2022 |
The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial.
Topics: Biomarkers; Female; Glucose Intolerance; Heart Failure; Humans; Male; Mineralocorticoid Receptor Ant | 2022 |
Screening-guided spironolactone treatment of subclinical left ventricular dysfunction for heart failure prevention in at-risk patients.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Spironolactone; Stroke Volume; | 2022 |
Screening-guided spironolactone treatment of subclinical left ventricular dysfunction for heart failure prevention in at-risk patients.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Spironolactone; Stroke Volume; | 2022 |
Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial.
Topics: Heart Failure; Humans; Magnesium; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Pro | 2022 |
Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial.
Topics: Heart Failure; Humans; Magnesium; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Pro | 2022 |
Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial.
Topics: Biomarkers; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brai | 2022 |
Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial.
Topics: Biomarkers; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brai | 2022 |
Time in Target Range for Systolic Blood Pressure and Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
Topics: Adolescent; Blood Pressure; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Prognosis | 2022 |
Time in Target Range for Systolic Blood Pressure and Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
Topics: Adolescent; Blood Pressure; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Prognosis | 2022 |
Prognostic Impact of Cardiovascular Versus Noncardiovascular Hospitalizations in Heart Failure With Preserved Ejection Fraction: Insights From TOPCAT.
Topics: Aftercare; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Natriuret | 2022 |
Prognostic Impact of Cardiovascular Versus Noncardiovascular Hospitalizations in Heart Failure With Preserved Ejection Fraction: Insights From TOPCAT.
Topics: Aftercare; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Natriuret | 2022 |
Time-averaged cumulative blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: analysis from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Topics: Antihypertensive Agents; Blood Pressure; Heart Failure; Hospitalization; Humans; Mineralocorticoid R | 2022 |
Time-averaged cumulative blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: analysis from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Topics: Antihypertensive Agents; Blood Pressure; Heart Failure; Hospitalization; Humans; Mineralocorticoid R | 2022 |
Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction.
Topics: Apelin; Biological Products; Caspases; Heart Failure; Humans; Insulins; Liver X Receptors; Mineraloc | 2022 |
Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction.
Topics: Apelin; Biological Products; Caspases; Heart Failure; Humans; Insulins; Liver X Receptors; Mineraloc | 2022 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
Topics: Aged; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Recept | 2023 |
Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial).
Topics: Heart Failure; Humans; Spironolactone; Stroke Volume; Ventricular Function, Left | 2023 |
Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial).
Topics: Heart Failure; Humans; Spironolactone; Stroke Volume; Ventricular Function, Left | 2023 |
The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
Topics: Chronic Disease; Eplerenone; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Anta | 2023 |
The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
Topics: Chronic Disease; Eplerenone; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Anta | 2023 |
Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trial.
Topics: Aged; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mineralocortico | 2023 |
Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trial.
Topics: Aged; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mineralocortico | 2023 |
Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction.
Topics: Aged; Diuretics; Echocardiography; Exercise Tolerance; Female; Heart Failure; Humans; Male; Myocardi | 2019 |
Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction.
Topics: Aged; Diuretics; Echocardiography; Exercise Tolerance; Female; Heart Failure; Humans; Male; Myocardi | 2019 |
Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial.
Topics: Heart Failure; Humans; Lung Diseases; Mineralocorticoid Receptor Antagonists; Prognosis; Spironolact | 2020 |
Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial.
Topics: Heart Failure; Humans; Lung Diseases; Mineralocorticoid Receptor Antagonists; Prognosis; Spironolact | 2020 |
Variation in Placebo Effect on Health-Related Quality of Life in Heart Failure (from the TOPCAT Trial).
Topics: Aged; Double-Blind Method; Female; Follow-Up Studies; Health Status; Heart Failure; Humans; Male; Mi | 2020 |
Variation in Placebo Effect on Health-Related Quality of Life in Heart Failure (from the TOPCAT Trial).
Topics: Aged; Double-Blind Method; Female; Follow-Up Studies; Health Status; Heart Failure; Humans; Male; Mi | 2020 |
MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT.
Topics: Age Factors; Aged; Aged, 80 and over; Eplerenone; Female; Heart Failure; Humans; Male; Meta-Analysis | 2019 |
MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT.
Topics: Age Factors; Aged; Aged, 80 and over; Eplerenone; Female; Heart Failure; Humans; Male; Meta-Analysis | 2019 |
Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
Topics: Age Factors; Aged; Aged, 80 and over; Double-Blind Method; Female; Heart Failure; Humans; Male; Midd | 2019 |
Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
Topics: Age Factors; Aged; Aged, 80 and over; Double-Blind Method; Female; Heart Failure; Humans; Male; Midd | 2019 |
Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; | 2019 |
Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; | 2019 |
Effect of Serum Albumin Levels in Patients With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
Topics: Aged; Biomarkers; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocor | 2020 |
Effect of Serum Albumin Levels in Patients With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
Topics: Aged; Biomarkers; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocor | 2020 |
Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.
Topics: Aged; Blood Pressure; Eplerenone; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor An | 2020 |
Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.
Topics: Aged; Blood Pressure; Eplerenone; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor An | 2020 |
Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.
Topics: Aged; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor | 2020 |
Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.
Topics: Aged; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor | 2020 |
Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HO
Topics: Aged; Aging; Biomarkers; Diabetes Mellitus, Type 2; Female; Fibrosis; Heart Failure; Humans; Male; N | 2020 |
Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HO
Topics: Aged; Aging; Biomarkers; Diabetes Mellitus, Type 2; Female; Fibrosis; Heart Failure; Humans; Male; N | 2020 |
Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Biomarkers; Cardiovascular System; Female; Heart F | 2020 |
Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Biomarkers; Cardiovascular System; Female; Heart F | 2020 |
Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Heart Fail | 2020 |
Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Heart Fail | 2020 |
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diuretics; Double | 2020 |
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diuretics; Double | 2020 |
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure.
Topics: Aged; Amber; Female; Heart Failure; Humans; Hyperkalemia; Hypertension; Male; Mineralocorticoid Rece | 2020 |
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure.
Topics: Aged; Amber; Female; Heart Failure; Humans; Hyperkalemia; Hypertension; Male; Mineralocorticoid Rece | 2020 |
Efficacy and Safety of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Eplerenone; Female; Heart Failure; Humans; Male; Spironolactone; Stroke Volume; Ventricular Fu | 2022 |
Efficacy and Safety of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Eplerenone; Female; Heart Failure; Humans; Male; Spironolactone; Stroke Volume; Ventricular Fu | 2022 |
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
Topics: Aged; Aging; Biomarkers; Female; Fibrosis; Heart Failure; Humans; Male; Peptide Fragments; Procollag | 2021 |
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
Topics: Aged; Aging; Biomarkers; Female; Fibrosis; Heart Failure; Humans; Male; Peptide Fragments; Procollag | 2021 |
Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension.
Topics: Aged; Antihypertensive Agents; Cohort Studies; Female; Heart Failure; Hospitalization; Humans; Hyper | 2020 |
Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension.
Topics: Aged; Antihypertensive Agents; Cohort Studies; Female; Heart Failure; Hospitalization; Humans; Hyper | 2020 |
Influence of polypharmacy on patients with heart failure with preserved ejection fraction: a retrospective analysis on adverse outcomes in the TOPCAT trial.
Topics: Aged; Brazil; Canada; Heart Failure; Humans; Polypharmacy; Prognosis; Retrospective Studies; Spirono | 2021 |
Influence of polypharmacy on patients with heart failure with preserved ejection fraction: a retrospective analysis on adverse outcomes in the TOPCAT trial.
Topics: Aged; Brazil; Canada; Heart Failure; Humans; Polypharmacy; Prognosis; Retrospective Studies; Spirono | 2021 |
Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
Topics: Aged; Cardiovascular Diseases; Case-Control Studies; Creatinine; Diabetes Mellitus; Disease Progress | 2021 |
Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
Topics: Aged; Cardiovascular Diseases; Case-Control Studies; Creatinine; Diabetes Mellitus; Disease Progress | 2021 |
Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Comorbidity; Diuretics; Double-Blind Method; Female; Heart Failure; Humans; Male; Obesity; Pre | 2021 |
Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Comorbidity; Diuretics; Double-Blind Method; Female; Heart Failure; Humans; Male; Obesity; Pre | 2021 |
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF.
Topics: Aged; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Natriuretic Pepti | 2021 |
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF.
Topics: Aged; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Natriuretic Pepti | 2021 |
Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; | 2021 |
Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; | 2021 |
The Effects of Spironolactone and Eplerenone on Left Ventricular Function Using Echocardiography in Symptomatic Patients With New-Onset Systolic Heart Failure: A Comparative Randomised Controlled Trial.
Topics: Echocardiography; Eplerenone; Heart Failure; Heart Failure, Systolic; Humans; Mineralocorticoid Rece | 2021 |
The Effects of Spironolactone and Eplerenone on Left Ventricular Function Using Echocardiography in Symptomatic Patients With New-Onset Systolic Heart Failure: A Comparative Randomised Controlled Trial.
Topics: Echocardiography; Eplerenone; Heart Failure; Heart Failure, Systolic; Humans; Mineralocorticoid Rece | 2021 |
Risk Stratification and Efficacy of Spironolactone in Patients with Heart Failure with Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.
Topics: Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Risk Assessment; Spi | 2022 |
Risk Stratification and Efficacy of Spironolactone in Patients with Heart Failure with Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.
Topics: Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Risk Assessment; Spi | 2022 |
Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.
Topics: Aged; Blood Pressure; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; P | 2022 |
Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.
Topics: Aged; Blood Pressure; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; P | 2022 |
Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST).
Topics: Animals; Benzazepines; Dog Diseases; Dogs; Heart Failure; Mitral Valve; Spironolactone; Treatment Ou | 2021 |
Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST).
Topics: Animals; Benzazepines; Dog Diseases; Dogs; Heart Failure; Mitral Valve; Spironolactone; Treatment Ou | 2021 |
Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy.
Topics: Animals; Atrial Fibrillation; Cardiomyopathy, Dilated; Death; Dog Diseases; Dogs; Euthanasia, Animal | 2022 |
Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy.
Topics: Animals; Atrial Fibrillation; Cardiomyopathy, Dilated; Death; Dog Diseases; Dogs; Euthanasia, Animal | 2022 |
Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial.
Topics: Aged; Biomarkers; Blood Proteins; Diabetes Mellitus; Diabetic Cardiomyopathies; Female; Heart Failur | 2021 |
Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial.
Topics: Aged; Biomarkers; Blood Proteins; Diabetes Mellitus; Diabetic Cardiomyopathies; Female; Heart Failur | 2021 |
Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction.
Topics: Aged; Atrial Fibrillation; Comorbidity; Double-Blind Method; Echocardiography, Doppler; Female; Hear | 2017 |
Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction.
Topics: Aged; Atrial Fibrillation; Comorbidity; Double-Blind Method; Echocardiography, Doppler; Female; Hear | 2017 |
Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiograph | 2017 |
Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiograph | 2017 |
Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction.
Topics: Aged; Cause of Death; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Miner | 2017 |
Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction.
Topics: Aged; Cause of Death; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Miner | 2017 |
Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction.
Topics: Aged; Cause of Death; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Heart Fai | 2017 |
Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction.
Topics: Aged; Cause of Death; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Heart Fai | 2017 |
Clinical and prognostic value of spot urinary creatinine in chronic heart failure-An analysis from GISSI-HF.
Topics: Aged; Biomarkers; Cause of Death; Creatinine; Double-Blind Method; Female; Follow-Up Studies; Glomer | 2017 |
Clinical and prognostic value of spot urinary creatinine in chronic heart failure-An analysis from GISSI-HF.
Topics: Aged; Biomarkers; Cause of Death; Creatinine; Double-Blind Method; Female; Follow-Up Studies; Glomer | 2017 |
Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.
Topics: Acute Disease; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; H | 2017 |
Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.
Topics: Acute Disease; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; H | 2017 |
Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study.
Topics: Aged; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Mineralocorti | 2017 |
Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study.
Topics: Aged; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Mineralocorti | 2017 |
Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial.
Topics: Aged; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studi | 2018 |
Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial.
Topics: Aged; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studi | 2018 |
Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Antihypertensive Agents; Argentina; Blood Pressure; Brazil; Canada; Drug Resistance; Female; H | 2018 |
Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Antihypertensive Agents; Argentina; Blood Pressure; Brazil; Canada; Drug Resistance; Female; H | 2018 |
The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathies; Cat Diseases; Cats; Diuretics; | 2018 |
The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathies; Cat Diseases; Cats; Diuretics; | 2018 |
Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Female; Heart | 2018 |
Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Female; Heart | 2018 |
The Effect of Mineralocorticoid Receptor Antagonists on Recruitment and Function of Endothelial Progenitor Cells in Patients with Congestive Heart Failure.
Topics: AC133 Antigen; Aged; Antigens, CD34; Cell Survival; Cohort Studies; Endothelial Progenitor Cells; Ep | 2018 |
The Effect of Mineralocorticoid Receptor Antagonists on Recruitment and Function of Endothelial Progenitor Cells in Patients with Congestive Heart Failure.
Topics: AC133 Antigen; Aged; Antigens, CD34; Cell Survival; Cohort Studies; Endothelial Progenitor Cells; Ep | 2018 |
Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Topics: Aged; Biomarkers; Cardiomyopathies; Disease Progression; Dose-Response Relationship, Drug; Double-Bl | 2018 |
Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Topics: Aged; Biomarkers; Cardiomyopathies; Disease Progression; Dose-Response Relationship, Drug; Double-Bl | 2018 |
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Diabe | 2018 |
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Diabe | 2018 |
Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease.
Topics: Aged; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Hum | 2018 |
Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease.
Topics: Aged; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Hum | 2018 |
Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.
Topics: Aged; Aged, 80 and over; Biomarkers; Cause of Death; Chlorides; Female; Heart Failure; Heart Ventric | 2018 |
Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.
Topics: Aged; Aged, 80 and over; Biomarkers; Cause of Death; Chlorides; Female; Heart Failure; Heart Ventric | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar | 2018 |
A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial.
Topics: Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Eplerenone; Female; | 2018 |
A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial.
Topics: Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Eplerenone; Female; | 2018 |
Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure.
Topics: Aged; Biological Availability; Biomarkers; Blood Pressure; Collagen; Drug Monitoring; Drug Resistanc | 2019 |
Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure.
Topics: Aged; Biological Availability; Biomarkers; Blood Pressure; Collagen; Drug Monitoring; Drug Resistanc | 2019 |
The frailty syndrome and outcomes in the TOPCAT trial.
Topics: Aged; Americas; Double-Blind Method; Female; Frail Elderly; Frailty; Georgia (Republic); Heart Failu | 2018 |
The frailty syndrome and outcomes in the TOPCAT trial.
Topics: Aged; Americas; Double-Blind Method; Female; Frail Elderly; Frailty; Georgia (Republic); Heart Failu | 2018 |
Topics: Adult; Aged; Animals; Astrocytes; Bariatric Surgery; Beta vulgaris; Bioreactors; Biotechnology; Bloo | 2018 |
Topics: Adult; Aged; Animals; Astrocytes; Bariatric Surgery; Beta vulgaris; Bioreactors; Biotechnology; Bloo | 2018 |
Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study).
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Heart Fail | 2019 |
Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study).
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Heart Fail | 2019 |
A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.
Topics: Aged; Double-Blind Method; Female; Heart Failure; Heart Ventricles; Humans; Hyperkalemia; Kidney Fai | 2019 |
A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.
Topics: Aged; Double-Blind Method; Female; Heart Failure; Heart Ventricles; Humans; Hyperkalemia; Kidney Fai | 2019 |
Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
Topics: Age Factors; Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; | 2019 |
Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
Topics: Age Factors; Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; | 2019 |
Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial.
Topics: Aged; Atrial Fibrillation; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male | 2020 |
Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial.
Topics: Aged; Atrial Fibrillation; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male | 2020 |
Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial.
Topics: Creatinine; Dose-Response Relationship, Drug; Drug Resistance; Follow-Up Studies; Glomerular Filtrat | 2019 |
Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial.
Topics: Creatinine; Dose-Response Relationship, Drug; Drug Resistance; Follow-Up Studies; Glomerular Filtrat | 2019 |
High-Dose Spironolactone When Patients With Acute Decompensated Heart Failure Are Resistant to Loop Diuretics: A Pilot Study.
Topics: Acute Disease; Aged; Diuretics; Drug Resistance; Female; Heart Failure; Humans; Male; Middle Aged; P | 2019 |
High-Dose Spironolactone When Patients With Acute Decompensated Heart Failure Are Resistant to Loop Diuretics: A Pilot Study.
Topics: Acute Disease; Aged; Diuretics; Drug Resistance; Female; Heart Failure; Humans; Male; Middle Aged; P | 2019 |
Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
Topics: Adrenergic Antagonists; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; | 2013 |
Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
Topics: Adrenergic Antagonists; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; | 2013 |
N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Dise | 2013 |
N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Dise | 2013 |
Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2013 |
Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2013 |
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Topics: Aged; Aged, 80 and over; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; K | 2013 |
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Topics: Aged; Aged, 80 and over; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; K | 2013 |
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Topics: Aged; Aged, 80 and over; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; K | 2013 |
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Topics: Aged; Aged, 80 and over; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; K | 2013 |
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Topics: Aged; Aged, 80 and over; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; K | 2013 |
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Topics: Aged; Aged, 80 and over; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; K | 2013 |
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Topics: Aged; Aged, 80 and over; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; K | 2013 |
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Topics: Aged; Aged, 80 and over; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; K | 2013 |
Race influences the safety and efficacy of spironolactone in severe heart failure.
Topics: Adult; Aged; Biomarkers; Black or African American; Chi-Square Distribution; Double-Blind Method; Fe | 2013 |
Race influences the safety and efficacy of spironolactone in severe heart failure.
Topics: Adult; Aged; Biomarkers; Black or African American; Chi-Square Distribution; Double-Blind Method; Fe | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Chronic Disease; Disease Progression; Diuretics; Edema; Fema | 2014 |
Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Chronic Disease; Disease Progression; Diuretics; Edema; Fema | 2014 |
Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) s
Topics: Aged; Arterial Pressure; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorti | 2014 |
Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) s
Topics: Aged; Arterial Pressure; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorti | 2014 |
Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial.
Topics: Aged; Cohort Studies; Double-Blind Method; Exercise Tolerance; Female; Heart Failure; Humans; Male; | 2013 |
Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial.
Topics: Aged; Cohort Studies; Double-Blind Method; Exercise Tolerance; Female; Heart Failure; Humans; Male; | 2013 |
Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms.
Topics: Aged; Aged, 80 and over; Creatinine; Disease-Free Survival; Female; Heart Failure; Hospitalization; | 2014 |
Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms.
Topics: Aged; Aged, 80 and over; Creatinine; Disease-Free Survival; Female; Heart Failure; Hospitalization; | 2014 |
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Echocardiography; Female; Heart Atria; Heart Failure; | 2014 |
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Echocardiography; Female; Heart Atria; Heart Failure; | 2014 |
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Echocardiography; Female; Heart Atria; Heart Failure; | 2014 |
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Echocardiography; Female; Heart Atria; Heart Failure; | 2014 |
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Echocardiography; Female; Heart Atria; Heart Failure; | 2014 |
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Echocardiography; Female; Heart Atria; Heart Failure; | 2014 |
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Echocardiography; Female; Heart Atria; Heart Failure; | 2014 |
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Echocardiography; Female; Heart Atria; Heart Failure; | 2014 |
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Eplerenone; Female; Follow-Up Studies; Glomerular Filt | 2014 |
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Eplerenone; Female; Follow-Up Studies; Glomerular Filt | 2014 |
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Eplerenone; Female; Follow-Up Studies; Glomerular Filt | 2014 |
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Eplerenone; Female; Follow-Up Studies; Glomerular Filt | 2014 |
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Eplerenone; Female; Follow-Up Studies; Glomerular Filt | 2014 |
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Eplerenone; Female; Follow-Up Studies; Glomerular Filt | 2014 |
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Eplerenone; Female; Follow-Up Studies; Glomerular Filt | 2014 |
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Eplerenone; Female; Follow-Up Studies; Glomerular Filt | 2014 |
Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure.
Topics: Aged; Blood Glucose; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Furosemide; H | 2014 |
Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure.
Topics: Aged; Blood Glucose; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Furosemide; H | 2014 |
The role of albuminuria as a non-invasive marker for congestive acutely decompensated chronic heart failure and the spironolactone effect in elderly Portuguese: a non-randomized trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Biomarkers; Female; Heart Failure; Humans; Male; Prospective S | 2014 |
The role of albuminuria as a non-invasive marker for congestive acutely decompensated chronic heart failure and the spironolactone effect in elderly Portuguese: a non-randomized trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Biomarkers; Female; Heart Failure; Humans; Male; Prospective S | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; He | 2014 |
Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study.
Topics: Double-Blind Method; Eplerenone; Female; Heart Failure; Humans; Length of Stay; Male; Middle Aged; M | 2014 |
Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study.
Topics: Double-Blind Method; Eplerenone; Female; Heart Failure; Humans; Length of Stay; Male; Middle Aged; M | 2014 |
Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
Topics: Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography; Follow-Up S | 2014 |
Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
Topics: Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography; Follow-Up S | 2014 |
Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction.
Topics: Aged; Diastole; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography, Doppler; Fe | 2014 |
Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction.
Topics: Aged; Diastole; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography, Doppler; Fe | 2014 |
Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
Topics: Aged; Double-Blind Method; Echocardiography, Doppler; Follow-Up Studies; Heart Failure; Heart Ventri | 2014 |
Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
Topics: Aged; Double-Blind Method; Echocardiography, Doppler; Follow-Up Studies; Heart Failure; Heart Ventri | 2014 |
Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study).
Topics: Aged; Biomarkers; Diuretics; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Fail | 2014 |
Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study).
Topics: Aged; Biomarkers; Diuretics; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Fail | 2014 |
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Topics: Aged; Creatinine; Double-Blind Method; Female; Georgia (Republic); Heart Failure; Humans; Hyperkalem | 2015 |
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Topics: Aged; Creatinine; Double-Blind Method; Female; Georgia (Republic); Heart Failure; Humans; Hyperkalem | 2015 |
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Topics: Aged; Creatinine; Double-Blind Method; Female; Georgia (Republic); Heart Failure; Humans; Hyperkalem | 2015 |
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Topics: Aged; Creatinine; Double-Blind Method; Female; Georgia (Republic); Heart Failure; Humans; Hyperkalem | 2015 |
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Topics: Aged; Creatinine; Double-Blind Method; Female; Georgia (Republic); Heart Failure; Humans; Hyperkalem | 2015 |
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Topics: Aged; Creatinine; Double-Blind Method; Female; Georgia (Republic); Heart Failure; Humans; Hyperkalem | 2015 |
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Topics: Aged; Creatinine; Double-Blind Method; Female; Georgia (Republic); Heart Failure; Humans; Hyperkalem | 2015 |
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Topics: Aged; Creatinine; Double-Blind Method; Female; Georgia (Republic); Heart Failure; Humans; Hyperkalem | 2015 |
Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial.
Topics: Aged; Blood Proteins; Diuretics; Female; Galectin 3; Galectins; Heart Failure; Humans; Male; Middle | 2015 |
Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial.
Topics: Aged; Blood Proteins; Diuretics; Female; Galectin 3; Galectins; Heart Failure; Humans; Male; Middle | 2015 |
[The TOPCAT study].
Topics: Aged; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Male; Mineralocorticoid | 2014 |
[The TOPCAT study].
Topics: Aged; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Male; Mineralocorticoid | 2014 |
Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER).
Topics: Acute Disease; Adult; Clinical Protocols; Double-Blind Method; Early Medical Intervention; Eplerenon | 2015 |
Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER).
Topics: Acute Disease; Adult; Clinical Protocols; Double-Blind Method; Early Medical Intervention; Eplerenon | 2015 |
Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial.
Topics: Aged; Aged, 80 and over; Comorbidity; Depression; Female; Heart Failure; Humans; Life Style; Logisti | 2015 |
Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial.
Topics: Aged; Aged, 80 and over; Comorbidity; Depression; Female; Heart Failure; Humans; Life Style; Logisti | 2015 |
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mine | 2015 |
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mine | 2015 |
Influence of spironolactone on matrix metalloproteinase-2 in acute decompensated heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Body Weight; Creatinine; Diuretics; Female; Heart Failure; H | 2015 |
Influence of spironolactone on matrix metalloproteinase-2 in acute decompensated heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Body Weight; Creatinine; Diuretics; Female; Heart Failure; H | 2015 |
Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF).
Topics: Aged; Double-Blind Method; Electrocardiography; Eplerenone; Female; Heart Failure; Hospitalization; | 2015 |
Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF).
Topics: Aged; Double-Blind Method; Electrocardiography; Eplerenone; Female; Heart Failure; Hospitalization; | 2015 |
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Heart Rate; Hospital | 2016 |
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Heart Rate; Hospital | 2016 |
Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Topics: Aged; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Recep | 2015 |
Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Topics: Aged; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Recep | 2015 |
Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect.
Topics: Aged; Aged, 80 and over; Biomarkers; Chi-Square Distribution; Female; France; Heart Failure; Hospita | 2016 |
Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect.
Topics: Aged; Aged, 80 and over; Biomarkers; Chi-Square Distribution; Female; France; Heart Failure; Hospita | 2016 |
Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
Topics: Argentina; Brazil; Canada; Double-Blind Method; Female; Georgia (Republic); Heart Failure; Humans; M | 2016 |
Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
Topics: Argentina; Brazil; Canada; Double-Blind Method; Female; Georgia (Republic); Heart Failure; Humans; M | 2016 |
A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease.
Topics: Adult; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; H | 2016 |
A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease.
Topics: Adult; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; H | 2016 |
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Topics: Age Factors; Aged; Canrenoic Acid; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up | 2016 |
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Topics: Age Factors; Aged; Canrenoic Acid; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up | 2016 |
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Topics: Age Factors; Aged; Canrenoic Acid; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up | 2016 |
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Topics: Age Factors; Aged; Canrenoic Acid; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up | 2016 |
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Topics: Age Factors; Aged; Canrenoic Acid; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up | 2016 |
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Topics: Age Factors; Aged; Canrenoic Acid; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up | 2016 |
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Topics: Age Factors; Aged; Canrenoic Acid; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up | 2016 |
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Topics: Age Factors; Aged; Canrenoic Acid; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mi | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mi | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mi | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mi | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mi | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mi | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mi | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mi | 2016 |
Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.
Topics: Acute Disease; Cause of Death; Disease Progression; Double-Blind Method; Dyspnea; Heart Failure; Hum | 2016 |
Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.
Topics: Acute Disease; Cause of Death; Disease Progression; Double-Blind Method; Dyspnea; Heart Failure; Hum | 2016 |
IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial.
Topics: Aged; Atrial Fibrillation; Diastole; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; | 2016 |
IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial.
Topics: Aged; Atrial Fibrillation; Diastole; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; | 2016 |
Population Pharmacokinetics of Eplerenone in Japanese Patients With Chronic Heart Failure.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Chronic Disease; Double-Blind Method; Eplerenone; Fema | 2017 |
Population Pharmacokinetics of Eplerenone in Japanese Patients With Chronic Heart Failure.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Chronic Disease; Double-Blind Method; Eplerenone; Fema | 2017 |
Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Ac
Topics: Aged; Biomarkers; Endothelin-1; Eplerenone; Female; Follow-Up Studies; Heart Failure; Humans; Male; | 2017 |
Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Ac
Topics: Aged; Biomarkers; Endothelin-1; Eplerenone; Female; Follow-Up Studies; Heart Failure; Humans; Male; | 2017 |
Influence of spironolactone therapy on thiamine blood levels in patients with heart failure.
Topics: Aged; Aged, 80 and over; Chi-Square Distribution; Chronic Disease; Cross-Sectional Studies; Diuretic | 2008 |
Influence of spironolactone therapy on thiamine blood levels in patients with heart failure.
Topics: Aged; Aged, 80 and over; Chi-Square Distribution; Chronic Disease; Cross-Sectional Studies; Diuretic | 2008 |
History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure.
Topics: Aged; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Sch | 2008 |
History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure.
Topics: Aged; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Sch | 2008 |
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
Topics: Aged; Eplerenone; Female; Heart Failure; Humans; Hyperkalemia; Incidence; Logistic Models; Male; Min | 2008 |
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
Topics: Aged; Eplerenone; Female; Heart Failure; Humans; Hyperkalemia; Incidence; Logistic Models; Male; Min | 2008 |
Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
Topics: Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Eplerenone; Health Care Costs; Heart F | 2008 |
Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
Topics: Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Eplerenone; Health Care Costs; Heart F | 2008 |
Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS).
Topics: Acute Disease; Aged; Cohort Studies; Eplerenone; Female; Follow-Up Studies; Health Care Costs; Healt | 2009 |
Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS).
Topics: Acute Disease; Aged; Cohort Studies; Eplerenone; Female; Follow-Up Studies; Health Care Costs; Healt | 2009 |
Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EP
Topics: Aged; Biomarkers; Collagen Type I; Collagen Type III; Death, Sudden, Cardiac; Eplerenone; Extracellu | 2009 |
Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EP
Topics: Aged; Biomarkers; Collagen Type I; Collagen Type III; Death, Sudden, Cardiac; Eplerenone; Extracellu | 2009 |
Spironolactone in chronic hemodialysis patients improves cardiac function.
Topics: Aged; Chronic Disease; Diuretics; Double-Blind Method; Female; Heart Failure; Humans; Hyperkalemia; | 2009 |
Spironolactone in chronic hemodialysis patients improves cardiac function.
Topics: Aged; Chronic Disease; Diuretics; Double-Blind Method; Female; Heart Failure; Humans; Hyperkalemia; | 2009 |
A history of systemic hypertension and incident heart failure hospitalization in patients with acute myocardial infarction and left ventricular systolic dysfunction.
Topics: Aged; Double-Blind Method; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hypertension; | 2009 |
A history of systemic hypertension and incident heart failure hospitalization in patients with acute myocardial infarction and left ventricular systolic dysfunction.
Topics: Aged; Double-Blind Method; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hypertension; | 2009 |
Usefulness of abnormal heart rate turbulence to predict cardiovascular mortality in high-risk patients with acute myocardial infarction and left ventricular dysfunction (from the EPHESUS study).
Topics: Aged; Electrocardiography, Ambulatory; Eplerenone; Female; Heart Failure; Heart Rate; Humans; Male; | 2009 |
Usefulness of abnormal heart rate turbulence to predict cardiovascular mortality in high-risk patients with acute myocardial infarction and left ventricular dysfunction (from the EPHESUS study).
Topics: Aged; Electrocardiography, Ambulatory; Eplerenone; Female; Heart Failure; Heart Rate; Humans; Male; | 2009 |
Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; B | 2009 |
Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; B | 2009 |
The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
Topics: Aged; Double-Blind Method; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Length of Sta | 2009 |
The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
Topics: Aged; Double-Blind Method; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Length of Sta | 2009 |
Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology.
Topics: Administration, Oral; Adult; Aged; Diastole; Diuretics; Dose-Response Relationship, Drug; Double-Bli | 2009 |
Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology.
Topics: Administration, Oral; Adult; Aged; Diastole; Diuretics; Dose-Response Relationship, Drug; Double-Bli | 2009 |
Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
Topics: Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure; Hospitalization; Hum | 2009 |
Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
Topics: Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure; Hospitalization; Hum | 2009 |
N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2010 |
N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2010 |
Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Topics: Aged; Cohort Studies; Double-Blind Method; Eplerenone; Female; Gated Blood-Pool Imaging; Heart Failu | 2010 |
Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Topics: Aged; Cohort Studies; Double-Blind Method; Eplerenone; Female; Gated Blood-Pool Imaging; Heart Failu | 2010 |
Renal function in outpatients with chronic heart failure.
Topics: Aged; Analysis of Variance; Antihypertensive Agents; Confidence Intervals; Female; Glomerular Filtra | 2010 |
Renal function in outpatients with chronic heart failure.
Topics: Aged; Analysis of Variance; Antihypertensive Agents; Confidence Intervals; Female; Glomerular Filtra | 2010 |
Efficacy of spironolactone therapy in patients with heart failure with normal ejection fraction.
Topics: Adult; Diuretics; Female; Heart Failure; Humans; Male; Middle Aged; Spironolactone; Stroke Volume | 2010 |
Efficacy of spironolactone therapy in patients with heart failure with normal ejection fraction.
Topics: Adult; Diuretics; Female; Heart Failure; Humans; Male; Middle Aged; Spironolactone; Stroke Volume | 2010 |
Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Diuretics; Dog Diseases; Dogs | 2011 |
Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Diuretics; Dog Diseases; Dogs | 2011 |
Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure.
Topics: Analysis of Variance; Biomarkers; Echocardiography, Doppler; Exercise Test; Female; Heart Failure; H | 2010 |
Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure.
Topics: Analysis of Variance; Biomarkers; Echocardiography, Doppler; Exercise Test; Female; Heart Failure; H | 2010 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Imp | 2011 |
Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure.
Topics: Aged; Biomarkers; Dose-Response Relationship, Drug; Eplerenone; Female; Glycated Hemoglobin; Heart F | 2010 |
Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure.
Topics: Aged; Biomarkers; Dose-Response Relationship, Drug; Eplerenone; Female; Glycated Hemoglobin; Heart F | 2010 |
Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure.
Topics: Aged; Echocardiography; Female; Heart Atria; Heart Conduction System; Heart Failure; Humans; Male; M | 2011 |
Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure.
Topics: Aged; Echocardiography; Female; Heart Atria; Heart Conduction System; Heart Failure; Humans; Male; M | 2011 |
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Double | 2011 |
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Double | 2011 |
Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF).
Topics: Aged; Aged, 80 and over; Biomarkers; Collagen; Double-Blind Method; Eplerenone; Female; Heart Failur | 2011 |
Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF).
Topics: Aged; Aged, 80 and over; Biomarkers; Collagen; Double-Blind Method; Eplerenone; Female; Heart Failur | 2011 |
Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
Topics: Aged; Eplerenone; Glomerular Filtration Rate; Heart Failure; Heart Failure, Systolic; Humans; Kidney | 2012 |
Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
Topics: Aged; Eplerenone; Glomerular Filtration Rate; Heart Failure; Heart Failure, Systolic; Humans; Kidney | 2012 |
Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Quality of | 2011 |
Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Quality of | 2011 |
Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
Topics: Aged; Biomarkers; Diuretics; Female; Follow-Up Studies; Heart Failure; Humans; Hyperkalemia; Inciden | 2012 |
Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
Topics: Aged; Biomarkers; Diuretics; Female; Follow-Up Studies; Heart Failure; Humans; Hyperkalemia; Inciden | 2012 |
Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease.
Topics: Aldosterone; Confidence Intervals; Double-Blind Method; Eplerenone; Female; Health Status Indicators | 2012 |
Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease.
Topics: Aldosterone; Confidence Intervals; Double-Blind Method; Eplerenone; Female; Health Status Indicators | 2012 |
A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis.
Topics: Adult; Aged; Analysis of Variance; Biomarkers; Chi-Square Distribution; Double-Blind Method; Drug Mo | 2012 |
A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis.
Topics: Adult; Aged; Analysis of Variance; Biomarkers; Chi-Square Distribution; Double-Blind Method; Drug Mo | 2012 |
Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Topics: Aged; Diabetes Mellitus; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Male; Mineraloc | 2012 |
Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Topics: Aged; Diabetes Mellitus; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Male; Mineraloc | 2012 |
A double-blind, randomized, parallel, placebo-controlled study examining the effect of cross-linked polyelectrolyte in heart failure patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Cross-Linking Reagents; Double-Blind Method; Electrolytes; Exercise Test; F | 2012 |
A double-blind, randomized, parallel, placebo-controlled study examining the effect of cross-linked polyelectrolyte in heart failure patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Cross-Linking Reagents; Double-Blind Method; Electrolytes; Exercise Test; F | 2012 |
Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study).
Topics: Diuretics; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; | 2012 |
Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study).
Topics: Diuretics; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; | 2012 |
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.
Topics: Aged; Argentina; Comorbidity; Depression; Double-Blind Method; Electrocardiography; Female; Heart Fa | 2013 |
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.
Topics: Aged; Argentina; Comorbidity; Depression; Double-Blind Method; Electrocardiography; Female; Heart Fa | 2013 |
Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Antihypertensive Agents; Atherect | 2002 |
Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Antihypertensive Agents; Atherect | 2002 |
Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Digoxin; Diureti | 2002 |
Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Digoxin; Diureti | 2002 |
Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.
Topics: Aged; Aged, 80 and over; Angiotensin II; Atrial Natriuretic Factor; Endothelin-1; Female; Heart Fail | 2002 |
Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.
Topics: Aged; Aged, 80 and over; Angiotensin II; Atrial Natriuretic Factor; Endothelin-1; Female; Heart Fail | 2002 |
Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines.
Topics: Aged; Guideline Adherence; Heart Failure; Humans; Hyperkalemia; Hyponatremia; Hypotension; Male; Mid | 2003 |
Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines.
Topics: Aged; Guideline Adherence; Heart Failure; Humans; Hyperkalemia; Hyponatremia; Hypotension; Male; Mid | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans.
Topics: Anticoagulants; Cardiac Pacing, Artificial; Defibrillators, Implantable; Electrocardiography; Eplere | 2003 |
Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans.
Topics: Anticoagulants; Cardiac Pacing, Artificial; Defibrillators, Implantable; Electrocardiography; Eplere | 2003 |
Late breaking heart failure trials from the 2003 ACC meeting: EPHESUS and COMPANION.
Topics: Aged; Defibrillators, Implantable; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Min | 2003 |
Late breaking heart failure trials from the 2003 ACC meeting: EPHESUS and COMPANION.
Topics: Aged; Defibrillators, Implantable; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Min | 2003 |
Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure.
Topics: Aged; Antihypertensive Agents; Cardiotonic Agents; Diuretics; Echocardiography; Heart Failure; Human | 2003 |
Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure.
Topics: Aged; Antihypertensive Agents; Cardiotonic Agents; Diuretics; Echocardiography; Heart Failure; Human | 2003 |
[Efficacy of an aldosterone receptor blocker eplerenone in high risk survivors of acute myocardial infarction with signs of heart failure: results of EPHESUS].
Topics: Acute Disease; Diabetes Complications; Drug Administration Schedule; Drug Therapy, Combination; Eple | 2003 |
[Efficacy of an aldosterone receptor blocker eplerenone in high risk survivors of acute myocardial infarction with signs of heart failure: results of EPHESUS].
Topics: Acute Disease; Diabetes Complications; Drug Administration Schedule; Drug Therapy, Combination; Eple | 2003 |
Effects of spironolactone and metoprolol on QT dispersion in heart failure.
Topics: Aged; Echocardiography; Electrocardiography; Electrophysiology; Female; Heart Failure; Humans; Male; | 2003 |
Effects of spironolactone and metoprolol on QT dispersion in heart failure.
Topics: Aged; Echocardiography; Electrocardiography; Electrophysiology; Female; Heart Failure; Humans; Male; | 2003 |
Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure.
Topics: Diuretics; Echocardiography; Female; Genotype; Heart Failure; Humans; Male; Middle Aged; Multivariat | 2004 |
Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure.
Topics: Diuretics; Echocardiography; Female; Genotype; Heart Failure; Humans; Male; Middle Aged; Multivariat | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy.
Topics: Aged; Aged, 80 and over; Brachial Artery; Coronary Circulation; Endothelium, Vascular; Female; Heart | 2004 |
Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy.
Topics: Aged; Aged, 80 and over; Brachial Artery; Coronary Circulation; Endothelium, Vascular; Female; Heart | 2004 |
Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment.
Topics: Adrenergic beta-Antagonists; Aged; Cross-Over Studies; Double-Blind Method; Drug Administration Sche | 2004 |
Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment.
Topics: Adrenergic beta-Antagonists; Aged; Cross-Over Studies; Double-Blind Method; Drug Administration Sche | 2004 |
Prognostic value of health status in patients with heart failure after acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Americas; Cardiovascular Diseases; Cohort Studies; Comorbidity; Dise | 2004 |
Prognostic value of health status in patients with heart failure after acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Americas; Cardiovascular Diseases; Cohort Studies; Comorbidity; Dise | 2004 |
Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.
Topics: Aged; Aorta; Compliance; Diastole; Dyspnea; Exercise Test; Exercise Tolerance; Female; Heart Atria; | 2004 |
Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.
Topics: Aged; Aorta; Compliance; Diastole; Dyspnea; Exercise Test; Exercise Tolerance; Female; Heart Atria; | 2004 |
Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction.
Topics: Adolescent; Adult; Aged; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Recepto | 2004 |
Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction.
Topics: Adolescent; Adult; Aged; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Recepto | 2004 |
[Angiotensin receptor blockers in heart failure. CHARM Study].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |
[Angiotensin receptor blockers in heart failure. CHARM Study].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |
Spironolactone improves lung diffusion in chronic heart failure.
Topics: Exercise Test; Female; Forced Expiratory Volume; Heart Failure; Humans; Male; Middle Aged; Mineraloc | 2005 |
Spironolactone improves lung diffusion in chronic heart failure.
Topics: Exercise Test; Female; Forced Expiratory Volume; Heart Failure; Humans; Male; Middle Aged; Mineraloc | 2005 |
Effects of a nurse-led, clinic and home-based intervention on recurrent hospital use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Female; Foll | 2005 |
Effects of a nurse-led, clinic and home-based intervention on recurrent hospital use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Female; Foll | 2005 |
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
Topics: Aged; Cause of Death; Comorbidity; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Eplerenon | 2005 |
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
Topics: Aged; Cause of Death; Comorbidity; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Eplerenon | 2005 |
[Randomized Aldactone Evaluation Study (RALES)].
Topics: Double-Blind Method; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2005 |
[Randomized Aldactone Evaluation Study (RALES)].
Topics: Double-Blind Method; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2005 |
[Eplerenone Post-AMI Heart Failure Efficacy and survival study (EPHESUS)].
Topics: Double-Blind Method; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid | 2005 |
[Eplerenone Post-AMI Heart Failure Efficacy and survival study (EPHESUS)].
Topics: Double-Blind Method; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid | 2005 |
RALES, EPHESUS and redox.
Topics: Aldosterone; Animals; Heart Failure; Humans; Inflammation; Mineralocorticoid Receptor Antagonists; M | 2005 |
RALES, EPHESUS and redox.
Topics: Aldosterone; Animals; Heart Failure; Humans; Inflammation; Mineralocorticoid Receptor Antagonists; M | 2005 |
Short- and long-term results of a programme for the prevention of readmissions and mortality in patients with heart failure: are effects maintained after stopping the programme?
Topics: Adrenergic beta-Antagonists; Aged; Cardiology Service, Hospital; Disease Management; Female; Follow- | 2005 |
Short- and long-term results of a programme for the prevention of readmissions and mortality in patients with heart failure: are effects maintained after stopping the programme?
Topics: Adrenergic beta-Antagonists; Aged; Cardiology Service, Hospital; Disease Management; Female; Follow- | 2005 |
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
Topics: Aged; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administrati | 2005 |
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
Topics: Aged; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administrati | 2005 |
Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study.
Topics: Adult; Aged; Biopsy; Cardiomyopathy, Dilated; Female; Fibrosis; Heart Failure; Humans; Male; Middle | 2005 |
Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study.
Topics: Adult; Aged; Biopsy; Cardiomyopathy, Dilated; Female; Fibrosis; Heart Failure; Humans; Male; Middle | 2005 |
Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2005 |
Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2005 |
Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction
Topics: Adult; Aged; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Sp | 2006 |
Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction
Topics: Adult; Aged; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Sp | 2006 |
Appropriateness of spironolactone prescribing in heart failure patients: a population-based study.
Topics: Aged; Drug Utilization Review; Female; Heart Failure; Humans; Hyperkalemia; Kidney; Male; Mineraloco | 2006 |
Appropriateness of spironolactone prescribing in heart failure patients: a population-based study.
Topics: Aged; Drug Utilization Review; Female; Heart Failure; Humans; Hyperkalemia; Kidney; Male; Mineraloco | 2006 |
Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2007 |
Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2007 |
Aldosterone antagonists: the most underutilized class of heart failure medications.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Dru | 2007 |
Aldosterone antagonists: the most underutilized class of heart failure medications.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Dru | 2007 |
Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure.
Topics: Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Erythrocytes; Exercise | 2007 |
Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure.
Topics: Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Erythrocytes; Exercise | 2007 |
Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Carbazoles; Carvedilol; Diuretics; Dose-Response | 2007 |
Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Carbazoles; Carvedilol; Diuretics; Dose-Response | 2007 |
Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Double-Blind Meth | 2007 |
Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Double-Blind Meth | 2007 |
Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compo | 2007 |
Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compo | 2007 |
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart fa
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Bipheny | 2008 |
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart fa
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Bipheny | 2008 |
[Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy].
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Exercise Test; Female; Follow-Up St | 2007 |
[Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy].
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Exercise Test; Female; Follow-Up St | 2007 |
[Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy].
Topics: Adult; Aged; Arrhythmias, Cardiac; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rat | 2008 |
[Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy].
Topics: Adult; Aged; Arrhythmias, Cardiac; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rat | 2008 |
The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction.
Topics: Aged; Algorithms; Blood Urea Nitrogen; Creatinine; Cyclic GMP; Diuresis; Drug Administration Schedul | 2008 |
The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction.
Topics: Aged; Algorithms; Blood Urea Nitrogen; Creatinine; Cyclic GMP; Diuresis; Drug Administration Schedul | 2008 |
Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease.
Topics: Chlorothiazide; Clinical Trials as Topic; Digoxin; Drug Therapy, Combination; Female; Heart Defects, | 1981 |
Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease.
Topics: Chlorothiazide; Clinical Trials as Topic; Digoxin; Drug Therapy, Combination; Female; Heart Defects, | 1981 |
Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.
Topics: Aged; Animals; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heart; Hear | 1995 |
Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.
Topics: Aged; Animals; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heart; Hear | 1995 |
Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure.
Topics: Adult; Aged; Cardiomyopathy, Dilated; Chemotherapy, Adjuvant; Chronic Disease; Coronary Disease; Cro | 1995 |
Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure.
Topics: Adult; Aged; Cardiomyopathy, Dilated; Chemotherapy, Adjuvant; Chronic Disease; Coronary Disease; Cro | 1995 |
Combined therapy of captopril and spironolactone for refractory congestive heart failure.
Topics: Adult; Aged; Aldosterone; Captopril; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; | 1994 |
Combined therapy of captopril and spironolactone for refractory congestive heart failure.
Topics: Adult; Aged; Aldosterone; Captopril; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; | 1994 |
ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES).
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Therap | 1995 |
ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES).
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Therap | 1995 |
Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Digitalis Glycosides; Diur | 1996 |
Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Digitalis Glycosides; Diur | 1996 |
Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Circadian Rhythm; Diuretics; Double-Blin | 1997 |
Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Circadian Rhythm; Diuretics; Double-Blin | 1997 |
Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Echocardiography; Electrolytes; Ex | 1998 |
Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Echocardiography; Electrolytes; Ex | 1998 |
[Spironolactone advantageous to heart failure patients].
Topics: Heart Failure; Humans; Spironolactone | 1999 |
[Spironolactone advantageous to heart failure patients].
Topics: Heart Failure; Humans; Spironolactone | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
What's old is new again. Spironolactone and heart failure.
Topics: Adult; Aged; Cause of Death; Diuretics; Double-Blind Method; Female; Heart Failure; Humans; Male; Mi | 1999 |
What's old is new again. Spironolactone and heart failure.
Topics: Adult; Aged; Cause of Death; Diuretics; Double-Blind Method; Female; Heart Failure; Humans; Male; Mi | 1999 |
[Study of the month. The RALES study (randomized aldactone evaluation study].
Topics: Death, Sudden, Cardiac; Disease Progression; Double-Blind Method; Female; Heart Failure; Humans; Mal | 1999 |
[Study of the month. The RALES study (randomized aldactone evaluation study].
Topics: Death, Sudden, Cardiac; Disease Progression; Double-Blind Method; Female; Heart Failure; Humans; Mal | 1999 |
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.
Topics: Aged; Angiotensin I; Angiotensin II; Chronic Disease; Cross-Over Studies; Diuretics; Double-Blind Me | 2000 |
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.
Topics: Aged; Angiotensin I; Angiotensin II; Chronic Disease; Cross-Over Studies; Diuretics; Double-Blind Me | 2000 |
Spironolactone and congestive heart-failure.
Topics: Adolescent; Adult; Diuretics; Heart Failure; Humans; Hyperkalemia; Risk Factors; Spironolactone | 2000 |
Spironolactone and congestive heart-failure.
Topics: Adolescent; Adult; Diuretics; Heart Failure; Humans; Hyperkalemia; Risk Factors; Spironolactone | 2000 |
Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy.
Topics: Analysis of Variance; Antihypertensive Agents; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Death, | 2000 |
Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy.
Topics: Analysis of Variance; Antihypertensive Agents; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Death, | 2000 |
[Blocking of aldosterone receptors reduces the risk of events in patients with severe cardiac failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Digitalis; Diuretics; Double-Blind Method; Drug Therapy, C | 2000 |
[Blocking of aldosterone receptors reduces the risk of events in patients with severe cardiac failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Digitalis; Diuretics; Double-Blind Method; Drug Therapy, C | 2000 |
Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Dose-Response Relationshi | 2000 |
Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Dose-Response Relationshi | 2000 |
[Comparison of the therapeutic efficacy of spironolactone and furosemide in patients with severe congestive heart failure].
Topics: Aged; Arrhythmias, Cardiac; Diuretics; Electrocardiography, Ambulatory; Female; Furosemide; Heart Fa | 2000 |
[Comparison of the therapeutic efficacy of spironolactone and furosemide in patients with severe congestive heart failure].
Topics: Aged; Arrhythmias, Cardiac; Diuretics; Electrocardiography, Ambulatory; Female; Furosemide; Heart Fa | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Topics: Aged; Aged, 80 and over; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metallopr | 2000 |
Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.
Topics: Aged; Aldosterone; Cardiac Volume; Endomyocardial Fibrosis; Female; Follow-Up Studies; Heart Failure | 2001 |
Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.
Topics: Aged; Aldosterone; Cardiac Volume; Endomyocardial Fibrosis; Female; Follow-Up Studies; Heart Failure | 2001 |
Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure.
Topics: Circadian Rhythm; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Heart Failur | 2001 |
Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure.
Topics: Circadian Rhythm; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Heart Failur | 2001 |
Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study).
Topics: Antihypertensive Agents; Cost-Benefit Analysis; Disease Progression; Eplerenone; Health Status Indic | 2002 |
Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study).
Topics: Antihypertensive Agents; Cost-Benefit Analysis; Disease Progression; Eplerenone; Health Status Indic | 2002 |
Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure.
Topics: Ambulatory Care; Cost-Benefit Analysis; Double-Blind Method; Economics, Pharmaceutical; Heart Failur | 2002 |
Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure.
Topics: Ambulatory Care; Cost-Benefit Analysis; Double-Blind Method; Economics, Pharmaceutical; Heart Failur | 2002 |
Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure.
Topics: Aged; Chronic Disease; Diuretics; Dose-Response Relationship, Drug; Exercise Tolerance; Female; Hear | 2002 |
Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure.
Topics: Aged; Chronic Disease; Diuretics; Dose-Response Relationship, Drug; Exercise Tolerance; Female; Hear | 2002 |
The efficacy and safety of furosemide and a combination of spironolactone and hydrochlorothiazide in congestive heart failure.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug Evaluation; Elec | 1977 |
The efficacy and safety of furosemide and a combination of spironolactone and hydrochlorothiazide in congestive heart failure.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug Evaluation; Elec | 1977 |
The effects of potassium supplements, spironolactone of amiloride on the potassium status of patients with heart failure.
Topics: Adult; Aged; Amiloride; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Potassium; Pot | 1978 |
The effects of potassium supplements, spironolactone of amiloride on the potassium status of patients with heart failure.
Topics: Adult; Aged; Amiloride; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Potassium; Pot | 1978 |
The supra-additive natriuretic effect addition of bendroflumethiazide and bumetanide in congestive heart failure. Permutation trial tests in patients in long-term treatment with bumetanide.
Topics: Adult; Bendroflumethiazide; Benzoates; Butylamines; Chlorides; Clinical Trials as Topic; Coronary Di | 1975 |
The supra-additive natriuretic effect addition of bendroflumethiazide and bumetanide in congestive heart failure. Permutation trial tests in patients in long-term treatment with bumetanide.
Topics: Adult; Bendroflumethiazide; Benzoates; Butylamines; Chlorides; Clinical Trials as Topic; Coronary Di | 1975 |
Carbenoxolone sodium for gastric ulcer.
Topics: Benzothiadiazines; Body Weight; Carbenoxolone; Clinical Trials as Topic; Diuretics; Duodenal Ulcer; | 1975 |
Carbenoxolone sodium for gastric ulcer.
Topics: Benzothiadiazines; Body Weight; Carbenoxolone; Clinical Trials as Topic; Diuretics; Duodenal Ulcer; | 1975 |
Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Drug Tolerance | 1986 |
Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Drug Tolerance | 1986 |
Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial hypertension.
Topics: Aged; Blood Pressure; Body Weight; Diuretics; Electrolytes; Female; Heart Failure; Humans; Hypertens | 1986 |
Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial hypertension.
Topics: Aged; Blood Pressure; Body Weight; Diuretics; Electrolytes; Female; Heart Failure; Humans; Hypertens | 1986 |
[Comparative study of 2 diuretic-containing combination preparations in patients with edematous heart failure].
Topics: Aged; Diuretics; Drug Combinations; Edema, Cardiac; Female; Furosemide; Heart Failure; Humans; Hydro | 1985 |
[Comparative study of 2 diuretic-containing combination preparations in patients with edematous heart failure].
Topics: Aged; Diuretics; Drug Combinations; Edema, Cardiac; Female; Furosemide; Heart Failure; Humans; Hydro | 1985 |
[Direct positive inotropic cardiac effect of aldactone (spironolactone, canrenoate-K)].
Topics: Administration, Oral; Body Weight; Carbon Dioxide; Clinical Trials as Topic; Digitalis Glycosides; D | 1972 |
[Direct positive inotropic cardiac effect of aldactone (spironolactone, canrenoate-K)].
Topics: Administration, Oral; Body Weight; Carbon Dioxide; Clinical Trials as Topic; Digitalis Glycosides; D | 1972 |
[Direct positive inotropic influencing on the heart using oral spironolactone therapy].
Topics: Administration, Oral; Carbon Dioxide; Clinical Trials as Topic; Female; Heart Failure; Heart Valve D | 1972 |
[Direct positive inotropic influencing on the heart using oral spironolactone therapy].
Topics: Administration, Oral; Carbon Dioxide; Clinical Trials as Topic; Female; Heart Failure; Heart Valve D | 1972 |
[Clinical amd metabolic results of a particular combination thiazide-antialdosterone in heart failure].
Topics: Clinical Trials as Topic; Diuretics; Drug Combinations; Drug Synergism; Ethacrynic Acid; Heart Failu | 1974 |
[Clinical amd metabolic results of a particular combination thiazide-antialdosterone in heart failure].
Topics: Clinical Trials as Topic; Diuretics; Drug Combinations; Drug Synergism; Ethacrynic Acid; Heart Failu | 1974 |
High doses of spironolactone (Aldactone, SC-14266, Verospirone) alone and in combination with triamterene and-or diuretics in the treatment of refractory edema associated with secondary hyperaldosteronism.
Topics: Adult; Aged; Body Weight; Chlorides; Clinical Trials as Topic; Clopamide; Creatinine; Diet, Sodium-R | 1970 |
High doses of spironolactone (Aldactone, SC-14266, Verospirone) alone and in combination with triamterene and-or diuretics in the treatment of refractory edema associated with secondary hyperaldosteronism.
Topics: Adult; Aged; Body Weight; Chlorides; Clinical Trials as Topic; Clopamide; Creatinine; Diet, Sodium-R | 1970 |
The supra-additive natriuretic effect addition of quinethazone or bendroflumethiazide during long-term treatment with furosemide and spironolactone. Permutation trial tests in patients with congestive heart failure.
Topics: Adult; Bendroflumethiazide; Clinical Trials as Topic; Diuresis; Drug Synergism; Furosemide; Heart Fa | 1971 |
The supra-additive natriuretic effect addition of quinethazone or bendroflumethiazide during long-term treatment with furosemide and spironolactone. Permutation trial tests in patients with congestive heart failure.
Topics: Adult; Bendroflumethiazide; Clinical Trials as Topic; Diuresis; Drug Synergism; Furosemide; Heart Fa | 1971 |
[Clinical test of a diuretic preparation combining a spironoloctone and a sulfonamide derivative].
Topics: Adult; Aged; Clinical Trials as Topic; Diuretics; Female; Heart Failure; Humans; Male; Middle Aged; | 1965 |
[Clinical test of a diuretic preparation combining a spironoloctone and a sulfonamide derivative].
Topics: Adult; Aged; Clinical Trials as Topic; Diuretics; Female; Heart Failure; Humans; Male; Middle Aged; | 1965 |
705 other studies available for spironolactone and Heart Failure
| Article | Year |
|---|---|
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
Topics: Animals; Antihypertensive Agents; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Anta | 2022 |
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
Topics: Animals; Antihypertensive Agents; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Anta | 2022 |
Ventricular longitudinal shortening is an independent predictor of death in heart failure patients with reduced ejection fraction.
Topics: Aged; Aspirin; Body Mass Index; Cicatrix; Diuretics; Female; Fibrosis; Follow-Up Studies; Heart Fail | 2021 |
Ventricular longitudinal shortening is an independent predictor of death in heart failure patients with reduced ejection fraction.
Topics: Aged; Aspirin; Body Mass Index; Cicatrix; Diuretics; Female; Fibrosis; Follow-Up Studies; Heart Fail | 2021 |
Spironolactone of no benefit in people with AF and HFpEF.
Topics: Atrial Fibrillation; Heart Failure; Humans; Spironolactone; Stroke Volume | 2021 |
Spironolactone of no benefit in people with AF and HFpEF.
Topics: Atrial Fibrillation; Heart Failure; Humans; Spironolactone; Stroke Volume | 2021 |
Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Antihypertensive Agents; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid R | 2021 |
Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Antihypertensive Agents; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid R | 2021 |
Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Heart Failure; | 2022 |
Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Heart Failure; | 2022 |
INFLUENCE OF COMPLEX TREATMENT WITH MAGNESIUM AND POTASSIUM SALTS OF GLUCONIC ACID, EPLERENONE AND RIVAROXABAN ON DYNAMICS OF INDICATORS OF ISCHEMIA AND MYOCARDIAL REMODELING IN PATIENTS WITH CHRONIC HEART FAILURE AFTER MYOCARDIAL INFARCTION.
Topics: Eplerenone; Gluconates; Heart Failure; Humans; Magnesium; Mineralocorticoid Receptor Antagonists; My | 2021 |
INFLUENCE OF COMPLEX TREATMENT WITH MAGNESIUM AND POTASSIUM SALTS OF GLUCONIC ACID, EPLERENONE AND RIVAROXABAN ON DYNAMICS OF INDICATORS OF ISCHEMIA AND MYOCARDIAL REMODELING IN PATIENTS WITH CHRONIC HEART FAILURE AFTER MYOCARDIAL INFARCTION.
Topics: Eplerenone; Gluconates; Heart Failure; Humans; Magnesium; Mineralocorticoid Receptor Antagonists; My | 2021 |
Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone | 2022 |
Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone | 2022 |
Event-specific win ratios for inference with terminal and non-terminal events.
Topics: Adult; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Proportional Hazards Models; S | 2022 |
Event-specific win ratios for inference with terminal and non-terminal events.
Topics: Adult; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Proportional Hazards Models; S | 2022 |
Loeys-Dietz Cardiomyopathy? Long-term Follow-up After Onset of Acute Decompensated Heart Failure.
Topics: Acute Disease; Bisoprolol; Cardiomegaly; Cardiomyopathies; Cardiovascular Agents; Echocardiography; | 2022 |
Loeys-Dietz Cardiomyopathy? Long-term Follow-up After Onset of Acute Decompensated Heart Failure.
Topics: Acute Disease; Bisoprolol; Cardiomegaly; Cardiomyopathies; Cardiovascular Agents; Echocardiography; | 2022 |
THE EFFECT OF SPIRONOLACTONE ON SERUM ELECTROLYTES AND RENAL FUNCTION TESTS IN PATIENTS WITH SEVERE CHRONIC HEART FAILURE.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Electrolytes; | 2021 |
THE EFFECT OF SPIRONOLACTONE ON SERUM ELECTROLYTES AND RENAL FUNCTION TESTS IN PATIENTS WITH SEVERE CHRONIC HEART FAILURE.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Electrolytes; | 2021 |
Prognostic value of cardiac magnetic resonance parameters and biomarkers following myocardial infarction; 10-year follow-up of the Eplerenone Remodelling in Myocardial Infarction without Heart Failure trial.
Topics: Biomarkers; Eplerenone; Follow-Up Studies; Heart Failure; Humans; Magnetic Resonance Spectroscopy; M | 2022 |
Prognostic value of cardiac magnetic resonance parameters and biomarkers following myocardial infarction; 10-year follow-up of the Eplerenone Remodelling in Myocardial Infarction without Heart Failure trial.
Topics: Biomarkers; Eplerenone; Follow-Up Studies; Heart Failure; Humans; Magnetic Resonance Spectroscopy; M | 2022 |
Real world comparison of spironolactone and eplerenone in patients with heart failure.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Prospective Studies; Spir | 2022 |
Real world comparison of spironolactone and eplerenone in patients with heart failure.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Prospective Studies; Spir | 2022 |
Rates of Spironolactone Initiation and Subsequent Hyperkalemia Hospitalizations in Patients with Heart Failure with Preserved Ejection Fraction Following the TOPCAT trial: A Cohort Study of Medicare Beneficiaries.
Topics: Aged; Aged, 80 and over; Cohort Studies; Female; Heart Failure; Hospitalization; Humans; Hyperkalemi | 2022 |
Rates of Spironolactone Initiation and Subsequent Hyperkalemia Hospitalizations in Patients with Heart Failure with Preserved Ejection Fraction Following the TOPCAT trial: A Cohort Study of Medicare Beneficiaries.
Topics: Aged; Aged, 80 and over; Cohort Studies; Female; Heart Failure; Hospitalization; Humans; Hyperkalemi | 2022 |
Comparison of chlorthalidone and spironolactone as additional diuretic therapy in patients with acute heart failure and preserved ejection fraction.
Topics: Aged, 80 and over; Chlorthalidone; Diuretics; Female; Heart Failure; Humans; Male; Sodium; Spironola | 2022 |
Comparison of chlorthalidone and spironolactone as additional diuretic therapy in patients with acute heart failure and preserved ejection fraction.
Topics: Aged, 80 and over; Chlorthalidone; Diuretics; Female; Heart Failure; Humans; Male; Sodium; Spironola | 2022 |
Is it time to shift our focus from treatment to prevention of heart failure with a mineralocorticoid receptor antagonist?
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2022 |
Is it time to shift our focus from treatment to prevention of heart failure with a mineralocorticoid receptor antagonist?
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2022 |
Paying Homage to the Power of Proteomics: Insights Into Obesity and Heart Failure From the HOMAGE Trial.
Topics: Heart Failure; History, 20th Century; Humans; Obesity; Proteomics; Spironolactone | 2022 |
Paying Homage to the Power of Proteomics: Insights Into Obesity and Heart Failure From the HOMAGE Trial.
Topics: Heart Failure; History, 20th Century; Humans; Obesity; Proteomics; Spironolactone | 2022 |
Osteoblast MR deficiency protects against adverse ventricular remodeling after myocardial infarction.
Topics: Animals; Heart Failure; Humans; Mice; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; | 2022 |
Osteoblast MR deficiency protects against adverse ventricular remodeling after myocardial infarction.
Topics: Animals; Heart Failure; Humans; Mice; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; | 2022 |
The longitudinal outcome of canine (K9) myxomatous mitral valve disease (LOOK-Mitral) registry: Baseline treatment characteristics.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Heart Failure; Heart Valve Diseases; Mitral Valve; | 2022 |
The longitudinal outcome of canine (K9) myxomatous mitral valve disease (LOOK-Mitral) registry: Baseline treatment characteristics.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Heart Failure; Heart Valve Diseases; Mitral Valve; | 2022 |
Non-steroidal aldosterone receptor antagonism: a 'fine' treatment for heart failure patients?
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorti | 2022 |
Non-steroidal aldosterone receptor antagonism: a 'fine' treatment for heart failure patients?
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorti | 2022 |
Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment.
Topics: Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Phenotype; Spironola | 2022 |
Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment.
Topics: Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Phenotype; Spironola | 2022 |
Homoarginine treatment of rats improves cardiac function and remodeling in response to pressure overload.
Topics: Animals; Blood Pressure; Heart Failure; Homoarginine; Hypertension; Lisinopril; Male; Myocardium; NG | 2022 |
Homoarginine treatment of rats improves cardiac function and remodeling in response to pressure overload.
Topics: Animals; Blood Pressure; Heart Failure; Homoarginine; Hypertension; Lisinopril; Male; Myocardium; NG | 2022 |
The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
Topics: Biomarkers; Cardiomyopathies; Clinical Trials as Topic; Collagen Type I; Collagen Type III; Echocard | 2022 |
The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
Topics: Biomarkers; Cardiomyopathies; Clinical Trials as Topic; Collagen Type I; Collagen Type III; Echocard | 2022 |
Spironolactone, fibrosis and heart failure with preserved ejection fraction.
Topics: Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volu | 2022 |
Spironolactone, fibrosis and heart failure with preserved ejection fraction.
Topics: Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volu | 2022 |
Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Sp | 2022 |
Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Sp | 2022 |
[Three ages of spironolactone. Evolution of views on spironolactone capabilities in the treatment of patients with heart failure.]
Topics: Aldosterone; Female; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; | 2022 |
[Three ages of spironolactone. Evolution of views on spironolactone capabilities in the treatment of patients with heart failure.]
Topics: Aldosterone; Female; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; | 2022 |
[Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes].
Topics: Aminobutyrates; Amyloidosis; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Hu | 2022 |
[Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes].
Topics: Aminobutyrates; Amyloidosis; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Hu | 2022 |
[Multidisciplinary expert consensus for clinical application of mineralocorticoid receptor antagonists in China].
Topics: Consensus; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2022 |
[Multidisciplinary expert consensus for clinical application of mineralocorticoid receptor antagonists in China].
Topics: Consensus; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2022 |
Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction.
Topics: Animals; Fibrosis; Furosemide; Heart Failure; Mineralocorticoid Receptor Antagonists; Mitral Valve I | 2022 |
Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction.
Topics: Animals; Fibrosis; Furosemide; Heart Failure; Mineralocorticoid Receptor Antagonists; Mitral Valve I | 2022 |
[Impact of Dapagliflozin on echocardiographic parameters in patients with heart failure and reduced ejection fraction: "About a monocentric series of 43 cases"].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; | 2022 |
[Impact of Dapagliflozin on echocardiographic parameters in patients with heart failure and reduced ejection fraction: "About a monocentric series of 43 cases"].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; | 2022 |
Hospital Variation of Spironolactone Use in Patients Hospitalized for Heart Failure in China-The China PEACE Retrospective Heart Failure Study.
Topics: Heart Failure; Hospitals; Humans; Mineralocorticoid Receptor Antagonists; Retrospective Studies; Spi | 2022 |
Hospital Variation of Spironolactone Use in Patients Hospitalized for Heart Failure in China-The China PEACE Retrospective Heart Failure Study.
Topics: Heart Failure; Hospitals; Humans; Mineralocorticoid Receptor Antagonists; Retrospective Studies; Spi | 2022 |
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; Ventri | 2022 |
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; Ventri | 2022 |
Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial.
Topics: Heart Failure; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume | 2023 |
Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial.
Topics: Heart Failure; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume | 2023 |
Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction.
Topics: Biomarkers; Fibroblasts; Glycogen Synthase Kinase 3; Heart Failure; Humans; Interleukin-6; Matrix Me | 2023 |
Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction.
Topics: Biomarkers; Fibroblasts; Glycogen Synthase Kinase 3; Heart Failure; Humans; Interleukin-6; Matrix Me | 2023 |
Heterogeneity in multicentre trial participating centers: lessons from the TOPCAT trial on interpreting trial data for clinical practice.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2023 |
Heterogeneity in multicentre trial participating centers: lessons from the TOPCAT trial on interpreting trial data for clinical practice.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2023 |
Improve heart function to improve heart failure outcomes: the disease-modifying effects of spironolactone.
Topics: Heart; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; | 2023 |
Improve heart function to improve heart failure outcomes: the disease-modifying effects of spironolactone.
Topics: Heart; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; | 2023 |
Improve heart function to improve heart failure outcomes: the disease-modifying effects of spironolactone.
Topics: Heart; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; | 2023 |
Improve heart function to improve heart failure outcomes: the disease-modifying effects of spironolactone.
Topics: Heart; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; | 2023 |
Improve heart function to improve heart failure outcomes: the disease-modifying effects of spironolactone.
Topics: Heart; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; | 2023 |
Improve heart function to improve heart failure outcomes: the disease-modifying effects of spironolactone.
Topics: Heart; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; | 2023 |
Improve heart function to improve heart failure outcomes: the disease-modifying effects of spironolactone.
Topics: Heart; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; | 2023 |
Improve heart function to improve heart failure outcomes: the disease-modifying effects of spironolactone.
Topics: Heart; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; | 2023 |
Mean corpuscular haemoglobin concentration and outcomes in heart failure with preserved ejection fraction.
Topics: Erythrocyte Indices; Heart Failure; Humans; Kidney Diseases; Spironolactone; Stroke Volume | 2023 |
Mean corpuscular haemoglobin concentration and outcomes in heart failure with preserved ejection fraction.
Topics: Erythrocyte Indices; Heart Failure; Humans; Kidney Diseases; Spironolactone; Stroke Volume | 2023 |
The Impact of Procyanidin Extracted from Crataegus azarolus on Rats with Induced Heart Failure.
Topics: Animals; Biomarkers; Crataegus; Digoxin; Heart Failure; Male; Natriuretic Peptide, Brain; Peptide Fr | 2022 |
The Impact of Procyanidin Extracted from Crataegus azarolus on Rats with Induced Heart Failure.
Topics: Animals; Biomarkers; Crataegus; Digoxin; Heart Failure; Male; Natriuretic Peptide, Brain; Peptide Fr | 2022 |
A machine learning-derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: Findings from the HOMAGE trial.
Topics: Biomarkers; Echocardiography; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antago | 2023 |
A machine learning-derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: Findings from the HOMAGE trial.
Topics: Biomarkers; Echocardiography; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antago | 2023 |
Role of eplerenone in the threatment of cardiovascular diseases.
Topics: Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; | 2023 |
Role of eplerenone in the threatment of cardiovascular diseases.
Topics: Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; | 2023 |
Usefulness of urinary potassium to creatinine ratio to predict diuretic response in patients with acute heart failure and preserved ejection fraction.
Topics: Aged, 80 and over; Chlorthalidone; Creatinine; Diuretics; Female; Heart Failure; Humans; Male; Potas | 2023 |
Usefulness of urinary potassium to creatinine ratio to predict diuretic response in patients with acute heart failure and preserved ejection fraction.
Topics: Aged, 80 and over; Chlorthalidone; Creatinine; Diuretics; Female; Heart Failure; Humans; Male; Potas | 2023 |
Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study.
Topics: Aged; Cohort Studies; Eplerenone; Heart Failure; Humans; Male; Spironolactone; Stroke Volume; Treatm | 2023 |
Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study.
Topics: Aged; Cohort Studies; Eplerenone; Heart Failure; Humans; Male; Spironolactone; Stroke Volume; Treatm | 2023 |
Using Sacubitril/Valsartan to Decrease Health care Costs in Population Health Patients.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Dr | 2023 |
Using Sacubitril/Valsartan to Decrease Health care Costs in Population Health Patients.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Dr | 2023 |
Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial.
Topics: Amyloidosis; Cardiomyopathies; Heart Failure; Humans; Prealbumin; Spironolactone; Stroke Volume; Tre | 2023 |
Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial.
Topics: Amyloidosis; Cardiomyopathies; Heart Failure; Humans; Prealbumin; Spironolactone; Stroke Volume; Tre | 2023 |
Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy.
Topics: Angiotensin II; Animals; Cardiomegaly; Fibrosis; Genetic Therapy; Glycogen Storage Disease Type IIb; | 2023 |
Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy.
Topics: Angiotensin II; Animals; Cardiomegaly; Fibrosis; Genetic Therapy; Glycogen Storage Disease Type IIb; | 2023 |
Pharmacological Management of Resistant Hypertension in Moderate-to-advanced CKD: A Glance at Novel Non-steroidal MRAs.
Topics: Heart Failure; Humans; Hypertension; Renal Insufficiency, Chronic; Spironolactone | 2023 |
Pharmacological Management of Resistant Hypertension in Moderate-to-advanced CKD: A Glance at Novel Non-steroidal MRAs.
Topics: Heart Failure; Humans; Hypertension; Renal Insufficiency, Chronic; Spironolactone | 2023 |
Cardiorenal Interactions, Diuretic Resistance, and Acute Heart Failure: Renal Response vs Renal Function.
Topics: Cardio-Renal Syndrome; Diuretics; Heart Failure; Humans; Risk Factors; Spironolactone | 2019 |
Cardiorenal Interactions, Diuretic Resistance, and Acute Heart Failure: Renal Response vs Renal Function.
Topics: Cardio-Renal Syndrome; Diuretics; Heart Failure; Humans; Risk Factors; Spironolactone | 2019 |
Effect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure.
Topics: Adult; Aged; Angiotensinogen; Cytochrome P-450 CYP11B2; Egypt; Female; Heart Failure; Humans; Male; | 2020 |
Effect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure.
Topics: Adult; Aged; Angiotensinogen; Cytochrome P-450 CYP11B2; Egypt; Female; Heart Failure; Humans; Male; | 2020 |
Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry.
Topics: Aged; Aged, 80 and over; Female; Guideline Adherence; Heart Failure; Humans; Hyperkalemia; Incidence | 2020 |
Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry.
Topics: Aged; Aged, 80 and over; Female; Guideline Adherence; Heart Failure; Humans; Hyperkalemia; Incidence | 2020 |
Age-Related Divergence of Risk-Benefit Relationship of Spironolactone Treatment for Heart Failure With Preserved Ejection Fraction.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Risk Assessment; Spironolactone; Stro | 2019 |
Age-Related Divergence of Risk-Benefit Relationship of Spironolactone Treatment for Heart Failure With Preserved Ejection Fraction.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Risk Assessment; Spironolactone; Stro | 2019 |
Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post-hoc analysis of the Aldo-DHF trial.
Topics: Adipose Tissue; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Phenotype; Spironolac | 2020 |
Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post-hoc analysis of the Aldo-DHF trial.
Topics: Adipose Tissue; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Phenotype; Spironolac | 2020 |
Heart Failure With Preserved Ejection Fraction: Many Emperors With Many Clothes.
Topics: Heart Failure; Humans; Phenotype; Prognosis; Spironolactone; Stroke Volume | 2020 |
Heart Failure With Preserved Ejection Fraction: Many Emperors With Many Clothes.
Topics: Heart Failure; Humans; Phenotype; Prognosis; Spironolactone; Stroke Volume | 2020 |
Spironolactone use is associated with improved outcomes in heart failure with mid-range ejection fraction.
Topics: Aged; Disease Progression; Female; Follow-Up Studies; Heart Failure; Humans; Male; Mineralocorticoid | 2020 |
Spironolactone use is associated with improved outcomes in heart failure with mid-range ejection fraction.
Topics: Aged; Disease Progression; Female; Follow-Up Studies; Heart Failure; Humans; Male; Mineralocorticoid | 2020 |
Alterations in Glucose Metabolism During the Transition to Heart Failure: The Contribution of UCP-2.
Topics: Animals; Blood Pressure; Cardiomegaly; Cell Survival; Chronic Disease; Female; Glucose; Glucose Tran | 2020 |
Alterations in Glucose Metabolism During the Transition to Heart Failure: The Contribution of UCP-2.
Topics: Animals; Blood Pressure; Cardiomegaly; Cell Survival; Chronic Disease; Female; Glucose; Glucose Tran | 2020 |
Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure.
Topics: Collagen Type I; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardi | 2020 |
Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure.
Topics: Collagen Type I; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardi | 2020 |
Evaluating the confounding effects of medical therapies on potassium intake assessment in patients with heart failure.
Topics: Aged; Diet Records; Female; Gastrointestinal Absorption; Heart Failure; Humans; Male; Middle Aged; M | 2020 |
Evaluating the confounding effects of medical therapies on potassium intake assessment in patients with heart failure.
Topics: Aged; Diet Records; Female; Gastrointestinal Absorption; Heart Failure; Humans; Male; Middle Aged; M | 2020 |
Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT).
Topics: Aged; Aged, 80 and over; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mineralo | 2020 |
Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT).
Topics: Aged; Aged, 80 and over; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mineralo | 2020 |
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.
Topics: Animals; Benzhydryl Compounds; Bisoprolol; Cardiovascular Agents; Chronic Disease; Disease Models, A | 2020 |
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.
Topics: Animals; Benzhydryl Compounds; Bisoprolol; Cardiovascular Agents; Chronic Disease; Disease Models, A | 2020 |
Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Heart Failure | 2020 |
Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Heart Failure | 2020 |
Cardiac Function and Sudden Cardiac Death in Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
Topics: Aged; Death, Sudden, Cardiac; Diastole; Echocardiography; Female; Heart Arrest; Heart Failure; Human | 2020 |
Cardiac Function and Sudden Cardiac Death in Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
Topics: Aged; Death, Sudden, Cardiac; Diastole; Echocardiography; Female; Heart Arrest; Heart Failure; Human | 2020 |
Electrolyte Abnormalities in Patients Presenting With Ventricular Arrhythmia (from the LYTE-VT Study).
Topics: Aged; Cardiomyopathies; Case-Control Studies; Diarrhea; Diuretics; Female; Heart Failure; Humans; Hy | 2020 |
Electrolyte Abnormalities in Patients Presenting With Ventricular Arrhythmia (from the LYTE-VT Study).
Topics: Aged; Cardiomyopathies; Case-Control Studies; Diarrhea; Diuretics; Female; Heart Failure; Humans; Hy | 2020 |
CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Cause of Death; Clinical Trials, Phase III as Topic; Decision Support Techn | 2020 |
CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Cause of Death; Clinical Trials, Phase III as Topic; Decision Support Techn | 2020 |
Secrets of spironolactone: continuing insights from TOPCAT Americas.
Topics: Americas; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volu | 2020 |
Secrets of spironolactone: continuing insights from TOPCAT Americas.
Topics: Americas; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volu | 2020 |
Clinical Phenogrouping and Systolic Performance in HFpEF.
Topics: Heart Failure; Humans; Phenotype; Prognosis; Spironolactone; Stroke Volume | 2020 |
Clinical Phenogrouping and Systolic Performance in HFpEF.
Topics: Heart Failure; Humans; Phenotype; Prognosis; Spironolactone; Stroke Volume | 2020 |
Furosemide and spironolactone doses and hyponatremia in patients with heart failure.
Topics: Aged; Aged, 80 and over; Diuretics; Female; Furosemide; Heart Failure; Hospitalization; Humans; Hydr | 2020 |
Furosemide and spironolactone doses and hyponatremia in patients with heart failure.
Topics: Aged; Aged, 80 and over; Diuretics; Female; Furosemide; Heart Failure; Hospitalization; Humans; Hydr | 2020 |
Impact of SLCO4C1 Genotypes, Creatinine, and Spironolactone on Digoxin Population Pharmacokinetic Variables in Patients With Cardiac Insufficiency.
Topics: Adult; Aged; Aged, 80 and over; Creatinine; Digoxin; Drug Monitoring; Female; Genotype; Heart Failur | 2020 |
Impact of SLCO4C1 Genotypes, Creatinine, and Spironolactone on Digoxin Population Pharmacokinetic Variables in Patients With Cardiac Insufficiency.
Topics: Adult; Aged; Aged, 80 and over; Creatinine; Digoxin; Drug Monitoring; Female; Genotype; Heart Failur | 2020 |
Spironolactone: diuretic or disease-modifying drug in heart failure with preserved ejection fraction?
Topics: Diuretics; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Pharmaceu | 2020 |
Spironolactone: diuretic or disease-modifying drug in heart failure with preserved ejection fraction?
Topics: Diuretics; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Pharmaceu | 2020 |
Aldosterone Antagonism in Atrial Fibrillation: Implications for AF-Predominant HFpEF.
Topics: Aldosterone; Atrial Fibrillation; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spi | 2020 |
Aldosterone Antagonism in Atrial Fibrillation: Implications for AF-Predominant HFpEF.
Topics: Aldosterone; Atrial Fibrillation; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spi | 2020 |
Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure: A Pharmacoepidemiological study.
Topics: Aged; Aged, 80 and over; Heart Failure; Humans; Incidence; Male; Middle Aged; Mineralocorticoid Rece | 2021 |
Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure: A Pharmacoepidemiological study.
Topics: Aged; Aged, 80 and over; Heart Failure; Humans; Incidence; Male; Middle Aged; Mineralocorticoid Rece | 2021 |
Estimating the Lifetime Benefits of Treatments for Heart Failure.
Topics: Eplerenone; Heart Failure; Humans; Infant; Mineralocorticoid Receptor Antagonists; Spironolactone; S | 2020 |
Estimating the Lifetime Benefits of Treatments for Heart Failure.
Topics: Eplerenone; Heart Failure; Humans; Infant; Mineralocorticoid Receptor Antagonists; Spironolactone; S | 2020 |
Spironolactone discontinuation in patients with heart failure: complex interactions with loop diuretics. Letter regarding the article 'Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT'.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Sodium Potassium Chloride Symporter I | 2021 |
Spironolactone discontinuation in patients with heart failure: complex interactions with loop diuretics. Letter regarding the article 'Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT'.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Sodium Potassium Chloride Symporter I | 2021 |
Cumulative events in the TOPCAT trial.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume | 2021 |
Cumulative events in the TOPCAT trial.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume | 2021 |
Efficacy and safety of spironolactone for the treatment of patients with acute heart failure: A protocol for systematic review.
Topics: Diuretics; Heart Failure; Humans; Spironolactone; Systematic Reviews as Topic | 2020 |
Efficacy and safety of spironolactone for the treatment of patients with acute heart failure: A protocol for systematic review.
Topics: Diuretics; Heart Failure; Humans; Spironolactone; Systematic Reviews as Topic | 2020 |
Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure.
Topics: Acute Kidney Injury; Adult; Aged; Diuretics; Female; Follow-Up Studies; Heart Failure; Humans; Hyper | 2020 |
Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure.
Topics: Acute Kidney Injury; Adult; Aged; Diuretics; Female; Follow-Up Studies; Heart Failure; Humans; Hyper | 2020 |
90-year-old man • dyspnea • lower extremity edema • limitations in daily activities • Dx?
Topics: Activities of Daily Living; Aged, 80 and over; Diagnosis, Differential; Diuretics; Dyspnea; Edema; F | 2020 |
90-year-old man • dyspnea • lower extremity edema • limitations in daily activities • Dx?
Topics: Activities of Daily Living; Aged, 80 and over; Diagnosis, Differential; Diuretics; Dyspnea; Edema; F | 2020 |
MitraClip or Ventricular Assist Device?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Resynchronization The | 2020 |
MitraClip or Ventricular Assist Device?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Resynchronization The | 2020 |
Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities.
Topics: Aging; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; ras Proteins; Spiron | 2021 |
Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities.
Topics: Aging; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; ras Proteins; Spiron | 2021 |
Aldosterone: Behind the Scenes of Depression and Heart Failure?
Topics: Aldosterone; Depression; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolacto | 2020 |
Aldosterone: Behind the Scenes of Depression and Heart Failure?
Topics: Aldosterone; Depression; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolacto | 2020 |
Evaluation of the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease.
Topics: Aged; Diuretics; Female; Glomerular Filtration Rate; Heart Failure; Humans; Hyperkalemia; Male; Rena | 2021 |
Evaluation of the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease.
Topics: Aged; Diuretics; Female; Glomerular Filtration Rate; Heart Failure; Humans; Hyperkalemia; Male; Rena | 2021 |
Proteomics as a Path to More Refined Heart Failure Therapeutics.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Proteomics; Spironolactone | 2021 |
Proteomics as a Path to More Refined Heart Failure Therapeutics.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Proteomics; Spironolactone | 2021 |
A retrospective study on the short-term effect of high-dose spironolactone (80 mg/d) on chronic congestive heart failure.
Topics: Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Heart Failure; Heart Function Test | 2021 |
A retrospective study on the short-term effect of high-dose spironolactone (80 mg/d) on chronic congestive heart failure.
Topics: Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Heart Failure; Heart Function Test | 2021 |
Association of Baseline Diuretic Use With Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Secondary Analysis From TOPCAT.
Topics: Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Vol | 2021 |
Association of Baseline Diuretic Use With Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Secondary Analysis From TOPCAT.
Topics: Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Vol | 2021 |
Ambulatory Worsening of Renal Function in Heart Failure With Preserved Ejection Fraction.
Topics: Heart Failure; Humans; Kidney; Spironolactone; Stroke Volume | 2021 |
Ambulatory Worsening of Renal Function in Heart Failure With Preserved Ejection Fraction.
Topics: Heart Failure; Humans; Kidney; Spironolactone; Stroke Volume | 2021 |
Impact of SLCO4C1 Genotypes, Creatinine, and Spironolactone on Digoxin Population Pharmacokinetic Variables in Patients With Cardiac Insufficiency.
Topics: Creatinine; Digoxin; Genotype; Heart Failure; Humans; Organic Anion Transporters; Spironolactone | 2021 |
Impact of SLCO4C1 Genotypes, Creatinine, and Spironolactone on Digoxin Population Pharmacokinetic Variables in Patients With Cardiac Insufficiency.
Topics: Creatinine; Digoxin; Genotype; Heart Failure; Humans; Organic Anion Transporters; Spironolactone | 2021 |
Spironolactone and Eplerenone Use at Discharge in Heart Failure Patients With Reduced Ejection Fraction at 3 Large Hospital Systems.
Topics: Eplerenone; Heart Failure; Hospitals; Humans; Mineralocorticoid Receptor Antagonists; Patient Discha | 2023 |
Spironolactone and Eplerenone Use at Discharge in Heart Failure Patients With Reduced Ejection Fraction at 3 Large Hospital Systems.
Topics: Eplerenone; Heart Failure; Hospitals; Humans; Mineralocorticoid Receptor Antagonists; Patient Discha | 2023 |
Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial.
Topics: Aged; Diabetes Mellitus; Eplerenone; Female; Heart Failure; Heart Failure, Systolic; Humans; Insulin | 2021 |
Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial.
Topics: Aged; Diabetes Mellitus; Eplerenone; Female; Heart Failure; Heart Failure, Systolic; Humans; Insulin | 2021 |
A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; Treatm | 2021 |
A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; Treatm | 2021 |
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Arrest; Heart Failure; Hospitalizati | 2017 |
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Arrest; Heart Failure; Hospitalizati | 2017 |
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Arrest; Heart Failure; Hospitalizati | 2017 |
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Arrest; Heart Failure; Hospitalizati | 2017 |
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Arrest; Heart Failure; Hospitalizati | 2017 |
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Arrest; Heart Failure; Hospitalizati | 2017 |
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Arrest; Heart Failure; Hospitalizati | 2017 |
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Arrest; Heart Failure; Hospitalizati | 2017 |
Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diuretics; Female; Follow-Up Studies; Heart Failure; | 2017 |
Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diuretics; Female; Follow-Up Studies; Heart Failure; | 2017 |
Monitoring renal safety in mineralocorticoid receptor antagonist trials.
Topics: Aldosterone; Heart Failure; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Spironolactone | 2017 |
Monitoring renal safety in mineralocorticoid receptor antagonist trials.
Topics: Aldosterone; Heart Failure; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Spironolactone | 2017 |
Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation.
Topics: Canada; Canrenone; Clinical Trials as Topic; Heart Failure; Humans; Medication Adherence; Mineraloco | 2017 |
Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation.
Topics: Canada; Canrenone; Clinical Trials as Topic; Heart Failure; Humans; Medication Adherence; Mineraloco | 2017 |
Emphasis on abdominal obesity as a modifier of eplerenone effect in heart failure: hypothesis-generating signals from EMPHASIS-HF.
Topics: Eplerenone; Heart Failure; Mineralocorticoid Receptor Antagonists; Obesity, Abdominal; Spironolacton | 2017 |
Emphasis on abdominal obesity as a modifier of eplerenone effect in heart failure: hypothesis-generating signals from EMPHASIS-HF.
Topics: Eplerenone; Heart Failure; Mineralocorticoid Receptor Antagonists; Obesity, Abdominal; Spironolacton | 2017 |
Topics: Heart Failure; Humans; Russia; Spironolactone; Stroke Volume | 2017 |
Topics: Heart Failure; Humans; Russia; Spironolactone; Stroke Volume | 2017 |
A rare form of extremely wide QRS complex due to reversed homologous electrical ventricular separation of acute heart failure.
Topics: Acute Disease; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Benzaze | 2018 |
A rare form of extremely wide QRS complex due to reversed homologous electrical ventricular separation of acute heart failure.
Topics: Acute Disease; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Benzaze | 2018 |
Cardiac Amyloidosis as a Potential Confounder in Heart Failure With Preserved Ejection Fraction Trials.
Topics: Amyloidosis; Heart Failure; Humans; Natriuretic Peptides; Spironolactone; Stroke Volume | 2017 |
Cardiac Amyloidosis as a Potential Confounder in Heart Failure With Preserved Ejection Fraction Trials.
Topics: Amyloidosis; Heart Failure; Humans; Natriuretic Peptides; Spironolactone; Stroke Volume | 2017 |
Interpretation of the ATHENA Trial-Caveats and Future Directions.
Topics: Atrial Fibrillation; Heart Failure; Humans; Spironolactone | 2018 |
Interpretation of the ATHENA Trial-Caveats and Future Directions.
Topics: Atrial Fibrillation; Heart Failure; Humans; Spironolactone | 2018 |
Mineralocorticoid Receptor Antagonists in High-Risk Heart Failure Patients With Diabetes Mellitus and/or Chronic Kidney Disease.
Topics: Diabetes Mellitus; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Renal Insufficienc | 2017 |
Mineralocorticoid Receptor Antagonists in High-Risk Heart Failure Patients With Diabetes Mellitus and/or Chronic Kidney Disease.
Topics: Diabetes Mellitus; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Renal Insufficienc | 2017 |
Mineralocorticoid Receptor Antagonists Treatment in Resistant Hypertension and HFpEF: Evidence and Courage.
Topics: Courage; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2018 |
Mineralocorticoid Receptor Antagonists Treatment in Resistant Hypertension and HFpEF: Evidence and Courage.
Topics: Courage; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2018 |
Clinical findings and survival time in dogs with advanced heart failure.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Female; Furosemide; Heart Failure; Male; Mitral Val | 2018 |
Clinical findings and survival time in dogs with advanced heart failure.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Female; Furosemide; Heart Failure; Male; Mitral Val | 2018 |
Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
Topics: Aged; Female; Heart; Heart Failure; Hospitalization; Humans; Hyperkalemia; Male; Middle Aged; Minera | 2018 |
Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
Topics: Aged; Female; Heart; Heart Failure; Hospitalization; Humans; Hyperkalemia; Male; Middle Aged; Minera | 2018 |
Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study.
Topics: Aged; Aged, 80 and over; Biomarkers; Denmark; Female; Heart Failure; Humans; Hyperkalemia; Incidence | 2018 |
Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study.
Topics: Aged; Aged, 80 and over; Biomarkers; Denmark; Female; Heart Failure; Humans; Hyperkalemia; Incidence | 2018 |
Mineralocorticoid receptor antagonists in heart failure: they work better when patients use them.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Registries; Spironolactone; Sweden | 2018 |
Mineralocorticoid receptor antagonists in heart failure: they work better when patients use them.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Registries; Spironolactone; Sweden | 2018 |
Fibrosis mechanistic phenotyping and antifibrotic response determination with biomarkers in heart failure: one single biomarker may not fit all settings.
Topics: Biomarkers; Fibrosis; Heart Failure; Humans; Spironolactone; Stroke Volume | 2018 |
Fibrosis mechanistic phenotyping and antifibrotic response determination with biomarkers in heart failure: one single biomarker may not fit all settings.
Topics: Biomarkers; Fibrosis; Heart Failure; Humans; Spironolactone; Stroke Volume | 2018 |
Determinants of the beneficial effect of mineralocorticoid receptor antagonism on exercise capacity in heart failure with reduced ejection fraction.
Topics: Aged; Exercise Tolerance; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Recept | 2018 |
Determinants of the beneficial effect of mineralocorticoid receptor antagonism on exercise capacity in heart failure with reduced ejection fraction.
Topics: Aged; Exercise Tolerance; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Recept | 2018 |
Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy.
Topics: Aldosterone; Heart Failure; Humans; Hyperkalemia; Incidence; Mineralocorticoid Receptor Antagonists; | 2018 |
Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy.
Topics: Aldosterone; Heart Failure; Humans; Hyperkalemia; Incidence; Mineralocorticoid Receptor Antagonists; | 2018 |
[Analysis of the mitochondrial function and ultrastructure in healthy albino mice treated with heart failure medications]
Topics: Animals; Antihypertensive Agents; Atenolol; Cardiotonic Agents; Digoxin; Disease Models, Animal; Diu | 2017 |
[Analysis of the mitochondrial function and ultrastructure in healthy albino mice treated with heart failure medications]
Topics: Animals; Antihypertensive Agents; Atenolol; Cardiotonic Agents; Digoxin; Disease Models, Animal; Diu | 2017 |
Association Between High-Dose Spironolactone and Decongestion in Patients with Acute Heart Failure: An Observational Retrospective Study.
Topics: Aged; Diuretics; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Retrospective | 2018 |
Association Between High-Dose Spironolactone and Decongestion in Patients with Acute Heart Failure: An Observational Retrospective Study.
Topics: Aged; Diuretics; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Retrospective | 2018 |
Risk of renal dysfunction in an elderly patient with chronic heart failure.
Topics: Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; Diclofenac; Digoxin; Drug Interactio | 2016 |
Risk of renal dysfunction in an elderly patient with chronic heart failure.
Topics: Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; Diclofenac; Digoxin; Drug Interactio | 2016 |
Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure.
Topics: Aged; Aged, 80 and over; Eplerenone; Female; Follow-Up Studies; Heart Failure; Humans; Male; Mineral | 2018 |
Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure.
Topics: Aged; Aged, 80 and over; Eplerenone; Female; Follow-Up Studies; Heart Failure; Humans; Male; Mineral | 2018 |
Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Female; Heart Failure; Humans; Hyperkalemia; Male; | 2018 |
Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Female; Heart Failure; Humans; Hyperkalemia; Male; | 2018 |
Mineralocorticoid Receptor Antagonism for the Treatment of AF and HFpEF: Preserving Hope.
Topics: Atrial Fibrillation; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Miner | 2018 |
Mineralocorticoid Receptor Antagonism for the Treatment of AF and HFpEF: Preserving Hope.
Topics: Atrial Fibrillation; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Miner | 2018 |
Outcomes of spironolactone treatment in patients in Northeast China suffering from heart failure with mid-range ejection fraction.
Topics: Aged; Cause of Death; China; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Inci | 2019 |
Outcomes of spironolactone treatment in patients in Northeast China suffering from heart failure with mid-range ejection fraction.
Topics: Aged; Cause of Death; China; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Inci | 2019 |
Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia.
Topics: Aged; Cost-Benefit Analysis; Diuretics; Economics, Pharmaceutical; Heart Failure; Hospitalization; H | 2018 |
Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia.
Topics: Aged; Cost-Benefit Analysis; Diuretics; Economics, Pharmaceutical; Heart Failure; Hospitalization; H | 2018 |
Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Eplerenone; Female; Follow-Up Studies; Heart Failure; Humans; Male; Mineralocor | 2019 |
Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Eplerenone; Female; Follow-Up Studies; Heart Failure; Humans; Male; Mineralocor | 2019 |
Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Aged; Aged, 80 and over; Creatinine; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male | 2019 |
Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Aged; Aged, 80 and over; Creatinine; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male | 2019 |
Impact of the duration of the evidence-based medicine use in acute heart failure: A nationwide cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Digitalis Glycosides; Evidence | 2018 |
Impact of the duration of the evidence-based medicine use in acute heart failure: A nationwide cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Digitalis Glycosides; Evidence | 2018 |
The Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction: What Phase of Diastole Is Helped?
Topics: Diastole; Heart Failure; Humans; Spironolactone; Stroke Volume | 2019 |
The Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction: What Phase of Diastole Is Helped?
Topics: Diastole; Heart Failure; Humans; Spironolactone; Stroke Volume | 2019 |
Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Albuminuria; Creatinine; Female; Heart Failure; Humans; Male; Middle Aged; | 2018 |
Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Albuminuria; Creatinine; Female; Heart Failure; Humans; Male; Middle Aged; | 2018 |
Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Female; Heart Failure; Humans; Male; Middle Aged; | 2018 |
Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Female; Heart Failure; Humans; Male; Middle Aged; | 2018 |
Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzym | 2019 |
Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzym | 2019 |
Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Deprescriptions; Disease Progression; | 2019 |
Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Deprescriptions; Disease Progression; | 2019 |
Balancing Benefits and Risks of Spironolactone in HFpEF and Chronic Kidney Disease Patients: Mind the Gap of Biological Monitoring!
Topics: Biological Monitoring; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Renal Insuffic | 2019 |
Balancing Benefits and Risks of Spironolactone in HFpEF and Chronic Kidney Disease Patients: Mind the Gap of Biological Monitoring!
Topics: Biological Monitoring; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Renal Insuffic | 2019 |
Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT.
Topics: Aged; Aged, 80 and over; Body Weight; Cardiovascular Diseases; Cause of Death; Female; Heart Failure | 2019 |
Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT.
Topics: Aged; Aged, 80 and over; Body Weight; Cardiovascular Diseases; Cause of Death; Female; Heart Failure | 2019 |
Is there a potential association between spironolactone and the risk of new-onset diabetes in a cohort of older patients with heart failure?
Topics: Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus; Diuretics; Female; Heart Failure; Humans | 2019 |
Is there a potential association between spironolactone and the risk of new-onset diabetes in a cohort of older patients with heart failure?
Topics: Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus; Diuretics; Female; Heart Failure; Humans | 2019 |
Mortality associated with cardiovascular drugs in patients with chronic obstructive pulmonary disease and right-sided heart failure - A danish nationwide registry-based study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2019 |
Mortality associated with cardiovascular drugs in patients with chronic obstructive pulmonary disease and right-sided heart failure - A danish nationwide registry-based study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2019 |
Detecting Anomalies Among Practice Sites Within Multicenter Trials.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Data Accuracy; Data Interpretation | 2019 |
Detecting Anomalies Among Practice Sites Within Multicenter Trials.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Data Accuracy; Data Interpretation | 2019 |
Generalizability and Implications of the H
Topics: Clinical Trials as Topic; Decision Support Techniques; Heart Failure; Humans; Mineralocorticoid Rece | 2019 |
Generalizability and Implications of the H
Topics: Clinical Trials as Topic; Decision Support Techniques; Heart Failure; Humans; Mineralocorticoid Rece | 2019 |
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2019 |
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2019 |
Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study.
Topics: Adult; Aged; Comorbidity; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypertension; Lo | 2019 |
Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study.
Topics: Adult; Aged; Comorbidity; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypertension; Lo | 2019 |
Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Antihypertensive Agents; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid R | 2019 |
Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Antihypertensive Agents; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid R | 2019 |
Use of Nitrates and Risk of Cardiovascular Events in Patients With Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarc | 2019 |
Use of Nitrates and Risk of Cardiovascular Events in Patients With Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarc | 2019 |
Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report.
Topics: Acute Disease; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Aortic Valve Stenosis; | 2019 |
Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report.
Topics: Acute Disease; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Aortic Valve Stenosis; | 2019 |
Application of the H
Topics: Aged; Double-Blind Method; Female; Heart Failure; Humans; Internationality; Male; Mineralocorticoid | 2019 |
Application of the H
Topics: Aged; Double-Blind Method; Female; Heart Failure; Humans; Internationality; Male; Mineralocorticoid | 2019 |
Personalized Medicine: Women in Heart Failure Clinical Trials, a Must!
Topics: Female; Heart Failure; Humans; Male; Precision Medicine; Sex Characteristics; Spironolactone | 2019 |
Personalized Medicine: Women in Heart Failure Clinical Trials, a Must!
Topics: Female; Heart Failure; Humans; Male; Precision Medicine; Sex Characteristics; Spironolactone | 2019 |
Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Electrophysiological Phenomena; Fibrosis; Heart Failure; Heart | 2013 |
Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Electrophysiological Phenomena; Fibrosis; Heart Failure; Heart | 2013 |
Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure.
Topics: Adult; Aged; Aged, 80 and over; Canrenoic Acid; Cohort Studies; Female; Follow-Up Studies; Heart Fai | 2015 |
Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure.
Topics: Adult; Aged; Aged, 80 and over; Canrenoic Acid; Cohort Studies; Female; Follow-Up Studies; Heart Fai | 2015 |
[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Benzimidazoles; beta-Alanine; C | 2013 |
[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Benzimidazoles; beta-Alanine; C | 2013 |
Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Coh | 2013 |
Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Coh | 2013 |
Predisposing factors for acute kidney injury in Hispanic patients treated with diuretics for decompensated heart failure.
Topics: Acute Kidney Injury; Adult; Aged; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus; Drug Utilizati | 2013 |
Predisposing factors for acute kidney injury in Hispanic patients treated with diuretics for decompensated heart failure.
Topics: Acute Kidney Injury; Adult; Aged; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus; Drug Utilizati | 2013 |
Eplerenone: another drug to add to the mix?
Topics: Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; Male; Mineralocorticoid Re | 2013 |
Eplerenone: another drug to add to the mix?
Topics: Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; Male; Mineralocorticoid Re | 2013 |
Brain natriuretic peptide-guided management of chronic heart failure: first do no harm.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2013 |
Brain natriuretic peptide-guided management of chronic heart failure: first do no harm.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2013 |
Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Diuretics | 2013 |
Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Diuretics | 2013 |
Eplerenone and chronic heart failure. No comparison with spironolactone.
Topics: Chronic Disease; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralo | 2013 |
Eplerenone and chronic heart failure. No comparison with spironolactone.
Topics: Chronic Disease; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralo | 2013 |
Patients' interest overlooked.
Topics: Chronic Disease; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironol | 2013 |
Patients' interest overlooked.
Topics: Chronic Disease; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironol | 2013 |
Spironolactone in mild chronic heart failure: insights from a propensity-matched analysis of the MUSIC study cohort.
Topics: Aged; Chronic Disease; Female; Heart Failure; Humans; Longitudinal Studies; Male; Middle Aged; Miner | 2013 |
Spironolactone in mild chronic heart failure: insights from a propensity-matched analysis of the MUSIC study cohort.
Topics: Aged; Chronic Disease; Female; Heart Failure; Humans; Longitudinal Studies; Male; Middle Aged; Miner | 2013 |
Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bisoprolo | 2014 |
Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bisoprolo | 2014 |
A cornerstone of heart failure treatment is not effective in experimental right ventricular failure.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Eplerenone; Heart Failure; Losartan; Mal | 2013 |
A cornerstone of heart failure treatment is not effective in experimental right ventricular failure.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Eplerenone; Heart Failure; Losartan; Mal | 2013 |
Eplerenone enhances cardioprotective effects of standard heart failure therapy through matricellular proteins in hypertensive heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Drug | 2013 |
Eplerenone enhances cardioprotective effects of standard heart failure therapy through matricellular proteins in hypertensive heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Drug | 2013 |
[REMINDER Study: myocardial infarct without heart failure: does eplerenone have an advantage?].
Topics: Double-Blind Method; Early Medical Intervention; Eplerenone; Germany; Heart Failure; Humans; Mineral | 2013 |
[REMINDER Study: myocardial infarct without heart failure: does eplerenone have an advantage?].
Topics: Double-Blind Method; Early Medical Intervention; Eplerenone; Germany; Heart Failure; Humans; Mineral | 2013 |
Use of natriuretic-doses of spironolactone for treatment of loop diuretic resistant acute decompensated heart failure.
Topics: Acute Disease; Aged; Diuretics; Drug Resistance; Female; Heart Failure; Humans; Middle Aged; Mineral | 2014 |
Use of natriuretic-doses of spironolactone for treatment of loop diuretic resistant acute decompensated heart failure.
Topics: Acute Disease; Aged; Diuretics; Drug Resistance; Female; Heart Failure; Humans; Middle Aged; Mineral | 2014 |
Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.
Topics: Adrenergic beta-Antagonists; Aged; Cardiac Resynchronization Therapy; Combined Modality Therapy; Com | 2013 |
Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.
Topics: Adrenergic beta-Antagonists; Aged; Cardiac Resynchronization Therapy; Combined Modality Therapy; Com | 2013 |
Functional capacity in heart failure with preserved ejection fraction: looking for interactions and explanations.
Topics: Exercise Tolerance; Female; Heart Failure; Humans; Male; Spironolactone; Stroke Volume | 2014 |
Functional capacity in heart failure with preserved ejection fraction: looking for interactions and explanations.
Topics: Exercise Tolerance; Female; Heart Failure; Humans; Male; Spironolactone; Stroke Volume | 2014 |
Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers.
Topics: Aged; Aldosterone; Arginase; Cell Survival; Drug Interactions; Eplerenone; Female; Gene Expression R | 2014 |
Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers.
Topics: Aged; Aldosterone; Arginase; Cell Survival; Drug Interactions; Eplerenone; Female; Gene Expression R | 2014 |
Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure.
Topics: Action Potentials; Animals; Anti-Inflammatory Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artifici | 2014 |
Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure.
Topics: Action Potentials; Animals; Anti-Inflammatory Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artifici | 2014 |
Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
Topics: Animals; Autoradiography; Cardiomegaly; Disease Models, Animal; Eplerenone; Heart Failure; Kidney Di | 2014 |
Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
Topics: Animals; Autoradiography; Cardiomegaly; Disease Models, Animal; Eplerenone; Heart Failure; Kidney Di | 2014 |
Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Cause of Death; Comorbidity; Coronary Thrombos | 2014 |
Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Cause of Death; Comorbidity; Coronary Thrombos | 2014 |
Lessons from the TOPCAT trial.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Lessons from the TOPCAT trial.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
[TOPCAT study. Heart failure: spironolactone disappoints in the "problem patient"].
Topics: Diuretics; Heart Failure; Humans; Multicenter Studies as Topic; Natriuretic Peptide, Brain; Peptide | 2013 |
[TOPCAT study. Heart failure: spironolactone disappoints in the "problem patient"].
Topics: Diuretics; Heart Failure; Humans; Multicenter Studies as Topic; Natriuretic Peptide, Brain; Peptide | 2013 |
Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction <45%, and estimated glomerular filtration rate <45 ml/min/1.73 m(2.).
Topics: Aged; Alabama; Diuretics; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Medicare; | 2014 |
Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction <45%, and estimated glomerular filtration rate <45 ml/min/1.73 m(2.).
Topics: Aged; Alabama; Diuretics; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Medicare; | 2014 |
[Multination clinical trials: what is the relevance and what are the lessons from across-country differences?].
Topics: Acute Coronary Syndrome; Adenosine; Americas; Benzazepines; Cardiovascular Agents; Cardiovascular Di | 2014 |
[Multination clinical trials: what is the relevance and what are the lessons from across-country differences?].
Topics: Acute Coronary Syndrome; Adenosine; Americas; Benzazepines; Cardiovascular Agents; Cardiovascular Di | 2014 |
Interplay of parathyroid hormone and aldosterone antagonist in prevention of heart failure hospitalizations in chronic kidney disease.
Topics: Aged; Aldosterone; Case-Control Studies; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meie | 2014 |
Interplay of parathyroid hormone and aldosterone antagonist in prevention of heart failure hospitalizations in chronic kidney disease.
Topics: Aged; Aldosterone; Case-Control Studies; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meie | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Spironolactone for heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Urinary composition during decongestive treatment in heart failure with reduced ejection fraction.
Topics: Administration, Oral; Aged; Biomarkers; Bumetanide; Chlorides; Diuretics; Dose-Response Relationship | 2014 |
Urinary composition during decongestive treatment in heart failure with reduced ejection fraction.
Topics: Administration, Oral; Aged; Biomarkers; Bumetanide; Chlorides; Diuretics; Dose-Response Relationship | 2014 |
Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Heart Ventricles; Humans; Magneti | 2014 |
Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Heart Ventricles; Humans; Magneti | 2014 |
Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Heart Ventricles; Humans; Magneti | 2014 |
Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Heart Ventricles; Humans; Magneti | 2014 |
Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Heart Ventricles; Humans; Magneti | 2014 |
Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Heart Ventricles; Humans; Magneti | 2014 |
Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Heart Ventricles; Humans; Magneti | 2014 |
Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Heart Ventricles; Humans; Magneti | 2014 |
Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
[Are aldosterone antagonists effective in patients with mild to moderate heart failure?].
Topics: Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Severity of Illness | 2014 |
[Are aldosterone antagonists effective in patients with mild to moderate heart failure?].
Topics: Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Severity of Illness | 2014 |
Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west.
Topics: Benzimidazoles; Biphenyl Compounds; Female; Fluorobenzenes; Geography; Heart Failure; Humans; Intern | 2015 |
Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west.
Topics: Benzimidazoles; Biphenyl Compounds; Female; Fluorobenzenes; Geography; Heart Failure; Humans; Intern | 2015 |
Do not analyze too quickly a result: how spironolactone is always point at!
Topics: Diuretics; Female; Heart Failure; Humans; Male; Patient Readmission; Spironolactone | 2015 |
Do not analyze too quickly a result: how spironolactone is always point at!
Topics: Diuretics; Female; Heart Failure; Humans; Male; Patient Readmission; Spironolactone | 2015 |
Reply: To PMID 24846806.
Topics: Diuretics; Female; Heart Failure; Humans; Male; Patient Readmission; Spironolactone | 2015 |
Reply: To PMID 24846806.
Topics: Diuretics; Female; Heart Failure; Humans; Male; Patient Readmission; Spironolactone | 2015 |
Biomarkers, mineralocorticoid receptor antagonism, and cardiorenal remodeling.
Topics: Acute Kidney Injury; Animals; Galectin 3; Heart Failure; Interleukins; Male; Myocardial Infarction; | 2015 |
Biomarkers, mineralocorticoid receptor antagonism, and cardiorenal remodeling.
Topics: Acute Kidney Injury; Animals; Galectin 3; Heart Failure; Interleukins; Male; Myocardial Infarction; | 2015 |
The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.
Topics: Acute Kidney Injury; Aldosterone; Animals; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay | 2015 |
The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.
Topics: Acute Kidney Injury; Aldosterone; Animals; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay | 2015 |
Male breast uptake in rubidium-82 PET due to spironolactone-induced gynecomastia.
Topics: Aged, 80 and over; Breast; Breast Neoplasms, Male; Diagnosis, Differential; Fibrosis; Gynecomastia; | 2015 |
Male breast uptake in rubidium-82 PET due to spironolactone-induced gynecomastia.
Topics: Aged, 80 and over; Breast; Breast Neoplasms, Male; Diagnosis, Differential; Fibrosis; Gynecomastia; | 2015 |
The year in cardiology: heart failure 2014.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Resynchronization The | 2015 |
The year in cardiology: heart failure 2014.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Resynchronization The | 2015 |
Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Case-Control S | 2015 |
Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Case-Control S | 2015 |
My approach to patients with heart failure and a normal ejection fraction.
Topics: Diuretics; Heart Failure; Humans; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone; St | 2015 |
My approach to patients with heart failure and a normal ejection fraction.
Topics: Diuretics; Heart Failure; Humans; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone; St | 2015 |
Cardiovascular medication utilization and adherence among heart failure patients in rural and urban areas: a retrospective cohort study.
Topics: Adrenergic Antagonists; Aged; Aged, 80 and over; Canada; Cardiotonic Agents; Cardiovascular Agents; | 2015 |
Cardiovascular medication utilization and adherence among heart failure patients in rural and urban areas: a retrospective cohort study.
Topics: Adrenergic Antagonists; Aged; Aged, 80 and over; Canada; Cardiotonic Agents; Cardiovascular Agents; | 2015 |
Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cohort Studies; Databases, Factual; Female; Heart Fa | 2015 |
Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cohort Studies; Databases, Factual; Female; Heart Fa | 2015 |
Healing the orphaned heart: heart failure in a patient with glucose-6-phosphate dehydrogenase deficiency.
Topics: Aged; Diuretics; Drug Therapy, Combination; Ethacrynic Acid; Female; Glucosephosphate Dehydrogenase | 2015 |
Healing the orphaned heart: heart failure in a patient with glucose-6-phosphate dehydrogenase deficiency.
Topics: Aged; Diuretics; Drug Therapy, Combination; Ethacrynic Acid; Female; Glucosephosphate Dehydrogenase | 2015 |
Clinical Development and Regulatory Approval of Acute Heart Failure Drugs in Japan : Editorial to: "Rationale and Design of Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients
Topics: Clinical Protocols; Early Medical Intervention; Female; Heart Failure; Humans; Male; Mineralocortico | 2015 |
Clinical Development and Regulatory Approval of Acute Heart Failure Drugs in Japan : Editorial to: "Rationale and Design of Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients
Topics: Clinical Protocols; Early Medical Intervention; Female; Heart Failure; Humans; Male; Mineralocortico | 2015 |
[Internal medicine in the hospital setting].
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Asymptomatic Diseases | 2015 |
[Internal medicine in the hospital setting].
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Asymptomatic Diseases | 2015 |
Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: Data from the Korean Heart Failure Registry.
Topics: Acute Disease; Aged; Aged, 80 and over; Female; Glomerular Filtration Rate; Heart Failure; Hospitali | 2015 |
Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: Data from the Korean Heart Failure Registry.
Topics: Acute Disease; Aged; Aged, 80 and over; Female; Glomerular Filtration Rate; Heart Failure; Hospitali | 2015 |
Post hoc subgroups in clinical trials: Anathema or analytics?
Topics: Algorithms; Data Interpretation, Statistical; Diuretics; Female; Forecasting; Heart Failure; Humans; | 2015 |
Post hoc subgroups in clinical trials: Anathema or analytics?
Topics: Algorithms; Data Interpretation, Statistical; Diuretics; Female; Forecasting; Heart Failure; Humans; | 2015 |
Early Spironolactone Treatment Attenuates Heart Failure Development by Improving Myocardial Function and Reducing Fibrosis in Spontaneously Hypertensive Rats.
Topics: Animals; Fibrosis; Heart; Heart Failure; Hypertension; Male; Mineralocorticoid Receptor Antagonists; | 2015 |
Early Spironolactone Treatment Attenuates Heart Failure Development by Improving Myocardial Function and Reducing Fibrosis in Spontaneously Hypertensive Rats.
Topics: Animals; Fibrosis; Heart; Heart Failure; Hypertension; Male; Mineralocorticoid Receptor Antagonists; | 2015 |
[Cardiovascular drugs in aged and multimorbid patients].
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; | 2015 |
[Cardiovascular drugs in aged and multimorbid patients].
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; | 2015 |
Successful Treatment with an Antihypertensive Drug Regimen Including Eplerenone in a Patient with Malignant Phase Hypertension with Renal Failure.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cal | 2015 |
Successful Treatment with an Antihypertensive Drug Regimen Including Eplerenone in a Patient with Malignant Phase Hypertension with Renal Failure.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cal | 2015 |
Rac1-Mediated Activation of Mineralocorticoid Receptor in Pressure Overload-Induced Cardiac Injury.
Topics: Animals; Disease Models, Animal; Eplerenone; Heart Failure; Male; Mice; Mice, Inbred C57BL; Mineralo | 2016 |
Rac1-Mediated Activation of Mineralocorticoid Receptor in Pressure Overload-Induced Cardiac Injury.
Topics: Animals; Disease Models, Animal; Eplerenone; Heart Failure; Male; Mice; Mice, Inbred C57BL; Mineralo | 2016 |
Device therapy and aldosterone antagonists in the prognosis of heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Mineralocorticoid Rece | 2016 |
Device therapy and aldosterone antagonists in the prognosis of heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Mineralocorticoid Rece | 2016 |
Drug-related problems vary with medication category and treatment duration in Taiwanese heart failure outpatients receiving case management.
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Case M | 2016 |
Drug-related problems vary with medication category and treatment duration in Taiwanese heart failure outpatients receiving case management.
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Case M | 2016 |
Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Databases, Factual; Drug Prescriptions; D | 2016 |
Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Databases, Factual; Drug Prescriptions; D | 2016 |
QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiovascular Diseases; Cohort Studies; Electrocardi | 2016 |
QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiovascular Diseases; Cohort Studies; Electrocardi | 2016 |
MRAs in Patients With AMI Without Early Evidence of Heart Failure: Time for Reappraisal?
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone | 2016 |
MRAs in Patients With AMI Without Early Evidence of Heart Failure: Time for Reappraisal?
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone | 2016 |
Fibroblast Senescence as a Therapeutic Target of Myocardial Fibrosis: Beyond Spironolactone?
Topics: Cardiomyopathies; Fibroblasts; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonis | 2016 |
Fibroblast Senescence as a Therapeutic Target of Myocardial Fibrosis: Beyond Spironolactone?
Topics: Cardiomyopathies; Fibroblasts; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonis | 2016 |
Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective.
Topics: Australia; Chronic Disease; Cost-Benefit Analysis; Eplerenone; Heart Failure; Hospitalization; Human | 2016 |
Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective.
Topics: Australia; Chronic Disease; Cost-Benefit Analysis; Eplerenone; Heart Failure; Hospitalization; Human | 2016 |
Spirolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats.
Topics: Animals; Epithelial-Mesenchymal Transition; Heart Failure; Kidney Diseases; Rats; Spironolactone; Tr | 2016 |
Spirolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats.
Topics: Animals; Epithelial-Mesenchymal Transition; Heart Failure; Kidney Diseases; Rats; Spironolactone; Tr | 2016 |
Rapid effects of aldosterone in primary cultures of cardiomyocytes - do they suggest the existence of a membrane-bound receptor?
Topics: A Kinase Anchor Proteins; Aldosterone; Animals; Atrial Natriuretic Factor; Cyclic AMP; Egtazic Acid; | 2016 |
Rapid effects of aldosterone in primary cultures of cardiomyocytes - do they suggest the existence of a membrane-bound receptor?
Topics: A Kinase Anchor Proteins; Aldosterone; Animals; Atrial Natriuretic Factor; Cyclic AMP; Egtazic Acid; | 2016 |
Association between long-term prescription of aldosterone antagonist and the progression of heart failure with preserved ejection fraction in hypertensive patients.
Topics: Antihypertensive Agents; Cardiotonic Agents; Cohort Studies; Disease Progression; Drug Administratio | 2016 |
Association between long-term prescription of aldosterone antagonist and the progression of heart failure with preserved ejection fraction in hypertensive patients.
Topics: Antihypertensive Agents; Cardiotonic Agents; Cohort Studies; Disease Progression; Drug Administratio | 2016 |
Clinical and echocardiographic characteristics and outcomes in congestive heart failure at the Hospital of The State University of Haiti.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Age Distribution; Aged; Aged, 80 and over; Angiotens | 2016 |
Clinical and echocardiographic characteristics and outcomes in congestive heart failure at the Hospital of The State University of Haiti.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Age Distribution; Aged; Aged, 80 and over; Angiotens | 2016 |
A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Spironola | 2016 |
A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Spironola | 2016 |
Serum Potassium Levels and Outcome in Patients With Chronic Heart Failure.
Topics: Aged; Aged, 80 and over; Chronic Disease; Cohort Studies; Diuretics; Female; Heart Failure; Humans; | 2016 |
Serum Potassium Levels and Outcome in Patients With Chronic Heart Failure.
Topics: Aged; Aged, 80 and over; Chronic Disease; Cohort Studies; Diuretics; Female; Heart Failure; Humans; | 2016 |
Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone.
Topics: Alabama; Female; Heart Failure; Humans; Insurance Benefits; Male; Medicare; Mineralocorticoid Recept | 2017 |
Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone.
Topics: Alabama; Female; Heart Failure; Humans; Insurance Benefits; Male; Medicare; Mineralocorticoid Recept | 2017 |
Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT.
Topics: Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Heart Failure; Humans; Hyperka | 2017 |
Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT.
Topics: Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Heart Failure; Humans; Hyperka | 2017 |
Spironolactone-potion or poison?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; H | 2017 |
Spironolactone-potion or poison?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; H | 2017 |
[Heart failure provoked by a pacemaker lead-induced tricuspid stenosis].
Topics: Aged; Angiography; Diuretics; Echocardiography; Furosemide; Heart Failure; Humans; Male; Pacemaker, | 2017 |
[Heart failure provoked by a pacemaker lead-induced tricuspid stenosis].
Topics: Aged; Angiography; Diuretics; Echocardiography; Furosemide; Heart Failure; Humans; Male; Pacemaker, | 2017 |
[Regulatory Adaptive Status in Assessment of Efficacy of Pharmacotherapy and Prognostication of Complications in Functional Class III Chronic Heart Failure].
Topics: Aged; Benzazepines; Cardiovascular Agents; Chronic Disease; Echocardiography; Exercise Test; Female; | 2016 |
[Regulatory Adaptive Status in Assessment of Efficacy of Pharmacotherapy and Prognostication of Complications in Functional Class III Chronic Heart Failure].
Topics: Aged; Benzazepines; Cardiovascular Agents; Chronic Disease; Echocardiography; Exercise Test; Female; | 2016 |
Comparison of one-year outcome (death and rehospitalization) in hospitalized heart failure patients with left ventricular ejection fraction >50% versus those with ejection fraction <50%.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Card | 2008 |
Comparison of one-year outcome (death and rehospitalization) in hospitalized heart failure patients with left ventricular ejection fraction >50% versus those with ejection fraction <50%.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Card | 2008 |
Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Signaling; Ca | 2008 |
Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Signaling; Ca | 2008 |
Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone.
Topics: Angiotensin Receptor Antagonists; Animals; Cytochrome P-450 CYP11B2; Endothelium, Vascular; Fadrozol | 2008 |
Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone.
Topics: Angiotensin Receptor Antagonists; Animals; Cytochrome P-450 CYP11B2; Endothelium, Vascular; Fadrozol | 2008 |
Fracture risk in men with congestive heart failure risk reduction with spironolactone.
Topics: Aged; Fractures, Bone; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagoni | 2008 |
Fracture risk in men with congestive heart failure risk reduction with spironolactone.
Topics: Aged; Fractures, Bone; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagoni | 2008 |
Hospital management of heart failure: improvement but still room for improvement at discharge...
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Diet; Diuretics; Drug Utilizat | 2008 |
Hospital management of heart failure: improvement but still room for improvement at discharge...
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Diet; Diuretics; Drug Utilizat | 2008 |
Evaluation of heart failure management in a Military Hospital.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Diet; Diuretics; Drug Utilizat | 2008 |
Evaluation of heart failure management in a Military Hospital.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Diet; Diuretics; Drug Utilizat | 2008 |
[Misdiagnosed emergency: heart failure symptoms after infarct. Rapid aldosterone block can safe the tired heart].
Topics: Drug Administration Schedule; Emergencies; Eplerenone; Heart Failure; Humans; Mineralocorticoid Rece | 2008 |
[Misdiagnosed emergency: heart failure symptoms after infarct. Rapid aldosterone block can safe the tired heart].
Topics: Drug Administration Schedule; Emergencies; Eplerenone; Heart Failure; Humans; Mineralocorticoid Rece | 2008 |
Association of blood pressure and its evolving changes with the survival of patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium | 2008 |
Association of blood pressure and its evolving changes with the survival of patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium | 2008 |
Clinical factors affecting serum potassium concentration in cardio-renal decompensation syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Con | 2010 |
Clinical factors affecting serum potassium concentration in cardio-renal decompensation syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Con | 2010 |
Hyperkalemia during spironolactone use in patients with decompensated heart failure.
Topics: Brazil; Epidemiologic Methods; Female; Heart Failure; Humans; Hyperkalemia; Male; Middle Aged; Miner | 2008 |
Hyperkalemia during spironolactone use in patients with decompensated heart failure.
Topics: Brazil; Epidemiologic Methods; Female; Heart Failure; Humans; Hyperkalemia; Male; Middle Aged; Miner | 2008 |
Eplerenone in patients with acute myocardial infarction complicated by heart failure.
Topics: Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Myocardial | 2008 |
Eplerenone in patients with acute myocardial infarction complicated by heart failure.
Topics: Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Myocardial | 2008 |
Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial.
Topics: Adult; Aged; Black or African American; Clinical Trials, Phase III as Topic; Drug Combinations; Drug | 2008 |
Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial.
Topics: Adult; Aged; Black or African American; Clinical Trials, Phase III as Topic; Drug Combinations; Drug | 2008 |
Safety of spironolactone use in ambulatory heart failure patients.
Topics: Aged; Ambulatory Care; Biomarkers; Cohort Studies; Creatinine; Disease Progression; Diuretics; Femal | 2008 |
Safety of spironolactone use in ambulatory heart failure patients.
Topics: Aged; Ambulatory Care; Biomarkers; Cohort Studies; Creatinine; Disease Progression; Diuretics; Femal | 2008 |
Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2009 |
Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2009 |
Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Angiotensin-Converting Enzyme Inhibitors; Datab | 2009 |
Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Angiotensin-Converting Enzyme Inhibitors; Datab | 2009 |
Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Angiotensin-Converting Enzyme Inhibitors; Datab | 2009 |
Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Angiotensin-Converting Enzyme Inhibitors; Datab | 2009 |
Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Angiotensin-Converting Enzyme Inhibitors; Datab | 2009 |
Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Angiotensin-Converting Enzyme Inhibitors; Datab | 2009 |
Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Angiotensin-Converting Enzyme Inhibitors; Datab | 2009 |
Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Angiotensin-Converting Enzyme Inhibitors; Datab | 2009 |
[Renal effect of treatment for heart failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathies; Diuretics; Furosemide; Heart Failure; Hu | 2009 |
[Renal effect of treatment for heart failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathies; Diuretics; Furosemide; Heart Failure; Hu | 2009 |
The role of aldosterone blockade in end-stage renal disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Ther | 2009 |
The role of aldosterone blockade in end-stage renal disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Ther | 2009 |
A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
Topics: Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Randomized | 2009 |
A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
Topics: Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Randomized | 2009 |
Prevalence and physiological predictors of sleep apnea in patients with heart failure and systolic dysfunction.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Body Mass Inde | 2009 |
Prevalence and physiological predictors of sleep apnea in patients with heart failure and systolic dysfunction.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Body Mass Inde | 2009 |
Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure.
Topics: Animals; Disease Models, Animal; Dogs; Electrocardiography; Eplerenone; Heart Failure; Mineralocorti | 2009 |
Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure.
Topics: Animals; Disease Models, Animal; Dogs; Electrocardiography; Eplerenone; Heart Failure; Mineralocorti | 2009 |
Safety of spironolactone use in ambulatory heart failure patients.
Topics: Aged; Ambulatory Care; Biomarkers; Chronic Disease; Creatinine; Evidence-Based Medicine; Female; Hea | 2009 |
Safety of spironolactone use in ambulatory heart failure patients.
Topics: Aged; Ambulatory Care; Biomarkers; Chronic Disease; Creatinine; Evidence-Based Medicine; Female; Hea | 2009 |
[Effects of various diuretics on cardiac function in rats with heart failure].
Topics: Animals; Cytochrome P-450 CYP11B2; Disease Models, Animal; Diuretics; Furosemide; Heart Failure; Hem | 2009 |
[Effects of various diuretics on cardiac function in rats with heart failure].
Topics: Animals; Cytochrome P-450 CYP11B2; Disease Models, Animal; Diuretics; Furosemide; Heart Failure; Hem | 2009 |
Triple therapy can achieve striking reductions in frusemide dosage.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Drug Therapy, Combination; Female; Furose | 2009 |
Triple therapy can achieve striking reductions in frusemide dosage.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Drug Therapy, Combination; Female; Furose | 2009 |
[Aldosterone antagonists for all patients with heart failure?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Death, Sudden, Cardiac; Drug Therapy, Combination; Epleren | 2009 |
[Aldosterone antagonists for all patients with heart failure?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Death, Sudden, Cardiac; Drug Therapy, Combination; Epleren | 2009 |
Dietary salt restriction activates mineralocorticoid receptor signaling in volume-overloaded heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Body Weight; Cell Size; Contraindications; Diet, So | 2009 |
Dietary salt restriction activates mineralocorticoid receptor signaling in volume-overloaded heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Body Weight; Cell Size; Contraindications; Diet, So | 2009 |
Complications during enalapril and diuretic therapy for congestive cardiac failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Digoxin; Diuretics; Drug Therapy, Comb | 2009 |
Complications during enalapril and diuretic therapy for congestive cardiac failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Digoxin; Diuretics; Drug Therapy, Comb | 2009 |
Spironolactone therapy in heart failure patients with chronic kidney disease.
Topics: Biomarkers; Chronic Disease; Creatinine; Heart Failure; Humans; Hyperkalemia; Kidney Diseases; Miner | 2009 |
Spironolactone therapy in heart failure patients with chronic kidney disease.
Topics: Biomarkers; Chronic Disease; Creatinine; Heart Failure; Humans; Hyperkalemia; Kidney Diseases; Miner | 2009 |
Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress.
Topics: Adrenocorticotropic Hormone; Aldosterone; Biomarkers; Chronic Disease; Diuretics; Follow-Up Studies; | 2009 |
Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress.
Topics: Adrenocorticotropic Hormone; Aldosterone; Biomarkers; Chronic Disease; Diuretics; Follow-Up Studies; | 2009 |
Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensinogen; Black or African American; Cohort Studies; Diuretics; Fem | 2010 |
Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensinogen; Black or African American; Cohort Studies; Diuretics; Fem | 2010 |
Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cost-Benefit Analysis; | 2010 |
Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cost-Benefit Analysis; | 2010 |
Combined amiodarone and low-dose carvedilol treatment for severe heart failure in childhood.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dos | 2010 |
Combined amiodarone and low-dose carvedilol treatment for severe heart failure in childhood.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dos | 2010 |
Slow adoption of helpful heart failure drug. Many people who could benefit from spironolactone aren't getting it.
Topics: Drug Utilization; Female; Gastrointestinal Hemorrhage; Health Education; Health Knowledge, Attitudes | 2010 |
Slow adoption of helpful heart failure drug. Many people who could benefit from spironolactone aren't getting it.
Topics: Drug Utilization; Female; Gastrointestinal Hemorrhage; Health Education; Health Knowledge, Attitudes | 2010 |
Spironolactone use and renal toxicity: population based longitudinal analysis.
Topics: Acute Kidney Injury; Aged; Angiotensin-Converting Enzyme Inhibitors; Creatine; Female; Heart Failure | 2010 |
Spironolactone use and renal toxicity: population based longitudinal analysis.
Topics: Acute Kidney Injury; Aged; Angiotensin-Converting Enzyme Inhibitors; Creatine; Female; Heart Failure | 2010 |
A preclinical pharmacokinetic and pharmacodynamic approach to determine a dose of spironolactone for treatment of congestive heart failure in dog.
Topics: Animals; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Heart Failure; Hyperaldosteronism; Ma | 2010 |
A preclinical pharmacokinetic and pharmacodynamic approach to determine a dose of spironolactone for treatment of congestive heart failure in dog.
Topics: Animals; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Heart Failure; Hyperaldosteronism; Ma | 2010 |
[An elderly man with known heart failure admitted with cardiogenic shock].
Topics: Acute Kidney Injury; Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Ang | 2010 |
[An elderly man with known heart failure admitted with cardiogenic shock].
Topics: Acute Kidney Injury; Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Ang | 2010 |
[Application of cardiac resynchronization therapy and ivabradine in a patient with chronic heart failure].
Topics: Benzazepines; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiova | 2010 |
[Application of cardiac resynchronization therapy and ivabradine in a patient with chronic heart failure].
Topics: Benzazepines; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiova | 2010 |
Aldosterone inhibition and cardiovascular protection: more important than it once appeared.
Topics: Aldosterone; Atherosclerosis; Blood Vessels; Cardiomegaly; Cardiotonic Agents; Endothelium; Heart Fa | 2010 |
Aldosterone inhibition and cardiovascular protection: more important than it once appeared.
Topics: Aldosterone; Atherosclerosis; Blood Vessels; Cardiomegaly; Cardiotonic Agents; Endothelium; Heart Fa | 2010 |
Temporal trends in adherence to cardiovascular medications in elderly patients after hospitalization for heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Card | 2010 |
Temporal trends in adherence to cardiovascular medications in elderly patients after hospitalization for heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Card | 2010 |
Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diuretics; Drug Therapy, Co | 2010 |
Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diuretics; Drug Therapy, Co | 2010 |
Aldosterone antagonists--last man standing?
Topics: Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Implantable; Eplerenone; Heart F | 2011 |
Aldosterone antagonists--last man standing?
Topics: Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Implantable; Eplerenone; Heart F | 2011 |
Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina Pectoris; Angiotensin-Converting Enzyme | 2011 |
Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina Pectoris; Angiotensin-Converting Enzyme | 2011 |
Assessment of drug treatment quality in two Danish health-care centres.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2011 |
Assessment of drug treatment quality in two Danish health-care centres.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2011 |
[Aldosterone blocker in heart failure: life prolonging even in mild symptoms].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Early Termination of Clinical | 2010 |
[Aldosterone blocker in heart failure: life prolonging even in mild symptoms].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Early Termination of Clinical | 2010 |
Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure.
Topics: Aged; Diabetic Angiopathies; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineraloc | 2011 |
Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure.
Topics: Aged; Diabetic Angiopathies; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineraloc | 2011 |
Eplerenone in mild heart failure.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Vo | 2011 |
Eplerenone in mild heart failure.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Vo | 2011 |
Eplerenone in mild heart failure.
Topics: Aldosterone; Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor | 2011 |
Eplerenone in mild heart failure.
Topics: Aldosterone; Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor | 2011 |
Eplerenone in mild heart failure.
Topics: Blood Pressure; Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Mineralocorticoid Recept | 2011 |
Eplerenone in mild heart failure.
Topics: Blood Pressure; Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Mineralocorticoid Recept | 2011 |
Eplerenone in mild heart failure.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2011 |
Eplerenone in mild heart failure.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2011 |
Microvascular tissue perfusion is impaired in acutely decompensated heart failure and improves following standard treatment.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2011 |
Microvascular tissue perfusion is impaired in acutely decompensated heart failure and improves following standard treatment.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2011 |
Prognostic value of plasma renin activity in heart failure.
Topics: Aged; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bioma | 2011 |
Prognostic value of plasma renin activity in heart failure.
Topics: Aged; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bioma | 2011 |
[The EMPHASIS-HF study].
Topics: Aldosterone; Biomarkers; Canrenone; Cause of Death; Double-Blind Method; Early Termination of Clinic | 2011 |
[The EMPHASIS-HF study].
Topics: Aldosterone; Biomarkers; Canrenone; Cause of Death; Double-Blind Method; Early Termination of Clinic | 2011 |
Use, tolerability and compliance of spironolactone in the treatment of heart failure.
Topics: Adult; Aged; Aged, 80 and over; Female; Heart Failure; Humans; Male; Medication Adherence; Middle Ag | 2011 |
Use, tolerability and compliance of spironolactone in the treatment of heart failure.
Topics: Adult; Aged; Aged, 80 and over; Female; Heart Failure; Humans; Male; Medication Adherence; Middle Ag | 2011 |
Cardiac AA amyloidosis in a patient with rheumatoid arthritis and systemic sclerosis: the therapeutic potential of biological reagents.
Topics: Aged; Amyloidosis; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis, Rheumatoid; Benzimidazo | 2011 |
Cardiac AA amyloidosis in a patient with rheumatoid arthritis and systemic sclerosis: the therapeutic potential of biological reagents.
Topics: Aged; Amyloidosis; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis, Rheumatoid; Benzimidazo | 2011 |
Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
Topics: Aged; Diuretics; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Hospita | 2011 |
Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
Topics: Aged; Diuretics; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Hospita | 2011 |
Eplerenone, an aldosterone antagonist, reduces hospitalization and death in heart failure patients with NYHA class II and an ejection fraction of less than 30%.
Topics: Eplerenone; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Randomiz | 2011 |
Eplerenone, an aldosterone antagonist, reduces hospitalization and death in heart failure patients with NYHA class II and an ejection fraction of less than 30%.
Topics: Eplerenone; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Randomiz | 2011 |
The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.
Topics: Angiotensin II Type 1 Receptor Blockers; Aortic Valve Stenosis; Benzimidazoles; Biphenyl Compounds; | 2012 |
The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.
Topics: Angiotensin II Type 1 Receptor Blockers; Aortic Valve Stenosis; Benzimidazoles; Biphenyl Compounds; | 2012 |
Upright T waves in lead aVR are associated with cardiac death or hospitalization for heart failure in patients with a prior myocardial infarction.
Topics: Age Factors; Aged; Anterior Wall Myocardial Infarction; Chi-Square Distribution; Death, Sudden, Card | 2012 |
Upright T waves in lead aVR are associated with cardiac death or hospitalization for heart failure in patients with a prior myocardial infarction.
Topics: Age Factors; Aged; Anterior Wall Myocardial Infarction; Chi-Square Distribution; Death, Sudden, Card | 2012 |
The number of leads with fragmented QRS is independently associated with cardiac death or hospitalization for heart failure in patients with prior myocardial infarction.
Topics: Age Factors; Aged; Electrocardiography; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meier | 2012 |
The number of leads with fragmented QRS is independently associated with cardiac death or hospitalization for heart failure in patients with prior myocardial infarction.
Topics: Age Factors; Aged; Electrocardiography; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meier | 2012 |
Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival St
Topics: Aged; Clinical Trials as Topic; Diuresis; Eplerenone; Female; Heart Failure; Humans; Male; Middle Ag | 2011 |
Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival St
Topics: Aged; Clinical Trials as Topic; Diuresis; Eplerenone; Female; Heart Failure; Humans; Male; Middle Ag | 2011 |
The month after a novel tale on eplerenone, but with a different ending.
Topics: Diuresis; Eplerenone; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; P | 2011 |
The month after a novel tale on eplerenone, but with a different ending.
Topics: Diuresis; Eplerenone; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; P | 2011 |
Ask the doctor. My 69-year-old husband has had cardiomyopathy and diabetes for several years. Lately his ankles are always swollen. At his last doctor's visit, my husband's cardiologist said his heart has leaky valves and his ejection fraction is 10%. Wha
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathies; Diabe | 2011 |
Ask the doctor. My 69-year-old husband has had cardiomyopathy and diabetes for several years. Lately his ankles are always swollen. At his last doctor's visit, my husband's cardiologist said his heart has leaky valves and his ejection fraction is 10%. Wha
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathies; Diabe | 2011 |
Mineralocorticoid receptor antagonists for heart failure.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spi | 2011 |
Mineralocorticoid receptor antagonists for heart failure.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spi | 2011 |
Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure.
Topics: Aldosterone; Animals; Cell Proliferation; Echocardiography; Heart Failure; Hypertension, Pulmonary; | 2011 |
Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure.
Topics: Aldosterone; Animals; Cell Proliferation; Echocardiography; Heart Failure; Hypertension, Pulmonary; | 2011 |
PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016.
Topics: Aged; Analysis of Variance; Female; Glomerular Filtration Rate; Health Status Indicators; Heart Fail | 2012 |
PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016.
Topics: Aged; Analysis of Variance; Female; Glomerular Filtration Rate; Health Status Indicators; Heart Fail | 2012 |
Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure.
Topics: Aged; Aged, 80 and over; Chronic Disease; Death, Sudden, Cardiac; Female; Follow-Up Studies; Heart F | 2013 |
Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure.
Topics: Aged; Aged, 80 and over; Chronic Disease; Death, Sudden, Cardiac; Female; Follow-Up Studies; Heart F | 2013 |
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Eplerenone; Heart; Heart Failure; Ho | 2012 |
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Eplerenone; Heart; Heart Failure; Ho | 2012 |
Therapeutic challenges and management of heart failure during pregnancy (part I).
Topics: Adult; Digitalis; Drug Therapy, Combination; Enalapril; Female; Furosemide; Heart Failure; Humans; M | 2012 |
Therapeutic challenges and management of heart failure during pregnancy (part I).
Topics: Adult; Digitalis; Drug Therapy, Combination; Enalapril; Female; Furosemide; Heart Failure; Humans; M | 2012 |
Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cel | 2012 |
Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cel | 2012 |
Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Endothelial Cells; Eplerenone; Exercise; Heart | 2012 |
Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Endothelial Cells; Eplerenone; Exercise; Heart | 2012 |
Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate.
Topics: Adenocarcinoma; Aged, 80 and over; Contraindications; Heart Failure; Humans; Male; Prostate-Specific | 2012 |
Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate.
Topics: Adenocarcinoma; Aged, 80 and over; Contraindications; Heart Failure; Humans; Male; Prostate-Specific | 2012 |
When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiotonic Agent | 2012 |
When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiotonic Agent | 2012 |
Effects of spironolactone alone and in addition to a β-blocker on myocardial histological and electrical remodeling in chronic severe failing rat hearts.
Topics: Adrenergic beta-Antagonists; Animals; Chronic Disease; Drug Therapy, Combination; Heart Failure; Mal | 2012 |
Effects of spironolactone alone and in addition to a β-blocker on myocardial histological and electrical remodeling in chronic severe failing rat hearts.
Topics: Adrenergic beta-Antagonists; Animals; Chronic Disease; Drug Therapy, Combination; Heart Failure; Mal | 2012 |
Hyperkalaemia in the age of aldosterone antagonism.
Topics: Algorithms; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Heart Failur | 2012 |
Hyperkalaemia in the age of aldosterone antagonism.
Topics: Algorithms; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Heart Failur | 2012 |
A case-control study of determinants for the occurrence of gouty arthritis in heart failure patients.
Topics: Aged; Antihypertensive Agents; Arthritis, Gouty; Case-Control Studies; Confidence Intervals; Female; | 2012 |
A case-control study of determinants for the occurrence of gouty arthritis in heart failure patients.
Topics: Aged; Antihypertensive Agents; Arthritis, Gouty; Case-Control Studies; Confidence Intervals; Female; | 2012 |
The 2012 ESC Guidelines on Heart Failure.
Topics: Benzazepines; Cardiac Resynchronization Therapy; Cardiotonic Agents; Eplerenone; Europe; Heart Failu | 2012 |
The 2012 ESC Guidelines on Heart Failure.
Topics: Benzazepines; Cardiac Resynchronization Therapy; Cardiotonic Agents; Eplerenone; Europe; Heart Failu | 2012 |
Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study.
Topics: Animals; Breast Neoplasms; Diuretics; Family Practice; Female; Heart Failure; Humans; Hypertension; | 2012 |
Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study.
Topics: Animals; Breast Neoplasms; Diuretics; Family Practice; Female; Heart Failure; Humans; Hypertension; | 2012 |
Community care in England: reducing socioeconomic inequalities in heart failure.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi | 2012 |
Community care in England: reducing socioeconomic inequalities in heart failure.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi | 2012 |
Recent developments in the management of heart failure.
Topics: Algorithms; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Eplerenone; Heart Failure; Humans | 2012 |
Recent developments in the management of heart failure.
Topics: Algorithms; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Eplerenone; Heart Failure; Humans | 2012 |
[Structural and functional changes in myocardium of patients with chronic heart failure treated with spironolactone].
Topics: Adult; Chronic Disease; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; | 2012 |
[Structural and functional changes in myocardium of patients with chronic heart failure treated with spironolactone].
Topics: Adult; Chronic Disease; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; | 2012 |
Ethics and eplerenone.
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Drug Costs; Eplerenone; Ethics Committees, Research | 2013 |
Ethics and eplerenone.
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Drug Costs; Eplerenone; Ethics Committees, Research | 2013 |
[Is eplerenone nephrotoxic?].
Topics: Aged; Controlled Clinical Trials as Topic; Creatinine; Dose-Response Relationship, Drug; Eplerenone; | 2012 |
[Is eplerenone nephrotoxic?].
Topics: Aged; Controlled Clinical Trials as Topic; Creatinine; Dose-Response Relationship, Drug; Eplerenone; | 2012 |
Moderate renal insufficiency does not attenuate the clinical benefit of aldosterone antagonists in heart failure.
Topics: Diuretics; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Spironolactone | 2012 |
Moderate renal insufficiency does not attenuate the clinical benefit of aldosterone antagonists in heart failure.
Topics: Diuretics; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Spironolactone | 2012 |
[Increased breast cancer risk caused by spironolactone?].
Topics: Breast Neoplasms; Cohort Studies; Diuretics; Female; Follow-Up Studies; Heart Failure; Humans; Hyper | 2012 |
[Increased breast cancer risk caused by spironolactone?].
Topics: Breast Neoplasms; Cohort Studies; Diuretics; Female; Follow-Up Studies; Heart Failure; Humans; Hyper | 2012 |
Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection.
Topics: Animals; Blotting, Western; Cardiomegaly; Cardiotonic Agents; Cell Line; Cytokines; Disease Models, | 2013 |
Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection.
Topics: Animals; Blotting, Western; Cardiomegaly; Cardiotonic Agents; Cell Line; Cytokines; Disease Models, | 2013 |
Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study.
Topics: Aged; Aged, 80 and over; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mi | 2013 |
Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study.
Topics: Aged; Aged, 80 and over; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mi | 2013 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Designing complex group sequential survival trials.
Topics: Clinical Trials as Topic; Cohort Studies; Computer Simulation; Heart Failure; Humans; Longitudinal S | 2002 |
Pharmacoepidemiologic detection of calcium channel blocker-induced change on digoxin clearance using multiple trough screen analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Calcium Channel Blockers; Creatinine; Digoxi | 2002 |
Pharmacoepidemiologic detection of calcium channel blocker-induced change on digoxin clearance using multiple trough screen analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Calcium Channel Blockers; Creatinine; Digoxi | 2002 |
The pharmacological treatment of heart failure: are we looking at the sunset of the neurohormonal hypothesis.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Hea | 2002 |
The pharmacological treatment of heart failure: are we looking at the sunset of the neurohormonal hypothesis.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Hea | 2002 |
Spironolactone for congestive heart failure.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Drug Administration Schedule; Drug T | 1999 |
Spironolactone for congestive heart failure.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Drug Administration Schedule; Drug T | 1999 |
Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Creatinine; Diuretics; Drug Thera | 2002 |
Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Creatinine; Diuretics; Drug Thera | 2002 |
New treatments for myocardial fibrosis.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Canrenone; Clinical Trials as Topic; | 2002 |
New treatments for myocardial fibrosis.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Canrenone; Clinical Trials as Topic; | 2002 |
[Selective aldosterone blocker for hypertension and heart failure. Better tolerance than previous drugs].
Topics: Aldosterone; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hypertension; Spironolacto | 2002 |
[Selective aldosterone blocker for hypertension and heart failure. Better tolerance than previous drugs].
Topics: Aldosterone; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hypertension; Spironolacto | 2002 |
Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
Topics: Administration, Oral; Animals; Chronic Disease; Disease Models, Animal; Disease Progression; Dogs; E | 2002 |
Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
Topics: Administration, Oral; Animals; Chronic Disease; Disease Models, Animal; Disease Progression; Dogs; E | 2002 |
[Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2002 |
[Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2002 |
Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats.
Topics: Aldosterone; Animals; Coronary Vessels; Heart Failure; Ligation; Male; Mineralocorticoid Receptor An | 2003 |
Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats.
Topics: Aldosterone; Animals; Coronary Vessels; Heart Failure; Ligation; Male; Mineralocorticoid Receptor An | 2003 |
Spironolactone in chronic heart failure:all's well that ends well.
Topics: Evidence-Based Medicine; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized C | 2003 |
Spironolactone in chronic heart failure:all's well that ends well.
Topics: Evidence-Based Medicine; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized C | 2003 |
Bedside B-type natriuretic peptide and functional capacity in chronic heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzy | 2003 |
Bedside B-type natriuretic peptide and functional capacity in chronic heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzy | 2003 |
Aldosterone blockade and heart failure.
Topics: Aldosterone; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial I | 2003 |
Aldosterone blockade and heart failure.
Topics: Aldosterone; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial I | 2003 |
Transcardiac gradient of aldosterone before and after spironolactone in patients with congestive heart failure.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Female; Heart Failure; Humans; Male; Middle Age | 2003 |
Transcardiac gradient of aldosterone before and after spironolactone in patients with congestive heart failure.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Female; Heart Failure; Humans; Male; Middle Age | 2003 |
Eplerenone (Inspra).
Topics: Diuresis; Dose-Response Relationship, Drug; Drug Interactions; Eplerenone; Fees, Pharmaceutical; Hal | 2003 |
Eplerenone (Inspra).
Topics: Diuresis; Dose-Response Relationship, Drug; Drug Interactions; Eplerenone; Fees, Pharmaceutical; Hal | 2003 |
More hope for heart failure. Findings suggest expanded use of aldosterone-blockers.
Topics: Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Humans; Mineralocorticoid Recep | 2003 |
More hope for heart failure. Findings suggest expanded use of aldosterone-blockers.
Topics: Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Humans; Mineralocorticoid Recep | 2003 |
Aldactone therapy in a peritoneal dialysis patient.
Topics: Heart Failure; Humans; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Peritoneal D | 2003 |
Aldactone therapy in a peritoneal dialysis patient.
Topics: Heart Failure; Humans; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Peritoneal D | 2003 |
Aldactone therapy in a peritoneal dialysis patient.
Topics: Animals; Heart Failure; Humans; Hyperkalemia; Kidney Failure, Chronic; Peritoneal Dialysis; Spironol | 2003 |
Aldactone therapy in a peritoneal dialysis patient.
Topics: Animals; Heart Failure; Humans; Hyperkalemia; Kidney Failure, Chronic; Peritoneal Dialysis; Spironol | 2003 |
Use of spironolactone in heart failure patients receiving angiotensin-converting enzyme inhibitors and beta-blockers.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; He | 2003 |
Use of spironolactone in heart failure patients receiving angiotensin-converting enzyme inhibitors and beta-blockers.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; He | 2003 |
Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure.
Topics: Administration, Oral; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriur | 2003 |
Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure.
Topics: Administration, Oral; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriur | 2003 |
Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Adhesion Molecules; Drug Therapy, Combinatio | 2003 |
Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Adhesion Molecules; Drug Therapy, Combinatio | 2003 |
Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Dis | 2003 |
Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Dis | 2003 |
Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Blotting, Western; Drug Therapy, Combinati | 2003 |
Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Blotting, Western; Drug Therapy, Combinati | 2003 |
Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2003 |
Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2003 |
Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.
Topics: Acute Kidney Injury; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Diuretics; Dru | 2003 |
Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.
Topics: Acute Kidney Injury; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Diuretics; Dru | 2003 |
Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh | 2003 |
Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh | 2003 |
The safety of spironolactone treatment in patients with heart failure.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzy | 2003 |
The safety of spironolactone treatment in patients with heart failure.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzy | 2003 |
Management of chronic heart failure due to systolic left ventricular dysfunction by cardiologist and non-cardiologist physicians.
Topics: Aged; Cardiology; Chronic Disease; Digoxin; Diuretics; Female; Guideline Adherence; Heart Failure; H | 2003 |
Management of chronic heart failure due to systolic left ventricular dysfunction by cardiologist and non-cardiologist physicians.
Topics: Aged; Cardiology; Chronic Disease; Digoxin; Diuretics; Female; Guideline Adherence; Heart Failure; H | 2003 |
Sparing a little may save a lot: lessons from the Studies of Left Ventricular Dysfunction (SOLVD).
Topics: Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Potassium; Renin-Angiotensin System; Spi | 2003 |
Sparing a little may save a lot: lessons from the Studies of Left Ventricular Dysfunction (SOLVD).
Topics: Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Potassium; Renin-Angiotensin System; Spi | 2003 |
Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cohort Studies; Diuretics; Female; Heart Fail | 2003 |
Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cohort Studies; Diuretics; Female; Heart Fail | 2003 |
Aldosterone blockade after myocardial infarction.
Topics: Double-Blind Method; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid | 2003 |
Aldosterone blockade after myocardial infarction.
Topics: Double-Blind Method; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid | 2003 |
Spironolactone used with mercaptomerin in the treatment of congestive cardiac failure.
Topics: Aldosterone; Diuretics; Heart Failure; Mineralocorticoid Receptor Antagonists; Organomercury Compoun | 1961 |
Spironolactone used with mercaptomerin in the treatment of congestive cardiac failure.
Topics: Aldosterone; Diuretics; Heart Failure; Mineralocorticoid Receptor Antagonists; Organomercury Compoun | 1961 |
A comparison of the properties of chlorothiazide, spironolactone and a combination of both as diuretic agents.
Topics: Aldosterone; Chlorothiazide; Diuretics; Heart Failure; Liver Cirrhosis; Mineralocorticoid Receptor A | 1961 |
A comparison of the properties of chlorothiazide, spironolactone and a combination of both as diuretic agents.
Topics: Aldosterone; Chlorothiazide; Diuretics; Heart Failure; Liver Cirrhosis; Mineralocorticoid Receptor A | 1961 |
[Spirolactones in the treatment of cardiac insufficiency].
Topics: Diuretics; Heart Failure; Spironolactone | 1961 |
[Spirolactones in the treatment of cardiac insufficiency].
Topics: Diuretics; Heart Failure; Spironolactone | 1961 |
Combined spironolactone-hydrochlorothiazide (Aldactazide) treatment in refractory congestive failure.
Topics: Chlorothiazide; Drug Combinations; Heart Failure; Hydrochlorothiazide; Lactones; Spironolactone | 1961 |
Combined spironolactone-hydrochlorothiazide (Aldactazide) treatment in refractory congestive failure.
Topics: Chlorothiazide; Drug Combinations; Heart Failure; Hydrochlorothiazide; Lactones; Spironolactone | 1961 |
[First results obtained with the use of the spirolactone SC-9420 (aldactone) in the treatment of cardiac edema].
Topics: Edema, Cardiac; Heart Failure; Lactones; Spironolactone | 1960 |
[First results obtained with the use of the spirolactone SC-9420 (aldactone) in the treatment of cardiac edema].
Topics: Edema, Cardiac; Heart Failure; Lactones; Spironolactone | 1960 |
[Apparently irreducible cardiac edema. Remarkable effect of a spirolactone].
Topics: Aldosterone; Diuretics; Edema, Cardiac; Heart Failure; Mineralocorticoid Receptor Antagonists; Spiro | 1961 |
[Apparently irreducible cardiac edema. Remarkable effect of a spirolactone].
Topics: Aldosterone; Diuretics; Edema, Cardiac; Heart Failure; Mineralocorticoid Receptor Antagonists; Spiro | 1961 |
[Spirolactone. Its use in the treatment of cardiac and cirrhotic edema. Apropos of 6 case reports].
Topics: Aldosterone; Diuretics; Edema; Heart Failure; Liver Cirrhosis; Spironolactone | 1961 |
[Spirolactone. Its use in the treatment of cardiac and cirrhotic edema. Apropos of 6 case reports].
Topics: Aldosterone; Diuretics; Edema; Heart Failure; Liver Cirrhosis; Spironolactone | 1961 |
[Spirolactones. Their use in the treatment of cardiac and cirrhotic edemas (apropos of 6 case reports)].
Topics: Aldosterone; Diuretics; Edema; Heart Failure; Liver Cirrhosis; Mineralocorticoid Receptor Antagonist | 1960 |
[Spirolactones. Their use in the treatment of cardiac and cirrhotic edemas (apropos of 6 case reports)].
Topics: Aldosterone; Diuretics; Edema; Heart Failure; Liver Cirrhosis; Mineralocorticoid Receptor Antagonist | 1960 |
[Observations on the use of an aldosterone antagonist (aldactone) in the therapy of water retention].
Topics: Aldosterone; Diuretics; Edema; Edetic Acid; Heart Failure; Humans; Mineralocorticoid Receptor Antago | 1962 |
[Observations on the use of an aldosterone antagonist (aldactone) in the therapy of water retention].
Topics: Aldosterone; Diuretics; Edema; Edetic Acid; Heart Failure; Humans; Mineralocorticoid Receptor Antago | 1962 |
[Diuretic and saluretic action of an aldosterone antagonist (spirolactone, SC-9420) associated with an iso-indoline derivative (Hygroton) in refractory cardiac edema].
Topics: Aldosterone; Antihypertensive Agents; Chlorthalidone; Diuretics; Edema, Cardiac; Heart Failure; Indo | 1962 |
[Diuretic and saluretic action of an aldosterone antagonist (spirolactone, SC-9420) associated with an iso-indoline derivative (Hygroton) in refractory cardiac edema].
Topics: Aldosterone; Antihypertensive Agents; Chlorthalidone; Diuretics; Edema, Cardiac; Heart Failure; Indo | 1962 |
[Diuretic action of chlorothiazide and spironolactone in edema of cardiac and hepatic origin].
Topics: Chlorothiazide; Diuretics; Edema; Heart Failure; Liver Diseases; Spironolactone | 1963 |
[Diuretic action of chlorothiazide and spironolactone in edema of cardiac and hepatic origin].
Topics: Chlorothiazide; Diuretics; Edema; Heart Failure; Liver Diseases; Spironolactone | 1963 |
[Trial use of spirolactones in cardiac insufficiency].
Topics: Heart Failure; Humans; Spironolactone | 1962 |
[Trial use of spirolactones in cardiac insufficiency].
Topics: Heart Failure; Humans; Spironolactone | 1962 |
[Aldactone as a drug controlling hypokalemia in diuretic therapy].
Topics: Diuretics; Heart Failure; Humans; Hypokalemia; Spironolactone | 1962 |
[Aldactone as a drug controlling hypokalemia in diuretic therapy].
Topics: Diuretics; Heart Failure; Humans; Hypokalemia; Spironolactone | 1962 |
Hypokalaemia, hypochloraemia, and baseosis in long-term treatment of oedematous heart failure with benzothiadiazine diuretics. III. Effect of spironolactone.
Topics: Acid-Base Imbalance; Alkalosis; Benzimidazoles; Chlorides; Edema; Heart Failure; Humans; Hypokalemia | 1962 |
Hypokalaemia, hypochloraemia, and baseosis in long-term treatment of oedematous heart failure with benzothiadiazine diuretics. III. Effect of spironolactone.
Topics: Acid-Base Imbalance; Alkalosis; Benzimidazoles; Chlorides; Edema; Heart Failure; Humans; Hypokalemia | 1962 |
Comparison of two spironolactone preparations in the longterm treatment of oedematous heart failure.
Topics: Edema; Heart Failure; Humans; Spironolactone | 1963 |
Comparison of two spironolactone preparations in the longterm treatment of oedematous heart failure.
Topics: Edema; Heart Failure; Humans; Spironolactone | 1963 |
[On the use of spironolactone-polysorbate 80].
Topics: Ascites; Heart Failure; Humans; Polysorbates; Spironolactone | 1963 |
[On the use of spironolactone-polysorbate 80].
Topics: Ascites; Heart Failure; Humans; Polysorbates; Spironolactone | 1963 |
Correction of hyperaldosteronism and of massive fluid retention of unknown cause by sympathomimetic agents.
Topics: Amphetamine; Edema; Heart Failure; Humans; Hyperaldosteronism; Hypotension; Hypotension, Orthostatic | 1962 |
Correction of hyperaldosteronism and of massive fluid retention of unknown cause by sympathomimetic agents.
Topics: Amphetamine; Edema; Heart Failure; Humans; Hyperaldosteronism; Hypotension; Hypotension, Orthostatic | 1962 |
[Aldosterone antagonists in the treatment of cardiac edema].
Topics: Edema, Cardiac; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Progesterone; Spirono | 1962 |
[Aldosterone antagonists in the treatment of cardiac edema].
Topics: Edema, Cardiac; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Progesterone; Spirono | 1962 |
Congestive heart failure.
Topics: Diet, Sodium-Restricted; Diuretics; Heart Failure; Humans; Organomercury Compounds; Spironolactone | 1962 |
Congestive heart failure.
Topics: Diet, Sodium-Restricted; Diuretics; Heart Failure; Humans; Organomercury Compounds; Spironolactone | 1962 |
Metabolic studies on patients with resistant heart failure treated by spironolactone.
Topics: Diuresis; Diuretics; Heart Failure; Humans; Hydrochlorothiazide; Potassium; Spironolactone | 1962 |
Metabolic studies on patients with resistant heart failure treated by spironolactone.
Topics: Diuresis; Diuretics; Heart Failure; Humans; Hydrochlorothiazide; Potassium; Spironolactone | 1962 |
[Clinical applications of spironolactone].
Topics: Ascites; Heart Failure; Humans; Hyperaldosteronism; Spironolactone | 1963 |
[Clinical applications of spironolactone].
Topics: Ascites; Heart Failure; Humans; Hyperaldosteronism; Spironolactone | 1963 |
[Physiological bases of the utilization of aldosterone antagonists. Their clinical applications].
Topics: Heart Failure; Humans; Hyperaldosteronism; Liver Cirrhosis; Mineralocorticoid Receptor Antagonists; | 1962 |
[Physiological bases of the utilization of aldosterone antagonists. Their clinical applications].
Topics: Heart Failure; Humans; Hyperaldosteronism; Liver Cirrhosis; Mineralocorticoid Receptor Antagonists; | 1962 |
[The effects of spironolactones in cardiac and hypertensive patients].
Topics: Heart Failure; Humans; Hyperaldosteronism; Hypertension; Spironolactone | 1963 |
[The effects of spironolactones in cardiac and hypertensive patients].
Topics: Heart Failure; Humans; Hyperaldosteronism; Hypertension; Spironolactone | 1963 |
[Treatment of 12 cases of so-called irreversible cardiac edemas by the antagonistic aldosterone medication].
Topics: Aldosterone; Edema, Cardiac; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironol | 1963 |
[Treatment of 12 cases of so-called irreversible cardiac edemas by the antagonistic aldosterone medication].
Topics: Aldosterone; Edema, Cardiac; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironol | 1963 |
[Pressure of the tissues in various post-infarct complications and under the influence of aldosterone, spirolactone and saline administration].
Topics: Aldosterone; Heart Failure; Humans; Myocardial Infarction; Sodium Chloride; Spironolactone | 1962 |
[Pressure of the tissues in various post-infarct complications and under the influence of aldosterone, spirolactone and saline administration].
Topics: Aldosterone; Heart Failure; Humans; Myocardial Infarction; Sodium Chloride; Spironolactone | 1962 |
[Limitations and effectiveness of aldactone on water-salt retention in congestive cardiocirculatory insufficiency (C.C.C.I.)].
Topics: Heart Failure; Humans; Natriuresis; Spironolactone; Water; Water-Electrolyte Balance | 1962 |
[Limitations and effectiveness of aldactone on water-salt retention in congestive cardiocirculatory insufficiency (C.C.C.I.)].
Topics: Heart Failure; Humans; Natriuresis; Spironolactone; Water; Water-Electrolyte Balance | 1962 |
[Preliminary observation on the clinical use of aldosterone antagonistic drugs (spironolactone) in edemigenic syndromes].
Topics: Aldosterone; Diuretics; Edema; Heart Failure; Humans; Liver Cirrhosis; Mineralocorticoid Receptor An | 1962 |
[Preliminary observation on the clinical use of aldosterone antagonistic drugs (spironolactone) in edemigenic syndromes].
Topics: Aldosterone; Diuretics; Edema; Heart Failure; Humans; Liver Cirrhosis; Mineralocorticoid Receptor An | 1962 |
[PATHOGENETIC ASPECTS AND THERAPEUTIC PROBLEMS IN CONGESTIVE INSUFFICIENCY OF THE GREATER CIRCULATION].
Topics: Aldosterone; Animals; Blood Pressure; Blood Pressure Determination; Blood Proteins; Capillary Permea | 1963 |
[PATHOGENETIC ASPECTS AND THERAPEUTIC PROBLEMS IN CONGESTIVE INSUFFICIENCY OF THE GREATER CIRCULATION].
Topics: Aldosterone; Animals; Blood Pressure; Blood Pressure Determination; Blood Proteins; Capillary Permea | 1963 |
[USE OF SPIRONOLACTONE IN THE THERAPY OF CONGESTIVE HEART FAILURE].
Topics: Body Fluids; Heart Failure; Humans; Hydrochlorothiazide; Potassium; Sodium; Sodium, Dietary; Spirono | 1963 |
[USE OF SPIRONOLACTONE IN THE THERAPY OF CONGESTIVE HEART FAILURE].
Topics: Body Fluids; Heart Failure; Humans; Hydrochlorothiazide; Potassium; Sodium; Sodium, Dietary; Spirono | 1963 |
OBSERVATIONS ON TRIAMTERENE--A NEW DIURETIC.
Topics: Chlorides; Chlorothiazide; Coronary Disease; Craniocerebral Trauma; Diuretics; Edema; Geriatrics; He | 1963 |
OBSERVATIONS ON TRIAMTERENE--A NEW DIURETIC.
Topics: Chlorides; Chlorothiazide; Coronary Disease; Craniocerebral Trauma; Diuretics; Edema; Geriatrics; He | 1963 |
[ON USE OF THE BLOCKING AGENT ALDOSTERONE].
Topics: Aldosterone; Aortic Valve; Diuretics; Heart Failure; Humans; Hyperaldosteronism; Mitral Valve Insuff | 1963 |
[ON USE OF THE BLOCKING AGENT ALDOSTERONE].
Topics: Aldosterone; Aortic Valve; Diuretics; Heart Failure; Humans; Hyperaldosteronism; Mitral Valve Insuff | 1963 |
COMPARATIVE STUDIES ON THE DIURETIC EFFECT OF CHLOROTHIAZIDE AND SPIRONOLACTONE IN CARDIAC AND HEPATOGENIC OEDEMA.
Topics: Chlorothiazide; Diuretics; Edema; Heart Failure; Liver Cirrhosis; Prednisone; Spironolactone | 1963 |
COMPARATIVE STUDIES ON THE DIURETIC EFFECT OF CHLOROTHIAZIDE AND SPIRONOLACTONE IN CARDIAC AND HEPATOGENIC OEDEMA.
Topics: Chlorothiazide; Diuretics; Edema; Heart Failure; Liver Cirrhosis; Prednisone; Spironolactone | 1963 |
EFFECT OF AN ALDOSTERONE ANTAGONIST (SPIRONOLACTONE) ON PATIENTS WITH SEVERE CONGESTIVE HEART FAILURE.
Topics: Aldosterone; Antihypertensive Agents; Body Fluids; Diuresis; Diuretics; Female; Geriatrics; Heart Fa | 1963 |
EFFECT OF AN ALDOSTERONE ANTAGONIST (SPIRONOLACTONE) ON PATIENTS WITH SEVERE CONGESTIVE HEART FAILURE.
Topics: Aldosterone; Antihypertensive Agents; Body Fluids; Diuresis; Diuretics; Female; Geriatrics; Heart Fa | 1963 |
SECONDARY ALDOSTERONISM AND REFRACTORY OEDEMATOUS STATES.
Topics: Betamethasone; Biochemical Phenomena; Biochemistry; Diuretics; Edema; Heart Failure; Hepatitis; Huma | 1963 |
SECONDARY ALDOSTERONISM AND REFRACTORY OEDEMATOUS STATES.
Topics: Betamethasone; Biochemical Phenomena; Biochemistry; Diuretics; Edema; Heart Failure; Hepatitis; Huma | 1963 |
ALDOSTERONE AND THE EDEMA OF CONGESTIVE HEART FAILURE.
Topics: Aldosterone; Chromatography; Diuretics; Edema; Geriatrics; Heart Diseases; Heart Failure; Hypertensi | 1964 |
ALDOSTERONE AND THE EDEMA OF CONGESTIVE HEART FAILURE.
Topics: Aldosterone; Chromatography; Diuretics; Edema; Geriatrics; Heart Diseases; Heart Failure; Hypertensi | 1964 |
ALDOSTERONE ANTAGONISTS IN DIURETIC THERAPY: THEIR EFFECT ON THE REFRACTORY PHASE.
Topics: Blood Chemical Analysis; Body Weight; Edema; Heart Failure; Hematocrit; Hydrochlorothiazide; Mineral | 1964 |
ALDOSTERONE ANTAGONISTS IN DIURETIC THERAPY: THEIR EFFECT ON THE REFRACTORY PHASE.
Topics: Blood Chemical Analysis; Body Weight; Edema; Heart Failure; Hematocrit; Hydrochlorothiazide; Mineral | 1964 |
[WATER RETENTION IN CIRRHOTICS. PHYSIOPATHOLOGICAL DATA AND THERAPEUTIC RESULTS].
Topics: Ascites; Edema; Heart Failure; Humans; Hypokalemia; Hyponatremia; Liver Cirrhosis; Mineralocorticoid | 1963 |
[WATER RETENTION IN CIRRHOTICS. PHYSIOPATHOLOGICAL DATA AND THERAPEUTIC RESULTS].
Topics: Ascites; Edema; Heart Failure; Humans; Hypokalemia; Hyponatremia; Liver Cirrhosis; Mineralocorticoid | 1963 |
SPIRONOLACTONE AS AN ADJUVANT TO THE TREATMENT OF CONGESTIVE CARDIAC FAILURE.
Topics: Blood; Body Weight; Chlorothiazide; Heart Failure; Humans; Potassium; Sodium; Spironolactone; Urea; | 1964 |
SPIRONOLACTONE AS AN ADJUVANT TO THE TREATMENT OF CONGESTIVE CARDIAC FAILURE.
Topics: Blood; Body Weight; Chlorothiazide; Heart Failure; Humans; Potassium; Sodium; Spironolactone; Urea; | 1964 |
[RESULTS OF EXPERIMENTATION WITH A MICRONIZED ALDACTONE (8013 MCB) AND SULFONAMIDE DIURETIC (8093 CB) COMBINATION IN THE TREATMENT OF EDEMA].
Topics: Ascites; Benzothiadiazines; Diuretics; Edema; Heart Failure; Humans; Liver Cirrhosis; Spironolactone | 1963 |
[RESULTS OF EXPERIMENTATION WITH A MICRONIZED ALDACTONE (8013 MCB) AND SULFONAMIDE DIURETIC (8093 CB) COMBINATION IN THE TREATMENT OF EDEMA].
Topics: Ascites; Benzothiadiazines; Diuretics; Edema; Heart Failure; Humans; Liver Cirrhosis; Spironolactone | 1963 |
[PERITONEAL DIALYSIS (D.P.): ITS EFFICIENCY IN IRREDUCIBLE EDEMAS AFTER FAILURE OF OTHER TREATMENTS].
Topics: Amyloidosis; Bronchiectasis; Dialysis; Edema; Empyema; Heart Failure; Liver Cirrhosis; Nephrosis; Pe | 1963 |
[PERITONEAL DIALYSIS (D.P.): ITS EFFICIENCY IN IRREDUCIBLE EDEMAS AFTER FAILURE OF OTHER TREATMENTS].
Topics: Amyloidosis; Bronchiectasis; Dialysis; Edema; Empyema; Heart Failure; Liver Cirrhosis; Nephrosis; Pe | 1963 |
THE DIURETIC EFFECT OF TRIAMTERENE.
Topics: Blood Chemical Analysis; Coronary Disease; Creatine; Creatinine; Diuretics; Heart Failure; Hypertens | 1964 |
THE DIURETIC EFFECT OF TRIAMTERENE.
Topics: Blood Chemical Analysis; Coronary Disease; Creatine; Creatinine; Diuretics; Heart Failure; Hypertens | 1964 |
[PRELIMINARY RESULTS OF THE USE OF SPIROLACTONE IN PATIENTS WITH CIRCULATORY INSUFFICIENCY].
Topics: Body Weight; Diuresis; Electrolytes; Heart Failure; Humans; Pericarditis; Pericarditis, Constrictive | 1963 |
[PRELIMINARY RESULTS OF THE USE OF SPIROLACTONE IN PATIENTS WITH CIRCULATORY INSUFFICIENCY].
Topics: Body Weight; Diuresis; Electrolytes; Heart Failure; Humans; Pericarditis; Pericarditis, Constrictive | 1963 |
TREATMENT OF ARTERIAL HYPERTENSIVE DISEASE WITH DIURETICS. III. CHLORTHALIDONE ALONE AND IN COMBINATION WITH SPIRONOLACTONE.
Topics: Bendroflumethiazide; Cardiomegaly; Chlorides; Chlorthalidone; Coronary Disease; Creatine; Creatinine | 1964 |
TREATMENT OF ARTERIAL HYPERTENSIVE DISEASE WITH DIURETICS. III. CHLORTHALIDONE ALONE AND IN COMBINATION WITH SPIRONOLACTONE.
Topics: Bendroflumethiazide; Cardiomegaly; Chlorides; Chlorthalidone; Coronary Disease; Creatine; Creatinine | 1964 |
[NATRIURETIC DRUGS].
Topics: Acetazolamide; Aldosterone; Ascites; Chlorothiazide; Dexamethasone; Diabetes Insipidus; Diuresis; Di | 1963 |
[NATRIURETIC DRUGS].
Topics: Acetazolamide; Aldosterone; Ascites; Chlorothiazide; Dexamethasone; Diabetes Insipidus; Diuresis; Di | 1963 |
[ON THE TREATMENT OF THERAPY-RESISTANT RETENTION OF FLUIDS WITH SPIROLACTONE].
Topics: Diuretics; Edema; Heart Failure; Humans; Liver Cirrhosis; Prednisolone; Spironolactone | 1964 |
[ON THE TREATMENT OF THERAPY-RESISTANT RETENTION OF FLUIDS WITH SPIROLACTONE].
Topics: Diuretics; Edema; Heart Failure; Humans; Liver Cirrhosis; Prednisolone; Spironolactone | 1964 |
[THE TREATMENT OF EDEMA WITH SULFONAMIDE DIURETICS].
Topics: Acetazolamide; Acidosis; Benzothiadiazines; Chlorothiazide; Chlorthalidone; Dehydration; Diuretics; | 1964 |
[THE TREATMENT OF EDEMA WITH SULFONAMIDE DIURETICS].
Topics: Acetazolamide; Acidosis; Benzothiadiazines; Chlorothiazide; Chlorthalidone; Dehydration; Diuretics; | 1964 |
[TREATMENT OF HEART INSUFFICIENCY].
Topics: Benzothiadiazines; Chlorides; Digitalis Glycosides; Heart Failure; Humans; Potassium; Sodium; Sodium | 1964 |
[TREATMENT OF HEART INSUFFICIENCY].
Topics: Benzothiadiazines; Chlorides; Digitalis Glycosides; Heart Failure; Humans; Potassium; Sodium; Sodium | 1964 |
TRIAMTERENE COMBINED WITH OTHER DIURETICS IN CONGESTIVE HEART FAILURE.
Topics: Chlorthalidone; Diuretics; Geriatrics; Heart Failure; Pterins; Spironolactone; Toxicology; Triamtere | 1964 |
TRIAMTERENE COMBINED WITH OTHER DIURETICS IN CONGESTIVE HEART FAILURE.
Topics: Chlorthalidone; Diuretics; Geriatrics; Heart Failure; Pterins; Spironolactone; Toxicology; Triamtere | 1964 |
[PLACE OF ALDACTONE IN THE THERAPY OF EDEMA].
Topics: Aldosterone; Edema; Heart Failure; Humans; Hyperaldosteronism; Liver Cirrhosis; Spironolactone | 1964 |
[PLACE OF ALDACTONE IN THE THERAPY OF EDEMA].
Topics: Aldosterone; Edema; Heart Failure; Humans; Hyperaldosteronism; Liver Cirrhosis; Spironolactone | 1964 |
[CLINICAL TRIALS OF THE NEW ALDOSTERONE ANTAGONISTS OF A STEROID NATURE].
Topics: Adolescent; Chronic Disease; Diabetes Mellitus; Extremities; Familial Mediterranean Fever; Geriatric | 1964 |
[CLINICAL TRIALS OF THE NEW ALDOSTERONE ANTAGONISTS OF A STEROID NATURE].
Topics: Adolescent; Chronic Disease; Diabetes Mellitus; Extremities; Familial Mediterranean Fever; Geriatric | 1964 |
[ON THE DIURETIC EFFECT OF THE ADRENOSTATIC DRUG METHOPYRAPONE].
Topics: Ascites; Dexamethasone; Diuretics; Edema; Heart Failure; Ketones; Liver Cirrhosis; Metyrapone; Miner | 1964 |
[ON THE DIURETIC EFFECT OF THE ADRENOSTATIC DRUG METHOPYRAPONE].
Topics: Ascites; Dexamethasone; Diuretics; Edema; Heart Failure; Ketones; Liver Cirrhosis; Metyrapone; Miner | 1964 |
[ON THE DIURETIC EFFECT OF THE ADRENOSTATIC DRUG METHOPYRAPONE].
Topics: Ascites; Dexamethasone; Diuretics; Edema; Heart Failure; Ketones; Liver Cirrhosis; Metyrapone; Miner | 1964 |
[ON THE DIURETIC EFFECT OF THE ADRENOSTATIC DRUG METHOPYRAPONE].
Topics: Ascites; Dexamethasone; Diuretics; Edema; Heart Failure; Ketones; Liver Cirrhosis; Metyrapone; Miner | 1964 |
CLINICAL ASSESSMENT OF DIURETICS.
Topics: Acetazolamide; Body Weight; Diuretics; Drug Therapy; Edema; Heart Failure; Liver Cirrhosis; Nephrosi | 1964 |
CLINICAL ASSESSMENT OF DIURETICS.
Topics: Acetazolamide; Body Weight; Diuretics; Drug Therapy; Edema; Heart Failure; Liver Cirrhosis; Nephrosi | 1964 |
CLINICAL EXPERIENCE WITH A NEW DIURETIC, TRIAMTERENE, IN CONJESTIVE HEART FAILURE.
Topics: Arrhythmias, Cardiac; Canada; Chlorides; Digitalis Glycosides; Diuretics; Edema; Heart Failure; Hydr | 1964 |
CLINICAL EXPERIENCE WITH A NEW DIURETIC, TRIAMTERENE, IN CONJESTIVE HEART FAILURE.
Topics: Arrhythmias, Cardiac; Canada; Chlorides; Digitalis Glycosides; Diuretics; Edema; Heart Failure; Hydr | 1964 |
A NEW EFFECTIVE DIURETIC--LASIX.
Topics: Chlorthalidone; Diuretics; Drug Therapy; Furosemide; Heart Failure; Hydrochlorothiazide; Hypokalemia | 1964 |
A NEW EFFECTIVE DIURETIC--LASIX.
Topics: Chlorthalidone; Diuretics; Drug Therapy; Furosemide; Heart Failure; Hydrochlorothiazide; Hypokalemia | 1964 |
BILATERAL RENAL ARTERY STENOSIS WITH ALDOSTERONISM.
Topics: Angiography; Chlorides; Electrocardiography; Guanethidine; Heart Failure; Humans; Hyperaldosteronism | 1964 |
BILATERAL RENAL ARTERY STENOSIS WITH ALDOSTERONISM.
Topics: Angiography; Chlorides; Electrocardiography; Guanethidine; Heart Failure; Humans; Hyperaldosteronism | 1964 |
[POTENTIATION OF MERCURIAL DIURETICS WITH PROGESTERONE].
Topics: Chemistry, Pharmaceutical; Diuretics; Edema; Heart Failure; Liver Cirrhosis; Mineralocorticoid Recep | 1964 |
[POTENTIATION OF MERCURIAL DIURETICS WITH PROGESTERONE].
Topics: Chemistry, Pharmaceutical; Diuretics; Edema; Heart Failure; Liver Cirrhosis; Mineralocorticoid Recep | 1964 |
[EFFECT OF THE MICRONIZED SPIRONOLACTONE-BENZTHIAZIDE ASSOCIATION ON CONGESTIVE CARDIAC INSUFFICIENCY. TEST OF CONTINUOUS TREATMENT].
Topics: Benzothiadiazines; Biomedical Research; Heart Failure; Spironolactone; Toxicology | 1964 |
[EFFECT OF THE MICRONIZED SPIRONOLACTONE-BENZTHIAZIDE ASSOCIATION ON CONGESTIVE CARDIAC INSUFFICIENCY. TEST OF CONTINUOUS TREATMENT].
Topics: Benzothiadiazines; Biomedical Research; Heart Failure; Spironolactone; Toxicology | 1964 |
ALDOSTERONE AND THE EDEMA OF CONGESTIVE HEART FAILURE.
Topics: Aldosterone; Drug Therapy; Edema; Heart Failure; Humans; Metabolism; Spironolactone | 1965 |
ALDOSTERONE AND THE EDEMA OF CONGESTIVE HEART FAILURE.
Topics: Aldosterone; Drug Therapy; Edema; Heart Failure; Humans; Metabolism; Spironolactone | 1965 |
STUDIES ON ETHACRYNIC ACID IN PATIENTS WITH REFRACTORY EDEMA.
Topics: Alkalosis; Blood; Chlorides; Creatine; Creatinine; Diuretics; Drug Therapy; Edema; Ethacrynic Acid; | 1965 |
STUDIES ON ETHACRYNIC ACID IN PATIENTS WITH REFRACTORY EDEMA.
Topics: Alkalosis; Blood; Chlorides; Creatine; Creatinine; Diuretics; Drug Therapy; Edema; Ethacrynic Acid; | 1965 |
DIURETICS.
Topics: Acetazolamide; Diuretics; Drug Therapy; Heart Failure; Organomercury Compounds; Spironolactone; Toxi | 1965 |
DIURETICS.
Topics: Acetazolamide; Diuretics; Drug Therapy; Heart Failure; Organomercury Compounds; Spironolactone; Toxi | 1965 |
ETHACRYNIC ACID: A NEW POTENT DIURETIC.
Topics: Alkalosis; Blood Chemical Analysis; Blood Urea Nitrogen; Body Weight; Digitalis Glycosides; Diuresis | 1965 |
ETHACRYNIC ACID: A NEW POTENT DIURETIC.
Topics: Alkalosis; Blood Chemical Analysis; Blood Urea Nitrogen; Body Weight; Digitalis Glycosides; Diuresis | 1965 |
FURTHER EXPERIENCE WITH SPIRONOLACTONE-HYDRO-CHLOROTHIAZIDE (ALDACTAZIDE-A) IN THE LONG-TERM TREATMENT OF REFRACTORY CARDIAC EDEMA.
Topics: Arteriosclerosis; Chlorothiazide; Coronary Disease; Drug Combinations; Drug Therapy; Edema; Edema, C | 1965 |
FURTHER EXPERIENCE WITH SPIRONOLACTONE-HYDRO-CHLOROTHIAZIDE (ALDACTAZIDE-A) IN THE LONG-TERM TREATMENT OF REFRACTORY CARDIAC EDEMA.
Topics: Arteriosclerosis; Chlorothiazide; Coronary Disease; Drug Combinations; Drug Therapy; Edema; Edema, C | 1965 |
[ACTION OF SPIRONOLACTONE IN THE TREATMENT OF EDEMA OF SECONDARY ALDOSTERONISM].
Topics: Edema; Heart Failure; Humans; Hyperaldosteronism; Nephrotic Syndrome; Spironolactone | 1965 |
[ACTION OF SPIRONOLACTONE IN THE TREATMENT OF EDEMA OF SECONDARY ALDOSTERONISM].
Topics: Edema; Heart Failure; Humans; Hyperaldosteronism; Nephrotic Syndrome; Spironolactone | 1965 |
[Clinical use of spirolactone SC-9420 "Aldactone"].
Topics: Aldosterone; Diuretics; Heart Failure; Mineralocorticoid Receptor Antagonists; Spironolactone | 1962 |
[Clinical use of spirolactone SC-9420 "Aldactone"].
Topics: Aldosterone; Diuretics; Heart Failure; Mineralocorticoid Receptor Antagonists; Spironolactone | 1962 |
[Aldostegone-antagonistic steroids as diuretics. Spironolactone in the treatment of hepatic and cardiac edemas].
Topics: Aldosterone; Diuretics; Edema, Cardiac; Edetic Acid; Heart Failure; Liver Cirrhosis; Mineralocortico | 1961 |
[Aldostegone-antagonistic steroids as diuretics. Spironolactone in the treatment of hepatic and cardiac edemas].
Topics: Aldosterone; Diuretics; Edema, Cardiac; Edetic Acid; Heart Failure; Liver Cirrhosis; Mineralocortico | 1961 |
[Hypokalemis, hypochloremia and alkalosis in the long-term treatment of edematous heart insufficiency with benzothiadiazine diuretics. III. Effects of spirolactone].
Topics: Aldosterone; Alkalosis; Chlorothiazide; Diuretics; Edema; Heart Failure; Mineralocorticoid Receptor | 1962 |
[Hypokalemis, hypochloremia and alkalosis in the long-term treatment of edematous heart insufficiency with benzothiadiazine diuretics. III. Effects of spirolactone].
Topics: Aldosterone; Alkalosis; Chlorothiazide; Diuretics; Edema; Heart Failure; Mineralocorticoid Receptor | 1962 |
[Aldactone (aldosterone antagonist SC-9, 420) in the treatment of the edemas of heart patients and cirrhotic patients. Bioclinical study].
Topics: Aldosterone; Diuretics; Edema; Heart Failure; Humans; Liver Cirrhosis; Mineralocorticoid Receptor An | 1962 |
[Aldactone (aldosterone antagonist SC-9, 420) in the treatment of the edemas of heart patients and cirrhotic patients. Bioclinical study].
Topics: Aldosterone; Diuretics; Edema; Heart Failure; Humans; Liver Cirrhosis; Mineralocorticoid Receptor An | 1962 |
Two better than one.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Animals; Class Ib Phosphatidylinositol 3-Kina | 2003 |
Two better than one.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Animals; Class Ib Phosphatidylinositol 3-Kina | 2003 |
Ask the doctor. I am a 50-year-old man with congestive heart failure. My doctor has me on all the usual drugs, and a couple of years ago added spironolactone. I did okay with it for a while, but then began to notice that my breasts were getting bigger and
Topics: Diuretics; Eplerenone; Gynecomastia; Heart Failure; Humans; Male; Middle Aged; Spironolactone | 2003 |
Ask the doctor. I am a 50-year-old man with congestive heart failure. My doctor has me on all the usual drugs, and a couple of years ago added spironolactone. I did okay with it for a while, but then began to notice that my breasts were getting bigger and
Topics: Diuretics; Eplerenone; Gynecomastia; Heart Failure; Humans; Male; Middle Aged; Spironolactone | 2003 |
The African-American Heart Failure Trial (A-HeFT): rationale and methodology.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2003 |
The African-American Heart Failure Trial (A-HeFT): rationale and methodology.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2003 |
[Which patient needs an aldosterone antagonist?].
Topics: Cardiovascular Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eplerenone; Hear | 2003 |
[Which patient needs an aldosterone antagonist?].
Topics: Cardiovascular Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eplerenone; Hear | 2003 |
Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study.
Topics: Aged; Aged, 80 and over; Diuretics; Female; Heart Failure; Humans; Hyperkalemia; Kidney Diseases; Ma | 2003 |
Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study.
Topics: Aged; Aged, 80 and over; Diuretics; Female; Heart Failure; Humans; Hyperkalemia; Kidney Diseases; Ma | 2003 |
The CHARM programme.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2003 |
The CHARM programme.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2003 |
[Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
Topics: Controlled Clinical Trials as Topic; Death, Sudden, Cardiac; Diuretics; Double-Blind Method; Epleren | 2003 |
[Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
Topics: Controlled Clinical Trials as Topic; Death, Sudden, Cardiac; Diuretics; Double-Blind Method; Epleren | 2003 |
[Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement].
Topics: Aldosterone; Clinical Trials as Topic; Eplerenone; Germany; Heart Failure; Humans; Mineralocorticoid | 2003 |
[Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement].
Topics: Aldosterone; Clinical Trials as Topic; Eplerenone; Germany; Heart Failure; Humans; Mineralocorticoid | 2003 |
Role of a selective aldosterone blocker in mice with chronic heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output; Collagen; Disease Models, Animal; | 2004 |
Role of a selective aldosterone blocker in mice with chronic heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output; Collagen; Disease Models, Animal; | 2004 |
The European Society of Cardiology working group on heart failure: Heart Failure Update 2003.
Topics: Carbazoles; Cardiac Pacing, Artificial; Carvedilol; Eplerenone; Europe; Heart Failure; Humans; Metop | 2003 |
The European Society of Cardiology working group on heart failure: Heart Failure Update 2003.
Topics: Carbazoles; Cardiac Pacing, Artificial; Carvedilol; Eplerenone; Europe; Heart Failure; Humans; Metop | 2003 |
The resurrection of spironolactone on its golden anniversary.
Topics: Aged; Eplerenone; Female; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolact | 2004 |
The resurrection of spironolactone on its golden anniversary.
Topics: Aged; Eplerenone; Female; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolact | 2004 |
Spironolactone use in patients with heart failure.
Topics: Adult; Aged; Aged, 80 and over; Concurrent Review; Drug Utilization Review; Female; Heart Failure; H | 2004 |
Spironolactone use in patients with heart failure.
Topics: Adult; Aged; Aged, 80 and over; Concurrent Review; Drug Utilization Review; Female; Heart Failure; H | 2004 |
Drug therapy in chronic heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Diuretics; Drug Combinations; Heart Failu | 2004 |
Drug therapy in chronic heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Diuretics; Drug Combinations; Heart Failu | 2004 |
Assessing the impact of heart failure specialist services on patient populations.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Combined Modality Therapy; Decision Support Tec | 2004 |
Assessing the impact of heart failure specialist services on patient populations.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Combined Modality Therapy; Decision Support Tec | 2004 |
Role of aldosterone blockade in managing heart failure: new and emerging treatment options. Introduction.
Topics: Aged; Eplerenone; Female; Heart Failure; Humans; Incidence; Male; Mineralocorticoid Receptor Antagon | 2004 |
Role of aldosterone blockade in managing heart failure: new and emerging treatment options. Introduction.
Topics: Aged; Eplerenone; Female; Heart Failure; Humans; Incidence; Male; Mineralocorticoid Receptor Antagon | 2004 |
Ask the doctors. I read about a new drug for heart failure called eplerenone. How does it work? Is it safe?
Topics: Contraindications; Diuretics; Drug Interactions; Eplerenone; Heart Failure; Humans; Spironolactone | 2004 |
Ask the doctors. I read about a new drug for heart failure called eplerenone. How does it work? Is it safe?
Topics: Contraindications; Diuretics; Drug Interactions; Eplerenone; Heart Failure; Humans; Spironolactone | 2004 |
Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Black or African Americ | 2004 |
Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Black or African Americ | 2004 |
Treatment of heart failure with spironolactone--trial and tribulations.
Topics: Adrenergic beta-Antagonists; Aging; Aldosterone; Drug Therapy, Combination; Glomerular Filtration Ra | 2004 |
Treatment of heart failure with spironolactone--trial and tribulations.
Topics: Adrenergic beta-Antagonists; Aging; Aldosterone; Drug Therapy, Combination; Glomerular Filtration Ra | 2004 |
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
Topics: Adrenergic beta-Antagonists; Adverse Drug Reaction Reporting Systems; Aged; Angiotensin-Converting E | 2004 |
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
Topics: Adrenergic beta-Antagonists; Adverse Drug Reaction Reporting Systems; Aged; Angiotensin-Converting E | 2004 |
How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Creatinine; Denmark; | 2004 |
How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Creatinine; Denmark; | 2004 |
Study warns of danger of combining spironolactone and ACE inhibitors in heart patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Interactions; Heart Failure; Hyperkalemia; Mineraloco | 2004 |
Study warns of danger of combining spironolactone and ACE inhibitors in heart patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Interactions; Heart Failure; Hyperkalemia; Mineraloco | 2004 |
Usefulness of spironolactone in a specialized heart failure clinic.
Topics: Aged; Aged, 80 and over; Alberta; Cardiology Service, Hospital; Cohort Studies; Diuretics; Female; H | 2004 |
Usefulness of spironolactone in a specialized heart failure clinic.
Topics: Aged; Aged, 80 and over; Alberta; Cardiology Service, Hospital; Cohort Studies; Diuretics; Female; H | 2004 |
[Hyperkalemia. Main symptoms: muscle weakness, cardiac arrhythmias].
Topics: Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Heart Failure; Humans; Hyperka | 2004 |
[Hyperkalemia. Main symptoms: muscle weakness, cardiac arrhythmias].
Topics: Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Heart Failure; Humans; Hyperka | 2004 |
[Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure. A retrospective analysis of 125 consecutive cases].
Topics: Aged; Aged, 80 and over; Diuretics; Female; Heart Failure; Humans; Hyperkalemia; Kidney Diseases; Ma | 2004 |
[Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure. A retrospective analysis of 125 consecutive cases].
Topics: Aged; Aged, 80 and over; Diuretics; Female; Heart Failure; Humans; Hyperkalemia; Kidney Diseases; Ma | 2004 |
Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message.
Topics: Age Factors; Aged; Aged, 80 and over; Chronic Disease; Cohort Studies; Creatinine; Female; Guideline | 2004 |
Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message.
Topics: Age Factors; Aged; Aged, 80 and over; Chronic Disease; Cohort Studies; Creatinine; Female; Guideline | 2004 |
The neuroendocrine-immune interface gone awry in aldosteronism.
Topics: Aldosterone; Animals; Central Nervous System; Heart Failure; Humans; Hyperaldosteronism; Kidney; Min | 2004 |
The neuroendocrine-immune interface gone awry in aldosteronism.
Topics: Aldosterone; Animals; Central Nervous System; Heart Failure; Humans; Hyperaldosteronism; Kidney; Min | 2004 |
The 'real' woman with heart failure. Impact of sex on current in-hospital management of heart failure by cardiologists and internists.
Topics: Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Female; Heart Failure; Hospital Mortalit | 2004 |
The 'real' woman with heart failure. Impact of sex on current in-hospital management of heart failure by cardiologists and internists.
Topics: Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Female; Heart Failure; Hospital Mortalit | 2004 |
[Therapy of heart failure after myocardial infarction. With eplerenone a new course].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Drug Therapy, Comb | 2004 |
[Therapy of heart failure after myocardial infarction. With eplerenone a new course].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Drug Therapy, Comb | 2004 |
[More benefit in hypertension and high-grade reduction of the pump performance. Earlier beginning of therapy maximizes the benefit].
Topics: Controlled Clinical Trials as Topic; Diuretics; Eplerenone; Heart Failure; Humans; Hypertension; Min | 2004 |
[More benefit in hypertension and high-grade reduction of the pump performance. Earlier beginning of therapy maximizes the benefit].
Topics: Controlled Clinical Trials as Topic; Diuretics; Eplerenone; Heart Failure; Humans; Hypertension; Min | 2004 |
Implementation of guidelines for management of heart failure in heart failure clinic: effects beyond pharmacological treatment.
Topics: Aged; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Practice Gui | 2004 |
Implementation of guidelines for management of heart failure in heart failure clinic: effects beyond pharmacological treatment.
Topics: Aged; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Practice Gui | 2004 |
Hyperkalemia after the publication of RALES.
Topics: Cause of Death; Heart Failure; Hospitalization; Humans; Hyperkalemia; Mineralocorticoid Receptor Ant | 2004 |
Hyperkalemia after the publication of RALES.
Topics: Cause of Death; Heart Failure; Hospitalization; Humans; Hyperkalemia; Mineralocorticoid Receptor Ant | 2004 |
Hyperkalemia after the publication of RALES.
Topics: Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Spironolactone | 2004 |
Hyperkalemia after the publication of RALES.
Topics: Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Spironolactone | 2004 |
Hyperkalemia after the publication of RALES.
Topics: Creatinine; Heart Failure; Hospitalization; Humans; Hyperkalemia; Kidney Diseases; Mineralocorticoid | 2004 |
Hyperkalemia after the publication of RALES.
Topics: Creatinine; Heart Failure; Hospitalization; Humans; Hyperkalemia; Kidney Diseases; Mineralocorticoid | 2004 |
Hyperkalemia after the publication of RALES.
Topics: Heart Failure; Hospitalization; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Spiron | 2004 |
Hyperkalemia after the publication of RALES.
Topics: Heart Failure; Hospitalization; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Spiron | 2004 |
[Spironolactone and potassium].
Topics: Diuretics; Heart Failure; Humans; Hyperkalemia; Potassium; Spironolactone | 2004 |
[Spironolactone and potassium].
Topics: Diuretics; Heart Failure; Humans; Hyperkalemia; Potassium; Spironolactone | 2004 |
Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Algorithms; Body Weight; Case-Control Studies; Creat | 2004 |
Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Algorithms; Body Weight; Case-Control Studies; Creat | 2004 |
Drug safety in patients with heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diuretics; Heart Failure; Humans; Hyperkalemia; Risk Facto | 2005 |
Drug safety in patients with heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diuretics; Heart Failure; Humans; Hyperkalemia; Risk Facto | 2005 |
Ga-67 citrate and F-18 FDG uptake in spironolactone-induced gynecomastia.
Topics: Artifacts; Citrates; Diuretics; Fluorodeoxyglucose F18; Gallium; Gynecomastia; Heart Failure; Humans | 2005 |
Ga-67 citrate and F-18 FDG uptake in spironolactone-induced gynecomastia.
Topics: Artifacts; Citrates; Diuretics; Fluorodeoxyglucose F18; Gallium; Gynecomastia; Heart Failure; Humans | 2005 |
Factors influencing medical treatment of heart failure patients in Spanish internal medicine departments: a national survey.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Ambulatory Care; Angiotensin-Converting Enzyme | 2005 |
Factors influencing medical treatment of heart failure patients in Spanish internal medicine departments: a national survey.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Ambulatory Care; Angiotensin-Converting Enzyme | 2005 |
ACE inhibitors and mineralocorticoid receptor blockade in patients with congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Hypertension; Mineralo | 2005 |
ACE inhibitors and mineralocorticoid receptor blockade in patients with congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Hypertension; Mineralo | 2005 |
Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload.
Topics: Animals; Aorta; Apoptosis; Blood Pressure; Cell Size; Chronic Disease; Constriction, Pathologic; Dru | 2005 |
Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload.
Topics: Animals; Aorta; Apoptosis; Blood Pressure; Cell Size; Chronic Disease; Constriction, Pathologic; Dru | 2005 |
Management of heart failure and left ventricular systolic dysfunction following acute myocardial infarction.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Sp | 2005 |
Management of heart failure and left ventricular systolic dysfunction following acute myocardial infarction.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Sp | 2005 |
[Effects of the RALE study. Hyperkalemia following spironolactone treatment].
Topics: Adrenergic beta-Antagonists; Adverse Drug Reaction Reporting Systems; Aged; Angiotensin-Converting E | 2005 |
[Effects of the RALE study. Hyperkalemia following spironolactone treatment].
Topics: Adrenergic beta-Antagonists; Adverse Drug Reaction Reporting Systems; Aged; Angiotensin-Converting E | 2005 |
The interaction among sex, hemoglobin and outcomes in a specialty heart failure clinic.
Topics: Age Distribution; Age Factors; Aged; Anemia, Iron-Deficiency; Angiotensin-Converting Enzyme Inhibito | 2005 |
The interaction among sex, hemoglobin and outcomes in a specialty heart failure clinic.
Topics: Age Distribution; Age Factors; Aged; Anemia, Iron-Deficiency; Angiotensin-Converting Enzyme Inhibito | 2005 |
Managed care patients with heart failure: spectrum of ventricular dysfunction and predictors of medication utilization.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Comorbidity; Diuretics; | 2005 |
Managed care patients with heart failure: spectrum of ventricular dysfunction and predictors of medication utilization.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Comorbidity; Diuretics; | 2005 |
Treatment with angiotensin converting enzyme inhibitors, angiotensin-II-antagonists and beta-blockers in an unselected group of patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angio | 2005 |
Treatment with angiotensin converting enzyme inhibitors, angiotensin-II-antagonists and beta-blockers in an unselected group of patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angio | 2005 |
Pharmacological treatment of congestive heart failure in Canada: a description of care in five provinces.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2005 |
Pharmacological treatment of congestive heart failure in Canada: a description of care in five provinces.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2005 |
Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Arteri | 2005 |
Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Arteri | 2005 |
Utilisation of medications recommended for chronic heart failure and the relationship with annual hospitalisation duration in patients over 75 years of age. A pharmacoepidemiological study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Case | 2005 |
Utilisation of medications recommended for chronic heart failure and the relationship with annual hospitalisation duration in patients over 75 years of age. A pharmacoepidemiological study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Case | 2005 |
Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blotting, Western; Collagen Ty | 2005 |
Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blotting, Western; Collagen Ty | 2005 |
Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Female; H | 2005 |
Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Female; H | 2005 |
Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.
Topics: Aged; Aged, 80 and over; Cohort Studies; Creatinine; Diuretics; Drug Prescriptions; Female; Follow-U | 2005 |
Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.
Topics: Aged; Aged, 80 and over; Cohort Studies; Creatinine; Diuretics; Drug Prescriptions; Female; Follow-U | 2005 |
Spironolactone improves carotid artery fibrosis and distensibility in rat post-ischaemic heart failure.
Topics: Animals; Carotid Arteries; Compliance; Drug Therapy, Combination; Echocardiography; Elasticity; Fibr | 2005 |
Spironolactone improves carotid artery fibrosis and distensibility in rat post-ischaemic heart failure.
Topics: Animals; Carotid Arteries; Compliance; Drug Therapy, Combination; Echocardiography; Elasticity; Fibr | 2005 |
[Heart failure after acute myocardial infarct. Early aldosterone blockade increases survival rate].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Hu | 2005 |
[Heart failure after acute myocardial infarct. Early aldosterone blockade increases survival rate].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Hu | 2005 |
[Neurohumoral systems escape control. Heart failure symptoms even once--long-term high risk prognosis].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Hu | 2005 |
[Neurohumoral systems escape control. Heart failure symptoms even once--long-term high risk prognosis].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Hu | 2005 |
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2005 |
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2005 |
Heart failure due to left ventricular systolic dysfunction: treatment at discharge from hospital and at one year.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Female; Foll | 2005 |
Heart failure due to left ventricular systolic dysfunction: treatment at discharge from hospital and at one year.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Female; Foll | 2005 |
Mortality in two recent reports of clinical trials on patients with congestive heart failure compared with mortality in three previous clinical trials.
Topics: Aged; Anti-Arrhythmia Agents; Clinical Trials as Topic; Denmark; Diuretics; Female; Heart Failure; H | 2000 |
Mortality in two recent reports of clinical trials on patients with congestive heart failure compared with mortality in three previous clinical trials.
Topics: Aged; Anti-Arrhythmia Agents; Clinical Trials as Topic; Denmark; Diuretics; Female; Heart Failure; H | 2000 |
How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiotensin-Converting | 2006 |
How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiotensin-Converting | 2006 |
Heart failure guidelines and prescribing in primary care across Europe.
Topics: Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Anticoag | 2005 |
Heart failure guidelines and prescribing in primary care across Europe.
Topics: Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Anticoag | 2005 |
The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
Topics: Aged; Clinical Laboratory Techniques; Cohort Studies; Creatinine; Diuretics; Drug Monitoring; Female | 2005 |
The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
Topics: Aged; Clinical Laboratory Techniques; Cohort Studies; Creatinine; Diuretics; Drug Monitoring; Female | 2005 |
Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction.
Topics: Animals; Atrial Fibrillation; Cardiomyopathy, Dilated; Fibrosis; Heart Atria; Heart Failure; Male; M | 2005 |
Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction.
Topics: Animals; Atrial Fibrillation; Cardiomyopathy, Dilated; Fibrosis; Heart Atria; Heart Failure; Male; M | 2005 |
Aldosterone antagonism and atrial fibrillation: time for clinical assessment?
Topics: Animals; Atrial Fibrillation; Cardiomyopathy, Dilated; Fibrosis; Heart Failure; Mineralocorticoid Re | 2005 |
Aldosterone antagonism and atrial fibrillation: time for clinical assessment?
Topics: Animals; Atrial Fibrillation; Cardiomyopathy, Dilated; Fibrosis; Heart Failure; Mineralocorticoid Re | 2005 |
Heart failure after acute ST-segment elevation myocardial infarction: what should we do about it?
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Pa | 2005 |
Heart failure after acute ST-segment elevation myocardial infarction: what should we do about it?
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Pa | 2005 |
Sudden death in patients with myocardial infarction.
Topics: Death, Sudden, Cardiac; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; M | 2005 |
Sudden death in patients with myocardial infarction.
Topics: Death, Sudden, Cardiac; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; M | 2005 |
Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme 2; Animals; Carboxypeptidases; Eplerenone; H | 2005 |
Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme 2; Animals; Carboxypeptidases; Eplerenone; H | 2005 |
Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2005 |
Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2005 |
Update on outpatient treatment of systolic heart failure.
Topics: Ambulatory Care; Black or African American; Diuretics; Drug Therapy, Combination; Heart Failure; Hum | 2005 |
Update on outpatient treatment of systolic heart failure.
Topics: Ambulatory Care; Black or African American; Diuretics; Drug Therapy, Combination; Heart Failure; Hum | 2005 |
High prevalence of microalbuminuria in chronic heart failure patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Aldosterone; Angiotensin-Converti | 2005 |
High prevalence of microalbuminuria in chronic heart failure patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Aldosterone; Angiotensin-Converti | 2005 |
[The place of aldosterone receptor blockers in the treatment of chronic heart failure].
Topics: Chronic Disease; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2005 |
[The place of aldosterone receptor blockers in the treatment of chronic heart failure].
Topics: Chronic Disease; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2005 |
Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
Topics: Aged; Aged, 80 and over; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Fe | 2006 |
Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
Topics: Aged; Aged, 80 and over; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Fe | 2006 |
Economic implications of treatment guidelines for congestive heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Canada; Databases as Topic; D | 2005 |
Economic implications of treatment guidelines for congestive heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Canada; Databases as Topic; D | 2005 |
Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Clinical Trials as Topic; Drug | 2006 |
Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Clinical Trials as Topic; Drug | 2006 |
[Heart failure after myocardial infarction. Increased risk, poorer treatment].
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Eplerenone; Heart Failure; Hospital Mortality; | 2005 |
[Heart failure after myocardial infarction. Increased risk, poorer treatment].
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Eplerenone; Heart Failure; Hospital Mortality; | 2005 |
Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Female; Furosemide; Heart Failure; | 2006 |
Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Female; Furosemide; Heart Failure; | 2006 |
[Late drug-induced hyperkalemia in a patient with congestive heart failure].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Diuretics; Female; Heart Fail | 2005 |
[Late drug-induced hyperkalemia in a patient with congestive heart failure].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Diuretics; Female; Heart Fail | 2005 |
Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
Topics: Clinical Trials as Topic; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial | 2006 |
Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
Topics: Clinical Trials as Topic; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial | 2006 |
Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production.
Topics: Animals; Endothelium, Vascular; Heart Failure; Hemodynamics; Male; Mineralocorticoid Receptor Antago | 2006 |
Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production.
Topics: Animals; Endothelium, Vascular; Heart Failure; Hemodynamics; Male; Mineralocorticoid Receptor Antago | 2006 |
Use and side-effect profile of spironolactone in a private cardiologist's practice.
Topics: Aged; Cardiology; Diuretics; Drug Utilization; Female; Heart Failure; Humans; Hyperkalemia; Hyperten | 2006 |
Use and side-effect profile of spironolactone in a private cardiologist's practice.
Topics: Aged; Cardiology; Diuretics; Drug Utilization; Female; Heart Failure; Humans; Hyperkalemia; Hyperten | 2006 |
Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; H | 2006 |
Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; H | 2006 |
Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure.
Topics: Administration, Oral; Animals; Dogs; Eplerenone; Heart Atria; Heart Conduction System; Heart Failure | 2006 |
Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure.
Topics: Administration, Oral; Animals; Dogs; Eplerenone; Heart Atria; Heart Conduction System; Heart Failure | 2006 |
Aldosterone antagonism as an antiarrhythmic approach for atrial arrhythmias in heart failure.
Topics: Administration, Oral; Animals; Dogs; Eplerenone; Heart Atria; Heart Conduction System; Heart Failure | 2006 |
Aldosterone antagonism as an antiarrhythmic approach for atrial arrhythmias in heart failure.
Topics: Administration, Oral; Animals; Dogs; Eplerenone; Heart Atria; Heart Conduction System; Heart Failure | 2006 |
Evidence-based treatment and quality of life in heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2006 |
Evidence-based treatment and quality of life in heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2006 |
[Cardiovascular medicine unit: preliminary results of an in-hospital multidisciplinary intervention in heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Coronary Angiography; Coronary Care Uni | 2006 |
[Cardiovascular medicine unit: preliminary results of an in-hospital multidisciplinary intervention in heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Coronary Angiography; Coronary Care Uni | 2006 |
The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats.
Topics: Actins; Aldosterone; Animals; Blotting, Western; Cytochrome P-450 CYP11B2; Drug Therapy, Combination | 2006 |
The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats.
Topics: Actins; Aldosterone; Animals; Blotting, Western; Cytochrome P-450 CYP11B2; Drug Therapy, Combination | 2006 |
Eplerenone inhibits tumour necrosis factor alpha shedding process by tumour necrosis factor alpha converting enzyme in monocytes from patients with congestive heart failure.
Topics: ADAM Proteins; ADAM17 Protein; Dose-Response Relationship, Drug; Eplerenone; Heart Failure; Humans; | 2006 |
Eplerenone inhibits tumour necrosis factor alpha shedding process by tumour necrosis factor alpha converting enzyme in monocytes from patients with congestive heart failure.
Topics: ADAM Proteins; ADAM17 Protein; Dose-Response Relationship, Drug; Eplerenone; Heart Failure; Humans; | 2006 |
Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
Topics: Adverse Drug Reaction Reporting Systems; Algorithms; Bayes Theorem; Bias; Causality; Data Collection | 2006 |
Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
Topics: Adverse Drug Reaction Reporting Systems; Algorithms; Bayes Theorem; Bias; Causality; Data Collection | 2006 |
Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiomyopathy, Dilated; Combined Modality | 2006 |
Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiomyopathy, Dilated; Combined Modality | 2006 |
Effect of spironolactone on C-reactive protein levels in patients with heart disease.
Topics: Biomarkers; C-Reactive Protein; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Rando | 2007 |
Effect of spironolactone on C-reactive protein levels in patients with heart disease.
Topics: Biomarkers; C-Reactive Protein; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Rando | 2007 |
Mineralocorticoid-receptor blockade, hypertension and heart failure.
Topics: Aldosterone; Clinical Trials as Topic; Eplerenone; Heart Failure; Hormone Antagonists; Humans; Hyper | 2005 |
Mineralocorticoid-receptor blockade, hypertension and heart failure.
Topics: Aldosterone; Clinical Trials as Topic; Eplerenone; Heart Failure; Hormone Antagonists; Humans; Hyper | 2005 |
Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure.
Topics: Animals; Cytokines; Drug Synergism; Echocardiography; Eplerenone; Etanercept; Heart Failure; Hypotha | 2006 |
Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure.
Topics: Animals; Cytokines; Drug Synergism; Echocardiography; Eplerenone; Etanercept; Heart Failure; Hypotha | 2006 |
International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Diur | 2007 |
International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Diur | 2007 |
Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
Topics: Aldosterone; Angiotensin II; Animals; Blotting, Western; Chromatography, High Pressure Liquid; Cytoc | 2007 |
Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
Topics: Aldosterone; Angiotensin II; Animals; Blotting, Western; Chromatography, High Pressure Liquid; Cytoc | 2007 |
[Cardioverter-defibrillator (ICD) and resynchronization in every patient with cardiac failure].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2006 |
[Cardioverter-defibrillator (ICD) and resynchronization in every patient with cardiac failure].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2006 |
[Effect of the optimal neurohormonal blockade on long-term survival in patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Drug T | 2006 |
[Effect of the optimal neurohormonal blockade on long-term survival in patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Drug T | 2006 |
Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart.
Topics: Animals; Cell Separation; Cricetinae; Electrocardiography; Electrophysiology; Eplerenone; Heart Cond | 2006 |
Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart.
Topics: Animals; Cell Separation; Cricetinae; Electrocardiography; Electrophysiology; Eplerenone; Heart Cond | 2006 |
Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil.
Topics: Adult; Aged; Aged, 80 and over; Benzimidazoles; Biphenyl Compounds; Carbazoles; Carvedilol; Drug The | 2006 |
Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil.
Topics: Adult; Aged; Aged, 80 and over; Benzimidazoles; Biphenyl Compounds; Carbazoles; Carvedilol; Drug The | 2006 |
Adherence to guidelines for patients hospitalized with heart failure: a nationwide survey.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Calc | 2006 |
Adherence to guidelines for patients hospitalized with heart failure: a nationwide survey.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Calc | 2006 |
Increased cyclooxygenase-2 expression in hypothalamic paraventricular nucleus in rats with heart failure: role of nuclear factor kappaB.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cyclooxygenase 2; Cytokines; Disease Models, Animal | 2007 |
Increased cyclooxygenase-2 expression in hypothalamic paraventricular nucleus in rats with heart failure: role of nuclear factor kappaB.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cyclooxygenase 2; Cytokines; Disease Models, Animal | 2007 |
Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure.
Topics: Aged; Aged, 80 and over; Aldosterone; C-Reactive Protein; Cause of Death; Cohort Studies; Comorbidit | 2007 |
Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure.
Topics: Aged; Aged, 80 and over; Aldosterone; C-Reactive Protein; Cause of Death; Cohort Studies; Comorbidit | 2007 |
[Portopulmonary hypertension due to schistosomiasis in two Malagasy patients].
Topics: Adolescent; Adult; Anthelmintics; Ascites; Combined Modality Therapy; Diet, Sodium-Restricted; Dyspn | 2007 |
[Portopulmonary hypertension due to schistosomiasis in two Malagasy patients].
Topics: Adolescent; Adult; Anthelmintics; Ascites; Combined Modality Therapy; Diet, Sodium-Restricted; Dyspn | 2007 |
The effect of spironolactone use on heart failure mortality: a population-based study.
Topics: Age Distribution; Aged; Cohort Studies; Comorbidity; Creatinine; Diabetes Mellitus; Diuretics; Femal | 2007 |
The effect of spironolactone use on heart failure mortality: a population-based study.
Topics: Age Distribution; Aged; Cohort Studies; Comorbidity; Creatinine; Diabetes Mellitus; Diuretics; Femal | 2007 |
Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
Topics: Aged; Clinical Trials as Topic; Diabetes Complications; Eplerenone; Female; Heart Failure; Humans; H | 2008 |
Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
Topics: Aged; Clinical Trials as Topic; Diabetes Complications; Eplerenone; Female; Heart Failure; Humans; H | 2008 |
[Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study].
Topics: Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; | 2007 |
[Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study].
Topics: Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; | 2007 |
Letter by Pascual-Figal et al regarding article, "Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival".
Topics: Heart Failure; Hormones; Humans; Male; Spironolactone | 2007 |
Letter by Pascual-Figal et al regarding article, "Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival".
Topics: Heart Failure; Hormones; Humans; Male; Spironolactone | 2007 |
Worsening of motor symptoms and gynecomastia during spironolactone treatment in a patient with Parkinson's disease and congestive heart failure.
Topics: Aged; Gynecomastia; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Movement Di | 2007 |
Worsening of motor symptoms and gynecomastia during spironolactone treatment in a patient with Parkinson's disease and congestive heart failure.
Topics: Aged; Gynecomastia; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Movement Di | 2007 |
Estrogen receptor activation--good, aldosterone receptor blockade--beneficial, communication between receptors...priceless.
Topics: Female; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Prognosis; Rand | 2007 |
Estrogen receptor activation--good, aldosterone receptor blockade--beneficial, communication between receptors...priceless.
Topics: Female; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Prognosis; Rand | 2007 |
Curriculum in cardiology: Integrated diagnosis and management of diastolic heart failure (Am Heart J 2007;153:189-200).
Topics: Adult; Aldosterone; Diastole; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spirono | 2007 |
Curriculum in cardiology: Integrated diagnosis and management of diastolic heart failure (Am Heart J 2007;153:189-200).
Topics: Adult; Aldosterone; Diastole; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spirono | 2007 |
[Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial infarction].
Topics: Acute Disease; Adult; Aged; Cause of Death; Comorbidity; Female; Follow-Up Studies; Heart Failure; H | 2006 |
[Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial infarction].
Topics: Acute Disease; Adult; Aged; Cause of Death; Comorbidity; Female; Follow-Up Studies; Heart Failure; H | 2006 |
Brain mechanisms contributing to sympathetic hyperactivity and heart failure.
Topics: Angiotensinogen; Animals; Animals, Genetically Modified; Gene Transfer Techniques; Heart Failure; In | 2007 |
Brain mechanisms contributing to sympathetic hyperactivity and heart failure.
Topics: Angiotensinogen; Animals; Animals, Genetically Modified; Gene Transfer Techniques; Heart Failure; In | 2007 |
Tailored hormonal therapy in secretory adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Aged; Aldosterone; Alkalosis; Ang | 2007 |
Tailored hormonal therapy in secretory adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Aged; Aldosterone; Alkalosis; Ang | 2007 |
Diuretics in obstructive sleep apnea with diastolic heart failure.
Topics: Adult; Aged; Blood Gas Analysis; Diastole; Diuretics; Drug Therapy, Combination; Echocardiography, D | 2007 |
Diuretics in obstructive sleep apnea with diastolic heart failure.
Topics: Adult; Aged; Blood Gas Analysis; Diastole; Diuretics; Drug Therapy, Combination; Echocardiography, D | 2007 |
Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance.
Topics: Creatinine; Diuresis; Diuretics; Female; Furosemide; Glomerular Filtration Rate; Glucocorticoids; He | 2007 |
Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance.
Topics: Creatinine; Diuresis; Diuretics; Female; Furosemide; Glomerular Filtration Rate; Glucocorticoids; He | 2007 |
Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance.
Topics: Creatinine; Diuresis; Diuretics; Female; Furosemide; Glomerular Filtration Rate; Glucocorticoids; He | 2007 |
Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance.
Topics: Creatinine; Diuresis; Diuretics; Female; Furosemide; Glomerular Filtration Rate; Glucocorticoids; He | 2007 |
Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance.
Topics: Creatinine; Diuresis; Diuretics; Female; Furosemide; Glomerular Filtration Rate; Glucocorticoids; He | 2007 |
Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance.
Topics: Creatinine; Diuresis; Diuretics; Female; Furosemide; Glomerular Filtration Rate; Glucocorticoids; He | 2007 |
Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance.
Topics: Creatinine; Diuresis; Diuretics; Female; Furosemide; Glomerular Filtration Rate; Glucocorticoids; He | 2007 |
Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance.
Topics: Creatinine; Diuresis; Diuretics; Female; Furosemide; Glomerular Filtration Rate; Glucocorticoids; He | 2007 |
Effect of long-term monotherapy with the aldosterone receptor blocker eplerenone on cytoskeletal proteins and matrix metalloproteinases in dogs with heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cytoskeletal Proteins; Dogs; Eplerenone; Heart Fa | 2007 |
Effect of long-term monotherapy with the aldosterone receptor blocker eplerenone on cytoskeletal proteins and matrix metalloproteinases in dogs with heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cytoskeletal Proteins; Dogs; Eplerenone; Heart Fa | 2007 |
Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES).
Topics: Adverse Drug Reaction Reporting Systems; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Bayes | 2007 |
Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES).
Topics: Adverse Drug Reaction Reporting Systems; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Bayes | 2007 |
Echocardiographic monitoring of patients with heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiology; Diastole; Echocar | 2007 |
Echocardiographic monitoring of patients with heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiology; Diastole; Echocar | 2007 |
Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs.
Topics: Animals; Atrial Fibrillation; Cardiac Volume; Collagen; Dogs; Heart Atria; Heart Failure; Hemodynami | 2008 |
Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs.
Topics: Animals; Atrial Fibrillation; Cardiac Volume; Collagen; Dogs; Heart Atria; Heart Failure; Hemodynami | 2008 |
Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response.
Topics: Aldosterone; Animals; Clodronic Acid; Collagen; Cytokines; Eplerenone; Factor XIIIa; Heart Failure; | 2008 |
Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response.
Topics: Aldosterone; Animals; Clodronic Acid; Collagen; Cytokines; Eplerenone; Factor XIIIa; Heart Failure; | 2008 |
Translational research goes both ways: lessons from clinical studies.
Topics: Aldosterone; Amino Acid Sequence; Antihypertensive Agents; Biomedical Research; Clinical Trials as T | 2008 |
Translational research goes both ways: lessons from clinical studies.
Topics: Aldosterone; Amino Acid Sequence; Antihypertensive Agents; Biomedical Research; Clinical Trials as T | 2008 |
Use of human spironolactone in dogs with heart failure.
Topics: Animals; Diuretics; Dog Diseases; Dogs; Drug Approval; Heart Failure; Humans; Spironolactone | 2008 |
Use of human spironolactone in dogs with heart failure.
Topics: Animals; Diuretics; Dog Diseases; Dogs; Drug Approval; Heart Failure; Humans; Spironolactone | 2008 |
Plasma concentrations of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and osteopontin reflect severity of heart failure in DOCA-salt hypertensive rat.
Topics: Animals; Biomarkers; Blood Pressure; Desoxycorticosterone; Gene Expression Regulation, Enzymologic; | 2008 |
Plasma concentrations of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and osteopontin reflect severity of heart failure in DOCA-salt hypertensive rat.
Topics: Animals; Biomarkers; Blood Pressure; Desoxycorticosterone; Gene Expression Regulation, Enzymologic; | 2008 |
Use of human spironolactone in dogs with heart failure.
Topics: Animals; Diuretics; Dog Diseases; Dogs; Drug Approval; Drug Prescriptions; Heart Failure; Humans; Le | 2008 |
Use of human spironolactone in dogs with heart failure.
Topics: Animals; Diuretics; Dog Diseases; Dogs; Drug Approval; Drug Prescriptions; Heart Failure; Humans; Le | 2008 |
Use of human spironolactone in dogs with heart failure.
Topics: Animals; Diuretics; Dog Diseases; Dogs; Drug Approval; Drug Prescriptions; Heart Failure; Humans; Le | 2008 |
Use of human spironolactone in dogs with heart failure.
Topics: Animals; Diuretics; Dog Diseases; Dogs; Drug Approval; Drug Prescriptions; Heart Failure; Humans; Le | 2008 |
The treatment of heart failure in the "intractable" (refractory) phase.
Topics: Aminophylline; Ammonium Chloride; Diet, Sodium-Restricted; Digitalis Glycosides; Ethacrynic Acid; He | 1966 |
The treatment of heart failure in the "intractable" (refractory) phase.
Topics: Aminophylline; Ammonium Chloride; Diet, Sodium-Restricted; Digitalis Glycosides; Ethacrynic Acid; He | 1966 |
Secondary aldosteronism in refractory edema.
Topics: Diuretics; Drug Synergism; Edema; Heart Failure; Humans; Hyperaldosteronism; Hypokalemia; Liver Cirr | 1967 |
Secondary aldosteronism in refractory edema.
Topics: Diuretics; Drug Synergism; Edema; Heart Failure; Humans; Hyperaldosteronism; Hypokalemia; Liver Cirr | 1967 |
Lasix.
Topics: Diuresis; Edema; Furosemide; Heart Failure; Humans; Kidney Diseases; Liver Cirrhosis; Potassium Defi | 1967 |
Lasix.
Topics: Diuresis; Edema; Furosemide; Heart Failure; Humans; Kidney Diseases; Liver Cirrhosis; Potassium Defi | 1967 |
[Metabolic balance in patients with cardiac cachexia].
Topics: Adult; Cachexia; Diet Therapy; Dietary Proteins; Diuretics; Female; Furosemide; Heart Failure; Human | 1967 |
[Metabolic balance in patients with cardiac cachexia].
Topics: Adult; Cachexia; Diet Therapy; Dietary Proteins; Diuretics; Female; Furosemide; Heart Failure; Human | 1967 |
[Behavior of salivary electrolytes in decompensated cardiology patients].
Topics: Adult; Aged; Calcium; Digitalis Glycosides; Diuretics; Female; Furosemide; Heart Failure; Humans; Ma | 1984 |
[Behavior of salivary electrolytes in decompensated cardiology patients].
Topics: Adult; Aged; Calcium; Digitalis Glycosides; Diuretics; Female; Furosemide; Heart Failure; Humans; Ma | 1984 |
Congestive heart failure due to giant cutaneous cavernous hemangioma.
Topics: Digoxin; Drug Resistance; Facial Neoplasms; Female; Furosemide; Heart Failure; Hemangioma, Cavernous | 1984 |
Congestive heart failure due to giant cutaneous cavernous hemangioma.
Topics: Digoxin; Drug Resistance; Facial Neoplasms; Female; Furosemide; Heart Failure; Hemangioma, Cavernous | 1984 |
[Heart failure therapy with digitalis and spironolactone--studies within the scope of preoperative treatment before lung resection].
Topics: Adult; Aged; Digitalis Glycosides; Digoxin; Drug Therapy, Combination; Female; Heart Failure; Hemody | 1984 |
[Heart failure therapy with digitalis and spironolactone--studies within the scope of preoperative treatment before lung resection].
Topics: Adult; Aged; Digitalis Glycosides; Digoxin; Drug Therapy, Combination; Female; Heart Failure; Hemody | 1984 |
Spironolactone-digoxin interaction.
Topics: Adult; Aged; Digoxin; Drug Interactions; Drug Therapy, Combination; Female; Heart Failure; Humans; M | 1983 |
Spironolactone-digoxin interaction.
Topics: Adult; Aged; Digoxin; Drug Interactions; Drug Therapy, Combination; Female; Heart Failure; Humans; M | 1983 |
[Long term experiences with a solid spironolactone-furosemide combination in heart insufficiency and hypertension].
Topics: Adult; Aged; Drug Combinations; Female; Furosemide; Heart Failure; Humans; Hypertension; Long-Term C | 1982 |
[Long term experiences with a solid spironolactone-furosemide combination in heart insufficiency and hypertension].
Topics: Adult; Aged; Drug Combinations; Female; Furosemide; Heart Failure; Humans; Hypertension; Long-Term C | 1982 |
[Long-term domiciliary oxygen therapy of cardiac failure and cardiac arrhythmia accompanying respiratory insufficiency (author's transl)].
Topics: Adult; Aged; Arrhythmias, Cardiac; Digitalis; Heart Failure; Humans; Long-Term Care; Male; Middle Ag | 1981 |
[Long-term domiciliary oxygen therapy of cardiac failure and cardiac arrhythmia accompanying respiratory insufficiency (author's transl)].
Topics: Adult; Aged; Arrhythmias, Cardiac; Digitalis; Heart Failure; Humans; Long-Term Care; Male; Middle Ag | 1981 |
A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure.
Topics: Chronic Disease; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Humans; Hydralazine; N | 1983 |
A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure.
Topics: Chronic Disease; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Humans; Hydralazine; N | 1983 |
Beta-blockers in dilated cardiomyopathies: they work.
Topics: Administration, Oral; Adult; Aged; Digoxin; Dilatation, Pathologic; Drug Therapy, Combination; Femal | 1983 |
Beta-blockers in dilated cardiomyopathies: they work.
Topics: Administration, Oral; Adult; Aged; Digoxin; Dilatation, Pathologic; Drug Therapy, Combination; Femal | 1983 |
The occurrence of hyperaldosteronism in infants with congestive heart failure.
Topics: Aldosterone; Body Weight; Epidemiologic Methods; Furosemide; Heart Failure; Humans; Hyperaldosteroni | 1980 |
The occurrence of hyperaldosteronism in infants with congestive heart failure.
Topics: Aldosterone; Body Weight; Epidemiologic Methods; Furosemide; Heart Failure; Humans; Hyperaldosteroni | 1980 |
Drug attributed alterations in potassium handling in congestive cardiac failure.
Topics: Adult; Aged; Blood Urea Nitrogen; Diuretics; Female; Furosemide; Heart Failure; Humans; Hyperkalemia | 1982 |
Drug attributed alterations in potassium handling in congestive cardiac failure.
Topics: Adult; Aged; Blood Urea Nitrogen; Diuretics; Female; Furosemide; Heart Failure; Humans; Hyperkalemia | 1982 |
[Therapy of cardiac insufficiency with diuretics].
Topics: Amiloride; Benzothiadiazines; Blood Glucose; Diuretics; Drug Administration Schedule; Female; Furose | 1982 |
[Therapy of cardiac insufficiency with diuretics].
Topics: Amiloride; Benzothiadiazines; Blood Glucose; Diuretics; Drug Administration Schedule; Female; Furose | 1982 |
[Diuretics in the therapy of chronic cardiac insufficiency].
Topics: Acetazolamide; Amiloride; Diuretics; Drug Interactions; Ethacrynic Acid; Heart Failure; Humans; Inda | 1982 |
[Diuretics in the therapy of chronic cardiac insufficiency].
Topics: Acetazolamide; Amiloride; Diuretics; Drug Interactions; Ethacrynic Acid; Heart Failure; Humans; Inda | 1982 |
[Value of successive use of aldactone and aldactacine in the management of congestive heart failure involving at the outset hypokalemia with or without cardiac rhythm disorders].
Topics: Adult; Aged; Arrhythmias, Cardiac; Drug Combinations; Female; Heart Failure; Humans; Hypokalemia; Ma | 1981 |
[Value of successive use of aldactone and aldactacine in the management of congestive heart failure involving at the outset hypokalemia with or without cardiac rhythm disorders].
Topics: Adult; Aged; Arrhythmias, Cardiac; Drug Combinations; Female; Heart Failure; Humans; Hypokalemia; Ma | 1981 |
[Spironolactone in digitalis-requiring cardiac insufficiency following pacemaker implantation].
Topics: Aged; Digitalis; Diuretics; Female; Heart Failure; Humans; Male; Pacemaker, Artificial; Plants, Medi | 1981 |
[Spironolactone in digitalis-requiring cardiac insufficiency following pacemaker implantation].
Topics: Aged; Digitalis; Diuretics; Female; Heart Failure; Humans; Male; Pacemaker, Artificial; Plants, Medi | 1981 |
Treatment of refractory congestive heart failure and normokalemic hypochloremic alkalosis with acetazolamide and spironolactone.
Topics: Acetazolamide; Aged; Alkalosis; Chlorides; Drug Therapy, Combination; Furosemide; Heart Failure; Hum | 1980 |
Treatment of refractory congestive heart failure and normokalemic hypochloremic alkalosis with acetazolamide and spironolactone.
Topics: Acetazolamide; Aged; Alkalosis; Chlorides; Drug Therapy, Combination; Furosemide; Heart Failure; Hum | 1980 |
Spironolactone in the long-term management of patients with congestive heart failure.
Topics: Aged; Edema, Cardiac; Electrolytes; Female; Heart Failure; Humans; Male; Spironolactone | 1980 |
Spironolactone in the long-term management of patients with congestive heart failure.
Topics: Aged; Edema, Cardiac; Electrolytes; Female; Heart Failure; Humans; Male; Spironolactone | 1980 |
[In the age of ACE inhibitors are there still indications for spironolactone in heart failure?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Hemodynamics; Humans; Renin-Angiotensin Sys | 1995 |
[In the age of ACE inhibitors are there still indications for spironolactone in heart failure?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Hemodynamics; Humans; Renin-Angiotensin Sys | 1995 |
Cardioprotective therapeutics--drugs used in hypertension, hyperlipidaemia, thromboembolization, arrhythmias, postmenopausal state and as anti-oxidants.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Drug Therapy, Combination; Heart | 1994 |
Cardioprotective therapeutics--drugs used in hypertension, hyperlipidaemia, thromboembolization, arrhythmias, postmenopausal state and as anti-oxidants.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Drug Therapy, Combination; Heart | 1994 |
Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Bumetanide; Drug Resistance; Drug | 1993 |
Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Bumetanide; Drug Resistance; Drug | 1993 |
Captopril and spironolactone therapy for refractory congestive heart failure.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Captopril; Drug Therapy, Combination; Female; Heart Fai | 1993 |
Captopril and spironolactone therapy for refractory congestive heart failure.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Captopril; Drug Therapy, Combination; Female; Heart Fai | 1993 |
Heart failure in the elderly.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Contraindications; Drug Interacti | 1997 |
Heart failure in the elderly.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Contraindications; Drug Interacti | 1997 |
Drugs for chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 1999 |
Drugs for chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 1999 |
Diuretics in congestive heart failure: new evidence for old problems.
Topics: Diuretics; Heart Failure; Humans; Hyperaldosteronism; Norepinephrine; Potassium; Sodium; Spironolact | 1999 |
Diuretics in congestive heart failure: new evidence for old problems.
Topics: Diuretics; Heart Failure; Humans; Hyperaldosteronism; Norepinephrine; Potassium; Sodium; Spironolact | 1999 |
Drug cuts deaths from heart failure by a third.
Topics: Death, Sudden, Cardiac; Diuretics; Heart Failure; Humans; Prognosis; Spironolactone | 1999 |
Drug cuts deaths from heart failure by a third.
Topics: Death, Sudden, Cardiac; Diuretics; Heart Failure; Humans; Prognosis; Spironolactone | 1999 |
Population analysis for the optimization of digoxin treatment in Japanese paediatric patients.
Topics: Age Factors; Body Weight; Cardiotonic Agents; Child; Child, Preschool; Digoxin; Drug Interactions; F | 1999 |
Population analysis for the optimization of digoxin treatment in Japanese paediatric patients.
Topics: Age Factors; Body Weight; Cardiotonic Agents; Child; Child, Preschool; Digoxin; Drug Interactions; F | 1999 |
Aldosterone and spironolactone in heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Hum | 1999 |
Aldosterone and spironolactone in heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Hum | 1999 |
Aldosterone antagonism in heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Hear | 1999 |
Aldosterone antagonism in heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Hear | 1999 |
[The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study].
Topics: Chronic Disease; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlle | 1999 |
[The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study].
Topics: Chronic Disease; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlle | 1999 |
[Pharma-clinics. How I treat...symptomatic heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Decision | 1999 |
[Pharma-clinics. How I treat...symptomatic heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Decision | 1999 |
Spironolactone for heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Diuretics; Dose-Response Relatio | 1999 |
Spironolactone for heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Diuretics; Dose-Response Relatio | 1999 |
Spironolactone an important addition to heart-failure treatment, study shows.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 1999 |
Spironolactone an important addition to heart-failure treatment, study shows.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 1999 |
New hope for heart failure.
Topics: Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 1999 |
New hope for heart failure.
Topics: Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 1999 |
[Chronic heart insufficiency should be treated also with spironolactone].
Topics: Chronic Disease; Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironola | 1999 |
[Chronic heart insufficiency should be treated also with spironolactone].
Topics: Chronic Disease; Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironola | 1999 |
New hope from a 40-year-old drug: deaths from heart failure cut by 30 percent.
Topics: Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Diuretics; Drug Approval; Health | 1999 |
New hope from a 40-year-old drug: deaths from heart failure cut by 30 percent.
Topics: Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Diuretics; Drug Approval; Health | 1999 |
An old drug provides surprising benefits for heart-failure patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diuretics; Heart Failure; Humans; Mineralocorticoid Recept | 1999 |
An old drug provides surprising benefits for heart-failure patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diuretics; Heart Failure; Humans; Mineralocorticoid Recept | 1999 |
Spironolactone in patients with heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Digoxin; Diuretics; Drug Therapy, Combination; Furosemide; | 2000 |
Spironolactone in patients with heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Digoxin; Diuretics; Drug Therapy, Combination; Furosemide; | 2000 |
Spironolactone in patients with heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hyperkal | 2000 |
Spironolactone in patients with heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hyperkal | 2000 |
Spironolactone in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Heart Failure; Humans; Mineralocorticoid Rec | 2000 |
Spironolactone in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Heart Failure; Humans; Mineralocorticoid Rec | 2000 |
Spironolactone in patients with heart failure.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Frail | 2000 |
Spironolactone in patients with heart failure.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Frail | 2000 |
Heart failure: highlights from new consensus guidelines.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Digoxin; | 2000 |
Heart failure: highlights from new consensus guidelines.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Digoxin; | 2000 |
Early uptake of research findings after fast-track publication.
Topics: Diffusion of Innovation; Diuretics; Heart Failure; Humans; Publishing; Research; Spironolactone | 2000 |
Early uptake of research findings after fast-track publication.
Topics: Diffusion of Innovation; Diuretics; Heart Failure; Humans; Publishing; Research; Spironolactone | 2000 |
Overview of current chronic heart failure therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Digoxin; Diuretics; Heart Fai | 2000 |
Overview of current chronic heart failure therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Digoxin; Diuretics; Heart Fai | 2000 |
[Spironolactone in heart failure].
Topics: Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Primary Health Care; Rando | 2000 |
[Spironolactone in heart failure].
Topics: Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Primary Health Care; Rando | 2000 |
[And spironolactone in the treatment of heart failure?].
Topics: Clinical Trials as Topic; Diuretics; Follow-Up Studies; Heart Failure; Humans; Mineralocorticoid Rec | 2000 |
[And spironolactone in the treatment of heart failure?].
Topics: Clinical Trials as Topic; Diuretics; Follow-Up Studies; Heart Failure; Humans; Mineralocorticoid Rec | 2000 |
[Decrease in mortality on spironolactone being added to the conventional treatment of heart failure].
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Diuretics; Dr | 2000 |
[Decrease in mortality on spironolactone being added to the conventional treatment of heart failure].
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Diuretics; Dr | 2000 |
Old drug gets new life in treating congestive heart failure.
Topics: Diuretics; Heart Failure; Humans; Spironolactone | 2000 |
Old drug gets new life in treating congestive heart failure.
Topics: Diuretics; Heart Failure; Humans; Spironolactone | 2000 |
[Results of the RALES trial: good news for patients with heart failure and ... for health administrations].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-Blind Method; Drug Costs; | 2000 |
[Results of the RALES trial: good news for patients with heart failure and ... for health administrations].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-Blind Method; Drug Costs; | 2000 |
Left ventricular dysfunction: causes, natural history, and hopes for reversal.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Coronary Disease; | 2000 |
Left ventricular dysfunction: causes, natural history, and hopes for reversal.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Coronary Disease; | 2000 |
Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Circadian Rhythm; Diuretics; Echocardiography; Electrocardiography, | 2000 |
Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Circadian Rhythm; Diuretics; Echocardiography; Electrocardiography, | 2000 |
Epidemiology and pathophysiology of heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Disease Progression | 2000 |
Epidemiology and pathophysiology of heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Disease Progression | 2000 |
Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure.
Topics: Adolescent; Adult; Aged; Aldosterone; Aorta; Coronary Vessels; Female; Heart Failure; Hemodynamics; | 2000 |
Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure.
Topics: Adolescent; Adult; Aged; Aldosterone; Aorta; Coronary Vessels; Female; Heart Failure; Hemodynamics; | 2000 |
[Medical treatment of heart failure: an analysis of actual treatment practices in outpatients in Switzerland. The Swiss "IMPROVEMENT of HF" Group].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Dig | 2000 |
[Medical treatment of heart failure: an analysis of actual treatment practices in outpatients in Switzerland. The Swiss "IMPROVEMENT of HF" Group].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Dig | 2000 |
Elderly heart failure patients with drug-induced serious hyperkalemia.
Topics: Aged; Aging; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Dose-Response Relationship, Drug; | 2000 |
Elderly heart failure patients with drug-induced serious hyperkalemia.
Topics: Aged; Aging; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Dose-Response Relationship, Drug; | 2000 |
Spironolactone in heart failure--a revived role for an old drug.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diuretics; Drug Monitoring; Drug Prescriptions; Drug Syner | 2000 |
Spironolactone in heart failure--a revived role for an old drug.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diuretics; Drug Monitoring; Drug Prescriptions; Drug Syner | 2000 |
Spironolactone in the management of congestive heart failure.
Topics: Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Top | 2000 |
Spironolactone in the management of congestive heart failure.
Topics: Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Top | 2000 |
Spironolactone for heart failure: spiraling out of control.
Topics: Diuretics; Heart Failure; Humans; Randomized Controlled Trials as Topic; Spironolactone | 2000 |
Spironolactone for heart failure: spiraling out of control.
Topics: Diuretics; Heart Failure; Humans; Randomized Controlled Trials as Topic; Spironolactone | 2000 |
[Cost-benefit analysis of spironolactone use in the treatment of chronic heart failure].
Topics: Chronic Disease; Cost-Benefit Analysis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonist | 2001 |
[Cost-benefit analysis of spironolactone use in the treatment of chronic heart failure].
Topics: Chronic Disease; Cost-Benefit Analysis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonist | 2001 |
[Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Heart Failure; Human | 2000 |
[Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Heart Failure; Human | 2000 |
Role of spironolactone in heart failure should be emphasised.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2000 |
Role of spironolactone in heart failure should be emphasised.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2000 |
Serious adverse events experienced by patients with chronic heart failure taking spironolactone.
Topics: Aged; Diarrhea; Diuretics; Fatal Outcome; Heart Arrest; Heart Failure; Humans; Hyperkalemia; Male; M | 2001 |
Serious adverse events experienced by patients with chronic heart failure taking spironolactone.
Topics: Aged; Diarrhea; Diuretics; Fatal Outcome; Heart Arrest; Heart Failure; Humans; Hyperkalemia; Male; M | 2001 |
Undertreatment of heart failure has high cost to patients.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Family Practice; H | 2001 |
Undertreatment of heart failure has high cost to patients.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Family Practice; H | 2001 |
How many medicines do patients with heart failure need?
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2001 |
How many medicines do patients with heart failure need?
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2001 |
New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Eplerenone; Heart F | 2001 |
New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Eplerenone; Heart F | 2001 |
The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
Topics: Aldosterone; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Anta | 2001 |
The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
Topics: Aldosterone; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Anta | 2001 |
Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Hea | 2001 |
Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Hea | 2001 |
Exciting new drugs on the horizon - eplerenone, a selective aldosterone receptor antagonist (SARA).
Topics: Eplerenone; Heart Failure; Humans; Hypertrophy, Left Ventricular; Mineralocorticoid Receptor Antagon | 2001 |
Exciting new drugs on the horizon - eplerenone, a selective aldosterone receptor antagonist (SARA).
Topics: Eplerenone; Heart Failure; Humans; Hypertrophy, Left Ventricular; Mineralocorticoid Receptor Antagon | 2001 |
Effects of beta-blocker therapy in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Diuretics; Drug Therapy, Combination; Heart Fai | 2001 |
Effects of beta-blocker therapy in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Diuretics; Drug Therapy, Combination; Heart Fai | 2001 |
[Cost effectiveness of the use of spironolactone in the treatment of chronic heart failure].
Topics: Cost-Benefit Analysis; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonist | 2001 |
[Cost effectiveness of the use of spironolactone in the treatment of chronic heart failure].
Topics: Cost-Benefit Analysis; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonist | 2001 |
Long-term therapy with spironolactone.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Female; Heart Failure; Hum | 2001 |
Long-term therapy with spironolactone.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Female; Heart Failure; Hum | 2001 |
Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure.
Topics: Animals; Baroreflex; Blood Pressure; Drinking; Heart; Heart Failure; Male; Mineralocorticoid Recepto | 2001 |
Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure.
Topics: Animals; Baroreflex; Blood Pressure; Drinking; Heart; Heart Failure; Male; Mineralocorticoid Recepto | 2001 |
Information from your family doctor. What should I know about heart failure?
Topics: Angiotensin-Converting Enzyme Inhibitors; Diuretics; Heart Failure; Humans; Patient Education as Top | 2001 |
Information from your family doctor. What should I know about heart failure?
Topics: Angiotensin-Converting Enzyme Inhibitors; Diuretics; Heart Failure; Humans; Patient Education as Top | 2001 |
Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
Topics: Adrenergic beta-Antagonists; Advisory Committees; Age Factors; Angiotensin Receptor Antagonists; Ang | 2001 |
Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
Topics: Adrenergic beta-Antagonists; Advisory Committees; Age Factors; Angiotensin Receptor Antagonists; Ang | 2001 |
Absolute, not relative, changes are important when interpreting trial data.
Topics: Clinical Trials as Topic; Heart Failure; Humans; Natriuretic Peptide, Brain; Spironolactone; Ventric | 2001 |
Absolute, not relative, changes are important when interpreting trial data.
Topics: Clinical Trials as Topic; Heart Failure; Humans; Natriuretic Peptide, Brain; Spironolactone; Ventric | 2001 |
Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Drug Therapy, Combination; Endothelium, Vascular; | 2002 |
Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Drug Therapy, Combination; Endothelium, Vascular; | 2002 |
Spironolactone prescribing in heart failure: comparison between general medical patients and those attending a specialist left ventricular dysfunction clinic.
Topics: Diuretics; Heart Failure; Humans; Medicine; Northern Ireland; Practice Patterns, Physicians'; Specia | 2001 |
Spironolactone prescribing in heart failure: comparison between general medical patients and those attending a specialist left ventricular dysfunction clinic.
Topics: Diuretics; Heart Failure; Humans; Medicine; Northern Ireland; Practice Patterns, Physicians'; Specia | 2001 |
The endothelin-aldosterone axis and cardiovascular diseases.
Topics: Adrenal Cortex; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clin | 2001 |
The endothelin-aldosterone axis and cardiovascular diseases.
Topics: Adrenal Cortex; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clin | 2001 |
Treatment of heart failure: state of the art and prospectives.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cardiomegaly; | 2001 |
Treatment of heart failure: state of the art and prospectives.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cardiomegaly; | 2001 |
Chronic heart failure guidelines.
Topics: Heart Failure; Humans; Practice Guidelines as Topic; Spironolactone | 2002 |
Chronic heart failure guidelines.
Topics: Heart Failure; Humans; Practice Guidelines as Topic; Spironolactone | 2002 |
Update on treatment for congestive heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Heart Failure; Hum | 2002 |
Update on treatment for congestive heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Heart Failure; Hum | 2002 |
[Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
[Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Collagen; Cytochrome P-450 CYP11B2; Diuretics; Drug | 2002 |
Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Collagen; Cytochrome P-450 CYP11B2; Diuretics; Drug | 2002 |
Left ventricular assist device.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Heart-Assist D | 2002 |
Left ventricular assist device.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Heart-Assist D | 2002 |
Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes.
Topics: Animals; Base Sequence; Disease Models, Animal; DNA, Complementary; Fibrosis; Gene Expression; Heart | 2002 |
Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes.
Topics: Animals; Base Sequence; Disease Models, Animal; DNA, Complementary; Fibrosis; Gene Expression; Heart | 2002 |
[Aldosterone blockade in heart failure. So much for so little].
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2002 |
[Aldosterone blockade in heart failure. So much for so little].
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2002 |
The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure.
Topics: Action Potentials; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Capto | 2002 |
The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure.
Topics: Action Potentials; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Capto | 2002 |
Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency.
Topics: Aged; Aortic Aneurysm, Abdominal; Blood Gas Analysis; Heart Failure; Humans; Hyperkalemia; Intraoper | 2002 |
Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency.
Topics: Aged; Aortic Aneurysm, Abdominal; Blood Gas Analysis; Heart Failure; Humans; Hyperkalemia; Intraoper | 2002 |
Postoperative synthetic human atrial natriuretic peptide infusion and oral spironolactone administration for a patient with giant atria and low plasma level of atrial natriuretic peptide.
Topics: Administration, Oral; Atrial Natriuretic Factor; Cardiopulmonary Bypass; Female; Heart Failure; Huma | 2002 |
Postoperative synthetic human atrial natriuretic peptide infusion and oral spironolactone administration for a patient with giant atria and low plasma level of atrial natriuretic peptide.
Topics: Administration, Oral; Atrial Natriuretic Factor; Cardiopulmonary Bypass; Female; Heart Failure; Huma | 2002 |
[Therapeutic experience with osyrol 100/Lasix in the treatment of congestive heart failure (author's transl)].
Topics: Digitalis Glycosides; Drug Combinations; Drug Evaluation; Furosemide; Heart Failure; Humans; Potassi | 1979 |
[Therapeutic experience with osyrol 100/Lasix in the treatment of congestive heart failure (author's transl)].
Topics: Digitalis Glycosides; Drug Combinations; Drug Evaluation; Furosemide; Heart Failure; Humans; Potassi | 1979 |
[Long term therapy over nine years with Spironolacton in hydropic cardiac insufficiency].
Topics: Aged; Blood Pressure; Body Weight; Cardiac Glycosides; Cardiomegaly; Diuretics; Drug Therapy, Combin | 1976 |
[Long term therapy over nine years with Spironolacton in hydropic cardiac insufficiency].
Topics: Aged; Blood Pressure; Body Weight; Cardiac Glycosides; Cardiomegaly; Diuretics; Drug Therapy, Combin | 1976 |
[Spironolactone in heart failure].
Topics: Heart Failure; Humans; Spironolactone | 1979 |
[Spironolactone in heart failure].
Topics: Heart Failure; Humans; Spironolactone | 1979 |
[Experiences with aldactone in pediatric cardiology (author's transl)].
Topics: Child; Child, Preschool; Dose-Response Relationship, Drug; Heart Failure; Humans; Hyperaldosteronism | 1979 |
[Experiences with aldactone in pediatric cardiology (author's transl)].
Topics: Child; Child, Preschool; Dose-Response Relationship, Drug; Heart Failure; Humans; Hyperaldosteronism | 1979 |
[Aldactazine in the treatment of congestive cardiac insufficiency].
Topics: Adolescent; Adult; Aged; Benzothiadiazines; Child; Child, Preschool; Diuretics; Drug Combinations; D | 1977 |
[Aldactazine in the treatment of congestive cardiac insufficiency].
Topics: Adolescent; Adult; Aged; Benzothiadiazines; Child; Child, Preschool; Diuretics; Drug Combinations; D | 1977 |
Potassium-level changes during long-term thiazide therapy.
Topics: Heart Failure; Humans; Hypertension; Hypokalemia; Magnesium; Potassium; Potassium Chloride; Spironol | 1978 |
Potassium-level changes during long-term thiazide therapy.
Topics: Heart Failure; Humans; Hypertension; Hypokalemia; Magnesium; Potassium; Potassium Chloride; Spironol | 1978 |
[Aldosterone antagonists in coronary insufficiency].
Topics: Arrhythmias, Cardiac; Canrenoic Acid; Heart Failure; Humans; Myocardial Contraction; Myocardial Infa | 1978 |
[Aldosterone antagonists in coronary insufficiency].
Topics: Arrhythmias, Cardiac; Canrenoic Acid; Heart Failure; Humans; Myocardial Contraction; Myocardial Infa | 1978 |
Management of intractable heart failure with hyponatremia.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Humans; Hy | 1978 |
Management of intractable heart failure with hyponatremia.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Humans; Hy | 1978 |
[The pharmacokinetics of digoxin during chronic spironolacton treatment (author's transl)].
Topics: Adult; Aged; Antipyrine; Digoxin; Feces; Female; Half-Life; Heart Failure; Humans; Kinetics; Male; M | 1978 |
[The pharmacokinetics of digoxin during chronic spironolacton treatment (author's transl)].
Topics: Adult; Aged; Antipyrine; Digoxin; Feces; Female; Half-Life; Heart Failure; Humans; Kinetics; Male; M | 1978 |
Clinical use of diuretics in congestive heart failure.
Topics: Amiloride; Benzothiadiazines; Diuretics; Ethacrynic Acid; Female; Furosemide; Heart Failure; Humans; | 1979 |
Clinical use of diuretics in congestive heart failure.
Topics: Amiloride; Benzothiadiazines; Diuretics; Ethacrynic Acid; Female; Furosemide; Heart Failure; Humans; | 1979 |
[Clinical experience in the use of Osyrol 100 and Osyrol for injection (author's transl)].
Topics: Administration, Oral; Aged; Blood Pressure; Body Weight; Canrenoic Acid; Female; Heart Failure; Huma | 1975 |
[Clinical experience in the use of Osyrol 100 and Osyrol for injection (author's transl)].
Topics: Administration, Oral; Aged; Blood Pressure; Body Weight; Canrenoic Acid; Female; Heart Failure; Huma | 1975 |
Alcohol-induced Cushingoid syndrome: a false diagnosis.
Topics: Alcoholism; Cushing Syndrome; Diagnostic Errors; Heart Failure; Humans; Male; Middle Aged; Spironola | 1977 |
Alcohol-induced Cushingoid syndrome: a false diagnosis.
Topics: Alcoholism; Cushing Syndrome; Diagnostic Errors; Heart Failure; Humans; Male; Middle Aged; Spironola | 1977 |
Elimination of canrenone in congestive heart failure and chronic liver disease.
Topics: Aged; Canrenone; Chronic Disease; Creatinine; Female; Half-Life; Heart Failure; Humans; Liver Diseas | 1977 |
Elimination of canrenone in congestive heart failure and chronic liver disease.
Topics: Aged; Canrenone; Chronic Disease; Creatinine; Female; Half-Life; Heart Failure; Humans; Liver Diseas | 1977 |
Panniculitis of the legs with urate crystal deposition.
Topics: Aged; Arthritis; Diagnosis, Differential; Female; Furosemide; Gout; Heart Failure; Humans; Lipase; S | 1977 |
Panniculitis of the legs with urate crystal deposition.
Topics: Aged; Arthritis; Diagnosis, Differential; Female; Furosemide; Gout; Heart Failure; Humans; Lipase; S | 1977 |
[Change in rheographic properties of blood in congestive circulatory insufficiency treated with diuretics].
Topics: Adult; Aged; Blood Circulation; Blood Viscosity; Diuretics; Erythrocyte Aggregation; Ethacrynic Acid | 1977 |
[Change in rheographic properties of blood in congestive circulatory insufficiency treated with diuretics].
Topics: Adult; Aged; Blood Circulation; Blood Viscosity; Diuretics; Erythrocyte Aggregation; Ethacrynic Acid | 1977 |
[Combined treatment with furosemide, aldactone and hygroton in chronic right-ventricular circulatory failure].
Topics: Chlorthalidone; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Heart Ventricles; Huma | 1977 |
[Combined treatment with furosemide, aldactone and hygroton in chronic right-ventricular circulatory failure].
Topics: Chlorthalidone; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Heart Ventricles; Huma | 1977 |
Effect of potassium-sparing diuretics on the renin-angiotensin-aldosterone system and potassium retention in heart failure.
Topics: Adult; Aged; Aldosterone; Amiloride; Angiotensin II; Digoxin; Female; Furosemide; Heart Failure; Hum | 1976 |
Effect of potassium-sparing diuretics on the renin-angiotensin-aldosterone system and potassium retention in heart failure.
Topics: Adult; Aged; Aldosterone; Amiloride; Angiotensin II; Digoxin; Female; Furosemide; Heart Failure; Hum | 1976 |
[Aldactone in the complex treatment of circulatory insufficiency in elderly patients].
Topics: Age Factors; Aged; Cardiac Glycosides; Drug Therapy, Combination; Heart Failure; Humans; Middle Aged | 1976 |
[Aldactone in the complex treatment of circulatory insufficiency in elderly patients].
Topics: Age Factors; Aged; Cardiac Glycosides; Drug Therapy, Combination; Heart Failure; Humans; Middle Aged | 1976 |
[Hormonal disturbances and the treatment of refractory forms of congestive circulatory insufficiency].
Topics: Aldosterone; Body Water; Circadian Rhythm; Diuresis; Drug Therapy, Combination; Furosemide; Glucocor | 1976 |
[Hormonal disturbances and the treatment of refractory forms of congestive circulatory insufficiency].
Topics: Aldosterone; Body Water; Circadian Rhythm; Diuresis; Drug Therapy, Combination; Furosemide; Glucocor | 1976 |
Some aspects of diuretic therapy.
Topics: Aged; Amiloride; Benzothiadiazines; Digitalis Glycosides; Diuretics; Drug Therapy, Combination; Etha | 1975 |
Some aspects of diuretic therapy.
Topics: Aged; Amiloride; Benzothiadiazines; Digitalis Glycosides; Diuretics; Drug Therapy, Combination; Etha | 1975 |
[Use of aldactone-saltucine for patients with chronic circulatory insufficiency].
Topics: Adult; Aged; Butanes; Creatinine; Diuresis; Diuretics; Drug Combinations; Drug Evaluation; Female; F | 1975 |
[Use of aldactone-saltucine for patients with chronic circulatory insufficiency].
Topics: Adult; Aged; Butanes; Creatinine; Diuresis; Diuretics; Drug Combinations; Drug Evaluation; Female; F | 1975 |
[Use of aldactone-saltucine in patients with heart failure].
Topics: Adult; Aged; Aldosterone; Body Weight; Butanes; Chlorides; Diuretics; Drug Combinations; Drug Evalua | 1975 |
[Use of aldactone-saltucine in patients with heart failure].
Topics: Adult; Aged; Aldosterone; Body Weight; Butanes; Chlorides; Diuretics; Drug Combinations; Drug Evalua | 1975 |
Aldosterone reduces baroreceptor discharge in the dog.
Topics: Aldosterone; Animals; Blood Pressure; Disease Models, Animal; Dogs; Endothelium, Vascular; Female; H | 1992 |
Aldosterone reduces baroreceptor discharge in the dog.
Topics: Aldosterone; Animals; Blood Pressure; Disease Models, Animal; Dogs; Endothelium, Vascular; Female; H | 1992 |
Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention.
Topics: Aldosterone; Atrial Natriuretic Factor; Female; Heart Failure; Humans; Male; Middle Aged; Natriuresi | 1991 |
Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention.
Topics: Aldosterone; Atrial Natriuretic Factor; Female; Heart Failure; Humans; Male; Middle Aged; Natriuresi | 1991 |
Observed changes in serum potassium concentration following repeat centrifugation of Sarstedt Serum Gel Safety Monovettes after storage.
Topics: Aged; Aged, 80 and over; Blood Preservation; Blood Specimen Collection; Centrifugation; Female; Furo | 1991 |
Observed changes in serum potassium concentration following repeat centrifugation of Sarstedt Serum Gel Safety Monovettes after storage.
Topics: Aged; Aged, 80 and over; Blood Preservation; Blood Specimen Collection; Centrifugation; Female; Furo | 1991 |
Considerations of aldosterone in congestive heart failure, arrhythmias and sudden cardiac death. Editorial overview.
Topics: Diuretics; Drug Therapy, Combination; Heart Failure; Humans; Spironolactone | 1990 |
Considerations of aldosterone in congestive heart failure, arrhythmias and sudden cardiac death. Editorial overview.
Topics: Diuretics; Drug Therapy, Combination; Heart Failure; Humans; Spironolactone | 1990 |
Short- and long-term mechanisms of sudden cardiac death in congestive heart failure.
Topics: Aldosterone; Arrhythmias, Cardiac; Death, Sudden; Diuretics; Heart Failure; Humans; Magnesium; Potas | 1990 |
Short- and long-term mechanisms of sudden cardiac death in congestive heart failure.
Topics: Aldosterone; Arrhythmias, Cardiac; Death, Sudden; Diuretics; Heart Failure; Humans; Magnesium; Potas | 1990 |
Spironolactone in the management of congestive heart failure.
Topics: Diuretics; Drug Therapy, Combination; Electrolytes; Heart Failure; Humans; Kidney Tubules; Spironola | 1990 |
Spironolactone in the management of congestive heart failure.
Topics: Diuretics; Drug Therapy, Combination; Electrolytes; Heart Failure; Humans; Kidney Tubules; Spironola | 1990 |
[Severe complications during enalapril therapy for heart insufficiency].
Topics: Acute Kidney Injury; Drug Interactions; Enalapril; Heart Failure; Humans; Hypotension; Male; Middle | 1988 |
[Severe complications during enalapril therapy for heart insufficiency].
Topics: Acute Kidney Injury; Drug Interactions; Enalapril; Heart Failure; Humans; Hypotension; Male; Middle | 1988 |
Spironolactone in the management of congestive cardiac failure: a review.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzothiadiazines; Cardioton | 1986 |
Spironolactone in the management of congestive cardiac failure: a review.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzothiadiazines; Cardioton | 1986 |
Combined spironolactone and converting-enzyme inhibitor therapy for refractory heart failure.
Topics: Adult; Captopril; Diuresis; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Humans; Mal | 1986 |
Combined spironolactone and converting-enzyme inhibitor therapy for refractory heart failure.
Topics: Adult; Captopril; Diuresis; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Humans; Mal | 1986 |
[Acute reversible kidney insufficiency due to enalapril during diuretic-treated heart insufficiency].
Topics: Acute Kidney Injury; Adult; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Humans; Hyp | 1987 |
[Acute reversible kidney insufficiency due to enalapril during diuretic-treated heart insufficiency].
Topics: Acute Kidney Injury; Adult; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Humans; Hyp | 1987 |
Potassium-sparing diuretics.
Topics: Amiloride; Diuretics; Heart Failure; Humans; Hypokalemia; Magnesium Deficiency; Potassium; Spironola | 1986 |
Potassium-sparing diuretics.
Topics: Amiloride; Diuretics; Heart Failure; Humans; Hypokalemia; Magnesium Deficiency; Potassium; Spironola | 1986 |
[The principal diuretics and their presentation].
Topics: Benzothiadiazines; Diuretics; Drug Combinations; Heart Failure; Humans; Hypertension; Sodium Chlorid | 1986 |
[The principal diuretics and their presentation].
Topics: Benzothiadiazines; Diuretics; Drug Combinations; Heart Failure; Humans; Hypertension; Sodium Chlorid | 1986 |
A fixed-dose combination of furosemide and spironolactone in digitalized congestive heart failure patients.
Topics: Aged; Digitalis Glycosides; Drug Combinations; Drug Therapy, Combination; Echocardiography; Female; | 1986 |
A fixed-dose combination of furosemide and spironolactone in digitalized congestive heart failure patients.
Topics: Aged; Digitalis Glycosides; Drug Combinations; Drug Therapy, Combination; Echocardiography; Female; | 1986 |
The treatment of non-digitalized congestive heart failure patients with a fixed-dose combination of furosemide and spironolactone.
Topics: Aged; Drug Combinations; Echocardiography; Female; Furosemide; Heart Failure; Humans; Male; Spironol | 1986 |
The treatment of non-digitalized congestive heart failure patients with a fixed-dose combination of furosemide and spironolactone.
Topics: Aged; Drug Combinations; Echocardiography; Female; Furosemide; Heart Failure; Humans; Male; Spironol | 1986 |
Updated diagnosis and management of congestive heart failure.
Topics: Aged; Aging; Angiography; Diagnosis, Differential; Diuretics; Echocardiography; Female; Heart Failur | 1986 |
Updated diagnosis and management of congestive heart failure.
Topics: Aged; Aging; Angiography; Diagnosis, Differential; Diuretics; Echocardiography; Female; Heart Failur | 1986 |
Total exchangeable potassium, sodium and chloride in patients with severe valvular heart disease during preparation for cardiac surgery.
Topics: Adult; Aortic Valve Insufficiency; Atrial Fibrillation; Bicarbonates; Blood Proteins; Body Compositi | 1973 |
Total exchangeable potassium, sodium and chloride in patients with severe valvular heart disease during preparation for cardiac surgery.
Topics: Adult; Aortic Valve Insufficiency; Atrial Fibrillation; Bicarbonates; Blood Proteins; Body Compositi | 1973 |
The value of diuretics in respiratory failure.
Topics: Aged; Blood Gas Analysis; Bronchitis; Diuretics; Female; Furosemide; Heart Failure; Humans; Male; Mi | 1966 |
The value of diuretics in respiratory failure.
Topics: Aged; Blood Gas Analysis; Bronchitis; Diuretics; Female; Furosemide; Heart Failure; Humans; Male; Mi | 1966 |
Direct current cardioversion in digitalized patients with mitral valve disease.
Topics: Adult; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia; Cardiac Complexes, Pr | 1969 |
Direct current cardioversion in digitalized patients with mitral valve disease.
Topics: Adult; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia; Cardiac Complexes, Pr | 1969 |
[Myocardial hyperexcitability in decompensated cardiopathies. Effect of spironolactone].
Topics: Cardiac Complexes, Premature; Dehydration; Digitalis Glycosides; Diuresis; Diuretics; Heart Failure; | 1969 |
[Myocardial hyperexcitability in decompensated cardiopathies. Effect of spironolactone].
Topics: Cardiac Complexes, Premature; Dehydration; Digitalis Glycosides; Diuresis; Diuretics; Heart Failure; | 1969 |
Glucagon in heart failure and in cardiogenic shock. Experience in 50 patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Body Weight; Digital | 1972 |
Glucagon in heart failure and in cardiogenic shock. Experience in 50 patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Body Weight; Digital | 1972 |
Idiopathic edema.
Topics: Adult; Age Factors; Aldosterone; Edema; Female; Heart Failure; Humans; Hydrochlorothiazide; Hydrosta | 1974 |
Idiopathic edema.
Topics: Adult; Age Factors; Aldosterone; Edema; Female; Heart Failure; Humans; Hydrochlorothiazide; Hydrosta | 1974 |
Chronic vasodilator therapy in the management of cardiogenic shock and intractable left ventricular failure.
Topics: Blood Pressure; Cardiac Output; Digoxin; Drug Evaluation; Ferricyanides; Furosemide; Heart Failure; | 1974 |
Chronic vasodilator therapy in the management of cardiogenic shock and intractable left ventricular failure.
Topics: Blood Pressure; Cardiac Output; Digoxin; Drug Evaluation; Ferricyanides; Furosemide; Heart Failure; | 1974 |
Heart failure and cardiac arrhythmias.
Topics: Arrhythmia, Sinus; Arrhythmias, Cardiac; Coronary Disease; Digoxin; Diuretics; Electroconvulsive The | 1974 |
Heart failure and cardiac arrhythmias.
Topics: Arrhythmia, Sinus; Arrhythmias, Cardiac; Coronary Disease; Digoxin; Diuretics; Electroconvulsive The | 1974 |
[A combination of diuretics from different classes in the treatment of cardiac insufficiency].
Topics: Adult; Aged; Chlorothiazide; Diuresis; Female; Heart Failure; Humans; Male; Middle Aged; Natriuresis | 1972 |
[A combination of diuretics from different classes in the treatment of cardiac insufficiency].
Topics: Adult; Aged; Chlorothiazide; Diuresis; Female; Heart Failure; Humans; Male; Middle Aged; Natriuresis | 1972 |
Hyperkalemic cardiac arrhythmia secondary to spironolactone.
Topics: Aged; Arrhythmias, Cardiac; Bicarbonates; Electrocardiography; Heart Failure; Heart Rate; Humans; Hy | 1973 |
Hyperkalemic cardiac arrhythmia secondary to spironolactone.
Topics: Aged; Arrhythmias, Cardiac; Bicarbonates; Electrocardiography; Heart Failure; Heart Rate; Humans; Hy | 1973 |
[Alterations in water-salt metabolism under the influence of diuretics in cardiac insufficiency].
Topics: Adult; Aged; Arteriosclerosis; Coronary Disease; Ethacrynic Acid; Female; Heart Failure; Humans; Mal | 1973 |
[Alterations in water-salt metabolism under the influence of diuretics in cardiac insufficiency].
Topics: Adult; Aged; Arteriosclerosis; Coronary Disease; Ethacrynic Acid; Female; Heart Failure; Humans; Mal | 1973 |
[Urea and spironolactone therapy].
Topics: Adolescent; Adult; Aged; Diuretics; Female; Glomerular Filtration Rate; Heart Failure; Humans; Hyper | 1973 |
[Urea and spironolactone therapy].
Topics: Adolescent; Adult; Aged; Diuretics; Female; Glomerular Filtration Rate; Heart Failure; Humans; Hyper | 1973 |
[Clinical study on the subtoxic full effective and maintenance dose of digoxin under the influence of spironolactone. Studies on the decompensated heart patient].
Topics: Administration, Oral; Aged; Digoxin; Drug Tolerance; Female; Heart Failure; Humans; Magnesium; Male; | 1973 |
[Clinical study on the subtoxic full effective and maintenance dose of digoxin under the influence of spironolactone. Studies on the decompensated heart patient].
Topics: Administration, Oral; Aged; Digoxin; Drug Tolerance; Female; Heart Failure; Humans; Magnesium; Male; | 1973 |
Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program.
Topics: Adult; Aged; Blood Urea Nitrogen; Coma; Dehydration; Diarrhea; Female; Gynecomastia; Headache; Heart | 1973 |
Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program.
Topics: Adult; Aged; Blood Urea Nitrogen; Coma; Dehydration; Diarrhea; Female; Gynecomastia; Headache; Heart | 1973 |
[Hyponatremia syndrome in congestive heart failure].
Topics: Female; Furosemide; Heart Failure; Humans; Hyponatremia; Middle Aged; Sodium; Spironolactone; Syndro | 1973 |
[Hyponatremia syndrome in congestive heart failure].
Topics: Female; Furosemide; Heart Failure; Humans; Hyponatremia; Middle Aged; Sodium; Spironolactone; Syndro | 1973 |
[Therapy of heart insufficiency using aldosterone antagonists].
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Water-Electrolyte Bal | 1973 |
[Therapy of heart insufficiency using aldosterone antagonists].
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Water-Electrolyte Bal | 1973 |
Salivary electrolytes in digitalis-treated patients with and without raised aldosterone excretion.
Topics: Adult; Aged; Aldosterone; Calcium; Digoxin; Female; Heart Failure; Humans; Male; Middle Aged; Potass | 1973 |
Salivary electrolytes in digitalis-treated patients with and without raised aldosterone excretion.
Topics: Adult; Aged; Aldosterone; Calcium; Digoxin; Female; Heart Failure; Humans; Male; Middle Aged; Potass | 1973 |
Clinico-pharmacological investigation with verospirone.
Topics: Adult; Aged; Female; Heart Failure; Humans; Liver Cirrhosis; Male; Middle Aged; Spironolactone | 1973 |
Clinico-pharmacological investigation with verospirone.
Topics: Adult; Aged; Female; Heart Failure; Humans; Liver Cirrhosis; Male; Middle Aged; Spironolactone | 1973 |
[New aspects of the use of spironolactone and its association with thiabutazide (per os and in injections) in the treatment of grave cardiac insufficiency].
Topics: Acute Kidney Injury; Administration, Oral; Adult; Aged; Benzothiadiazines; Diabetes Complications; D | 1974 |
[New aspects of the use of spironolactone and its association with thiabutazide (per os and in injections) in the treatment of grave cardiac insufficiency].
Topics: Acute Kidney Injury; Administration, Oral; Adult; Aged; Benzothiadiazines; Diabetes Complications; D | 1974 |
Renal tubular secretion of digoxin.
Topics: Adult; Aged; Digoxin; Female; Glomerular Filtration Rate; Heart Failure; Humans; Inulin; Kidney Tubu | 1974 |
Renal tubular secretion of digoxin.
Topics: Adult; Aged; Digoxin; Female; Glomerular Filtration Rate; Heart Failure; Humans; Inulin; Kidney Tubu | 1974 |
Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.
Topics: Adult; Aged; Carboxylic Acids; Female; Fluorometry; Half-Life; Heart Failure; Humans; Ketosteroids; | 1974 |
Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.
Topics: Adult; Aged; Carboxylic Acids; Female; Fluorometry; Half-Life; Heart Failure; Humans; Ketosteroids; | 1974 |
[Distribution of fluid between the cells and the extracellular media and mineralocorticoid function of the adrenal glands in cardiac insufficiency].
Topics: Adrenal Glands; Adult; Aldosterone; Antipyrine; Body Fluids; Chromatography, Paper; Coronary Disease | 1969 |
[Distribution of fluid between the cells and the extracellular media and mineralocorticoid function of the adrenal glands in cardiac insufficiency].
Topics: Adrenal Glands; Adult; Aldosterone; Antipyrine; Body Fluids; Chromatography, Paper; Coronary Disease | 1969 |
Hyperkalemic intermittent paralysis associated with spironolactone in a patient with cardiac cirrhosis.
Topics: Acetazolamide; Adult; Aldosterone; Ascites; Female; Furosemide; Heart Failure; Heart Valve Diseases; | 1968 |
Hyperkalemic intermittent paralysis associated with spironolactone in a patient with cardiac cirrhosis.
Topics: Acetazolamide; Adult; Aldosterone; Ascites; Female; Furosemide; Heart Failure; Heart Valve Diseases; | 1968 |
[Malignant arterial hypertension. Intensive treatment by acute sodium depletion and antihypertensive agents].
Topics: Adult; Antihypertensive Agents; Body Weight; Creatinine; Diet, Sodium-Restricted; Diuretics; Female; | 1972 |
[Malignant arterial hypertension. Intensive treatment by acute sodium depletion and antihypertensive agents].
Topics: Adult; Antihypertensive Agents; Body Weight; Creatinine; Diet, Sodium-Restricted; Diuretics; Female; | 1972 |
Treatment of heart failure. 2.
Topics: Acetazolamide; Diuretics; Ethacrynic Acid; Furosemide; Heart Failure; Humans; Morphine; Pulmonary Ed | 1972 |
Treatment of heart failure. 2.
Topics: Acetazolamide; Diuretics; Ethacrynic Acid; Furosemide; Heart Failure; Humans; Morphine; Pulmonary Ed | 1972 |
[Electrocardiographic observations in secondary aldosteronism].
Topics: Aged; Aldosterone; Body Weight; Digitalis Glycosides; Diuresis; Electrocardiography; Female; Heart F | 1972 |
[Electrocardiographic observations in secondary aldosteronism].
Topics: Aged; Aldosterone; Body Weight; Digitalis Glycosides; Diuresis; Electrocardiography; Female; Heart F | 1972 |
Clinical study of verospirone and spironolactone.
Topics: Adult; Aged; Diuretics; Female; Heart Failure; Humans; Hyperaldosteronism; Liver Cirrhosis; Male; Mi | 1972 |
Clinical study of verospirone and spironolactone.
Topics: Adult; Aged; Diuretics; Female; Heart Failure; Humans; Hyperaldosteronism; Liver Cirrhosis; Male; Mi | 1972 |
Spironolactone and ammonium and potassium chloride.
Topics: Acidosis; Ammonium Chloride; Drug Interactions; Female; Heart Failure; Humans; Middle Aged; Potassiu | 1972 |
Spironolactone and ammonium and potassium chloride.
Topics: Acidosis; Ammonium Chloride; Drug Interactions; Female; Heart Failure; Humans; Middle Aged; Potassiu | 1972 |
[Joint study on the effectiveness of diuretic measures in hydropic diseases. IV. Statistical analysis of the relationship of the data collected].
Topics: Ascites; Biometry; Body Weight; Diet Therapy; Diuresis; Diuretics; Edema; Factor Analysis, Statistic | 1971 |
[Joint study on the effectiveness of diuretic measures in hydropic diseases. IV. Statistical analysis of the relationship of the data collected].
Topics: Ascites; Biometry; Body Weight; Diet Therapy; Diuresis; Diuretics; Edema; Factor Analysis, Statistic | 1971 |
[Concentration of metabolizable sodium in patients with circulatory insufficiency].
Topics: Adult; Aged; Arteriosclerosis; Female; Heart Failure; Humans; Male; Middle Aged; Rheumatic Heart Dis | 1971 |
[Concentration of metabolizable sodium in patients with circulatory insufficiency].
Topics: Adult; Aged; Arteriosclerosis; Female; Heart Failure; Humans; Male; Middle Aged; Rheumatic Heart Dis | 1971 |
Diuretics in cardiac edema--1969.
Topics: Benzothiadiazines; Carbonic Anhydrase Inhibitors; Diuretics; Ethacrynic Acid; Furosemide; Glucocorti | 1969 |
Diuretics in cardiac edema--1969.
Topics: Benzothiadiazines; Carbonic Anhydrase Inhibitors; Diuretics; Ethacrynic Acid; Furosemide; Glucocorti | 1969 |
Severe hypernatremia complicating heart valve surgery. A preliminary report.
Topics: Aortic Valve; Aortic Valve Stenosis; Body Weight; Chlorides; Heart Failure; Heart Valve Prosthesis; | 1969 |
Severe hypernatremia complicating heart valve surgery. A preliminary report.
Topics: Aortic Valve; Aortic Valve Stenosis; Body Weight; Chlorides; Heart Failure; Heart Valve Prosthesis; | 1969 |
[Advances in the treatment of edema with intravenous application of spirolactone].
Topics: Edema; Heart Failure; Humans; Injections, Intravenous; Liver Cirrhosis; Spironolactone | 1969 |
[Advances in the treatment of edema with intravenous application of spirolactone].
Topics: Edema; Heart Failure; Humans; Injections, Intravenous; Liver Cirrhosis; Spironolactone | 1969 |
[Induced aldosteronism in hydropic heart insufficiency].
Topics: Acid-Base Equilibrium; Adult; Aged; Aldosterone; Body Weight; Carbon Isotopes; Cardiac Glycosides; E | 1969 |
[Induced aldosteronism in hydropic heart insufficiency].
Topics: Acid-Base Equilibrium; Adult; Aged; Aldosterone; Body Weight; Carbon Isotopes; Cardiac Glycosides; E | 1969 |
[Effect of diuretic measures in hydropic conditions. I. Planning, results in heart insufficiency].
Topics: Adult; Aged; Body Weight; Diet, Sodium-Restricted; Diuresis; Diuretics; Documentation; Edema; Female | 1969 |
[Effect of diuretic measures in hydropic conditions. I. Planning, results in heart insufficiency].
Topics: Adult; Aged; Body Weight; Diet, Sodium-Restricted; Diuresis; Diuretics; Documentation; Edema; Female | 1969 |
[The patient with edema].
Topics: Adolescent; Adult; Dietary Proteins; Diuretics; Edema; Electrocardiography; Female; Heart Failure; H | 1969 |
[The patient with edema].
Topics: Adolescent; Adult; Dietary Proteins; Diuretics; Edema; Electrocardiography; Female; Heart Failure; H | 1969 |
Effect of spironolactone on body potassium in heart failure and hypertension.
Topics: Body Composition; Cell Membrane; Heart Failure; Humans; Hypertension; Potassium; Rheumatic Heart Dis | 1969 |
Effect of spironolactone on body potassium in heart failure and hypertension.
Topics: Body Composition; Cell Membrane; Heart Failure; Humans; Hypertension; Potassium; Rheumatic Heart Dis | 1969 |
Spironolactone (aldactone) bodies: concentric lamellar formations in the adrenal cortices of patients treated with spironolactone.
Topics: Adrenal Glands; Adult; Aged; Chronic Disease; Cytoplasmic Granules; Female; Heart Failure; Heart Neo | 1970 |
Spironolactone (aldactone) bodies: concentric lamellar formations in the adrenal cortices of patients treated with spironolactone.
Topics: Adrenal Glands; Adult; Aged; Chronic Disease; Cytoplasmic Granules; Female; Heart Failure; Heart Neo | 1970 |
[Acid-base equilibrium and blood gas analysis in clinical cardiology].
Topics: Acetazolamide; Acid-Base Equilibrium; Bicarbonates; Blood Gas Analysis; Body Weight; Diagnosis, Diff | 1970 |
[Acid-base equilibrium and blood gas analysis in clinical cardiology].
Topics: Acetazolamide; Acid-Base Equilibrium; Bicarbonates; Blood Gas Analysis; Body Weight; Diagnosis, Diff | 1970 |
Heart failure. II.
Topics: Aged; Aortic Valve Insufficiency; Digitoxin; Digoxin; Ethacrynic Acid; Female; Furosemide; Heart Fai | 1971 |
Heart failure. II.
Topics: Aged; Aortic Valve Insufficiency; Digitoxin; Digoxin; Ethacrynic Acid; Female; Furosemide; Heart Fai | 1971 |
[Clinical study of the use of "Spirolang" 50].
Topics: Adult; Aged; Ascites; Chronic Disease; Digitalis Glycosides; Diuresis; Electrolytes; Ethacrynic Acid | 1971 |
[Clinical study of the use of "Spirolang" 50].
Topics: Adult; Aged; Ascites; Chronic Disease; Digitalis Glycosides; Diuresis; Electrolytes; Ethacrynic Acid | 1971 |
[Chronic cardiac insufficiency and ventricular hyperexcitability: value of unjectable anti-aldosterone with quick action].
Topics: Adult; Aged; Diuresis; Electrolytes; Female; Heart Failure; Humans; Injections, Intramuscular; Injec | 1971 |
[Chronic cardiac insufficiency and ventricular hyperexcitability: value of unjectable anti-aldosterone with quick action].
Topics: Adult; Aged; Diuresis; Electrolytes; Female; Heart Failure; Humans; Injections, Intramuscular; Injec | 1971 |
[Changes in the acid-base equilibrium in cardiac insufficiency].
Topics: Acid-Base Equilibrium; Acidosis; Acidosis, Respiratory; Alkalosis; Bicarbonates; Heart Diseases; Hea | 1967 |
[Changes in the acid-base equilibrium in cardiac insufficiency].
Topics: Acid-Base Equilibrium; Acidosis; Acidosis, Respiratory; Alkalosis; Bicarbonates; Heart Diseases; Hea | 1967 |
[Comparative assessment of the efficacy of diuretic action of aldoctone A and lasix in cardiac insufficiency].
Topics: Aged; Diuresis; Female; Furosemide; Heart Failure; Humans; Middle Aged; Spironolactone | 1967 |
[Comparative assessment of the efficacy of diuretic action of aldoctone A and lasix in cardiac insufficiency].
Topics: Aged; Diuresis; Female; Furosemide; Heart Failure; Humans; Middle Aged; Spironolactone | 1967 |
[Prevention of potassium metabolism disorders arising during the treatment of cardiac insufficiency with diuretics].
Topics: Adult; Digitalis Glycosides; Diuretics; Drug Synergism; Female; Furosemide; Heart Failure; Humans; H | 1967 |
[Prevention of potassium metabolism disorders arising during the treatment of cardiac insufficiency with diuretics].
Topics: Adult; Digitalis Glycosides; Diuretics; Drug Synergism; Female; Furosemide; Heart Failure; Humans; H | 1967 |
[Use of aldosterone antagonists in cardiac insufficiency].
Topics: Adult; Drug Synergism; Female; Heart Failure; Humans; Male; Middle Aged; Spironolactone | 1967 |
[Use of aldosterone antagonists in cardiac insufficiency].
Topics: Adult; Drug Synergism; Female; Heart Failure; Humans; Male; Middle Aged; Spironolactone | 1967 |
Amiloride. A potassium-sparing natriuretic agent.
Topics: Acetazolamide; Aldosterone; Ammonia; Ascites; Bicarbonates; Blood Pressure; Chlorides; Chlorothiazid | 1968 |
Amiloride. A potassium-sparing natriuretic agent.
Topics: Acetazolamide; Aldosterone; Ammonia; Ascites; Bicarbonates; Blood Pressure; Chlorides; Chlorothiazid | 1968 |
The role of catecholamines in circulatory regulation on the chronic congestive heart failure. Clinical study of the urinary catecholamine excretion in the patients with chronic congestive heart failure.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cardiomyopathies; Catecholamines; Coronary Disease; Digital | 1968 |
The role of catecholamines in circulatory regulation on the chronic congestive heart failure. Clinical study of the urinary catecholamine excretion in the patients with chronic congestive heart failure.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cardiomyopathies; Catecholamines; Coronary Disease; Digital | 1968 |
Ethacrynic acid diuretic effect in 50 patients.
Topics: Diuresis; Ethacrynic Acid; Heart Failure; Humans; Spironolactone | 1968 |
Ethacrynic acid diuretic effect in 50 patients.
Topics: Diuresis; Ethacrynic Acid; Heart Failure; Humans; Spironolactone | 1968 |
[Hyperaldosteronism and the use of aldactone in cardiac insufficiency].
Topics: Adult; Aldosterone; Blood Flow Velocity; Blood Volume; Cardiac Output; Diuresis; Female; Heart Failu | 1968 |
[Hyperaldosteronism and the use of aldactone in cardiac insufficiency].
Topics: Adult; Aldosterone; Blood Flow Velocity; Blood Volume; Cardiac Output; Diuresis; Female; Heart Failu | 1968 |
[Effect of spironolactone on the excretion of sodium and potassium in the saliva in secondary hyperaldosteronism].
Topics: Heart Failure; Humans; Hyperaldosteronism; Liver Cirrhosis; Potassium; Saliva; Sodium; Spironolacton | 1969 |
[Effect of spironolactone on the excretion of sodium and potassium in the saliva in secondary hyperaldosteronism].
Topics: Heart Failure; Humans; Hyperaldosteronism; Liver Cirrhosis; Potassium; Saliva; Sodium; Spironolacton | 1969 |
[Clinical use of concurrent antagonists of aldosterone in patients with cardiac insufficiency].
Topics: Adult; Arrhythmias, Cardiac; Caproates; Cardiac Glycosides; Diuretics; Drug Tolerance; Ethisterone; | 1969 |
[Clinical use of concurrent antagonists of aldosterone in patients with cardiac insufficiency].
Topics: Adult; Arrhythmias, Cardiac; Caproates; Cardiac Glycosides; Diuretics; Drug Tolerance; Ethisterone; | 1969 |
Clinical studies on the acid-base balance disturbance in congestive heart failure.
Topics: Acid-Base Equilibrium; Acidosis, Respiratory; Adult; Aldosterone; Alkalosis; Arteries; Benzothiadiaz | 1969 |
Clinical studies on the acid-base balance disturbance in congestive heart failure.
Topics: Acid-Base Equilibrium; Acidosis, Respiratory; Adult; Aldosterone; Alkalosis; Arteries; Benzothiadiaz | 1969 |
[Therapeutically induced aldosteronism in hydropic cardiac insufficiency].
Topics: Aldosterone; Carbon Isotopes; Cardiac Glycosides; Diuretics; Heart Failure; Humans; Hyperaldosteroni | 1969 |
[Therapeutically induced aldosteronism in hydropic cardiac insufficiency].
Topics: Aldosterone; Carbon Isotopes; Cardiac Glycosides; Diuretics; Heart Failure; Humans; Hyperaldosteroni | 1969 |
Ethacrynic acid: two years' experience with a new diuretic.
Topics: Benzothiadiazines; Blood; Edema; Ethacrynic Acid; Heart Failure; Liver Cirrhosis; Nephrotic Syndrome | 1965 |
Ethacrynic acid: two years' experience with a new diuretic.
Topics: Benzothiadiazines; Blood; Edema; Ethacrynic Acid; Heart Failure; Liver Cirrhosis; Nephrotic Syndrome | 1965 |
[Treatment of cardiac edemas by a combination of micronized aldactone and Altizide].
Topics: Diuretics; Heart Failure; Humans; Spironolactone | 1965 |
[Treatment of cardiac edemas by a combination of micronized aldactone and Altizide].
Topics: Diuretics; Heart Failure; Humans; Spironolactone | 1965 |
[Effect of spironolactone on the myocardial hyperexcitability of decompensated cardiopathies].
Topics: Heart Failure; Humans; Spironolactone | 1965 |
[Effect of spironolactone on the myocardial hyperexcitability of decompensated cardiopathies].
Topics: Heart Failure; Humans; Spironolactone | 1965 |
[Secondary hyperaldosteronism as a secondary disease in intractable cardiac decompensation].
Topics: Adult; Cardiac Surgical Procedures; Digitalis Glycosides; Diuresis; Electrocardiography; Female; Hea | 1965 |
[Secondary hyperaldosteronism as a secondary disease in intractable cardiac decompensation].
Topics: Adult; Cardiac Surgical Procedures; Digitalis Glycosides; Diuresis; Electrocardiography; Female; Hea | 1965 |
Fatal hyperkalemic paralysis associated with spironalactone. Observation on a patient with severe renal disease and refractory edema.
Topics: Adult; Diabetes Mellitus; Diabetic Nephropathies; Edema; Heart Failure; Humans; Hyperkalemia; Hypert | 1966 |
Fatal hyperkalemic paralysis associated with spironalactone. Observation on a patient with severe renal disease and refractory edema.
Topics: Adult; Diabetes Mellitus; Diabetic Nephropathies; Edema; Heart Failure; Humans; Hyperkalemia; Hypert | 1966 |
Pulmonary venous and arterial hypertension due to chronic fibrous mediastinitis. Hemodynamics and pulmonary function.
Topics: Adult; Chlorothiazide; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Lung; Male; Med | 1966 |
Pulmonary venous and arterial hypertension due to chronic fibrous mediastinitis. Hemodynamics and pulmonary function.
Topics: Adult; Chlorothiazide; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Lung; Male; Med | 1966 |
[On the mechanism of action of antialdosterone compounds (aldactone and progesterone) in the treatment of cardiac edema].
Topics: Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Progestero | 1966 |
[On the mechanism of action of antialdosterone compounds (aldactone and progesterone) in the treatment of cardiac edema].
Topics: Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Progestero | 1966 |
[Diuresis therapy in hyperaldosteronism].
Topics: Adult; Aged; Aorta; Edema; Female; Heart Failure; Humans; Hyperaldosteronism; Liver Cirrhosis; Male; | 1966 |
[Diuresis therapy in hyperaldosteronism].
Topics: Adult; Aged; Aorta; Edema; Female; Heart Failure; Humans; Hyperaldosteronism; Liver Cirrhosis; Male; | 1966 |